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Abstract	
Preventing	 hospitalised	 patients	 from	 suffering	 adverse	 event	 (AEs)	 (unexpected	 cardiac,	 arrest,	
intensive	care	unit	admission,	surgery	or	death)	is	a	priority	in	healthcare.	Almost	50%	of	these	AEs,	
caused	 by	mistakes/poor	 standards	 of	 care,	 are	 thought	 to	 be	 preventable.	 The	 identification	 and	
referral	of	a	patient	at	risk	of	an	AE	to	a	dedicated	rapid	response	team	is	a	key	mechanism	for	their	
reduction.		
	
Focussing	 on	 variables	 that	 are	 routinely	 collected	 and	 electronically	 stored	 (blood	 test	 data,	 and	
administrative	data:	demographics,	date	and	method	of	admission,	and	co-morbidities),	along	with	
their	 trends,	 I	 have	 collected	data	on	~8	million	 admissions.	 I	 have	explained	how	 to	navigate	 the	
complex	 ethical	 and	 legal	 landscape	 of	 performing	 such	 an	 ambitious	 data	 linkage	 and	 collection	
project.	
	
Analysing	data	on	~2	million	hospital	admissions	with	an	in-hospital	blood	test	result,	I	have		
1. described	how	these	variables	(particularly	urea	and	creatinine	blood	tests,	method	of	admission,	
and	date	of	admission)	influence	in-hospital	mortality	rate	in	different	groups	of	patient.	
2. created	 four	 machine	 learning	 (ML)	 models	 that	 have	 the	 highest	 accuracy	 yet	 described	 for	
identifying	a	patient	at	risk	of	an	SAE,	while	at	the	same	time	capturing	the	majority	of	patients	
likely	to	die	(high	sensitivity).	These	models	ML-Dehydration,	ML-AKI,	ML-Admission,	and	ML-Two-
Tests,	 can	be	applied	 to	admissions	with	 limited	data,	 specific	 syndromes,	or	on	all	patients	 in	
hospital	 at	 different	 time	 points	 in	 their	 hospital	 trajectory	 respectively.	 Their	 area	 under	 the	
receiver	operator	curves	are	79.6%,	85.9%,	93%	and	90.6%	respectively.	
3. built	and	deployed	a	technology	platform	Patient	Rescue	that	allows	for	the	automated	application	
of	any	model	in	any	hospital,	as	well	as	the	communication	of	rich	patient	level	reports	to	clinicians,	
all	in	real-time.	
	
The	ML	models	and	the	Patient	Rescue	platform	together	form	the	ML	–	Early	Warning	System.	 	
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Chapter	1:	Introduction	
1.1	Introduction	
My	 responsibilities	 as	 an	 anaesthesiologist	 apart	 from	 intraoperative	 anaesthesia	 include	 the	
management	of	patients	who	have	had	a	cardiac	arrest	(as	a	member	of	the	cardiac	arrest	team),	the	
optimisation	of	patients	who	need	emergency	surgery,	and	assisting	in	the	management	of	patients	
who	have	severely	deteriorated	and	are	peri-arrest	(as	a	member	of	the	outreach	team).	When	I	am	
referred	these	patients	I	almost	always	notice,	a)	their	physiological	deterioration	had	been	going	on	
for	some	time	prior	to	them	being	referred	to	me,	and	b)	important	interventions,	whether	they	were	
additional	tests	or	treatments,	were	either	not	done	or	were	delayed.	I	believe	that	early	identification,	
enabling	 immediate	 appropriate	 intervention,	would	prevent	 such	patient	deterioration.	 This	 early	
identification	needs	to	occur	in	the	resource	constrained	environment	of	the	healthcare	system	(e.g.	
it	must	not	require	expensive	additional	tests),	and	must	fit	in	with	existing	modes	and	processes	of	
clinical	 care	 (i.e.	 there	 must	 be	 simple	 mechanisms	 for	 its	 implementation).	 The	 challenges	 are	
therefore	to	demonstrate	a)	that	early	identification	is	possible	using	existing	data,	and	2)	a	system	to	
enable	this	early	identification	can	be	implemented	that	fits	into	both	existing	clinical	workflows,	and	
integrates	with	existing	healthcare	information	technology	(IT).	This	belief	and	drive	to	improve	patient	
care	are	 the	motivations	behind	my	doctoral	 research.	My	hypothesis	 is-	 “Better	understanding	of	
already	captured	clinical	data,	using	machine	learning,	and	the	application	of	advanced	information	
technology	can	enable	early,	automatic	and	real	time	identification	of	all	hospitalised	patients	at	risk	
of	future	deterioration”.		
	
Adverse	events	(AE)	are	defined	as	harm	to	a	patient	as	a	result	of	medical	care	or	those	that	occur	
within	a	health	care	setting1.	These	include	unexpected	prolongation	of	hospitalisation,	cardiac	arrest,	
emergency	surgery,	emergency	 intensive	care	admission,	and	patient	death.	They	may	also	 include	
any	 untoward	 medical	 occurrence	 that	 result	 in	 persistent	 or	 significant	 disability,	 congenital	
abnormality,	or	birth	defect.	The	primary	focus	of	this	research	will	be	on	the	AE	of	in-hospital	patient	
death.	
	
An	AE	indicates	that	the	care	resulted	in	an	undesirable	clinical	outcome	and	may	have	involved	errors,	
negligence,	 or	 poor-quality	 care.	 Although	 this	 does	 not	 necessarily	 mean	 that	 the	 events	 were	
preventable2,	a	significant	number	appear	 to	be	of	 this	 type.	For	example,	a	2010	United	States	of	
America	(USA)	Government	Investigation	found	that	‘44%	of	AEs	were	clearly	or	likely	preventable’3.	
Similarly,	a	2011	United	Kingdom	(UK)	investigation	reported	less	than	half	(48%)	of	high-risk	surgical	
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patients	received	good	care4.	Disease-specific	reports	support	these	findings:	only	50%	of	patients	who	
died	of	acute	kidney	injury	(AKI)	received	‘good’	care5.		20–30%	of	the	total	number	of	AKI	cases	(fatal	
and	non-fatal)	were	regarded	as	being	preventable.	Intervention-specific	reports,	in	this	case	regarding	
the	administration	of	intravenous	fluids,	found	that	a	significant	number	of	hospitalised	patients	were	
dying	as	a	result	of	the	infusion	of	too	much	or	too	little	fluid6.		
	
The	potential	for	improving	the	quality	of	in-hospital	care,	and	for	the	reduction	of	adverse	outcomes,	
is	clear.	These	goals	have	been	incorporated	in	national	clinical	guidelines	in	the	UK6,7,	highlighted	in	
government	 and	 patient	 reports4,5,8,9,10,11,12,	 and	 linked	 to	 reimbursement	 via	 quality	 improvement	
metrics13,14.	 The	UK,	National	 Institute	 for	Health	and	Care	Excellence	 (NICE),	National	Confidential	
Enquiry	 into	 Patient	 Outcome	 and	 Death	 (NCEPOD)	 and	 the	 Royal	 College	 of	 Physicians	 (RCP)	 all	
advocate	programmes	to	reduce	AE	frequency	through	the	early	recognition	of	patient	decline.	In	the	
USA,	as	a	condition	of	participation	in	the	Medicare	and	Medicaid	programmes,	Federal	regulations	
require	 that	 hospitals	 develop	 and	 maintain	 Quality	 Assessment	 and	 Performance	 Improvement	
(QAPI)	Programmes13.	As	a	part	of	their	QAPI	programmes,	hospitals	must	‘track	medical	errors	and	
adverse	 patient	 events,	 analyse	 their	 causes,	 and	 implement	 preventative	 actions’.	 In	 the	 UK,	
commissioning	for	quality	and	innovation	(CQUIN)	payments14	are	similar	vehicles	for	prioritising	AE	
reduction	in	hospitals.	
	
Fulfilling	these	requirements	of	reducing	AEs	 is	a	challenge.	The	substantial	and	continuously	rising	
cost	of	healthcare	dictates,	in	my	opinion,	that	it	is	economically	unfeasible	to	address	the	problems	
of	AEs	by	simply	increasing	funding	for	the	healthcare	services.	Instead,	improved	quality	of	care	must	
accompany	increased	healthcare	efficiency.		
	
The	key	components	of	a	programme	of	cardiac	arrest	reduction,	as	an	example	of	an	AE,		have	been	
described	as	a	‘Chain	of	Prevention’15,	requiring	the	successful	implementation	of	all	the	following:	
§ Education:	Recognition	of	the	signs	of	deterioration;	appreciating	clinical	urgency;	use	of	an	early-
warning	score;	when	and	how	to	use	simple	interventions;	successful	teamwork	and	organization;	
and	end-of-life	care.	
§ Monitoring:	Includes	patient	assessment	and	measurement,	and	recording	of	vital	signs.	
§ Recognition	of	all	patients	likely	to	deteriorate	in	the	near	future,	or	currently	declining.	This	is	
difficult	to	achieve,	and	failure	to	do	so	is	one	of	the	most	common	features	of	AEs.	
§ Call	 for	help	 (communication):	Communication	of	 this	deterioration	 to	 the	appropriate	 clinical	
team	(e.g.	the	rapid	response	team	(RRT)).	
§ Response	(intervention)	that	successfully	stabilises	the	patient	or	prevents	the	deterioration	from	
occurring.	Many	countries	have	introduced	RRTs	to	which	deteriorating	patients	can	be	referred.	
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For	 my	 doctoral	 research,	 I	 have	 focussed	 on	 ‘Recognition’	 of	 the	 deteriorating	 patient,	 using	 a	
different	modality	of	monitoring	the	patient.	Existing	programmes	of	‘Monitoring’	of	patients	rely	on	
the	measurement	of	vital	signs7.	Utilisation	of	laboratory	blood	test	results,	with	patient	administrative	
data,	could	be	a	novel	alternative.	It	is	possible	that	an	early	warning	score	(EWSC)	based	on	multiple	
variables	(including	but	not	limited	to	patient	demographics,	co-morbidities,	and	admission	dates)	may	
have	a	high	accuracy	in	identifying	those	who	are	at	an	increased	risk	to	suffer	AEs.	Because	these	data	
are	quality-controlled	and	stored	electronically,	theoretically	this	should	make	them	easy	to	access,	
and	amenable	to	complex	computational	analysis.	In	this	thesis	I	have	first	applied	advanced	analytical	
techniques,	specifically	machine	learning,	to	laboratory	and	administrative	data,	to	build	models	that	
predict	which	hospitalised	patients	are	 likely	 to	 suffer	an	AE	 (with	a	particular	 focus	on	mortality).		
Second,	I	have	built	an	advanced	computer	system	(‘Patient	Rescue’)	that	enables	the	application	of	
such	models	to	any	healthcare	provider	in	the	world.	
1.2	The	Problem	
A	 significant	 proportion	 of	 hospitalised	 patients	 receive	 sub-optimal	 care7.	 This	 leads	 to	 increased	
mortality	and	morbidity.	Key	factors	in	this	sub-optimal	care	of	patients	are:	1)	the	lack	of	recognition	
of	the	seriousness	of	a	patient’s	condition	on	first	presentation	to	a	hospital;	2)	lack	of	recognition	of	a	
patient’s	 subsequent	 clinical	 deterioration	 while	 in	 hospital;	 and	 3)	 despite	 indications	 of	 clinical	
deterioration	being	present,	 it	 is	neither	appropriately	recognised	nor	acted	upon7.	Multiple	reports	
from	the	UK	NCEPOD	have	focussed	on	these	issues	and	highlighted	that	many	cases	may	have	been	
preventable.	A	summary	of	each	of	these	influential	reports	is	described	below.	
§ ‘An	Acute	Problem’,	published	in	20058,	focussed	on	patients	admitted	to	the	Intensive	Care	Unit	
(ICU).	Among	its	key	findings	it	found	that	‘Patients	often	had	prolonged	periods	of	physiological	
instability	prior	to	admission	to	ICU.	In	patients	who	had	been	in	hospital	more	than	24	hours	prior	
to	ICU	admission,	66%	exhibited	physiological	instability	for	more	than	12	hours.’	The	report	also	
highlighted	the	inadequacy	of	physiological	monitoring,	and	the	lack	of	both	early	warning	systems	
(EWS)	and	critical	care	outreach	teams.	Two	of	the	key	recommendations	of	the	report	were:	1)	
increased	 attention	 to	 patients	 exhibiting	 physiological	 abnormalities,	 as	 this	 is	 a	 marker	 of	
increased	mortality;	and	2)	Deployment	of	EWSCs	to	cover	all	hospitalised	patients.	These	EWSCs	
should	be	linked	to	a	RRT	that	was	appropriately	skilled	to	manage	the	deteriorating	patient.	
§ ‘Emergency	 Admissions:	 a	 journey	 in	 the	 right	 direction?’,	 published	 in	 20079,	 focussed	 on	
emergency	 admissions	 to	 hospitals.	 It	 highlighted	 that	 34.8%	of	 patients	 received	 substandard	
care,	and	that	 the	 initial	assessment	and	management	plan	 for	 these	patients	was	 inadequate,	
with	a	failure	to	perform	appropriate	investigations	and	to	recognise	critically	ill	patients.	Among	
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its	principal	recommendations	were	training	to	enable	recognition	of	critically	 ill	patients	and	a	
clear	physiological	monitoring	plan	for	each	patient,	commensurate	with	their	clinical	condition.	
This	physiological	monitoring	plan	should	detail	what	is	to	be	monitored,	the	desirable	parameters	
and	the	frequency	of	observations.	It	should	also	include	an	explicit	statement	of	parameters	that	
would	prompt	escalation	of	care,	and	review	by	an	expert	multidisciplinary	team;	 i.e.	an	EWSC	
linked	to	a	RRT.	
§ ‘Adding	 Insult	 to	 Injury.	 A	 review	 of	 the	 care	 of	 patients	who	 died	 in	 hospital	 with	 a	 primary	
diagnosis	of	acute	kidney	injury	(acute	renal	failure)’,	published	in	20095,	focussed	on	patients	who	
developed	AKI.	Among	its	key	findings	were:	a)	there	was	an	unacceptable	delay	 in	recognising	
hospital-acquired	AKI	in	43%	of	patients;	b)	20%	of	hospital-acquired	AKI	cases	were	avoidable;	c)	
complications	of	AKI	were	missed	in	13%	of	cases,	and	avoidable	in	17%;	and	d)	50%	of	patients	
received	 substandard	 care.	 Among	 the	 report’s	 many	 recommendations	 was	 the	 robust	
implementation	 of	 ‘NICE	 Clinical	 Guidance	 50’,	 which	 are	 systems	 for	 recognising	 acutely	 ill	
patients.		
§ ‘Caring	 to	 the	 End?	 A	 review	 of	 the	 care	 of	 patients	who	 died	 in	 hospital	within	 four	 days	 of	
admission’,	published	in	200910,	highlighted	issues	of	inadequate	early	assessment,	investigation,	
diagnosis,	and	management	of	patients	on	admission.	It	also	focussed	on	the	failure	to	urgently	
escalate	care	of	these	patients	to	a	senior	clinician	or	consultant.	
§ ‘Knowing	 the	Risk.	A	 review	of	 the	peri-operative	 care	of	 surgical	patients’,	published	 in	20114	
focussed	on	the	care	of	high-risk	surgical	patients.	Among	 its	key	findings	were:	a)	only	48%	of	
high-risk	 patients	 received	 care	 that	 was	 ‘good’;	 b)	 there	was	 a	 lack	 of	 consensus	 as	 to	what	
constitutes	high	peri-operative	risk	(a	recognition	problem);	c)	24%	of	patients	were	not	monitored	
by	an	early	warning	system;	and	d)	there	were	inadequate	pre-operative	interventions	to	optimise	
a	 patient’s	 nutritional	 and	 fluid	 status,	 resulting	 in	 poor	 outcomes	 for	 those	 cases	 where	
optimisation	 did	 not	 occur.	 The	 key	 recommendations	 included	 better	 assessment	 of	 high-risk	
patients	and	optimisation	of	their	nutritional	and	fluid	status,	along	with	the	escalation	of	their	
care	to	an	enhanced	recovery	pathway.	
§ ‘Time	to	Intervene?	A	review	of	patients	who	underwent	cardiopulmonary	resuscitation	as	a	result	
of	an	 in-hospital	cardiorespiratory	arrest’,	published	 in	201211,	 focussed	on	patients	who	had	a	
cardiac	arrest	in	hospital.	It	found	that	64%	of	cardiac	arrests	were	predictable,	with	warning	signs	
for	imminent	cardiac	arrest	present	in	75%	of	cases.	The	report	also	claimed	38%	of	cardiac	arrests	
were	avoidable.	Key	 factors	 in	 this	poor	antecedent	patient	care	were	 identified	as	 the	 lack	of	
‘recognition’	 and	 failure	 to	 escalate	 the	 care	 of	 these	 deteriorating	 patients.	 Again,	 the	
implementation	of	‘NICE	Clinical	Guidance	50’	was	one	of	the	key	recommendations.	
§ Finally,	 in	 ‘Just	 Say	 Sepsis!	 A	 review	 of	 the	 process	 of	 care	 received	 by	 patients	 with	 sepsis’,	
published	in	201512,	the	principal	recommendations	included:	a)	the	implementation	of	a	formal	
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protocol	to	enable	the	early	identification	and	management	of	patients	with	sepsis;	b)	the	use	of	
an	EWSC,	such	as	the	National	Early	Warning	Score	(NEWS);	c)	adequate	vital	sign	monitoring;	d)	
adequate	staffing	and	resources;	and	e)	implementation	of	‘care	bundles’.	
	
Two	overriding	themes	emerge,	 first	poor	 identification	of	patients	at	high	risk	of	deterioration,	or	
those	who	are	already	deteriorating;	and	second	 inadequate	urgency	 in	 the	escalation	of	care	and	
review	of	these	patients,	by	an	appropriate	senior	clinician	(consultant	or	specialist	nursing	team).	
1.3	The	Current	Solution:	Rapid	Response	Systems	
Addressing	the	problems	of	poor	or	delayed	identification	of	high-risk	or	acutely	ill	patients	is	complex,	
and	apart	from	rapid	identification	and	effective	clinical	intervention,	this	involves:	education,	training	
and	resourcing.	Resourcing	applies	to	adequacy	in	staff	and	facilities	e.g.		critical	care	beds.		
	
The	key	components	of	a	programme	of	AE	reduction-	the	‘Chain	of	Prevention’15,	are	described	in	
detail	 in	 Section	 1.1.	 To	 deal	 specifically	 with	 1)	 monitoring	 and	 identification	 of	 the	 high-
risk/deteriorating	 patient,	 and	 2)	 the	 call	 for	 help	 and	 response	 components,	 the	 most	 widely	
implemented	solution	has	been	the	rapid	response	system	(RRS).	The	RRS	is	composed	of	an	afferent	
limb	of	monitoring,	recognition	and	alerting	(call	for	help),	namely	the	EWSC,	and	an	efferent	limb	of	
intervention	(response),	which	is	the	RRT.	These	are	described	below	(in	reverse	order):	
1.3.1	The	Efferent	Limb:	Rapid	Response	Team		
RRTs	 are	 referred	 to	 by	 a	 variety	 of	 names,	 including	 ‘medical	 emergency	 team’,	 ‘outreach	 team’,	
‘critical	care	outreach	team’,	‘emergency	response	team’,	or	‘patient	emergency	response	team’.	The	
RRT	is	a	designated	group	of	healthcare	professionals	with	a	mixture	of	skills.	According	to	Jones	et	al,	
‘These	teams	are	key	components	of	rapid-response	systems,	which	have	been	put	in	place	because	
of	 evidence	 of	 “failure	 to	 rescue”	with	 available	 clinical	 services,	 leading	 to	 AEs’16.	 As	 a	minimum	
requirement,	 each	 RRT	 includes	 a	 senior	 clinician	 (acute	 medicine	 physician,	 anaesthetist	 or	
intensivist)	and	a	critical	care	nurse,	though	the	composition	varies	by	institution.	The	RRT	differs	from	
the	traditional	‘cardiac	arrest’	team	(‘code	team’	in	the	USA)	in	a	number	of	ways	(Figure	1.1)16.	The	
RRT	assesses	a	larger	number	of	hospitalised	patients	at	an	earlier	stage	of	their	clinical	deterioration.	
The	RRT’s	role	 is	to	 immediately	assess	and	treat	a	patient	showing	objective	or	subjective	signs	of	
clinical	deterioration.	The	RRT’s	goal	is	to	reverse	the	patient’s	deterioration	and	prevent	an	AE.	The	
RRT	 responds	 to	 emergencies,	 proactively	 evaluates	 high-risk	 ward	 patients,	 educates	 and	 acts	 in	
liaison	with	ward	staff.	The	RRT	may	also	follow	up	on	patients	discharged	from	an	ICU.	RRTs	have	
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been	 introduced	 in	 many	 countries,	 including	 for	 example	 Australia,	 Canada,	 Denmark,	 the	
Netherlands,	New	Zealand,	Sweden,	UK	and	USA.	
	
Figure	1.116	
	
1.3.2	The	Afferent	Limb:	Vital	Sign	EWSCs	
It	is	well	recognised	that,	prior	to	an	in-hospital	patient	having	a	cardiac	arrest,	being	admitted	to	an	
ICU,	or	dying;	they	exhibit	a	period	of	physiological	deterioration	that	is	potentially	recognisable	and	
reversible4,8,9,10,11,12.	However,	frontline	medical	staff	often	ignore	this.	As	a	result,	the	use	of	an	EWSC	
has	been	mandated	in	health	care	settings,	in	order	to	aid	the	detection	and	escalation	of	care	of	the	
high-risk/deteriorating	patient.		
	
EWSC	were	developed	to	facilitate	early	detection	of	deterioration	by	categorising	a	patient’s	severity	
of	illness	and	prompting	frontline	medical	staff	to	request	a	medical	review	at	specific	trigger	points7.	
EWSC	are	sometimes	referred	to	as	‘Track	and	Trigger	Score’.7	Each	of	a	patient’s	vital	signs	(blood	
pressure,	heart	rate,	respiratory	rate,	etc.),	is	allocated	a	numerical	score	depending	on	its	absolute	
value.	Individual	scores	are	added	to	give	the	total	score	for	that	patient,	which	is	their	EWSC.	A	high	
or	 rising	 EWSC	 value	 indicates	 a	 patient	 has	 or	 is	 deteriorating,	 while	 falling	 values	 indicate	 their	
improvement.	Thresholds	are	set,	where	if	a	patient’s	score	is	equal	to	or	above	a	certain	value,	specific	
actions	are	recommended,	from	increasing	the	frequency	of	recording	the	vital	signs	to	immediately	
calling	 the	RRT.	 It	 is	also	not	always	necessary	 to	aggregate	 the	 individual	vital	 signs	 together,	and	
some	countries,	particularly	the	USA,	have	instituted	MET	(medical	emergency	team)	calling	criteria,	
which	are	dependent	only	on	the	absolute	values	of	individual	vital	signs.	Examples	of	MET	and	EWSC	
calling	criteria	are	shown	 in	Figures	1.2	and	1.3.	At	some	hospitals,	patients	themselves	and	family	
members	may	trigger/call	the	rapid	response	team.	
	
	
22	
In	the	UK,	in	2007	the	NICE	issued	guidance	that	all	patients	in	hospital	should	be	monitored	using	an	
EWSC	with	 appropriate	 escalation.7	 In	 2012,	 The	 RCP	 published	 the	 ‘National	 Early	Warning	 Score	
(NEWS):	 Standardising	 the	 assessment	 of	 acute-illness	 severity	 in	 the	 NHS’	 report.17	 In	 this,	 it	
recommended	that	a	new	EWSC,	known	as	‘NEWS’,	be	implemented	across	all	NHS	hospitals.	In	2014,	
the	Irish	National	Clinical	Effectiveness	Committee	issued	its	National	Clinical	Guideline	No.	1,	namely	
the	National	Early	Warning	Score	(NEWS),	and	recommended	its	introduction	in	Ireland.18	Figure	1.4	
details	the	assigned	values	for	each	vital	sign	parameter	of	NEWS,	and	Figure	1.5	shows	the	thresholds	
and	triggers	of	the	aggregated	values.	NEWS	was	evaluated	against	a	range	of	other	EWSC,	and	was	
shown	to	have	an	area	under	the	receiver	operator	curve	(AUROC)	of	89%	for	discriminating	for	in-
hospital	mortality	within	24	hours	of	NEWS	assessment,	for	patients	admitted	to	a	medical	admissions	
unit	 (medical	 emergency	 admissions).	 As	 a	 result,	 rapid	 response	 systems	 (RRS)	 are	 now	 standard	
practice	in	the	UK	and	in	most	developed	countries.	
	
Figure	1.2:	Single-parameter	MET	calling	criteria16	
	
A	hospital	poster	listing	criteria	for	activation	of	a	rapid	response	team.	Such	posters	are	displayed	on	the	walls	of	hospitals	
to	remind	caregivers	of	abnormalities	in	vital	signs	that	are	considered	to	require	intervention.	This	poster	is	based	on	one	
displayed	at	Austin	Hospital,	Heidelberg,	Victoria,	Australia	16	
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Figure	1.3:	Multi-parameter	EWSC19	
	
Figure	1.4:	National	Early	Warning	Score	(NEWS)	
	
	
	
Figure	1.5:	National	Early	Warning	Score	(NEWS)	escalation	criteria	
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1.3.3	Issues	with	Vital	Sign	EWSCs	
Before,	embarking	on	creating	an	EWSC	based	on	blood	results,	administrative	data	was	undertaken,	
an	understanding	of	the	key	problems	with	vital	sign	based	EWSCs	was	carried	out.	I	did	this	to	mitigate	
any	of	 these	 issues	arising	 in	my	ML	based	approach.	Although,	 vital-sign-based	EWSCs	have	been	
widely	 implemented.	 I	 believe	 there	 remain	 significant	 issues	 with	 their	 use,	 which	 limits	 their	
effectiveness	in	adequately	identifying	the	high-risk/deteriorating	patient.		
In	my	opinion,	the	two	most	significant	problems	are	
§ Limitations	on	the	measurement	of	vital	signs	
§ Poor	positive	predictive	value	in	the	identification	of	the	high-risk/deteriorating	patient	
Both	of	which	are	explored	in	below.	
1.3.3.1	Limitations	on	the	measurement	of	vital	signs	
Measuring	vital	signs	is	routine.	Vital	signs	are	used	to	help	diagnose	and	monitor	the	health	status	of	
the	patient,	and	their	response	to	clinical	 interventions.	However,	there	are	numerous	studies	that	
have	shown	that	such	measurements	may	not	be	performed	predictably,	accurately	or	completely.16	
In	addition,	the	frequency	of	measuring	vital	signs	has	been	shown	to	be	inadequate	and	a	cause	for	
the	delayed	detection	of	a	deteriorating	patient.8,9,10,12	Thus,	if	monitoring	is	not	being	carried	out,	or	
the	values	recorded	from	it	are	inaccurate,	then	any	escalation	of	care	that	relies	on	the	interpretation	
of	the	vital	signs	is	bound	to	be	detrimentally	affected,	reducing	the	effectiveness	of	a	vital-sign-based	
EWSC.		
1.3.3.2	Poor	positive	predictive	value	in	the	identification	of	the	high-risk/deteriorating	patient	
There	 is	 significant	 variation	 in	 the	 predictive	 performance	 of	 a	 vital-sign-based	 EWSC	 to	 identify	
patients	at	risk	of	an	AE20,	21.	
	
Single-parameter	EWSCs	comprise	escalation	criteria	based	on	the	values	of	single	variables	only,	such	
as	‘heart	rate	<	40	beats	per	minute	(bpm)	or	>	130	bpm’,	 ‘respiratory	rate	<	8	breaths	per	minute	
(brpm)	 or	 >	 30	 brpm’,	 etc.	 Smith	 et	 al.	 compared	 80	 single-parameter	 EWSCs	 in	 9,987	 emergency	
medical	patients,	 and	demonstrated	variations	 in	 their	positive	predictive	 values	 (PPVs)	 to	 identify	
death	within	hospital,	which	ranged	from	13.5%	to	26.1%.20	Sensitivities	varied	from	7.3%	to	52.5%,	
with	 specificities	 ranging	 from	 69.1%	 to	 98.1%.	 The	 maximum	 positive	 predictive	 value	 (PPV)	 of	
identifying	a	patient	dying	 in	hospital	was	26.1%,	which	equates	 to	one	patient	death	 in	every	3.8	
(1:3.8)	predicted	patient	deaths.	However,	this	particular	EWSC	had	a	sensitivity	of	only	7.3%;	i.e.	it	
identified	only	7.3%	of	all	patients	who	died	 in	hospital.	A	 slightly	more	effective	single-parameter	
EWSC	was	that	of	Salamonson22,	which	had	a	marginally	lower	PPV	of	25.7%	(1:3.9),	but	identified	only	
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19%	of	patients	likely	to	die.	The	single-parameter	EWSC	with	the	highest	sensitivity	of	52.8%	had	a	
PPV	of	only	13.5%	(1:7.4).23	
	
Multiple-parameter	 EWSCs	 perform	 substantially	 better.	 For	 the	 same	 vital	 sign	 database	 used	 to	
evaluate	the	single-parameter	EWSCs	above,	the	area	under	the	receiver	operator	curve	(AUROC)	for	
death	within	24	hours	of	the	vital	signs	being	measured	varied	from	65.7%	to	78.2%.21	This	comparative	
analysis	was	repeated	on	a	larger	dataset	(35,585	admissions,	198,755	vital	sign	observation	sets)	with	
the	NEWS.24	NEWS	achieved	an	AUROC	for	identifying	death	within	24	hours	of	89.4%,	with	the	other	
EWSCs’	 AUROCs	 ranging	 from	 81.3%	 to	 85.8%.	 No	 positive	 predictive	 values,	 sensitivities	 or	
specificities	for	any	threshold	 levels	(the	numerical	value	of	the	EWSC)	were	explicitly	stated	in	the	
paper.	However,	for	NEWS,	 it	was	 indicated	that	when	the	value	was	5,	the	sensitivity	of	capturing	
patients	who	died	within	24	hours	was	75%.	In	a	separate	study,	two	EWSCs,	ViEWS	(Vitalpac	Early	
Warning	 Score,	 the	basis	 for	NEWS)	 and	MEWS	 (Modified	 Early	Warning	 Score),	were	 tested	on	 a	
dataset	of	1.15	million	vital	signs	obtained	from	42,230	admissions.25	The	mortality	rate	in	this	study	
was	 1.79%	 (756	 deaths).	 ViEWS	 achieved	 an	 AUROC	 of	 86.2%,	 while	MEWS’s	 AUROC	was	 86.5%.	
However,	for	ViEWS,	the	positive	predictive	value	in	discriminating	whether	the	patient	was	likely	to	
die,	even	at	a	relatively	high	threshold	value	of	11	(the	recommended	threshold	for	a	severe	patient	is	
7),	was	only	1:4.5	(22.1%),	and	this	was	achieved	with	a	poor	sensitivity	of	only	30.7%.	Another	study,	
by	 Romero-Brufau	 et	 al.26,	 used	 a	 different	 dataset	 of	 almost	 seven	 million	 sets	 of	 vital	 sign	
observations	from	46,366	admissions,	and	compared	various	EWSCs	for	their	predictive	accuracy	in	
correctly	classifying	a	composite	outcome.	The	composite	outcome	was	positive	if	it	occurred	within	
36	hours,	and	included	cardiac	arrest,	unplanned	transfer	to	ICU,	resuscitation	call,	or	RRT	activation.	
This	study	relied	not	just	on	admission	data,	but	also	on	data	collected	throughout	a	patient’s	hospital	
stay.	The	maximum	PPV	attained	by	an	EWSC	was	21%,	but	this	was	paired	with	a	poor	sensitivity	of	
only	8%.	NEWS	seemed	to	consistently	have	a	PPV	of	less	than	10%	(the	sensitivity	was	not	reported).	
The	 exact	 threshold	 value	 for	 NEWS	was	 not	 stated,	 but	 it	 can	 be	 estimated	 to	 be	 either	 5	 or	 7,	
corresponding	to	the	moderate	or	severe	thresholds	respectively.		
	
In	summary,	existing	vital	sign	based	EWSCs	do	not	offer	good	predictive	value	for	RRT	activation,	and	
better	EWSCs	need	to	be	developed	and	validated.	
1.4	An	Alternative	Afferent	Limb:	Use	of	Laboratory	Data	
An	alternative	to	using	an	EWSC	based	on	vital	signs	would	be	to	use	existing	quality-controlled	data	
stored	electronically	in	hospital.	This	would	mitigate	issues	affecting	data	quality	and	calculations.	
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Medical	professionals	already	use	the	results	of	blood	tests	to	help	them	diagnose,	prognosticate	and	
monitor	 interventions.	 Although	 not	 regarded	 as	 an	 EWSC,	 blood	 test	 results	 are	 already	 used	 to	
identify	high-risk/deteriorating	patients.	Diagnoses	are	normally	made	by	interpreting	individual	blood	
results	and	their	trends,	ratios	of	different	blood	results,	simple	combinations	of	a	few	blood	results,	
and	 in	 the	 case	 of	 blood	 gas	 measurements:	 to	 aid	 the	 diagnosis	 of	 metabolic	 vs	 respiratory	
acidosis/alkalosis.	Scoring	systems	also	exist	which	use	blood	result	data	to	aid	diagnosis	and	severity	
grading	of	diseases,	for	example	Ranson’s	criteria	for	predicting	the	severity	of	acute	pancreatitis.27	
	
In	 my	 opinion,	 four	 specific	 methods	 by	 which	 blood	 results	 are	 interpreted,	 their	 use	 in	 clinical	
practice,	and	their	potential	for	use	as	an	EWSC,	are	given	below	(ranked	in	increasing	complexity):	
1. Simple	single-parameter:	Reference	intervals.	
2. Simple	dual-parameter:	Dehydration	(urea	to	creatinine	ratio).	
3. Dynamic	single-parameter:	AKI.	
4. Aggregated	multi-parameter:	potential	laboratory-based	EWSCs.	
	
In	this	thesis,	I	have	explored	each	of	the	above	methods.	I	have	specifically	in	Chapters	3,	4	and	5,	
used	the	methods,	of	2,	3	and	4	above.		
	
In	each	of	these	chapters	and	for	each	use	case	I	have	demonstrated		
1. the	inadequacy	of	that	method	in	discriminating	between	patients	likely	to	die	or	not	
2. the	substantial	improvement	in	discrimination	an	ML	approach	achieves	
I	have	shown	this	by	the	application	of	three	techniques		
1	adding	additional	variables		
2	incorporating	dynamic	change	
3	applying	ML	techniques	
	
The	background	behind	each	of	these	existing	methods	of	interpretation	follows	below.	
1.4.1	Simple	single	parameter:	Reference	intervals	
Most	blood	results	are	reported	with	a	reference	 interval	 (RI).	The	purpose	of	 the	RI	 is	 to	help	the	
clinician	to	 interpret	the	blood	result.	The	display	of	these	RIs	 is	a	 legal	requirement	 in	Europe	(EU	
Directive	98/79/EC)	and	the	rest	of	the	world28,	and	each	laboratory	calculates	and	presents	the	RI	for	
each	blood	test	performed28.	These	RIs	may	vary	slightly	between	laboratories.	RIs	are	usually	derived	
from	a	95%	interval	of	a	reference	distribution	of	values	present	in	that	population28.	The	population	
used	to	calculate	the	reference	range	of	a	test	should	be	representative	of	the	healthy	population	on	
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whom	the	test	will	used.	However,	frequently	the	sample	population	is	not	representative	and	is	based	
on	young	Caucasian	males,	rather	than	the	diverse	ethnicities	and	ages	of	the	population	who	present	
for	 medical	 treatment28.	 Disease	 states	 themselves	 may	 shift	 the	 appropriate	 RIs	 for	 patients	 for	
example	chronic	kidney	disease	patients	having	known	and	stable	creatinine	results	of	between	100	
and	200	micromol/L.	
	
RI’s	 date	 back	 to	 1968.29	 The	 use	 of	 RI’s	 is	 supported	 by	 the	 International	 Federation	 of	 Clinical	
Chemistry,	which	in	1991	recommended	that	each	laboratory	follow	defined	procedures	to	produce	
its	own	reference	values	for	tests	carried	out.28	The	latest,	most	significant	step	in	the	development	
and	harmonisation	of	reference	ranges	is	the	2010	EP28-A3C	guideline.30	
	
Frequently	confused	with	RIs	are	clinical	decision	limits	(CDLs).	According	to	Yesim	Ozarda	in	his	recent	
review	of	RIs28,			
‘CDLs	are	thresholds	above	or	below	which	a	specific	medical	decision	is	recommended.	
CDLs	 are	 based	 on	 the	 diagnostic	 question	 and	 are	 obtained	 from	 specific	 clinical	
studies	 to	 define	 the	 probability	 of	 the	 presence	 of	 a	 certain	 disease	 or	 a	 different	
outcome.	These	limits	lead	to	the	decision	that	individuals	with	values	above	or	below	
the	decision	limit	should	be	treated	differently’.	
Examples	of	CDLs	include	cholesterol,	troponin,	HBA1C,	and	blood	transfusion	thresholds28.	Although	
RIs	and	CDLs	are	distinct,	they	are	commonly	reported	in	the	same	reference	interval/range	field	when	
a	result	is	displayed.	The	consequence	of	this	is	that,	RI’s	maybe	be	inappropriately	regarded	as	a	CDL,	
rather	 than	 just	 a	 statistical	 range,	 especially	 by	 junior	 clinicians.	 This	 may	 cause	 them	 to	
inappropriately	believe	the	patient	is	free	from	disease.		
	
High	or	low	values	for	a	range	of	blood	tests,	such	as	for	sodium,	glucose,	white	cell	count,	urea	and	
Ur:Cr	 ratio,	 have	 been	 shown	 to	 correlate	 with	 poor	 outcomes	 in	 various	 hospital	 populations.31	
Figures	1.6	and	1.7	are	two	examples	of	univariate	analysis	on	individual	blood	results,	which	highlight	
increased	patient	mortality	when	their	blood	test	result	is	outside	its	RI.	Using	individual	blood	results,	
the	odds	ratio	for	mortality	for	results	outside	the	RI	range	from	0.6	to	13.8,	for	lymphocytes	>	3	and	
age	>	65	respectively	(Figure	1.6).	Similarly,	the	AUROC	for	predicting	mortality	for	individual	blood	
results	range	from	0.5788	to	0.8069	for	haematocrit	and	pH	respectively	(Figure	1.7).	As	for	single-
parameter	 vital-sign-based	 EWSCs,	 univariate	 analysis	 on	 individual	 blood	 tests	 provides	 poor	
discrimination	 for	 predicting	 in-hospital	 mortality.	 Thus,	 although	 essential	 for	 diagnosis	 and	
monitoring	or	patient	health,	an	EWSC	based	only	on	individual	blood	tests	results	has	little	utility.		
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Figure	1.6:	Individual	blood	test	results:	Odds	ratio	for	in-hospital	mortality	31	
	
	
	
Figure	1.7:	Individual	blood	test	results:	Area	under	the	receiver	operator	curve	for	in-hospital	
mortality	32		
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1.4.2	Simple	dual-parameter:	Dehydration	(urea	to	creatinine	ratio):		
One	of	the	simplest	ways	two	blood	result	variables	have	been	used	in	conjunction	has	been	the	urea	
to	creatinine	ratio	(Ur:Cr)	as	a	non	specific	surrogate	for	dehydration.33	
	
Dehydration	 is	a	 reduction	 in	 total	body	water.	This	can	occur	due	to	 reduced	 intake,	or	 increased	
losses.	A	reduction	in	the	intravascular	volume	without	a	reduction	in	total	body	water,	which	occurs	
when	intravascular	water	moves	into	the	third	spaces	(interstitial,	peritoneum,	etc.),	is	intravascular	
hypovolaemia.	 Most	 clinical	 measurements	 of	 dehydration	 rely	 on	 sampling	 of	 the	 intravascular	
plasma	and	thus	cannot	normally	differentiate	between	the	two.34	Understanding	the	specific	type	of	
dehydration	 is	 critical	 to	 initiating	 the	 appropriate	 treatment.	 This	 section	 however,	 focusses	 on	
providing	an	overview	of	the	deleterious	effects	on	the	body	of	dehydration	(total	body	water	and	
hypovolaemia),	when	measured	primarily	using	Ur:Cr.	
	
Water	accounts	for	some	60%	of	adult	body	mass	and	is	essential	for	human	life:	it	is	the	environment	
in	which	most	biochemical	reactions	occur,	and	is	necessary	for	the	convective	transport	of	nutrients,	
oxygen	and	metabolic	waste	products.	Dehydration	disturbs	these	functions,	reducing	cardiac	output	
and	 cell	 volume,	 increasing	 plasma	 osmolality	 and	 blood	 viscosity,	 and	 driving	 visceral	 blood	 flow	
redistribution	(including	a	reduction	in	cutaneous	blood	flow).35,36	
	
A	laboratory-based	marker	for	classifying	whether	or	not	a	patient	is	dehydrated	is	the	serum	Ur:Cr.	
Ur:Cr	is	an	historical	means	of	diagnosing	dehydration.33	Urea	is	the	end	product	of	nitrogen-containing	
amino-acid	 metabolism.	 In	 the	 kidneys,	 urea	 is	 freely	 filtered	 by	 the	 glomerulus,	 as	 well	 as	 both	
resorbed	and	secreted	by	renal	tubules.	Creatinine	is	derived	from	the	metabolism	of	muscle	creatine.	
In	the	kidneys,	creatinine	is	freely	filtered	and	secreted	by	the	proximal	renal	tubular.	Ur:Cr	changes	
when	there	is	either	a	disproportionate	fall	in	creatinine	vs	urea,	or	a	disproportionate	rise	of	urea	vs	
creatinine.	 In	 individuals	who	are	 	dehydrated,	urea	concentrations	 in	 the	 renal	medulla	 (and	 thus	
plasma)	rise37	whilst	creatinine	continues	to	be	freely	filtered.	This	results	in	a	rise	in	the	Ur:Cr.	A	Ur:Cr	
>80	 mmol/L:mmol/L	 (BUN:CR	 >20	 mg/l:mg/l))	 has	 been	 traditionally	 considered	 a	 marker	 of	
dehydration	(or	intravascular	volume	depletion).38,39	However,	Ur:Cr	may	rise	for	other	reasons:	urea	
for	 instance,	 also	 rises	 in	 hypercatabolic	 states	 (sepsis,	major	 surgery,	 starvation)40;	with	 the	 large	
‘blood	 protein	 meal’	 of	 an	 upper	 gastrointestinal	 bleed41,42;	 or	 with	 high-dose	 glucocorticoid	
administration.43	 Alternatively,	 in	 the	 context	 of	 a	 low	 skeletal	 muscle	 mass	 (e.g.	 in	 the	 elderly,	
cachectic	or	chronically	malnourished)40,44,45,	where	a	rise	in	Ur:Cr	may	be	due	to	a	fall	in	creatinine.	
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Hospitalised	 patients	 are	 at	 risk	 of	 dehydration,	 due	 to	 impaired	 intake	 (resulting	 from	 cerebral,	
musculoskeletal	or	gastrointestinal	pathology)	or	excessive	 losses	 (e.g.	enteric,	 renal	or	 insensible).	
Even	modest	dehydration	(<2%	loss	of	body	mass)	may	impair	cognitive46	and	physical	performance47,	
mood48	which	can	manifest	as	delirium	in	the	elderly49,	and	impair	thermoregulation.50	It	can	cause	
constipation,	and	is	associated	with	impaired	wound	healing51,	urolithiasis	and	urinary	tract	infection.36	
Dehydration	 also	 leads	 to	 renal	 hypoperfusion,	 and	 plays	 an	 important	 pathogenic	 role	 in	 the	
development	 of	 AKI.5,52	 Specifically,	 a	 raised	Ur:Cr	 is	 associated	with	 an	 increased	 risk	 of	 death	 in	
patients	with	AKI53	and	in	those	on	long-term	dialysis.54,55	In	stroke,	it	is	associated	with	early	clinical	
deterioration56,	 impaired	 functional	 outcome57,58,	 thromboembolism37	 and	 mortality57,58.	 Elevated	
Ur:Cr	 is	 also	 an	 independent	 marker	 of	 mortality	 in	 critical	 care40,59,	 heart	 failure60,	 myocardial	
infarction61	 and	 gastrointestinal	 cancer39,	 and	 also	 indicates	 functional	 impairment62	 and	 poor	
rehabilitation	in	the	elderly.63		
	
Independently,	both	low	creatinine	and	raised	urea	levels	are	also	associated	with	poor	outcomes.	Low	
Cr	marks	a	poor	outcome	in	critical	illness45,	and	raised	Ur	indicates	a	poor	outcome	in	pneumonia64,65,	
acute	pancreatitis66,	coronary	artery	bypass	grafting67,	myocardial	infarction61,	decompensated68	and	
chronic60	heart	failure,	and	critical	illness.40		
	
The	 impact	 of	 dehydration	 on	 healthcare	 costs	 and	 outcomes	 is	 causing	 increasing	 concern	 to	
England’s	 Care	 Quality	 Commission69,	 patient	 associations70	 and	 the	 Parliamentary	 Ombudsman71,	
with	such	concerns	being	echoed	 in	recent	 independent	 inquiries72	and	 in	the	media.73,74,75,76,77	The	
NICE	has	recently	issued	clinical	guidelines	in	an	effort	to	improve	the	prevention	and	management	of	
dehydration	and	AKI.6,78	However,	despite	concerns	over	the	clinical	 impact	of	dehydration	and	the	
awareness	 that	 it	 may	 be	 more	 commonplace	 than	 expected,	 the	 true	 current	 prevalence	 of	
dehydration	 in	hospital	patients	 is	not	 known.	 In	1991,	6.7%	of	731,695	USA	Medicare	admissions	
recorded	dehydration	as	a	cause	for	admission.79	From	1994	to	2000,	admission	rates	for	dehydration	
ranged	from	130	to	134	admissions	per	100,000	population.69	In	England	in	2012–2013,	some	11,417	
(0.075%)	of	all	hospital	admissions	 (n=15.1	million),	and	16,928	(0.095%)	of	all	consultant	episodes	
(n=17.7	million)	 were	 coded	 for	 primary	 dehydration	 (International	 Classification	 of	 Diseases,	 10th	
edition,	code:	E86.X).80	This	rose	to	243,161	(1.7%)	of	all	consultant	episodes,	if	dehydration	was	coded	
either	as	a	primary	or	an	associated	diagnosis.	When	Ur:Cr	is	used	to	define	dehydration,	estimates	of	
the	prevalence	of	dehydration	rise	dramatically:	54%	of	all	elderly	orthopaedic	rehabilitation	patients	
(n=39)	were	dehydrated	at	the	point	of	admission.63	Likewise,	between	a	quarter	and	a	half	of	stroke	
patients	were	dehydrated	on	admission56,81,	and	62%	suffered	this	condition	at	some	point	during	their	
hospital	stay	(n=2591).58	
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Thus,	 two	 routinely	 performed	 blood	 tests,	 whether	 viewed	 independently	 or	 interpreted	 in	
conjunction,	provide	significant	insight	into	the	condition	of	the	majority	of	hospitalised	patients.	The	
results	of	these	tests,	and	in	particular	their	ratio,	are	strongly	associated	with	in-hospital	mortality.	It	
is,	 however,	 yet	 to	 be	 established	 whether	 an	 EWS,	 applicable	 to	 all	 hospitalised	 patients,	 that	
incorporates	the	Ur:Cr	of	a	patient	and	tracks	its	change,	could	be	developed	and	used	to	identify	high-
risk/deteriorating	patients.	This	is	because	all	reported	studies	to	date	have	been	single-site,	and	either	
disease-	or	speciality-specific.	
1.4.3	Dynamic	single-parameter:	AKI	
The	trends	of	blood	results,	i.e.	their	rise	or	fall,	have	always	been	extremely	valuable	to	clinicians.	A	
recent	and	highly	publicised	interpretation	of	a	very	specific	dynamic	change	in	just	one	specific	blood	
result	(creatinine)	is	that	of	AKI.82	
	
AKI	is	an	abrupt	impairment	in	kidney	function	that	results	in	a	rise	in	serum	creatinine	concentration	
or	a	fall	in	urine	output.	AKI	is	a	broad	clinical	syndrome	that	encompasses	a	number	of	aetiologies,	
including	 but	 not	 limited	 to	 kidney	 diseases	 (e.g.	 acute	 interstitial	 nephritis;	 acute	 glomerular	 and	
vasculitic	 renal	 diseases;	 ischaemia,	 toxic	 injury),	 extra-renal	 pathology	 (for	 example,	 pre-renal	
azotaemia,	acute	post-renal	obstructive	nephropathy,	sepsis).	More	than	one	of	these	conditions	may	
coexist	 in	 the	 same	 patient.	 In	 2012,	 to	 harmonise	 the	 detection	 and	 treatment	 of	 AKI,	 a	 rise	 in	
patient’s	serum	creatinine	and	a	fall	in	their	urine	output	measures	were	used	by	the	Kidney	Disease:	
Improving	Global	Outcomes	 (KDIGO)	group,	 to	 standardise	definitions	of	 its	presence	and	 stage	of	
severity	(stages	1–3).83		
	
One	in	every	five	hospitalised	adults	(21%)	suffer	AKI84,	worldwide;	with	a	prevalence	of	14%	reported	
amongst	UK	 hospital	 admissions.79	 AKI	 is	 also	 associated	with	 increased	 risk	 of	 death85,	 prolonged	
hospitalisation86,	requirement	for	renal	replacement	therapy87,	or	the	development	of	chronic	kidney	
disease.88	The	associated	health	care	costs	of	AKI	exceed	£1	billion	per	year	in	the	UK.79	Over	50%	of	
AKI-associated	 morbidity	 and	mortality	 may	 be	 preventable	 with	 early	 detection	 and	 appropriate	
intervention.5	A	more	systematic	approach	that	does	not	rely	on	any	one	individual	checking	or	acting	
on	results,	rather	a	process	that	used	existing	data	to	alert	health	care	staff	that	a	patient	is	at	high	
risk	of	an	poor	outcome	based	on	their	results	is	now	achievable,	given	the	way	we	store	and	report	
blood	test	results.			
	
In	 response,	 initiatives	 throughout	 the	 world	 have	 attempted	 to	 promote	 AKI	 recognition	 and	
encourage	 timely	 interventions	 to	 hasten	 its	 resolution.82	 In	 2015,	 the	 National	 Health	 Service	 of	
England	(NHSE)	mandated	the	implementation	of	a	standardised	AKI	detection	algorithm	(based	on	
	
32	
KDIGO,	 Table	 1.1)	 in	 hospital	 laboratory	 information-management	 systems	 (NHSE-AKI	 algorithm,	
Figure	1.8).	 The	NHSE-AKI	 algorithm	compares	 the	 current	 creatinine	 result	of	 a	patient	with	 their	
previous	results,	to	determine	whether	a	significant	rise	has	occurred.	Specifically,	the	current	result	
is	 compared	 to	 a	 ‘baseline	 creatinine’	 value,	 which	 is	 calculated	 as	 either	 the	 patient’s	 minimum	
creatinine	 result	 in	 the	 previous	 seven	 days,	 or	 the	 median	 of	 all	 their	 creatinine	 results	 in	 the	
preceding	8–365	days,	whichever	is	lower.		
	
Table	1.1:	Kidney	Disease	Improving	Global	Outcomes	(KDIGO):	Staging	of	AKI	
Stage	 Serum	Creatinine	 Urine	output	
1	
1.5–1.9	times	baseline	
or	
>0.3	mg/dl	(>26.5	mol/l)	increase	
<	 0.5ml/kg/hr	 for	 6-
12	hours	
2	 2.0–2.9	times	baseline	
<	 0.5	 ml/kg/hr	 for	 >	
12	hours	
3	
3.0	times	baseline	
or	
Increase	in	serum	creatinine	to	>4.0	mg/dl	(>353.6	mol/l)	
or	
Initiation	of	renal	replacement	therapy	
or	
In	patients	<18	years,	decrease	in	eGFR	to	<35	ml/min	per	1.73	m2	
<	 0.3	 ml/kg/hr	 for	 >	
24	hours	
or	
Anuria	for	>	12	hours	
	
	
The	NHSE-AKI	algorithm	is	intended	to	alert	clinicians	to	potential	AKI	cases	and	their	likely	severity	
stage,	and	thus	identify	those	at	risk	of	subsequent	AEs,	such	as	death	or	renal	replacement	therapy	
(Drrt).89	 Clinical	 assessment	 following	 such	 an	 AKI	 alert	may	 lead	 to	 an	 escalation	 of	 intervention	
according	to	the	AKI	stage	(Figure	1.9).	Thus,	although	not	explicitly	 labelled	as	such,	the	NHSE-AKI	
algorithm	could	be	regarded	as	the	afferent	limb	of	a	‘rapid	response	system’	(RRS),	where	the	efferent	
limb	‘rapid	response	team’	(RRT)	includes	a	nephrologist.		
	
However,	whilst	clinicians	may	consider	more	severe	AKI	stages	to	be	more	dangerous	(and	worthy	of	
prioritisation	of	care),	the	degree	to	which	this	is	correct	is	unclear.	Patient	heterogeneity	or	clinical	
state	(e.g.	the	presence	of	dehydration	or	of	co-morbidities)	might	influence	the	degree	of	risk	within	
any	one	AKI	stage,	or	across	stages.	Likewise,	multiple	trigger	routes	can	lead	to	the	same	AKI	stage	
(Figure	 1.8),	 but	 might	 be	 associated	 with	 different	 outcomes.	 None	 of	 these	 issues	 have	 been	
sufficiently	evaluated	on	a	 large	multisite	dataset,	and	thus	we	have	yet	to	establish	the	benefit	of	
implementing	an	existing	AKI	algorithm,	which	does	not	account	for	all	of	these	factors,	as	the	afferent	
limb	of	a	referral	system.	
	 	
	
33	
Figure	1.8:	The	NHS	England	Acute	Kidney	Injury	Algorithm	(NHSE-AKI	algorithm)	
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Figure	1.9:	Stage-based	management	of	AKI	
	
Shading	of	boxes	indicates	priority	of	action:	solid	shading	indicates	actions	that	are	equally	appropriate	at	all	
stages	whereas	graded	shading	indicates	increasing	priority	as	intensity	increases.	AKI:	acute	kidney	injury;	ICU:	
intensive	care	unit.	
1.4.4	Aggregated	multi-parameter	
The	use	of	multiple	laboratory	based	variables	(parameters)	in	a	formal	score	is	not	commonplace	in-
hospital.	However,	one	field	of	medicine	where	occasionally	an	aggregated	scoring	system	is	used	to	
modify	 the	 care	 a	 patient	 receives,	 is	 that	 of	 perioperative	 medicine.	 For	 example,	 for	 patients	
undergoing	major	 surgery,	 some	doctors	calculate	a	 score	 that	helps	 them	determine	whether	 the	
patient	should	be	transferred	to	intensive	care	post-operatively,	and	arrangements	are	made	prior	to	
the	commencement	of	surgery.	A	recent	review	article	by	Moonesinghe	et	al.90	summarises	the	most	
common	of	these	surgical	scoring	systems.	The	models	in	this	review	use	a	mixture	of	data,	comprising	
demographic,	 co-morbidities,	 lifestyle	 questions,	 surgical	 questions,	 vital-sign	 and	 laboratory	
information,	 in	 both	 the	 pre-operative	 and	 post-operative	 periods.	 In	 this	 review,	 P-POSSUM	
(Portsmouth	Physiology	and	Operative	Severity	Score	for	enUmeration	of	Mortality)	and	the	Surgical	
Risk	Scale	were	highlighted	as	being	the	most	validated	and	accurate.	
	
Outside	of	perioperative	medicine,	the	use	of	multi-parameter	laboratory-based	models	for	assessing	
the	risk	of	mortality	in	all	hospital	patients	has	not	been	implemented	individually	or	at	scale.	However,	
as	 individual	 blood	 test	 results	 are	 known	 to	 correlate	 with	 in-hospital	 mortality	 (Section	 1.4.1),	
researchers	have	explored	combining	these	with	basic	demographic	data	(i.e.	age,	sex),	to	predict	risk	
of	death.	Researchers	have	developed	a	number	of	such	models	(Table	1.2).		
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Table	1.2:	Existing	aggregated	multi-parameter	EWSC	
Model	
Patient	
Group	
No.	
of	
Sites	
No.	 of	
Patients	
Predictor	
Variables	
Modelling	
Technique	
AUROC	
Biochemistry	and	
Haematology	Outcome	
Model	(BHOM),	2005	
91		
All	medical	
admissions	 1	
9,497	
	
Train:	2,257	
Test:	7,240	
Sodium	
Potassium	
Urea	
Creatinine	
Ur:Cr	
Albumin	
Haemoglobin	
White	cell	count	
Sex	
Method	 of	
admission	
Logistic	
regression	
76.7	%	
Hucker,	2005	92		
Accident	and	
emergency	
admissions	
	
1	
1,424	
	
Train:	681	
Test:	743	
Albumin	
Phosphate	
Heart	rate	
Age	
Logistic	
regression	
82	%	
Medical	Admissions	
Risk	System	(MARS),	
2010	93		
Emergency	
medical	
admissions	
2	
16,779	
	
Train:	
13,182	
Test:	3,597	
Potassium	
Urea	
Haematocrit	
White	cell	count	
Heart	rate	
Mean	 arterial	
pressure	
Respiratory	rate	
Temperature	
Age	
Logistic	
regression	
90	%	
Asadollahi	‘detailed	
model’,	2011	31		
All	
admissions	 1	
6,478	
	
Train	1,650	
Test	4,828	
	
Sodium	
Potassium	
Urea	
Creatinine	
Chloride		
Glucose		
Bicarbonate	
Haemoglobin	
Platelets		
White	cell	count	
Neutrophils		
Lymphocytes		
Age	
Logistic	
regression	
	
86.1	%	
Asadollahi	‘simple	
model’	variable,	2011	
31		
Sodium	
Urea	
Glucose	
Haemoglobin	
Platelets	
White	cell	count	
Age	
84.8	%	
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	Loekito,	2012	94		
All	
admissions	
with	a	LoS	
>24	hours	
2	
55,818	
	
Train	42,701	
Test		13,317	
Urea	
Creatinine	
Albumin	
Bilirubin	
Bicarbonate	
Haemoglobin	
Haematocrit	
White	cell	count	
pH	
Logistic	
regression	
88	%	
Mohammed	Reference	
Intervals,	2012	95		 All	
emergency	
admissions	
2	
87,014	
	
Train:	
10,050	Test	
76,964	
Sodium	
Potassium	
Urea	
Creatinine	
Albumin	
Haemoglobin	
White	cell	count	
Decision	
trees	
	
	
86.6	%	
Mohammed	Raw	
Values,	2012	95		
88.2	%	
Laboratory	Decision	
Tree	Early	Warning	
Score,	2013	96		
Emergency	
medical	
admissions	
1	
86,472	
	
Train:	3,496	
Test:	82,976	
Sodium	
Potassium	
Urea	
Creatinine	
Albumin	
Haemoglobin	
White	cell	count	
Sex	
Decision	
trees	
75.5	%	-	
80.1	%	
Train:	size	of	the	training	data	set;	Test:	size	of	the	testing	data	set;	Colour	Blue:	vital	sign	parameters	
	
The	 AUROC	 for	 these	multi-parameter	models	 range	 from	 76.7%91	 to	 90%93.	 However,	when	 only	
laboratory	and	demographic	variables	are	used	as	predictor	variables	(i.e.	vital	signs	are	excluded),	the	
maximum	AUROC	achieved	 falls	 to	88.2%.	Despite	 some	of	 these	models	having	a	 reasonably	high	
AUROC,	the	positive	predictive	value	(when	calculated)	of	identifying	a	patient	likely	to	die	is	quite	low.	
The	Loekito	model	(AUROC	88%)94	only	attained	a	maximum	positive	predictive	value	(PPV)	of	19%	
(1:5.3)	on	a	sensitivity	of	14.9%	(i.e.	only	14.9%	of	patients	who	died	were	identified).	Using	a	different	
threshold	with	a	sensitivity	of	40%,	the	model’s	PPV	dropped	to	only	10%	(1:10).	
	
Overall,	 a	 range	 of	 multi-parameter	 models	 have	 been	 built,	 some	 of	 which	 have	 reasonable	
discrimination	 (AUROC	>	 80%).	However,	 there	 are	 a	 range	of	 issues	 concerning	 these	 laboratory-
based	EWSCs,	as	follows.	
§ Most	of	the	models	were	derived	from	single-hospital	datasets	and	were	used	in	sub-groups	of	
patients	(for	example,	emergency	medical	admissions	or	medical	patients	only),	and	thus	may	not	
be	applicable	to	the	entire	patient	population.		
§ No	model	takes	into	account	the	trends	of	any	blood	results;	i.e.	whether	they	have	risen,	fallen	
or	stayed	the	same	since	they	were	last	tested.	
§ No	model	analyses	the	time	when	the	blood	test	was	performed	(e.g.	2	p.m.	or	2	a.m.),	or	the	time	
between	blood	tests	(1	hour	or	24	hours).		
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§ None	of	these	models	include	additional	a	priori	known	administrative	data	about	the	patient	co-
morbidities,	 or	 day	 and	month	 of	 admission.	 All	 of	 these	 factors	may	 have	 an	 influence	 on	 a	
patient’s	health	status.	
§ The	 majority	 of	 algorithms	 built	 for	 surgical	 perioperative	 outcomes,	 and	 the	 various	 EWSCs,	
whether	they	are	vital-sign-based	or	laboratory-based,	use	variants	of	logistic	regression	to	create	
their	respective	models.	The	key	problem	with	this	approach	is	that	the	models	assume	that	the	
dependent	 variables	 (the	 variables	 used	 to	 predict	 the	 outcome,	 such	 as	 heart	 rate,	 etc.)	 are	
completely	 independent	 from	each	other.	However,	 this	 is	 not	 the	 case;	 for	 example,	 age	and	
creatinine	could	be	 inversely	correlated,	as	 increasing	age	 is	associated	with	decreasing	muscle	
mass97,	and	thus	with	falls	in	creatinine.98	Similarly,	many	variables	rise	or	fall	together	in	certain	
pathological	 processes,	 such	 as	 dehydration	 (urea,	 creatinine	 and	possibly	 sodium)	 and	 severe	
malnutrition	 (falls	 in	 both	 haemoglobin	 and	 albumin,	 and	 rises	 or	 falls	 in	 mean	 cell	 volume,	
depending	 on	 the	 specific	 nutrients	 that	 are	 lacking).	 Although	 outcome	 prediction	 may	 be	
maintained	despite	multicollinearity	in	logistic	models,	the	actual	variable	coefficients	would	be	
meaningless	as	markers	for	variable	influence.	
§ If	the	outcome	of	a	model	is	used	to	determine	to	determine	escalation	of	care,	such	as	activation	
of	a	RRT,	the	number	of	patients	referred	for	every	patient	likely	to	die	is	low	(i.e.	low	PPVs).	
§ There	are	newer,	more	appropriate	analytical	techniques	to	create	models	from	data:	specifically,	
advanced	machine	learning	methods.	
	
Thus,	there	is	at	present	no	laboratory-based	model	that	has	a	sufficiently	high	PPV	(along	with	high	
sensitivity	and	specificity)	to	be	used	as	the	afferent	 limb	for	a	rapid	response	system.	Advances	 in	
machine	learning	offer	an	opportunity	to	create	an	EWSC	using	existing	laboratory	and	administrative	
data.		
1.5	Machine	Learning	and	application	to	health	care	
Machine	learning	(ML)	is	a	method	of	automating	model	building	using	iterative	algorithms	which	learn	
from	the	data.	This	method	allows	a	machine	to	find	insights	without	being	explicitly	programmed	to	
look.		The	first	reference	to	ML	was	in	1959,	Arthur	Samuel	stated	‘programming	computers	to	learn	
from	experience	should	eventually	eliminate	the	need	for	much	of	this	detailed	programming	effort.’,	
this	concept	eventually	became	known	as	ML.99	Tom	Mitchell	in	his	book	Machine	Learning	stated	that	
‘The	field	of	machine	learning	seeks	to	answer	the	question:	How	can	we	build	computer	systems	that	
automatically	improve	with	experience,	and	what	are	the	fundamental	laws	that	govern	all	learning	
processes?’.100	 ML	 lies	 at	 the	 intersection	 of	 computer	 science,	 engineering,	 mathematics	 and	
statistics.		
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In	 the	 context	 of	 my	 research,	 ML	 can	 be	 described	 as	 a	 group	 of	 techniques	 which	 enable	 the	
automatic	creation	of	models	from	data;	models	which	can	then	be	applied	to	new	unseen	data	to	
predict	characteristics/outcomes.	
	
ML	is	widely	applied	in	the	modern	connected	world.	Examples	include:	
§ Cameras	which	automatically	highlight	and	focus	on	a	person’s	face	in	a	photo	or	video	
§ Recommendations	of	which	movie	to	watch	next	on	Netflix	
§ Recommendations	of	which	product	to	buy	on	Amazon	
§ Automatic	credit	card	fraud	detection	
§ Self-driving	cars	
§ Computer	voice	assistants:	SIRI	(Apple)	and	Alexa	(Amazon)	
§ Algorithmic	equity	(stocks/shares)	trading	by	computers	
§ Automatic	spellchecking	and	correction	software	
§ Handwriting	recognition,	optical	character	recognition	systems	
§ Automatic	language	translation,	both	voice	(now	available	on	Skype)	and	text	
	
Even	 in	medicine,	ML	 is	 in	 some	niche	 cases	 being	 applied,	 such	 as	 to	 diagnose	 arrhythmias	 from	
electrocardiographs	(ECGs)	and	highlight	fractures	in	radiographs	(x-rays).	101	
	
Broadly,	ML	tasks	can	be	divided	into	three	categories,	as	follows	(though	in	reality	there	are	overlaps	
in	the	computational	theory,	and	multiple	methodologies	may	be	applied	to	solve	a	particular	task).	
§ Supervised	learning:	The	computer	system	is	provided	with	data	that	is	labelled	for	a	particular	
outcome;	 for	 example,	 blood	 results	 and	 mortality	 outcomes.	 Supervised	 learning	 tasks	 are	
categorised	in	‘classification’	and	‘regression’	problems.	In	a	classification	problem,	the	goal	is	to	
predict	results	with	a	discrete	output,	such	as	whether	it	will	rain	tomorrow.	In	a	regression	task,	
the	goal	is	to	predict	an	actual	value,	such	as	how	many	centimetres	of	rain	will	fall	tomorrow.	
§ Unsupervised	 learning:	 A	 computer	 system	 is	 provided	with	 data,	 but	 neither	 a	 structure	 nor	
labels	 are	 defined.	 For	 example,	 blood	 results	 alone	 are	 provided.	 The	 task	 of	 unsupervised	
learning	is	to	describe	the	hidden	structure	of	the	data.		
§ Reinforcement	learning:	This	refers	to	learning	behaviour;	how	to	map	situations	to	actions,	so	as	
to	maximize	a	numerical	reward	signal.	The	learner	is	not	told	which	actions	to	take,	as	in	most	
forms	of	ML,	but	instead	must	discover	which	actions	yield	the	most	reward	by	trying	them.	In	the	
most	interesting	and	challenging	cases,	actions	may	affect	not	only	the	immediate	reward,	but	also	
the	next	situation	and,	through	that,	all	subsequent	rewards.	These	two	characteristics,	trial-and-
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error	 search	 and	 delayed	 reward,	 are	 the	 two	 most	 important	 distinguishing	 features	 of	
reinforcement	learning.	
	
The	task	of	building	an	EWSC	based	on	blood	results	and	administrative	data	falls	into	the	category	of	
supervised	learning.	It	is	in	addition	a	categorisation	problem,	as	the	prediction	goal	is	whether	or	not	
a	patient	is	likely	to	die	in	hospital.		
	
The	two	most	popular	and	accurate	algorithms	for	the	supervised	learning	of	multivariate	structured	
data	are	the	random	forest	(RF)	and	gradient	boosting	(GB).	Both	RF	and	GB	are	ensemble	techniques	
that	combine	multiple	learning	methods	to	achieve	better	predictive	performance.	
1.5.1	Random	Forest	
RF	 is	 an	 ensemble	 technique	 that,	 at	 its	 simplest,	 combines	 random	decision	 trees	with	bootstrap	
aggregating	(bagging).	In	this	method	multiple	decision	trees	are	built,	each	tree	in	this	ensemble	only	
uses	a	randomly	drawn	subset	of	the	training	data.	This	forest	of	trees	then	votes	on	the	classification	
outcome.	RF	is	a	low-bias,	high-variance	method	that	reduces	bias	by	increasing	the	number	of	trees,	
and	 averaging	 (for	 regression),	 or	 using	 the	mode	 for	 classification,	 the	 predictive	 output	 of	 each	
individual	tree.	RFs	were	first	described	by	Ho	in	1995.102	He	established	that	if	multiple	decision	trees	
were	built,	but	each	tree	used	only	a	random	selection	of	the	total	number	of	variables,	then	the	depth	
of	each	tree	could	increase,	and	thus	increase	prediction	accuracy,	without	suffering	from	overtraining.	
RFs	as	they	are	implemented	today	are	based	on	work	by	Leo	Breiman103,	who	described	a	method	of	
building	 decision	 trees	 that	 combined	 randomised	 optimisation	 at	 each	 node	 with	 bootstrap	
aggregating	(bagging).	
1.5.2	Gradient	Boosting		
Gradient	boosting	 is	an	ensemble	technique	that	combines	weak	prediction	models	 (high	bias,	 low	
variance),	typically	decision	trees.	A	model	is	built	in	a	step	wise	fashion,	weak	classification	algorithms	
are	sequentially	applied	to	a	dataset,	all	misclassified	data	is	used	for	the	next	iteration.	Thus	producing	
a	series,	in	this	case,	of	decision	trees.	The	model	is	generalised	by	optimisation	of	a	differentiable	loss	
function	(gradient).104		The	concept	of	gradient	boosting	was	introduced	in	the	form	recognised	today	
by	Friedman	in	2001.	Gradient	boosting	is	currently	the	best	performing	algorithm	for	classification	
tasks	on	structured	data.		
1.5.3	Software	toolkits	
There	are	a	number	of	software	toolkits	that	have	optimised	the	implementation	of	GBs	and	RFs,	as	
well	as	many	other	ML	algorithms.	The	key	optimisations	are	that	the	software	can	run	on	different	
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operating	systems,	or	be	controlled	using	different	programming	languages;	but	most	important	of	all,	
that	the	implementation	of	the	ML	algorithm	can	be	distributed	across	multiple	cores	and	processors	
(multiple	cores	make	up	a	processor),	parallelising	the	computation	and	thus	reducing	the	time	it	takes	
to	 complete.	One	popular	 software	 toolkit	 is	 ‘H2O’.105	 It	 is	 implemented	 in	 the	 JAVA	programming	
language,	and	has	a	version	that	works	on	the	two	most	common	technologies	in	the	‘big	data’	space-	
‘Hadoop’	and	‘Spark’,	thus	making	it	‘futureproof’	for	at	least	the	near	future.	H2O	has	implemented	
a	 wide	 range	 of	 algorithms,	 is	 open-source,	 and	 is	 freely	 available	 to	 use.	 It	 has	 excellent	
documentation,	and	the	company	that	develops	and	maintains	it	is	quick	to	respond	to	any	queries.105	
1.5.4	Key	concepts	
The	process	of	building	and	deploying	ML	models	broadly	involves	four	steps:		
1. Data	collection:	Identifying	and	collecting	the	data	to	be	used	for	model	creation.	
2. Data	pre-processing:	The	process	of	ensuring	that	the	collected	data	 is	clean	and	consistent.	 It	
includes	 tasks	 such	 as	 integrating	 multiple	 data,	 handling	 missing	 or	 inconsistent	 data,	 and	
converting	data	types	to	a	canonical	(standard)	format.	
3. Model	creation:	The	process	of	using	appropriate	software	to	generate	models	from	the	data.	This	
usually	involves		
I. feature	engineering	and	selection	
II. splitting	 the	dataset	 into	 training	and	 testing	datasets	 (an	additional	 validation	dataset	
could	also	be	created,	but	a	better	method	of	validation	is	n-1	cross-validation)		
III. building	the	model	using	the	training	dataset	(the	optimal	model	is	selected	by	tuning	the	
hyper-parameters	of	the	model	and	measuring	the	prediction	errors	using	either	cross-
validation	or	on	the	validation	dataset)		
IV. testing	the	model’s	performance	on	the	test	dataset	
4. Model	deployment:	A	final	model	can	be	operationalised	on	an	appropriate	computer	system,	
enabling	live	or	batch	predictions.	
	
Some	important	additional	ML	concepts	are:	
§ Feature	Engineering	is	the	process	of	extracting	or	selecting	features	(variables)	from	a	dataset	in	
order	 to	 enhance	 the	 dataset	 and	 improve	 the	 creation	 of	 accurate	 predictive	 models.	 For	
example,	patient	admission	data	could	be	enhanced	by	creating	a	feature	(variable)	that	is	the	day	
of	 admission	 (Mon–Sun),	 and	blood	 result	data	 could	be	enhanced	by	 calculating	 the	absolute	
difference	between	consecutive	blood	results.	
§ Generalisation	usually	refers	to	a	ML	model’s	ability	to	perform	well	on	new	unseen	data.	 It	 is	
related	to	the	concept	of	overfitting.		
	
41	
§ Hyper-Parameter	Tuning	–	Grid	search:	ML	algorithms	have	a	variety	of	inputs	(hyper-parameters)	
in	addition	to	the	training	data.	These	inputs	provide	instructions	for	how	the	algorithm	should	
model	 the	data.	These	parameters	determine	 ‘higher	 level’	properties	of	 the	model	such	as	 its	
complexity	and	how	fast	it	should	‘learn’.	Grid	search	is	the	traditional	method	of	hyper-parameter	
optimisation;	 sometimes	 referred	 to	 as	 parameter	 sweep,	 it	 simply	 refers	 to	 building	multiple	
models	 from	 the	 same	dataset	 by	 iterating	 through	multiple	 different	 hyper-parameters	 of	 an	
algorithm.	The	model	which	has	the	highest	performance	based	on	a	specific	performance	metric	
(logloss	or	AUROC),	either	via	cross-validation	or	on	a	validation	dataset	(not	on	the	test	dataset),	
is	the	selected	machine-learning	model;	the	performance	of	this	model	can	then	be	tested	on	the	
test	dataset.	
§ N-fold	Cross-Validation:	To	enable	optimisation	of	a	model	and	enhance	its	predictive	accuracy,	it	
needs	to	be	iteratively	tested	on	an	independent	dataset,	modified	and	then	re-tested.	However,	
because	the	independent	test	dataset	is	used	for	final	performance	testing,	an	additional	dataset	
distinct	 from	 the	 train	dataset	 is	 required.	Rather	 than	 just	 splitting	 the	 train	dataset	 into	 two	
parts,	n-fold	cross-validation	offers	an	alternative.	For	n-fold	cross-validation	where	n	=	5,	the	train	
dataset	is	split	into	five	parts,	four	of	which	are	used	to	train	the	model,	while	the	fifth	part	is	used	
to	 test	 it.	 This	 process	 is	 repeated	 a	minimum	 of	 five	 times,	 with	 the	model	 iteratively	 being	
improved,	especially	for	generalisation.	The	mean	performance	metrics	(AUROC,	logloss)	of	all	the	
models	 provide	 an	 indication	 of	 the	 final	model’s	 theoretical	 performance	 on	 an	 independent	
dataset.	
§ Overfitting	 occurs	 when	 an	 algorithm	 models	 random	 error	 or	 noise,	 rather	 than	 an	 actual	
relationship	within	the	data;	thus,	when	the	resultant	model	is	applied	to	an	independent	dataset,	
it	performs	poorly.	
§ Tree	depth,	and	leaf:	the	depth	of	a	tree	(in	a	ML	algorithm)	is	the	number	of	edges	from	the	node	
to	the	tree’s	root	node.	A	tree	can	have	multiple	depths	depending	on	the	distribution	of	leaves.	
Maximum,	minimum,	and	mean	are	the	usual	ways	of	communicating	tree	depth	e.g.	minimum	
tree	depth	would	be	the	shortest	number	of	edges	from	a	leaf	node	to	the	root	node.	A	leaf	is	a	
vertex	of	degree	one	in	a	tree	(decision,	boosted,	etc.).	
§ Train	and	Test	Datasets:	The	pre-processed	dataset	is	split,	ideally	using	randomisation,	into	two	
prior	to	model	training.	Ensuring	that	both	the	train	and	test	datasets	have	similar	outcomes	and	
underlying	characteristics.	There	 is	no	universally	agreed	percentage	split,	but	a	70:30	 split	 for	
train:test	is	common.	
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1.6	Aims	and	Objectives	
1.6.1	Aim	
To	develop	a	system	for	predicting	AEs	in	all	hospitalised	patients,	using	ML	of	routinely	collected	blood	
test	results	and	existing	electronically	held	patient	data	relating	to	co-morbidities	and	demographics.	
1.6.2	Objectives	
1. To	identify	the	appropriate	universally	accessible	datasets	and	their	specific	variables	to	build	and	
implement	ML-EWS.	
2. To	map	both	the	ethical	and	legal	landscape	required	to	undertake	a	multi-site	‘big	data’	study.	
3. To	create	a	large	dataset	of	~1	million	patients,	and	their	blood	results	and	administrative	data,	
from	multiple	acute	hospitals	in	different	geographic	locations	in	the	UK.	
4. To	develop	expertise	 in	programming,	 to	undertake	 large-scale	data	capture	and	manipulation,	
and	to	implement	ML	models.	
5. To	investigate	mortality	associated	with	known	models	of	disease.	Specifically:	
a. For	Dehydration,			
i. To	understand	the	effect	of	dehydration	(Ur:Cr)	on	outcome	
ii. To	understand	changes	in	dehydration	(Ur:Cr),	combined	with	AKI,	on	outcome	
iii. To	 create	 a	 model	 that	 incorporates	 urea	 and	 creatinine	 results	 with	 simple	
demographic	data	to	identify	those	at	risk	of	poor	outcome	
b. For	AKI,	
i. the	epidemiology	of	patients	admitted	to	hospital	who	are	diagnosed	with	AKI		
ii. the	 relationship	 between	 the	 NHSE-AKI	 algorithm	 defined	 AKI	 stage	 and	 in-hospital	
outcome	(Death	or	Renal	Replacement	Therapy	(Drrt)),	and	whether	this	relationship	
differs	according	to	method	of	admission	and	existing	co-morbidities	
iii. whether	the	Drrt	risk	differs	depending	on	the	route	by	which	the	AKI	stage	is	defined	
iv. whether	the	NHSE-AKI	algorithm	fails	to	identify	patients	who	continue	to	have	AKI	
v. whether	a	ML	approach	can	better	stratify	risk	than	the	current	NHSE-AKI	algorithm.	
6. To	build	ML	models	that	can	be	used	on	all	patients	 in	hospital	 in	order	to	identify	their	risk	of	
dying	in	hospital,	both	on	admission	and	subsequently.	
7. To	build	a	proof-of-concept	computer	system	that	is	agnostic	to	the	internal	IT	infrastructure	of	a	
hospital,	but	which	can	deploy	advanced	ML	models	by	ingesting	hospital	data	and	relaying	results	
to	the	hospital/clinician	in	real	time.	
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Chapter	2:	The	Data,	Ethical	and	Legal	Frame	
To	undertake	an	investigation	using	electronically	stored	data,	the	ideal	source	for	these	data	must	be	
identified	and	understood.	These	sources	of	data	must	be	both	accessible	for	this	 investigation	but	
also	amenable	to	real	time	access,	so	they	may	be	used	for	the	real	time	implementation	of	the	models	
developed.	 Issues	 with	 data	 access	 and	 use	 must	 be	 explored,	 specifically	 the	 legal	 and	 ethical	
framework	as	well	as	the	technical	issues	of	acquisition	and	transformation.	Investigation	into	these	
issues,	have	highlighted	their	complexity	and	frequently	conflicting	framework.	
	
In	this	chapter,	I	will	describe	in	detail		
1. the	data,		
2. the	ethical	and	legal	framework,	and		
3. data	acquisition	and	transformation,		
providing	their	context,	and	highlighting	the	challenges	I	faced	and	how	I	overcame	them.	
2.1	The	Data	
The	 data	 I	 required	 for	 my	 study	 included	 administrative	 information:	 patient	 demographics,	
admission	 and	 discharge	 dates,	 methods	 of	 admission,	 as	 well	 as	 information	 relating	 to	 patient	
diagnoses	 and	 treatments	 in-hospital.	 There	 are	 many	 electronic	 sources	 in	 a	 hospital	 that	 store	
patient	information,	ranging	from	the	electronic	health	record	(EHR),	patient	administration	system	
(PAS),	 theatre	 booking	 system,	 dedicated	 diagnostic	 coding	 software,	 etc.,	 all	 of	 which	 vary	
significantly	between	hospitals.	As	my	investigation	was	requesting	data	from	multiple	NHS	Trusts,	a	
common	dataset	and	a	standard	extraction	method	of	requesting	the	data	needed	to	be	found.	Rather	
than	creating	my	custom	requirements,	I	chose	to	align	my	data	request	to	match	one	of	the	national	
mandatory	data	submissions	that	all	hospitals	are	required	to	perform-	the	Commissioning	Dataset	for	
Admitted	Patient	Care	(CDS.APC).		
	
In	addition,	I	needed	access	to	blood	test	results,	unfortunately	there	is	no	common	standard	for	their	
use,	and	custom	extractions	needed	to	be	performed	at	each	NHS	Trust	in	my	study.	As	opposed	to	
the	CDS.APC	data,	blood	results	are	used	almost	exclusively	for	clinical	purposes.	
	
Thus,	the	two	existing	data	sources	I	used	to	capture	patient	trajectory,	and	thus	develop	models	to	
predict	patient	trajectory,	were:	
1. The	Commissioning	Dataset	for	Admitted	Patient	Care	(CDS.APC)	
2. Blood	results	
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These	datasets	have	in	common	that	they	are	both	created,	stored,	transmitted	and	interrogated	or	
viewed	 via	 electronic	 means,	 and	 that	 the	 entirety	 of	 the	 data	 is	 stored	 in	 multiple	 databases.	
Theoretically,	this	enables	easy	access	to	the	entirety	of	the	data.	The	specific	characteristics	of	each	
dataset	are	described	below.	
2.1.1	CDS.APC	(Commissioning	Data	Set	for	Admitted	Patient	Care)	
The	CDS.APC	dataset	is	a	national	UK	dataset;	such	datasets	‘define	a	standard	set	of	information	that	
is	generated	from	care	records,	from	any	organisation	or	system	that	captures	the	base	data.	They	are	
structured	lists	of	individual	data	items,	each	with	a	clear	label,	definition	and	set	of	permissible	values,	
codes	and	classifications’.106	
	
Commissioning	Data	Sets	(CDS)	are	patient-level	datasets	intended	to	deliver	robust,	comprehensive,	
nationally	 consistent	 and	 comparable	 person-based	 information	 on	 activity,	 in	 order	 to	 support	 a	
variety	of	secondary	use	purposes	(i.e.	not	for	the	direct	care	of	the	patient).	The	CDS	are	the	primary	
mechanism	for	the	reporting	of	secondary	care	(in-hospital)	activity	that	is	either	NHS	funded	and/or	
provided	by	NHS	organisations.	They	support	a	number	of	high-profile	national	NHS	 requirements,	
including	 the	 current	HealthCare	 Resource	Group	 (HRG)	 version	 for	 the	 calculation	 of	 payment	 to	
trusts,	and	monitoring	or	other	initiatives	such	as	Referral	to	Treatment	(RTT),	as	well	as	the	national	
reporting	of	activity	through	Hospital	Episode	Statistics	(HES).	The	dataset	I	have	focussed	on	is	the	
‘Admitted	Patient	Care	–	Finished	General	Episode	CDS’	 (CDS.APC).	This	covers	all	NHS	and	private	
Admitted	Patient	Care	 (day	 case	and	 inpatient)	activity	 taking	place	 in	any	of	 the	 following:	acute,	
community	 or	 mental	 health	 NHS	 trusts,	 other	 NHS	 hospitals,	 non-NHS	 hospitals,	 and	 non-NHS	
hospitals	or	institutions	where	the	care	delivered	is	NHS-funded.	The	complete	list	of	CDS	datasets	is	
provided	 in	Appendix	1106,	highlighting	 the	complexity	of	 the	various	datasets	available	 in	 terms	of	
number	as	well	as	similarity.	
	
The	CDS.APC	dataset	is	created	by	multiple	teams	within	an	organisation.	The	nature	and	composition	
of	 these	 teams	varies	by	organisation,	and	 I	did	not	 find	a	standard	organisational	 framework	 that	
dictates	who	collects,	validates,	transforms	and	submits	the	data	to	Health	and	Social	Care	Information	
Centre	(HSCIC,	recently	restructured	into	a	new	organisation	NHS	Digital).	Frequently,	different	tasks	
are	 undertaken	 by	 different	 departments	 within	 the	 organisation,	 with	 some	 tasks	 also	 being	
outsourced	to	commercial	entities.	This	results	 in	multiple	different	workflows	within	and	between	
different	organisations,	 for	what	 is	a	mandatory	and	standardised	national	data	submission.	 In	one	
organisation,	a	common	example	would	be	as	follows:	post	discharge	of	a	patient	from	hospital,	the	
patient’s	 notes	 would	 be	 transferred	 to	 the	 clinical	 coding	 team,	 who	 would	 examine	 these	 to	
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determine	 not	 only	what	 diseases	 the	 patient	 suffers	 from	 chronically,	 but	 also	 any	 specific	 acute	
conditions	 that	were	 treated	 in	 their	most	 recent	hospitalisation.	This	 information	would	 form	 the	
basis	of	the	patient’s	ICD10	(International	Classification	of	Diseases	Version	10),	Treatment	Function	
and	Main	 Specialty	 codes.	 However,	 in	 another	 organisation,	 the	 admitting	 or	 discharging	 doctor	
would	be	responsible	for	listing	all	the	relevant	patient’s	diseases,	enabling	the	coding	team	to	easily	
assign	 ICD	 codes	 based	 on	 a	 clinical	 summary.	 OPCS-4	 (OPCS	 Classification	 of	 Interventions	 and	
Procedures,	version	4)	codes	are	similarly	transcribed	by	different	teams,	from	a	variety	of	sources,	
which	include	operating	theatre	lists,	radiology	intervention	lists,	day	case	procedure	lists,	and	again,	
from	the	examination	of	raw	text	from	the	patient’s	notes.	The	potential	for	mislabelling	and	omitting	
relevant	ICD10	and	OPCS-4	codes	is	significant;	and	indeed,	analysis	of	Hospital	Episode	Statistics	for	
CDS.APC	data	has	highlighted	such	errors107	:	e.g.	every	year,	a	number	of	male	patients	have	been	
coded	to	have	had	a	hysterectomy	(removal	of	the	uterus).	
	
The	 data	 for	 each	 patient	 episode	 (row)	 in	 this	 dataset	 is	 usually	 compiled	 after	 the	 patient	 has	
completed	their	‘episode’	of	care	in	their	Secondary	Care	Organisation.	In	the	context	of	this	research	
project,	 this	will	 always	be	an	NHS	Trust.	 It	 is	 important	 to	note	 that	 a	patient	may	have	multiple	
‘episodes’	of	care	during	one	hospital	admission.	The	combination	of	all	applicable	patient	‘episodes’	
makes	up	a	patient’s	‘spell’,	which	is	equivalent	to	a	single	hospital	admission.	Episodes	are	meant	to	
represent	contained	healthcare	activity	under	a	single	named	consultant,	and	when	a	patient’s	care	is	
transferred	 to	 another	 consultant,	 a	 new	 episode	 begins.	 The	 data	 elements	 that	 comprise	 the	
CDS.APC	dataset	are	extremely	comprehensive,	though	not	all	the	fields	present	are	necessarily	filled.	
The	 full	 list	 of	 all	 CDS.APC	 variables	 is	 available	 online	 at:	
‘http://www.datadictionary.nhs.uk/data_dictionary/messages/cds_v6-2/data_sets/cds_v6-
2_type_130_-_admitted_patient_care_-_finished_general_episode_cds_fr.asp?shownav=1’.	
The	key	variables	 I	required	from	organisations,	and	their	attributes,	are	described	 in	the	following	
tables.	 These	 are	 a	 description	 of	 the	 raw	 data,	 and	 where	 mentioned,	 the	 equivalent	
anonymised/grouped	data	that	was	provided	by	the	collaborating	NHS	Trusts	for	this	project.	
§ Organisation	 details:	 The	 organisation	 code	 of	 the	 secondary	 care	 provider:	 a	 series	 of	 3–4	
alphanumeric	characters	denoting	the	organisation	code.	
§ Patient	characteristics	(Table	2.1)	
§ Hospital	provider	spell	characteristics	(Table	2.2)	
§ Treatment	function	code	is	recorded	to	report	the	specialised	service	within	which	the	patient	is	
treated.	It	is	based	on	‘Main	Specialty’,	but	also	includes	approved	sub-specialities	and	treatment	
specialties	used	by	lead	‘Care	Professionals’.106	
§ ICD10	 codes:	 These	 are	 listed	 as	 comprising	 one	 primary	 diagnosis,	 and	 up	 to	 fifty	 secondary	
diagnoses.	 The	 order	 of	 the	 diagnoses	 is	 not	 usually	 based	 on	 the	 guidance	 by	 healthcare	
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professionals	 (based	 on	 discussion	 with	 the	 clinical	 coders),	 but	 is	 usually	 ordered	 so	 as	 to	
maximise	 the	Health	 Care	 Resource	Group	Code,	 and	 thus	 generate	maximum	 income	 for	 the	
Trust.	The	International	Statistical	Classification	of	Diseases	and	Related	Health	Problems	(ICD)	is	
a	 comprehensive	classification	of	 causes	of	morbidity	and	mortality.	All	 inpatient	episodes	and	
attendances	that	contain	diagnoses	must	be	recorded	to	the	mandated	version	of	 ICD.	 ‘ICD-10’	
refers	to	the	tenth	revision.	The	World	Health	Organisation	(WHO)	publishes	and	distributes	the	
ICD-10	classification.	WHO	is	the	copyright	holder	of	ICD-10,	which	is	used	under	licence	for	United	
Kingdom	 government	 purposes.	 The	 full	 list	 of	 ICD-10	 codes	 is	 available	 at:	
‘http://apps.who.int/classifications/icd10/browse/2010/en’.	
§ OPCS-4	 codes:	 Upto	 fifty	 OPCS-4	 codes	 are	 listed,	 along	 with	 the	 date	 on	 which	 said	
procedure/intervention	was	performed.	The	Classification	of	Surgical	Operations	and	Procedures	
was	originally	issued	by	the	Office	of	Population	Censuses	and	Surveys	(OPCS).	The	fourth	revision	
was	first	implemented	in	hospital	 information	systems	in	1987.	This	was	subject	to	a	significant	
number	 of	 amendments,	 and	 a	 consolidated	 version	 was	 reproduced	 in	 1990.	 The	 OPCS	
Classification	of	 Interventions	and	Procedures	 (OPCS-4.2)	was	substantially	enhanced	to	ensure	
that	modern	clinical	practice	was	represented	appropriately	within	the	classification,	and	a	new	
version	was	 implemented	 in	 2006,	 titled	 ‘OPCS	 Classification	 of	 Interventions	 and	 Procedures’	
(OPCS-4.3),	with	a	commitment	to	undertake	an	annual	review	and	potential	update.	The	current	
version	 is	 OPCS-4.7.	 The	 classification	 comprises	 a	 list	 of	 alphanumeric	 codes	 with	 mainly	
anatomically	based	chapters,	most	of	which	relate	to	the	whole	or	part	of	a	body	system.	Each	
chapter	is	designated	alphabetically;	e.g.	Chapter	A	covers	the	nervous	system	and	Chapter	K	is	
assigned	to	the	heart.	The	alphabetic	character	for	each	chapter	forms	the	prefix	of	the	3-	and	4-
digit	codes	within	it.	The	strict	link	between	chapters	and	body	systems,	with	specific	procedures	
for	 individual	organs,	was	broken	 in	OPCS-4.3	because	of	 limited	capacity.	A	 full	 list	of	OPVSv4	
codes	is	available	at	‘http://systems.hscic.gov.uk/data/clinicalcoding/codingstandards/opcs4’.	
§ CCMDS:	 The	 data	 in	 the	 Critical	 Care	 Minimum	 Data	 Set	 primarily	 relates	 to	 any	 part	 of	 the	
patient’s	 hospital	 spell	 that	 requires	 care	 in	 a	 designated	 critical	 care	 bed.	 Although	 this	
information	was	requested,	the	amount	of	missing	data	and	poor	quality	of	the	data	received	from	
the	participating	NHS	Trusts	led	to	its	exclusion	from	my	research.	
	
The	key	 issues	of	accessing	these	data	are	the	difficulty	of	using	varying	 local	data	schemas,	which	
would	have	to	be	transformed	post-collection	to	the	national	standard,	and	also	of	determining	which	
team	in	each	collaborating	Trust	could	provide	the	data.	
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Table	2.1:	Patient	characteristics	
Raw	Data	 Attributes	 Requested	 New	Attributes	
NHSNumber	
10	digit	numerical,	with	internal	
validation	structure	
Anonymised	
NHSNumber	
Variable	length	and	
variable	character	
encoding	
Local	Patient	
Identifier	(LPI)	/	
Medical	Record	
Number	(MRN)	
Custom	per	organisation	variable	
length	with	both	alphanumeric	
characters	
Anonymised	
LPI/MRN	
Variable	length	and	
variable	character	
encoding	
Postcode	of	usual	
address	
UK	postcodes	
Only	the	first	half	of	
postcode	(3/4	
characters)	
Max	length	of	4	
alphanumeric	
characters	
Patient	Birth	Date	 Day,	month	and	year	of	birth	
Only	the	Month	and	
Year	of	Birth	
Month	and	year	of	
birth-	numeric	
format	
Person	Gender	 0:	not	known,	1:	Male,	2:	Female	 Same	
0,1,2	but	also	arrives	
as	M:Male,	F:Female	
or	U:unknown	
Ethnic	Category	
Caucasian	
Same	 Same	
A	 British	
B	 Irish	
C	 Any	other	white	background	
Mixed	
D	 White	and	Black	Caribbean	
E	 White	and	black	African	
F	 White	and	Asian	
G	 Any	other	mixed	background	
Asian	or	Asian	British	
H	 Indian	
J	 Pakistani	
K	 Bangladeshi	
L	 Any	other	Asian	background	
Black	or	Black	British	
M	 Caribbean	
N	 African	
P	 Any	other	black	background	
Other	Ethnic	Groups	
R	 Chinese	
S	 Any	other	ethnic	group	
Z	 Not	stated	
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Table	2.2:	Hospital	provider	spell	characteristics	
Variable	 Attributes	
	
National	
Code	
Description	
Admission	
Method	
Elective	Admission	
11	 Waiting	list	
12	 Booked	
13	 Planned	
Emergency	Admission	
21	
Accident	and	emergency	or	dental	casualty	department	of	the	Health	Care	
Provider	
22	
GENERAL	PRACTITIONER:	after	a	request	for	immediate	admission	has	been	
made	direct	to	a	Hospital	Provider,	i.e.	not	through	a	Bed	bureau,	by	a	
GENERAL	PRACTITIONER	or	deputy	
23	 Bed	bureau	
24	 Consultant	Clinic,	of	this	or	another	Health	Care	Provider	
25	 Admission	via	Mental	Health	Crisis	Resolution	Team	
2A	
Accident	and	Emergency	Department	of	another	provider	where	the	PATIENT	
had	not	been	admitted	
2B	
Transfer	of	an	admitted	PATIENT	from	another	Hospital	Provider	in	an	
emergency	
2C	 Baby	born	at	home	as	intended	
2D	 Other	emergency	admission	
28	 Other	means	
Maternity	Admission	
31	 Admitted	ante-partum	
32	 Admitted	post-partum	
Other	Admission	
82	 The	birth	of	a	baby	in	this	Health	Care	Provider	
83	
Baby	born	outside	the	Health	Care	Provider	except	when	born	at	home	as	
intended.	
81	
Transfer	of	any	admitted	PATIENT	from	other	Hospital	Provider	other	than	in	
an	emergency	
Source	of	
Admission	
19	
Usual	place	of	residence	unless	listed	below,	for	example,	a	private	dwelling	
whether	owner	occupied	or	owned	by	Local	Authority,	housing	association	or	
other	landlord.	This	includes	wardened	accommodation	but	not	residential	
accommodation	where	health	care	is	provided.	It	also	includes	PATIENTS	with	
no	fixed	abode.	
29	 Temporary	place	of	residence	when	usually	resident	elsewhere	(e.g.	hotels,	
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residential	Educational	Establishments)	
39	 Penal	establishment,	Court,	or	Police	Station	/	Police	Custody	Suite	
49	
NHS	other	Hospital	Provider	-	high	security	psychiatric	accommodation	in	an	
NHS	Hospital	Provider	(NHS	Trust	or	NHS	Foundation	Trust)	
51	
NHS	other	Hospital	Provider	-	WARD	for	general	PATIENTS	or	the	younger	
physically	disabled	or	A	&	E	department	
52	 NHS	other	Hospital	Provider	-	WARD	for	maternity	PATIENTS	or	Neonates	
53	
NHS	other	Hospital	Provider	-	WARD	for	PATIENTS	who	are	mentally	ill	or	have	
Learning	Disabilities	
54	 NHS	run	Care	Home	
55	
Hospital	site	within	the	same	Trust	-	ward	for	general	patients	or	young	
physically	disabled	or	A	&	E	department	
56	 Hospital	site	within	the	same	Trust	-	ward	for	maternity	patients	or	neonates	
57	
Hospital	site	within	the	same	Trust	-	ward	for	patients	who	are	mentally	ill	or	
have	learning	disabilities	
65	 Local	Authority	residential	accommodation	i.e.	where	care	is	provided	
66	 Local	Authority	foster	care	
79	 Babies	born	in	or	on	the	way	to	hospital	
85	 Non-NHS	(other	than	Local	Authority)	run	Care	Home	
86	 Non-NHS	(other	than	Local	Authority)	run	Nursing	Home	
87	 Non	NHS	run	hospital	
88	 Non-NHS	(other	than	Local	Authority)	run	Hospice	
99	 Not	known:	a	validation	error	
Discharge	
Method	
1	 PATIENT	discharged	on	clinical	advice	or	with	clinical	consent	
2	 PATIENT	discharged	him/herself	or	was	discharged	by	a	relative	or	advocate	
3	 PATIENT	discharged	by	mental	health	review	tribunal,	Home	Secretary	or	Court	
4	 PATIENT	died	
5	 Stillbirth	
8	
Not	applicable	-	hospital	provider	spell	not	finished	at	episode	end	(i.e.	not	
discharged,	or	current	episode	unfinished)	
9	 Not	known:	a	validation	error	
Discharge	
destination	
19	
Usual	place	of	residence	unless	listed	below,	for	example,	a	private	dwelling	
whether	owner	occupied	or	owned	by	Local	Authority,	housing	association	or	
other	landlord.	This	includes	wardened	accommodation	but	not	residential	
accommodation	where	health	care	is	provided.	It	also	includes	PATIENTS	with	
no	fixed	abode.	
29	
Temporary	place	of	residence	when	usually	resident	elsewhere	(includes	hotel,	
residential	Educational	Establishment)	
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30	
Repatriation	from	high	security	psychiatric	accommodation	in	an	NHS	Hospital	
Provider	(NHS	Trust	or	NHS	Foundation	Trust)	
37	 Court	
38	 Penal	establishment	or	police	station	
48	 High	Security	Psychiatric	Hospital,	Scotland	
49	 NHS	other	Hospital	Provider	-	high	security	psychiatric	accommodation	
50	 NHS	other	Hospital	Provider	-	medium	secure	unit	
51	
NHS	other	Hospital	Provider	-	WARD	for	general	PATIENTS	or	the	younger	
physically	disabled	
52	 NHS	other	Hospital	Provider	-	WARD	for	maternity	PATIENTS	or	Neonates	
53	
NHS	other	Hospital	Provider	-	WARD	for	PATIENTS	who	are	mentally	ill	or	have	
Learning	Disabilities	
54	 NHS	run	Care	Home	
55	
Hospital	site	within	the	same	Trust	-	ward	for	general	patients	or	young	
physically	disabled	or	A	&	E	department	
56	 Hospital	site	within	the	same	Trust	-	ward	for	maternity	patients	or	neonates	
57	
Hospital	site	within	the	same	Trust	-	ward	for	patients	who	are	mentally	ill	or	
have	learning	disabilities	
65	 Local	Authority	residential	accommodation	i.e.	where	care	is	provided	
66	 Local	Authority	foster	care	
79	 Not	applicable	-	PATIENT	died	or	still	birth	
84	 Non-NHS	run	hospital	-	medium	secure	unit	
85	 Non-NHS	(other	than	Local	Authority)	run	Care	Home	
86	 Non-NHS	(other	than	Local	Authority)	run	Nursing	Home	
87	 Non-NHS	run	hospital	
88	 Non-NHS	(other	than	Local	Authority)	run	Hospice	
98	
Not	applicable	-	hospital	provider	spell	not	finished	at	episode	end	(i.e.	not	
discharged,	or	current	episode	unfinished)	
99	 Not	known:	a	validation	error	
Start	Date	
Hospital	
provider	
Spell	
is	the	date	of	admission:	the	CONSULTANT	or	MIDWIFE	has	assumed	responsibility	for	care	
following	the	DECISION	TO	ADMIT	the	PATIENT.	
Age	on	
Admission	
is	derived	as	the	number	of	completed	years	between	the	PERSON	BIRTH	DATE	of	the	
PATIENT	and	the	START	DATE	(HOSPITAL	PROVIDER	SPELL)	
Discharge	
Date	
(HOSPITAL	
PROVIDER	
DISCHARGE	DATE	(HOSPITAL	PROVIDER	SPELL)	is	the	date	a	PATIENT	was	discharged	from	a	
Hospital	Provider	Spell.	
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SPELL)	
Episode	
number	
is	the	same	as	attribute	ACTIVITY	IDENTIFIER	and	is	used	to	uniquely	identify	episodes,	and	
is	a	sequence	number	for	each	Consultant	Episode	(Hospital	Provider)	in	a	Hospital	Provider	
Spell.	The	first	episode	of	each	new	Hospital	Provider	Spell	(including	re-admitted	PATIENTS)	
commences	at	01.	A	known	episode	number	can	be	between	01	-	87	
LAST	
EPISODE	IN	
SPELL	
INDICATOR	
CODE	
is	a	derived	data	element	which	identifies	whether	the	consultant	episode	is	the	final	
episode	in	the	Hospital	Provider	Spell	Data	attributes:	1:	This	episode	is	the	last	episode	in	
the	Hospital	Provider	Spell.	2:	The	episode	is	not	the	last	episode	in	the	Hospital	Provider	
Spell.	
Episode	Start	
Date	
start	date	of	the	patient	episode	
Episode	End	
Date	
date	of	completion	of	this	specific	patient	episode	
2.1.2	Blood	results	
Blood	test	results	form	a	core	component	in	over	seventy	percent	of	all	clinical	interventions.	They	are	
used	in	determining	diagnosis,	choice	of	treatment,	and	efficacy	of	treatment.	In	England	and	Wales	
alone,	over	300,000	patients	undergo	a	blood	test	every	working	day,	equating	to	nearly	800	million	
tests	performed	annually.	Of	 these	800	million,	 500	million	are	biochemistry	 tests	 and	130	million	
haematology	tests.108	
	
For	this	thesis	I	have	focussed	on	routine	biochemistry	and	haematology	tests,	and	how	these	routine	
measures	can	be	used	in	AE	prediction.	Biochemistry	and	haematology	tests	are	ordered	for	almost	
every	patient,	either	immediately	prior	to	admission,	or	on	admission	to	hospital.	In	addition,	hospital	
laboratories	frequently	provide	pathology	services	to	patients	in	the	community	(rather	than	admitted	
patients),	and	these	results	are	also	available.	The	specific	data	variables	I	requested	for	blood	results	
are	described	in	Table	2.3.	I	decided	on	these	variables	after	examining	the	various	potential	sources	
of	blood	result	data,	the	most	common	being	the	laboratory	information	management	system	(LIMS).		
	
Table	2.3:	Blood	Result	Characteristics	
Variable	Name	 Attributes	 Requested	 New	Attributes	
TestName	
Name	of	the	blood	result	
test	performed	e.g.	
haemoglobin	
Same	 Same	
Result	value	 Full	result	 Same	 Same	
Result	numeric	
Numerical	component	of	
the	result	value	 Same	
Same	
Units	 e.g.	mg/L	 Same	 Same	
Sample	source	
Source	of	the	sample	
e.g.	venous	blood	 Same	
Same	
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Location	the	test	was	
performed	
The	physical	location	
(hospital	site,	or	ward)	 Same	
Deleted	
Upper	reference	range	 Numerical	value	 Same	 Majority	missing	
Lower	reference	range	 Numerical	value	 Same	 Majority	missing	
Sample	collected	date	and	
time	
Date	and	time	the	
sample	was	collected	
from	the	patient		
Same	 Deleted	
Sample	received	in	the	
laboratory	date	and	time	
Date	and	time	the	
sample	was	logged	as	
being	processed	in	the	
laboratory	
Same	 Deleted	
Validated	date	and	time	
Date	and	time	the	result	
of	the	test	was	
validated/available	
Same	 Same	
NHSNumber	
10	digit	numerical,	with	
internal	validation	
structure	
Anonymised	
NHSNumber	
Variable	length	and	
variable	character	
encoding	
Local	Patient	Identifier(LPI)	/	
Medical	Record	
Number(MRN)	
Custom	per	organisation	
variable	length	with	
both	alphanumeric	
characters	
Anonymised	LPI/MRN	
Variable	length	and	
variable	character	
encoding	
	
LIMS	is	the	software	that	underpins	the	pathology	laboratory	to	perform	its	operations.	The	LIMS	is	a	
regulated	 system,	 specifically	 licensed	 and	 approved	 for	 the	processing	of	 pathology	 samples.	 The	
LIMS	enables:		
§ Processing	the	order	for	a	sample	from	the	order	communication	system	of	the	requesting	entity.	
§ Reception	and	log-in	of	the	sample	and	its	associated	patient	data.	
§ Assignment,	scheduling	and	tracking	of	the	sample	and	its	subsequent	analysis.	
§ The	process	and	quality	control	associated	with	the	sample	and	the	equipment	that	was	used	for	
its	analysis.	
§ Storage	of	all	data	associated	with	both	the	inputs	and	the	outputs	of	the	analysis.	
§ The	inspection,	approval	and	reporting	of	the	results	of	the	analysis.	
Additional	features	are	frequently	added	onto	these	systems,	such	as	triggers	for	alarms	based	on	the	
results	of	certain	tests,	clinical	decision	support,	rules	for	ordering	additional	tests,	and	triggers	for	
secondary	verification,	to	name	but	a	few.	
	
Such	LIMS	have	been	ubiquitous	in	the	NHS,	and	most	developed	healthcare	systems.	As	such,	there	
is	a	vast	repository	of	pathology	data	theoretically	available	for	analysis,	however	because	1)	the	LIMS	
are	commercially	proprietary	closed	systems,	and	2)	the	contracts	with	the	LIMS	providers	restrict	any	
changes	 to	 the	 system	 setup,	 this	 potential	 has	 not,	 until	 now,	 been	 realised.	 The	 technology	
architecture	powering	the	LIMS	is	not	usually	shared	with	customers,	and	even	when	known,	access	
to	the	data	within	the	LIMS	is	only	possible	through	specific	non-standard	interfaces,	which	are	not	
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designed	 for	 large-scale	 data	 extraction	 or	 querying.	 It	 is	 understandable	 that	 in	 a	 critical	 system,	
processes	 and	 queries	 that	 are	 not	 related	 to	 the	 immediate	 task	 of	 live	 sample	 and	 result	
management	do	not	 interfere	with	the	running	of	a	 laboratory.	However,	 the	difficulty	and	cost	of	
customising	 the	 LIMS	 for	 additional	 tasks	 impedes	 research,	 and	 ultimately	 limits	 the	 further	
integration	of	pathology	results	into	clinical	pathways.	LIMS	providers	frequently	charge	substantial	
consultancy	fees	for	these	‘additional’	services,	such	as	data	extraction.	In	fact,	during	the	course	of	
this	 project,	 I	 received	 quotes	 of	 £50,000–100,000	 for	 accessing	 pathology	 results	 from	 different	
Trusts’	LIMS	(personal	communication).		
	
In	addition	to	the	technical	and	fiscal	challenges	to	pathology	data	access,	there	is	no	robustly	adhered-
to	information	standard	of	nomenclature	for	the	tests	carried	out,	or	for	samples.	This	means	that	the	
same	 test	 performed	 on	 the	 same	 type	 of	 sample	 may	 be	 referred	 to	 differently	 in	 different	
organisations.		
‘Most	 laboratories	and	clinical	services	use	HL7	(the	medical	messaging	standard)	to	
send	 their	 results	 electronically	 from	 their	 reporting	 systems	 to	 their	 care	 systems.	
However,	 the	 tests	 in	 these	 messages	 are	 identified	 by	 means	 of	 their	 internal,	
idiosyncratic	 code	 values.	 As	 a	 result,	 the	 receiving	 care	 system	 cannot	 fully	
“understand”	 and	 properly	 file	 the	 results	 they	 receive	 unless	 they	 either	 adopt	 the	
producer's	test	codes	(which	is	impossible	if	they	receive	results	from	multiple	sources),	
or	invest	in	the	work	to	map	each	result	producer's	code	system	to	their	internal	code	
system’	109.	
In	fact,	HSCIC	succinctly	defined	the	problem	as	follows:		
‘Up	until	now,	 there	has	been	no	way	of	 reporting	pathology	 results	 in	a	consistent,	
standardised	way	across	the	country.	Different	names	in	different	settings	could	have	
meant	the	same	or	different	things.	This	has	led	to	problems.	A	patient	may	have	a	test	
in	 one	 region	which	 could	 be	 interpreted	 as	 a	 different	 test	 in	 another	 region	 and,	
consequently,	might	either	have	to	repeat	the	same	test	or	might	not	receive	a	test	they	
need.	Without	official	names	for	tests,	or	a	national	mechanism	to	agree	whether	or	
not	a	test	was	worth	using,	there	has	been	potential	for	misinterpretation,	confusion	
and	waste’	110.	
	
In	1994,	Clem	McDonald,	an	investigator	at	the	Regenstrief	Institute,	begun	to	address	this	problem,	
particularly	because	of	the	electronic	transmission	of	blood	results	between	organisations.	He	setup	
the	 LOINC	 committee	 in	 1994,	 whose	 task	 was	 to	 develop	 a	 common	 terminology	 for	 laboratory	
results.109	 ‘LOINC’	 refers	 to	 Logical	 Observation	 Identifiers	 Names	 and	 Codes111	 and	 is	 now	 the	
unofficial	 international	standard.	In	the	last	decade,	NHS	England	has	taken	steps	to	try	to	mitigate	
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this	issue	as	well,	with	the	development	of	the	National	Pathology	Exchange	(NPEx)	and	of	the	National	
Laboratory	Medicines	Catalogue	(NLMC)110	.	NPEx	connects	NHS	pathology	laboratories	across	the	UK	
to	a	national	hub,	so	that	test	referrals	and	results	can	be	sent	between	laboratories	electronically	in	
a	few	seconds.	The	NPEx	service	is	available	to	all	NHS	pathology	labs	in	the	UK	at	no	cost	other	than	
a	modest	support	fee.	Connecting	to	the	national	exchange	allows	a	lab	to	use	its	lab	system	(LIMS)	to	
send	its	test	requests	to	any	other	lab	using	the	exchange,	and	receive	the	results	back	electronically,	
directly	into	their	LIMS.	The	NLMC	is	a	list	of	pathology	tests	that	have	been	validated	for	use	within	
the	NHS.	A	team	of	Pathology	Discipline	Leads,	led	by	a	National	Clinical	Lead,	defines	the	tests,	which	
are	then	reviewed	by	Subject	Matter	Experts.	Each	item	in	the	list	is	coded	based	on	a	number	of	core	
attributes	that	make	each	definition	unique.	This	means	that	hospital	doctors,	GPs,	nurses	and	other	
health	professionals	can	be	certain	they	are	requesting	the	right	test	every	time.	However,	despite	
being	a	national	standard	and	essentially	free	to	use,	these	systems	are	not	ubiquitous	across	the	NHS.	
Individual	Trusts	still	use	their	own	standards	and	nomenclature,	possibly	due	to	the	costs	of	upgrading	
their	LIMS	and	all	allied	systems	to	this	new	standard.	This	was	estimated	at	between	5–10	million	
pounds	for	one	large	multisite	trust	(personal	communication).	As	the	NLMC	is	still	a	work	in	progress,	
I	therefore	decided	to	use	the	international	LOINC	nomenclature	for	my	canonical	standard.	
	
In	summary,	the	two	major	technical	challenges	I	needed	to	overcome	in	order	to	access	and	utilise	
pathology	data	were:	
1. Access	to	the	pathology	data	from	various	LIMS	and/or	other	databases	at	each	NHS	Trust.	
2. Interpretation	of	the	data:	conversion	of	the	pathology	data	into	a	canonical	standard.	
	
One	key	issue	I	have	not	addressed	is	whether	pathology	results	can	be	compared	between	healthcare	
organisations.	The	answer	to	this	query	should	undoubtedly	be	‘YES’.	From	the	point	of	view	of	the	
end	 user,	 either	 the	 healthcare	 professional	 looking	 after	 the	 patient,	 or	 indeed	 the	 patient	
him/herself,	they	both	interpret	a	pathology	result	as	being	absolute	and	comparable,	regardless	of	
where	it	was	obtained.	In	reality,	the	result	is	only	bound	by	the	quality	assurance	standard	of	the	local	
organisation,	 which	 does	 not	 guarantee	 interchange	 between	 organisations,	 though	 the	 National	
Pathology	Programme	is	trying	to	address	this.	 I	have	specifically	decided	to	not	address	this	 issue,	
partly	because	it	 is	a	task	that	is	unachievable	in	the	scope	of	my	research,	but	also	because	for	an	
individual	patient	episode/spell,	all	pathology	results	would	be	obtained	from	the	same	Trust.	
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2.2	The	Ethical	and	Legal	Framework	
Before	any	patient	data	could	be	requested	and	used,	the	appropriate	ethical,	legal	and	information	
governance	 permissions	 were	 needed.	 However,	 identifying	 the	 precise	 requirements	 of	 these	
permissions	based	on	the	work	I	wanted	to	undertake	was	not	an	easy	task,	as	described	below.	
	
The	ethics	of	conducting	medical	research	are	based	upon	the	World	Medical	Association’s	Declaration	
of	 Helsinki.112	 This	 is	 a	 statement	 of	 the	 ethical	 principles	 for	 medical	 research	 involving	 human	
subjects,	 including	 research	 on	 identifiable	material	 and	 data.	 In	 the	UK,	 the	 research	 governance	
framework	for	health	and	social	care113	outlines	the	principles	of	good	governance	that	apply	to	all	
research	 within	 the	 NHS.	 Both	 these	 documents	 emphasise	 that	 ‘The	 dignity,	 rights,	 safety	 and	
wellbeing	of	participants	must	be	the	primary	consideration	in	any	research	study’,	and	that	‘informed	
consent	is	at	the	heart	of	ethical	research’.	
	
For	research	focussing	on	data,	there	are	two	broad	types	of	data	available:		
§ Research	data	is	created/collected	solely	for	the	purpose	of	the	research	study,	and	is	not	used	for	
the	direct	care	of	the	patient.	This	requires,	in	the	vast	majority	of	cases,	informed	consent,	and	
specific	legal	safeguards	must	be	in	place	for	individuals	who	cannot	give	such	consent.	
§ Healthcare	 data	 is	 primarily	 created	 for	 one	 specific	 purpose:	 the	 direct	 care	 of	 an	 individual	
patient.	There	are,	however,	a	multitude	of	secondary	uses	 (not	 for	direct	patient	care)	of	 this	
data.	Capturing	 the	details	of	a	patient,	 their	co-morbidities,	 their	acute	condition,	 the	specific	
procedures	and	interventions	carried	out	in	their	care,	and	various	administrative	details,	allows	a	
patient’s	 medical	 interventions	 to	 be	 categorised,	 costed	 and	 appropriately	 reimbursed.	
Reimbursement	to	the	healthcare	establishment	(and	individuals)	for	providing	medical	care	is	in	
fact	 the	 leading	 use	 of	 such	 data,	 after	 its	 utilisation	 for	 direct	 patient	 care.	 Whether	 this	
reimbursement	 be	 via	 a	 government	 organisation,	 such	 as	 the	 NHS	 in	 the	 UK	 or	 via	
Medicare/Medicaid	in	the	USA,	via	health	insurance,	or	from	the	patient	him/herself,	the	principle	
of	the	secondary	use	of	this	data	is	the	same.	
	
The	legal	and	ethical	issues	arise	when	data	collected	for	one	purpose,	in	this	case	for	the	direct	care	
of	 the	 patient,	 is	 utilised	 for	 another;	 specifically,	 research.	 There	 is,	 on	 the	 surface,	 conflicting	
guidance	 and	 advice	 from	 the	 UK	 Health	 Research	 Authority	 (HRA)	 (www.hra.nhs.uk).	 The	 HRA	
guidance	states	that,	regarding	NHS	Research,		
‘Research	limited	to	secondary	use	of	information	previously	collected	in	the	course	of	
normal	 care	 (without	an	 intention	 to	use	 it	 for	 research	at	 the	 time	of	 collection)	 is	
generally	excluded	from	REC	(research	ethics	committee),	provided	that	the	patients	or	
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services	users	are	not	identifiable	to	the	research	team	carrying	out	the	research.	This	
exception	 also	 applies	 to	 research	 undertaken	 by	 staff	 within	 a	 care	 team	 using	
information	previously	collected	in	the	course	of	care	for	their	own	patients	or	client,	
provided	that	data	is	anonymised	in	conducting	the	research.’	114	
However,	within	the	REC	application	process,	there	exists	a	subset	of	questions	relating	specifically	to	
research	on	anonymised	data,	and	recommending	submission	for	REC	approval.	Specifically,	an	REC	
review	is	required	if	a	specific	research	project	involves:		
‘use	of	previously	collected	tissue	or	information	from	which	individual	past	or	present	
users	of	these	services	could	be	identified,	either	directly	from	that	tissue	or	information,	
or	from	its	combination	with	other	tissue	or	information	in,	or	likely	to	come	into,	the	
possession	of	someone	to	whom	the	tissue	or	information	is	made	available.’		
Also,	both	university	and	NHS	Trust	research	offices	advise	that	any	research	conducted	on	even	the	
data	of	NHS	patients	must	be	submitted	to	a	REC	for	approval	before	the	research	can	be	considered,	
either	for	sponsorship	or	for	initiation	as	a	study.		
	
The	Health	Research	Authority’s	own	tool	to	determine	whether	a	study	utilising	previously	collected	
data	 needs	 REC	 approval	 (http://hra-decisiontools.org.uk/ethics/)	makes	 its	 decision	 solely	 on	 the	
potential	of	whether	 the	 supposedly	anonymised	data	obtained	could,	 if	 combined	with	any	other	
data,	be	used	to	identify	any	patients	by	members	of	the	research	team.	There	is	thus	a	‘grey	area’,	in	
both	legal	and	ethical	terms,	when	conducting	such	research.	This	is	further	compounded	by	the	fact	
that	the	data	required	for	research	frequently	does	not	exist	in	an	anonymised	form,	and	there	is	no	
existing	formal	mechanism	to	carry	out	this	anonymisation	prior	to	the	research	team’s	involvement.	
Thus,	 identifiable	data	must	be	accessed	and	manipulated	by	a	 team	that	 is	distinct	 from	both	the	
clinical	and	research	teams,	purely	for	the	reason	of	carrying	out	research.	
	
It	is	important	to	note	here	that	REC	approval	is	not	a	confirmation	of	the	legal	basis	for	conducting	
research	or	accessing	and	utilising	data.	As	stated	in	the	governance	arrangements	for	research	ethics	
committees115:		
‘It	is	not	the	role	of	the	REC	to	offer	a	legal	opinion	on	research	proposals.	
Researchers,	 sponsors	 and	 organisations	 where	 the	 research	 is	 carried	 out	 remain	
responsible	 for	 making	 sure	 the	 research	 is	 conducted	 in	 accordance	 with	 the	
requirements	of	law,	relevant	regulators	and	guidance,	e.g.	the	Data	Protection	Act,	the	
Codes	 of	 Practice	 issued	 under	 the	Mental	 Capacity	 Act	 and	 Human	 Tissue	 Act,	 or	
recognised	standards	of	Good	Clinical	Practice.’		
Additional	 legal	 requirements	 that	 healthcare	data	used	 for	 research	must	 comply	with	 are	1)	 the	
European	Union	Directive	95/46/EC:	The	Data	Protection	Directive	(which	is	 in	the	process	of	being	
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replaced	by	the	General	Data	Protection	regulation	adopted	in	April	2016);	and	2)	the	UK	Human	Rights	
Act	(based	on	the	European	Convention	on	Human	Rights).	However,	it	 is	unknown	how	long	these	
European	directives	will	continue	to	apply	in	the	UK,	following	the	UK’s	decision	to	leave	the	European	
Union.	
2.2.1	The	ethical	and	legal	considerations	for	conducting	research	with	‘grey	area’	
anonymised	data	
First	 of	 all,	we	 need	 to	 explore	 the	 precise	 definition	 of	 anonymised	 data.	 The	word	 ‘anonymous’	
comes	via	late	Latin	from	the	Greek	anōnumos	'nameless'	(from	an-	'without'	+	onoma	'name').	It	refers	
to	a	person,	or	in	this	case	data,	that	cannot	be	identified	or	attributed	to	a	specific	name	(person).	
However,	 the	 problem	 with	 the	 concept	 of	 anonymised	 data	 is	 that	 there	 must	 be	 sufficient	
obfuscation	of	the	data	to	ensure	that	any	individual	in	the	dataset	cannot	be	identified	directly	from	
the	 data	 itself,	 but	 it	 may	 not	 be	 possible	 to	 ensure	 this	 if	 the	 data	 is	 combined	 with	 any	 other	
information.	 The	 UK	 Information	 Commissioners	 Office	 (ICO)	 has	 produced	 a	 code	 of	 practice,	
‘Anonymisation:	 managing	 data	 protection	 risk’	 (‘the	 code’),	 to	 govern	 the	 anonymisation	 of	
identifiable	 data.116	 The	 ICO	 acknowledges	 within	 ‘the	 code’	 the	 risk	 of	 re-identification,	 and,	
dependent	on	the	potential	consequences	of	such	re-identification,	recommends	either	 (1)	 limiting	
access	to	this	‘grey	data’,	along	with	implementing	robust	governance	processes;	(2)	more	rigorous	
risk	analysis	and	anonymisation;	or	 (3)	seeking	the	data	subjects’	consent	 for	 the	disclosure	of	 this	
anonymised	data,	explaining	its	possible	consequences.	
	
Dame	Fiona	Caldicott,	in	both	her	original	1997	Caldicott	Review117,	which	led	to	the	appointment	of	
Caldicott	Guardians,	and	her	subsequent	Information	Governance	Review118	in	2013,	also	concurred	
with	and	drew	on	the	ICO’s	Anonymisation	Code	of	Practice.116	She	has	suggested	a	simple	framework	
that	describes	three	different	forms	of	data,	and	the	conditions	under	which	data	can	be	processed	
and	disclosed.	These	are:	
§ Data	for	publication:	This	is	data	that	has	been	anonymised	in	line	with	the	ICO	anonymisation	
code	 to	 the	 point	 where	 determining	 individual	 identities	 from	 the	 data	 is	 unlikely,	 requiring	
unreasonable	effort.	The	data	does	not	require	a	legal	or	contractual	basis	for	processing	it,	and	
can	be	publicly	disclosed.	This	data	is	called	‘de-identified	data	for	publication’.	
§ Personal	 confidential	data:	 This	 is	data	 in	which	 individuals	are	clearly	 identified,	or	are	easily	
identifiable.	This	data	should	not	be	processed	without	a	clear	legal	basis.	Personal	confidential	
data	should	only	be	disclosed	with	consent	or	under	statute,	and	any	disclosure	must	always	be	
limited	 and	 accompanied	 by	 a	 contractual	 agreement	 that	 mitigates	 the	 risk	 of	 misuse	 and	
inappropriate	disclosure.	The	contractual	agreement	needs	to	set	out,	as	a	minimum,	the	 legal	
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basis	for	the	data	flow,	the	purposes	to	which	the	data	can	be	put,	the	safeguards	that	should	be	
in	place	to	protect	data,	and	how	the	public	are	informed	about	these	purposes.	
§ Data	for	limited	disclosure:	This	data	is	called	‘de-identified	data	for	limited	disclosure	or	access’.	
This	is	data	that	has	been	through	a	process	of	anonymisation,	such	as	removing	formal	personal	
identifiers,	using	coded	references	or	pseudonyms	in	their	place,	or	by	aggregating	data	together	
so	that	it	is	not	possible	to	identify	individuals.	However,	it	would	be	relatively	straightforward	for	
a	third	party	to	re-identify	individuals	or	de-anonymise	the	data,	especially	if	combined	with	other	
data.	This	represents	the	‘grey	area’	of	data.	
	
However,	 nowhere	 is	 the	 distinction	 clearly	 defined	 between	 what	 precisely	 constitutes	 the	 truly	
anonymised	dataset	and	this	grey	area	of	data	that	could	potentially,	at	some	point	in	the	future,	be	
de-anonymised.	 There	 are	 numerous	mechanisms	 to	 perform	 this	 process,	 one	 of	 which	 involves	
linking	 the	 ‘anonymised’	 dataset	 to	 another,	 accessible	 dataset.	 There	 are	 numerous	 very	 large	
population-level	datasets	that	are	available,	either	free	of	charge	or	at	a	cost.	These	datasets	include	
national	data,	such	as	the	electoral	register,	London	Oyster	Card	usage,	and	‘Boris	Bike’	use,	which	
include	a	mixture	of	identifiable	and	pseudonymised	data.	In	addition,	‘cookies’	on	websites	and	‘apps’	
on	smartphones	can	effectively	track	a	user’s	location	and	browsing	habits,	and	identify	them	by	age,	
sex,	ethnicity,	and	even	by	name.	Social	media	provides	intimate	knowledge	about	many	individuals,	
and	 local/national	 news	 has	 information	 about	 specific	 individuals.	 Any	 of	 these	 datasets	 could	
potentially	be	linked	to	supposedly	anonymised	medical	data.	An	individual	may	him/herself	overtly,	
though	inadvertently,	enable	such	linkages	to	take	place,	by	their	personal	use	of	Twitter,	which	has	
minimal	data	protection,	and	which	thrives	on	the	‘openness’	and	transparency	of	its	platform.	I	could,	
using	Twitter’s	own	API	(application	protocol	interface),	download	all	tweets	from	a	certain	location	
and	 from	 a	 certain	 time	 that	 state	 something	 specific,	 such	 as	 ‘arrived	 in	 hospital’.	 Thus,	 if	 I	 pre-
emptively	want	to	find	a	data-point	in	an	anonymised	dataset	that	links	to	a	known	identifiable	person	
using	freely	available	and	publicly	shared	data,	this	may	potentially	be	possible.	
	
In	this	environment	of	lack	of	clarity,	and	lack	of	communication	with	the	ultimate	providers	of	the	
data,	i.e.	patients,	is	the	UK	government’s	commitment	to	encouraging	medical	research.	The	National	
Data	Guardian	Consultation	paper119	clearly	states:		
‘Medical	 research	 relies	 on	 people’s	 health	 data	 to	 develop	 new	 medicines	 and	
treatments	 to	 transform	 and	 save	 people’s	 lives.	 Therefore,	 the	 Government	 is	
committed	to	do	all	it	can	to	encourage	people	to	allow	their	data	and	information	to	
be	used	to	help	realise	the	opportunities	for	further	progress.	There	is	a	need	to	continue	
to	 build	 on	 the	 public’s	 confidence	 in	 how	 data	 about	 individuals	 is	 used	 and	
safeguarded.’		
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These	are	some	of	the	key	challenges	in	the	‘big	data’	world,	which	research	and	medical	providers	
have,	unfortunately,	yet	to	completely	grasp.	This	shortfall	in	both	guidance	and	mechanisms	to	ensure	
the	 principles	 of	 ethics	 and	data	 protection	 for	 large	 patient	 datasets	 is	 still	 not	 being	 adequately	
addressed.	These	problems	are	impeding	both	medical	research	and	the	linkage	of	patient	data	across	
organisations.	 Nowhere	 is	 this	 more	 apparent,	 than	 in	 what	 could	 be	 regarded	 as	 NHS	 England’s	
flagship	large	scale	data	project	‘Care.Data’.	Understanding	the	controversies	surrounding	Care.Data	
was	necessary	to	prevent	my	study	encountering	the	same	issues.	
2.2.1.1	Care.Data	
NHS	England’s	Care.Data	programme120	aim	is	to	extract	data	from	all	general	practitioners	(GPs)	and	
upload	and	link	this	information	to	the	existing	national	databases	maintained	by	the	HSCIC	(renamed	
‘NHS	Digital’	in	June	2016).	However,	the	implementation	of	this	initiative	has	been	dubbed	a	‘fiasco’121	
and	denounced	by	the	press122,	and	privacy	groups.123	The	issues	that	led	to	and	continue	to	plague	
the	Care.Data	initiative	are	the	problem	of	‘implied	consent’,	and	the	potential	sharing	of	this	linked	
database	with	non	clinical	organisations	not	only	within	the	NHS	(e.g.	clinical	commissioning	bodies),	
but	also	outside	it	(e.g.	pharmaceutical	companies,	insurance	companies	and	consulting	companies,	
as	well	as	universities,	think-tanks	and	health	charities).	As	previously	mentioned,	if	data	is	not	being	
used	for	the	direct	care	of	the	patient,	then	it	is	considered	as	‘secondary	use’.	Normally,	this	would	
require	consent.	However,	 this	 requirement	was	bypassed	by	the	Health	and	Social	Care	Act	2012,	
which	legally	obliges	GPs	to	hand	over	patient	data	if	NHS	England	directs	HSCIC	to	request	it.	This	Act	
put	 the	GPs	 in	 an	 ethical	 and	 legal	 quandary,	where	 they	 had	 to	 act	 in	 the	 best	 interests	 of	 their	
patients,	but	at	the	same	time	were	forced	to	share	their	patients’	data.	As	such,	a	large	number	of	
GPs	have	objected	to	the	Care.Data	initiative.	Even	the	patient’s	choice	to	opt	out	of	handing	over	this	
data	is	not	a	legal	requirement,	but	due	to	the	initial	public	outcry	against	this	initiative,	a	mechanism	
was	hastily	put	in	place.	Two	additional	perceptions	are	affecting	the	Care.Data	initiative:	firstly,	a	lack	
of	trust	in	the	government	to	actually	do	what	it	says	it	is	doing	with	the	data	(this	has	been	fuelled	by	
the	recent	Edward	Snowden	revelations);	and	secondly,	that	creating	such	a	central	store	of	all	the	
data	makes	 it	 vulnerable	 to	being	 ‘hacked’,	 and	 thus	private	patient	 data	 is	 no	 longer	 private	 and	
becomes	 freely	 available.	 For	 all	 of	 the	above	 reasons,	 the	Care.Data	 initiative	 remained	 in	 a	pilot	
phase,	 with	 national	 rollout	 being	 repeatedly	 postponed.	 Finally,	 in	 July	 2016	 the	 Care.Data	
programme	was	officially	suspended,	however	it	is	thought	that	the	sharing	of	patient	data	would	still	
take	place,	but	be	rebranded	as	another	initiative.	Failure	to	make	the	case	for	personal	health	data	
linkage	is	regarded,	by	NHS	England	(personal	communication),	as	the	primary	reason	for	failure	of	the	
original	Care.Data	initiative.		
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2.2.2	My	Approach	
Considering	the	granularity	and	breadth	of	information	I	would	be	requesting,	and	the	access	that	I	
myself	as	a	doctor	have	to	clinical	 information	systems	at	many	of	the	Trusts	providing	the	data,	 it	
would	be	 inappropriate,	 and	 indeed	 illegal,	 to	 treat	 the	data	as	being	 completely	anonymised.	My	
study	is	different	from	the	Care.Data	initiative,	in	that	although	I	would	be	requesting	the	linkage	of	
two	normally	separate	datasets	(CDS.APC	and	Pathology),	the	linkages	would	occur	within	each	NHS	
Trust.	Anonymisation	of	these	linked	data	would	also	take	place	within	the	confines	of	each	NHS	Trust,	
with	no	sharing	of	any	identifiable	data	outside	each	organisation.		
	
Hence,	 in	 accordance	 with	 guidance	 (ethical	 and	 legal),	 and	 based	 on	 both	mine	 and	 that	 of	 my	
university’s	 information	 governance	 lead’s	 interpretation,	 of	 the	 relevant	 regulations/laws,	 I	 have	
regarded	and	communicated	my	study	data	as	being	of	the	category:	 ‘data	for	 limited	disclosure’.	I	
applied	 for	and	received	NHS	Research	Ethics	Committee	approval	 (REC	No:	13/WS/0243).	 I	 liaised	
with	every	Trust’s	research	and	information	governance	teams,	not	only	to	clarify	the	purpose	of	the	
project,	 but	 also	 to	 reassure	 them	 regarding	 the	 study’s	 compliance	 with	 the	 principles	 of	 data	
protection	and	 information	governance.	 I	 clearly	 stated	 that	 the	data	 they	were	providing	was	not	
going	 to	 be	 regarded	 as	 a	 freely	 usable	 anonymised	 dataset,	 and	 absolutely	 no	 attempt	 to	 de-
anonymise	 the	 data	would	 be	made.	 As	 the	 Information	Governance	 Review	 118	was	 published	 as	
recently	 as	 March	 2013,	 the	 recommended	 ‘Accredited	 Safe	 Havens’	 for	 such	 ‘data	 for	 limited	
disclosure’	had	yet	to	be	established	and	accessible	at	the	beginning	of	my	study;	and	indeed,	even	
now	in	2016,	my	local	‘Accredited	Safe	Haven’	does	not	have	sufficient	storage	or	computing	resources	
to	allow	resource-intensive	(computing	and	storage)	research	to	be	carried	out	within	it.	I	therefore	
followed	the	principles	of	the	ICO’s	‘limited	access	safeguards’	116	to	define	the	data	management	of	
my	study,	specifically:	
§ Purpose	limitation:	The	purpose	of	the	acquisition	of	the	data	was	clearly	defined	and	restricted	
to	my	study	only.	The	protocol	of	my	study	was	made	available	to	all	research	sites	(NHS	Trusts)	
(Appendix	2).	
§ Training	of	 recipients’	 staff	with	access	 to	data,	especially	on	security	and	data	minimisation	
principles:	 I	would	be	the	only	person	with	direct	access	to	the	dataset,	and	as	such	 I	not	only	
undertook	Good	Clinical	Practice	certification	and	UCL	Information	Governance	certification,	but	
also	liaised	extensively	with	the	Information	Governance	Lead	for	UCL	on	all	aspects	of	the	project.	
In	addition,	I	consulted	with	both	the	IT	teams	at	UCL	to	understand	the	IT	infrastructure	at	UCL,	
as	well	as	external	entities	that	provide	NHS	storage	and	computing	resources,	to	determine	the	
appropriate	way	to	store	and	access	the	data.	
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§ Personnel	background	checks	for	those	granted	access	to	the	data:	As	a	medical	doctor,	I	have	
regular	Disclosure	and	Barring	Service	(DBS)	(formerly	known	as	CRB	–	Criminal	Records	Bureau)	
checks	carried	out,	all	of	which	have	raised	no	concerns.	In	addition,	I	am	bound	by	the	General	
Medical	Council	standards	of	‘Good	Medical	Practice’.	
§ Controls	 over	 the	 ability	 to	 bring	 other	 data	 into	 the	 environment,	 allowing	 the	 risk	 of	 re-
identification	by	linkage	or	association	to	be	managed:	A	firm	commitment	was	made	to	all	study	
sites	and	written	 into	all	 the	 study	documents,	 guaranteeing	 that	 ‘No	attempt	 to	 link	 the	data	
obtained	from	the	various	organisations	with	any	other	research	database	will	be	made’.	
§ Limitation	of	the	use	of	the	data	to	a	particular	project:	A	firm	commitment	was	made	to	all	study	
sites	and	written	into	all	the	study	documents,	guaranteeing	that	the	data	would	only	be	used	for	
my	PhD	project	as	defined	by	the	protocol:	‘The	data	will	be	used	solely	for	this	project’;	and	in	
addition,	that	‘The	data	will	not	be	shared	with	any	other	investigators’.	
§ Restriction	on	 the	disclosure	of	 the	data:	A	 firm	commitment	was	made	 to	all	 study	sites	and	
written	into	all	the	study	documents,	guaranteeing	that	‘The	data	will	not	be	shared	with	any	other	
investigators’.	
§ Prohibition	 on	 any	 attempt	 at	 re-identification	 and	 measures	 for	 the	 destruction	 of	 any	
accidentally	 re-identified	 personal	 data:	 A	 firm	 commitment	was	made	 to	 all	 study	 sites	 and	
written	into	all	the	study	documents,	guaranteeing	that	‘No	attempt	to	link	the	data	obtained	from	
the	various	organisations	with	any	other	research	database	will	be	made’.	
§ Arrangements	for	technical	and	organisational	security:		Appropriate	computational	technologies	
would	be	used	to	store	and	handle	the	data,	and	all	would	be	compliant	(in	terms	of	security	and	
so	 forth)	 with	 data	 protection	 needs.	 Some	 of	 the	 specific	 measures	 stated	 in	 the	 various	
documents	were:	 ‘Dr	Vishal	Nangalia,	 the	Chief	 Investigator,	will	analyse	 the	data	at	University	
College	London.’,	‘All	the	anonymised	electronic	data	will	be	stored	on	secure,	password	protected	
and	encrypted	computers	at	UCL.’,	‘Access	to	the	Dr	Nangalia’s	office	at	UCL	is	only	available	via	a	
security	controlled	gate	and	only	to	authorised	members	of	staff.	He	will	use	secure,	password	
protected	and	encrypted	computers	for	the	storage	and	analysis	of	the	“anonymised”	data’.	
§ Encryption	and	key	management	to	restrict	access	to	data:	Only	secure,	password	protected	and	
encrypted	computers	at	UCL	would	be	used	for	data	storage	and	analysis.	The	only	person	to	have	
access	to	this	system,	and	indeed	the	data	from	the	study,	would	be	Dr	Vishal	Nangalia.	
§ Limiting	 the	 copying	of,	 or	 the	number	of	 copies	of	 the	data:	Only	 local	 copies,	 on	 the	 same	
computer	system,	of	the	data	would	be	made,	apart	from	a	single	additional	backup.	The	backup	
would	also	be	encrypted,	and	only	Dr	Nangalia	would	have	access	to	it.	
	
In	addition	to	the	above,	as	part	of	 the	protocol	of	 the	study,	specific	measures	were	put	 in	place,	
specifically	for	data	collection:	
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§ A	local	collaborator	would	be	identified	at	each	individual	NHS	Trust.	
§ The	data	 extraction	 and	 anonymisation	would	 be	 carried	 out	 by	 the	 information	 teams	 at	 the	
respective	NHS	Trusts,	using	existing	hospital	systems.	
§ It	was	explicitly	stated	that	the	following	would	be	carried	out	with	regard	to	specific	data	fields	in	
the	dataset:	
o Removal	of	patients’	names	
o Removal	of	patients’	addresses	
o Partial	 removal	 of	 postcodes.	 Only	 the	 first	 4	 characters	 (including	 spaces)	 would	 be	
requested,	 thus	 placing	 each	 partial	 postcode	 within	 a	 group	 of	 approximately	 8,600	
households.	 However,	 post	 collection,	 I	made	 the	 decision	 to	 delete	 all	 postcode	 data	
completely	to	further	the	anonymisation	of	the	dataset.	
o Removal	of	day	of	birth	from	date	of	birth.	Only	the	month	and	year	of	birth	would	be	
requested.	
§ Each	 NHS	 Trust’s	 own	 Research	 and	 Development,	 Information	 Governance	 and	 Caldicott	
Guardian	teams	would	approve	the	‘anonymised’	data	extraction.	
§ No	patient-identifiable	data	would	leave	the	NHS	Trust	or	be	shared	with	the	researcher.	
§ The	data	would	be	collected	by	the	Chief	Investigator	from	each	individual	trust,	using	an	NHS-
approved	encrypted	USB	(Universal	Serial	Bus)	stick	‘IRONKEY’.	
	
I	also	provided	guidance	to	the	local	NHS	Trust	information	teams	on	how	the	anonymisation	of	the	
data	should	be	carried	out,	in	addition	to	being	available	for	advice	on	technical	methods	to	remove	
identifiable	data.	Regarding	the	anonymisation	of	the	NHS	Number	and	Local	Hospital	Number	(MRN-
Medical	Record	Number),	I	advised	the	use	of	a	one-way	cryptographic	hash	function	with	the	inclusion	
of	a	‘SALT’.		The	addition	of	a	random	SALT,	which	was	not	to	be	shared	with	me,	the	researcher,	would	
guarantee	the	irreversibility	of	the	encryption/anonymisation	of	the	specific	data	field.	According	to	
Wikipedia:	‘In	cryptography,	a	SALT	is	random	data	that	is	used	as	an	additional	input	to	a	one-way	
function	that	hashes	a	password	or	passphrase.	The	primary	function	of	SALTs	 is	 to	defend	against	
dictionary	attacks	versus	a	list	of	password	hashes	and	against	pre-computed	rainbow	table	attacks.’	
Unlike	secret-key	or	public-key	algorithms,	hash	functions	use	one-way	encryption	and	have	no	key.	A	
fixed-length	hash	value	is	computed	based	on	the	plaintext	input,	in	such	a	way	that	it	is	impossible	
for	 either	 the	 length	 of	 the	 original	 plaintext	 or	 the	 contents	 to	 be	 determined.	 The	 algorithm	 I	
recommended	was	the	SHA2_256	function,	which	is	present	in	SQLServer	2012	onwards.	The	‘256’	in	
the	SQLServer	‘hashbytes’	function	refers	to	the	blocksize	that	the	SHA2_256	function	employs,	in	this	
case	256-bit	(32	bytes).	It	also	utilizes	64	rounds	of	the	algorithm	to	generate	the	final	hash.		
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A	‘dictionary	attack’	refers	to	‘a	technique	for	defeating	a	cipher	or	authentication	mechanism	by	trying	
to	 determine	 its	 decryption	 key	 or	 passphrase	 by	 trying	 hundreds	 or	 sometimes	millions	 of	 likely	
possibilities,	 such	 as	 words	 in	 a	 dictionary’.	 A	 pre-computed	 rainbow	 table	 attack	 is	 similar	 to	 a	
dictionary	attack,	but	in	this	case	the	dictionary	is	already	associated	with	pre-computed	hash	values.	
This	method	 is	void	 if	a	SALT	 is	added	 to	 the	data	prior	 to	 the	hash	 function	being	employed.	 It	 is	
important	 to	 note,	 though,	 that	 my	 recommendations	 for	 anonymisation	 were	 no	 more	 than	
recommendations,	and	it	was	the	responsibility	of	the	local	Trusts’	information	teams	to	decide	the	
exact	anonymisation	method	used,	which	I	advised	them	not	to	share	with	me.		
	
Finally,	as	‘Chief	Investigator’	of	my	study,	I	was	the	person	with	primary	responsibility	for	the	design,	
conduct	 and	 reporting	 of	 the	 study,	 despite	 not	 being	 an	 investigator	 at	 any	 particular	 site.	 I	was	
responsible	for:	
§ Developing	proposals	that	were	scientifically	sound	and	ethical.	
§ Submitting	the	design	for	independent	expert	review.	
§ Submitting	the	study	(or	proposal)	for	independent	ethical	review.	
§ Conducting	a	study	to	the	agreed	protocol	(or	proposal),	in	accordance	with	legal	requirements,	
guidance	and	accepted	standards	of	good	practice.	
§ Preparing	and	providing	information	for	participants.	
§ Ensuring	participants’	welfare	during	the	study.	
§ Arranging	to	make	findings	accessible,	following	expert	review.	
§ Feeding	back	results	of	the	research	to	participants.	
	
The	 documents	 relating	 to	 the	 study	 included	 the	 Protocol	 (Appendix	 2),	 the	 Research	 Ethics	
Committee	 Application	 Form,	 The	 NHS	 Research	 and	 Development	 Application	 Form,	 Site-Specific	
Application	Forms,	and	Proof	of	Insurance	Indemnity.	
	
I	believe	the	ethicality	of	the	use	of	medical	data	depends	on	who	owns	that	data.	The	ownership	of	a	
patient’s	 individual	healthcare	record	is	currently	unclear,	and	unfortunately,	 it	seems	that	minimal	
steps	 are	 being	 taken	 to	 address	 this	 issue.	 There	 is	 the	 risk	 that	 patients,	 as	 data	 owners,	 could	
withdraw	their	consent	for	the	use	of	their	data	for	any	purpose	other	than	their	direct	clinical	care.	
Even	when	their	record	is	used	for	their	direct	clinical	care,	patients	may	decide	to	restrict	the	access	
of	healthcare	providers/individuals	to	parts	of	their	record.	The	ongoing	paternalistic	attitude	of	the	
medical	 profession,	 the	 healthcare	 providers,	 and	 the	 government,	 as	 well	 as	 the	 introduction	 of	
legislation	 such	 as	 the	 Health	 and	 Social	 Care	 Act	 2012,	 has,	 in	 my	 opinion,	 so	 far	 prevented	 a	
meaningful	and	open	debate	of	this	particular	issue.	Until	such	a	time	as	this	issue	is	clearly	resolved,	
my	approach,	as	outlined	above,	could	serve	as	a	model	for	linking	datasets	at	source,	and	carrying	
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out	 research	 which	 would	 comply	 with	 both	 ethical	 and	 legal	 requirements.	 This	 approach	 is	 of	
particular	 value	 in	 the	 context	 of	 resource-intensive	 (computing	 and	 storage)	 machine-learning	
projects	that	cannot	be	accommodated	within	existing	‘Accredited	Safe	Havens’.	
2.3	Data	Acquisition	and	Pre-Processing	
2.3.1	Data	Acquisition	
Ethical	 approval	was	 just	 the	 beginning	 of	 the	 long	 process	 of	 acquiring	 the	 data.	 The	 process	 for	
initiating	my	study	involved		
1. Protocol	approval	and	agreement	with	the	sponsor,	in	this	case	my	university.	
2. NHS	REC	approval	
3. Clinical	Research	Network	(CRN)	application	for	inclusion	as	a	national	portfolio	study;		
4. Approaching	 individual	 NHS	 Trusts	 to	 encourage	 adoption	 of	 the	 study	 in	 their	 respective	
organisations	 (which	entailed	discussions	and	approval	of	 the	 local	 research	and	development,	
information	 governance,	 Caldicott	 Guardian,	 and	 the	 specific	 hospital	 teams	 who	 would	 be	
carrying	out	the	study).	I	also	identified	a	local	site	investigator	who	would	take	responsibility	for	
their	specific	organisation.	
5. Liaising	with	the	local	IT	teams	to	discuss	actual	data	extraction,	modification,	anonymisation,	and	
ultimately	transfer.	
	
Processes	1	and	2	proceeded	smoothly;	however,	due	to	an	error	made	 in	the	application	process,	
automatic	CRN	and	national	portfolio	inclusion	did	not	occur.	This	process	had	to	be	repeated,	with	a	
separate	formal	application	to	the	CRN	justifying	why	CRN	inclusion	was	applicable.	The	justification	
for	my	study’s	inclusion	was	that	it	was	directly	funded	by	the	Medical	Research	Council,	and	that	it	
had	undergone	a	process	of	extensive	external	peer	 review	before	 funding	had	been	awarded.	My	
study’s	CRN	approval	 arrived	approximately	nine	months	after	ethical	 clearance	was	 received.	The	
specific	advantages	of	CRN	and	portfolio	inclusion	for	my	study	were	that	these	offered:	1)	support	for	
the	 local	NHS	 sites	 to	 assess	 and	ultimately	 approve	 the	 study	by	providing	 access	 to	CRN-funded	
research	 delivery	 staff	 (research	 nurses,	 data	 managers,	 etc.);	 2)	 access	 to	 a	 central	 document	
management	system	for	all	the	documents	and	approvals	relating	to	the	study;	3)	re-imbursement	to	
the	local	NHS	sites	for	participation	in	the	study,	which	thus	encouraged	them	to	participate;	and	4)	
site	selection.	After	being	made	aware	of	my	study	via	their	local	CRN,	local	researchers	at	several	sites	
contacted	me	and	requested	to	participate	in	the	study.	
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Recently	(as	of	Spring	2016),	there	has	been	a	substantial	change	in	the	way	research	in	the	NHS	is	
approved	and	managed.	The	HRA	has	shifted	some	of	the	responsibilities	of	research	and	development	
approval	away	from	local	NHS	trusts	to	a	central	body.	However,	when	my	study	was	initiated,	a	full	
review	was	required	at	each	study	site	(NHS	Trust),	prior	to	initiation	of	the	study	at	that	site.	
	
The	issues	I	encountered	during	local	approval	and	data	collection	are	summarised	as	follows:	
1. Information	governance	issues:	
a. Discussing	why	patient	consent	was	not	required:	i.e.	this	would	be	an	anonymised	extract	
used	only	for	a	‘limited’	purpose,	with	strict	access	controls	(i.e.	only	one	person,	myself,	
would	have	access	to	this	anonymised	dataset).	
b. Clarifying	that	the	project	already	had	ethical	approval.	
c. Clarifying	 why	 initial	 extraction	 of	 the	 data	 (but	 not	 transfer)	 required	 certain	 patient	
identifiers	to	be	retained,	so	that	the	two	different	datasets	could	be	linked	together.	After	
this	stage,	removal	of	identifiers	and	further	anonymisation	could	be	carried	out	on	the	
linked	dataset	prior	to	its	transfer	to	me.	
d. Providing	reassurance	that	the	data	would	only	be	used	for	the	project	specified,	and	not	
shared	with	any	other	individual	or	group.	
e. Providing	reassurance	that	each	NHS	Trust’s	data	would	not	be	compared	with	any	that	of	
other	NHS	Trust;	i.e.	the	data	would	only	be	analysed	as	a	grouped	cohort.	
	
2. Technical	issues	
a. Identification	 of	 the	 relevant	 information	 teams	 at	 each	 NHS	 hospital,	 these	 being	
responsible	 for	 maintaining	 or	 providing	 data	 from	 each	 of	 the	 two	 data	 repositories	
(CDS.APC	and	blood	results).	
b. Identifying	the	individual	with	the	authority	to	authorise	the	task	of	extracting	the	data.	
c. Understanding	the	variable	IT	and	data	landscapes	at	each	NHS	Trust,	and	identifying	the	
optimal	systems	by	which	to	extract	the	required	data.	
d. Convincing	the	various	information	team	individuals	that	it	was	possible	to	extract	the	data	
I	was	requesting	from	either	the	databases	or	the	relevant	IT	system.	
e. Convincing	the	various	information	team	individuals	that	the	work	of	extracting	the	data	
from	either	the	database	or	the	IT	system	would	not	require	months	of	work.	
f. Convincing	the	various	information	team	individuals	that	external	IT	consultants	did	not	
need	to	be	hired,	at	a	cost	of	approximately	£50,000,	to	extract,	link	and	anonymise	the	
data	I	was	requesting.	
	
66	
g. Convincing	the	various	information	team	individuals	to	prioritise	and	actually	carry	out	the	
data	extraction.	The	individuals	concerned	were	frequently	overworked,	in	departments	
which	were	struggling	to	manage	their	routine	workload.	
h. Most	 NHS	 Trusts	 were	 unable	 to	 access	 their	 datasets	 from	 as	 long	 ago	 as	 2005	 (the	
requested	data	extraction	 start	date),	and	 thus	 shorter	historic	 time	periods	had	 to	be	
accepted.	
	
To	resolve	the	above	issues,	1)	I	learnt	about	the	workings	of	the	clinical	IT	systems,	frequently	from	
the	manufacturers	of	such	systems,	and	provided	technical	support	to	the	relevant	individuals	at	each	
NHS	Trust,	to	help	them	extract/link/anonymise	the	data;	and	2)	made	multiple	visits	to	every	NHS	
trust	enrolled	in	the	study,	along	with	making	weekly/fortnightly	phone	calls.		
	
The	initial	timeline	for	this	phase	(data	collection)	of	my	study	was	set	at	six	months.	However,	the	
entire	process,	up	to	the	point	of	receiving	an	anonymised	dataset,	took	approximately	two-and-a-half	
years.	For	all	the	NHS	Trusts,	this	was	the	first	time	they	had	been	involved	in	a	study	in	which	such	
large	amounts	of	data	were	extracted,	 linked	between	different	hospital	 systems,	anonymised	and	
transferred	 to	 an	 external	 investigator.	 The	 full	 list	 of	 NHS	 Trusts	 that	 enrolled	 in	 the	 study	 and	
provided	data	is	shown	in	Table	2.4.	A	number	of	NHS	Trusts	either	declined	to	participate	in	the	study,	
or	enrolled	and	passed	information-governance	approval,	but	were	then	unable	to	provide	any	data,	
due	to	an	inability	to	resolve	some	of	the	technical	issues	previously	outlined.	
	
Table	2.4:	List	of	all	NHS	Trusts	participating	in	the	ML-EWS	Study	
	 NHS	Trust	
1	 Barnet	and	Chase	Farm	Hospitals	NHS	Trust,	England	
2	 Barts	Health	NHS	Trust,	England	
3	 Betsi	Cadwaladr	University	Health	Board,	Wales	
4	 Cardiff	and	Vale	Health	Board,	Wales	
5	 Colchester	Hospital	University	NHS	Trust,	England	
6	 Epsom	and	St	Helier	University	Hospital	NHS	Trust,	England	
7	 George	Eliot	Hospital	NHS	Trust,	England	
8	 Homerton	University	Hospital	NHS	Trust,	England	
9	 Imperial	College	Healthcare	NHS	Trust,	England	
10	 Royal	Cornwall	Hospitals	NHS	Trust,	England	
11	 Royal	Free	NHS	Trust,	England	
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12	 Royal	Marsden	Hospital	NHS	Trust,	England	
13	 University	College	London	NHS	Trust,	England	
14	 Whittington	Hospital	NHS	Trust,	England	
	
2.3.1	Pre-Processing	of	the	Collected	Data	
The	challenges	encountered	with	the	data	collection	continued	during	the	transfer	of	the	anonymised	
datasets	 to	 me.	 In	 fact,	 the	 most	 technically	 challenging	 aspect	 of	 data	 acquisition	 was	 the	 pre-
processing	of	the	transferred	data.	Pre-processing	involves	1)	ingestion	of	the	data	to	a	database;	2)	
transformation:	the	conversion	of	the	data	to	a	standard	format	(for	example	male	=	‘1’	as	opposed	to	
male	=	‘M’);	3)	cleaning:	identification	of	incomplete,	inaccurate,	and	irrelevant	data	and	conversion	
or	removal	of	such	data;	4)	feature	engineering:	creation	of	new	variables	(features)	from	the	raw	data;	
and	 5)	 variable	 selection:	 selecting	 the	 specific	 variables	 needed	 to	 build	 a	 model.	 The	 feature	
engineering	and	variable	selection	for	each	model	will	be	described	in	the	relevant	chapters	for	each	
model	 (Chapters	 3,	 4	 and	5).	Here,	 I	 describe	 the	 challenges	 and	 steps	 involved	 in	performing	 the	
ingestion,	transformation	and	cleaning	aspects	of	pre-processing.	
2.3.1.1	Data	Ingestion	
The	data	from	the	various	NHS	Trusts	were	inserted	into	a	SQL	Server	2014	database,	using	the	SQL	
Server	‘import	wizard’.	The	database	was	initially	housed	on	a	secure	and	dedicated	workstation,	and	
then	transferred	to	a	secure	dedicated	server;	both	computers	were	only	used	for	this	project,	and	
had	all	appropriate	security	measures	deployed	(as	described	in	my	ethics	submission	and	research	
protocol).	The	data	themselves	were	occasionally	provided	by	the	NHS	Trusts	as	a	database	backup,	
but	most	commonly	as	a	number	of	simple	text	files	(‘flat	files’).	The	‘flat	files’	consisted	of	plain	text	
with	a	delimiter	between	each	variable,	such	as:	‘-‘	(dash),	‘|’	(pipe),	or	‘||’	(double	pipe).	Occasionally	
the	variables	within	 the	 files	were	either	placed	 in	 fixed-width	slots	 (i.e.	variable	one	occupied	 the	
space	 for	 characters	1–10;	 variable	 two,	 characters	11–20,	etc.),	 or	were	 separated	by	 fixed-width	
empty	 spaces	 (‘tabs’).	 The	 initial	 import	 of	 the	 data	was	 performed	 using	 a	 ‘catch-all’	 philosophy,	
where	 all	 the	 data	were	 imported	 into	 a	 text	 format	 that	 allowed	 for	 various	 types	 of	 characters	
(‘varchar’).	Thus	dates,	text	and	numbers	were	all	regarded	as	strings	of	characters.	Despite	this	catch-
all	 approach	 with	 no	 initial	 quality	 control,	 there	 were	 still	 issues	 with	 the	 data	 ingestion.	 Most	
commonly,	 1)	 the	 delimiters	 within	 the	 data	 changed	 part-way	 through	 a	 file,	 or	 2)	 there	 were	
additions	of	comments	within	the	file	that	were	not	 in	the	same	format	as	the	rest	of	the	data.	To	
correct	these	and	other	errors,	I	utilised	special	software	tools	such	as	‘R’	and	‘Notepad++’	to	manually	
inspect	the	data	files	and	fix/remove	corrupted	segments.	
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The	above	procedure	was	carried	out	for	every	data	file	received	from	every	NHS	Trust.	This	was	a	long	
and	 laborious	 process,	 as	 not	 only	 did	 the	 data	 files	 differ	 between	NHS	 Trusts,	 but	when	 a	 Trust	
consisted	of	multiple	hospitals,	the	data	was	commonly	provided	on	a	per	hospital	basis,	each	with	its	
own	 data	 structures.	 In	 addition,	 as	 data	 from	multiple	 years	was	 requested	 (2005	 onwards),	 the	
majority	of	NHS	Trusts	decided	to	extract	their	data	on	a	yearly	basis,	and	rather	than	consolidating	it	
all	into	one	dataset,	they	provided	multiple	files	for	a	specific	dataset,	sometimes	covering	only	one	
year	at	a	time.	The	data	structure	within	these	files	also	changed	every	few	years,	for	every	NHS	trust.	
A	factor	that	further	complicated	this	entire	process	was	that	there	was	frequently	no	documentation	
available	 for	 any	 of	 this	 historic	 data.	 Thus,	 data	 transformation	 had	 to	 be	 carried	 out	 by	 visual	
inspection	of	the	data	contents.	
2.3.1.2	Data	Transformation	
Despite	requesting	data	that	is	shared	nationally	using	two	national	standards	(CDS.APC	and	NLMC),	
and	requesting	 the	data	 in	 these	national	 formats,	none	of	 the	NHS	Trusts	who	participated	 in	my	
study	provided	me	with	this	data	in	the	respective	national	formats.	In	fact,	every	NHS	Trust	provided	
the	data	using	its	own	customised	format.	These	customised	formats	used	different	names	not	only	
for	 the	 same	 variables	 (for	 example,	 ‘sex’	 could	 be	 ‘persongender’	 or	 ‘persongendercurrent’,	 or	
‘gender’),	but	also	for	the	data	items	within	the	variables	(for	example:	male	could	be:	‘1’,	‘M’	or	‘male’;	
hemoglobin	could	be:	‘Hb’,	‘hb’,	‘haemoglobin’,	‘HB’,	‘serum_HB’,	‘venous_HB’,	etc).	Surprising	as	this	
may	seem,	the	creation	and	maintenance	of	local	customised	data	models	(as	opposed	to	the	adoption	
of	 a	 national	 standard),	 seems	 to	 be	 the	 path	 of	 least	 resistance	within	 NHS	 Trusts.	 Consider	 the	
CDS.APC	 dataset:	 although	 it	 is	 a	 national	 requirement	 to	 submit	 these	 data	monthly	 to	 HSCIC	 in	
England	(NWIS	in	Wales),	not	a	single	NHS	Trust	in	my	cohort	submitted	this	data	directly	to	its	relevant	
national	body.	Instead,	each	NHS	Trust	submitted	its	data	to	a	commercial	data	processing	company	
(most	commonly	Indigo	Ltd).	Indigo	would	then	1)	perform	quality	checks	on	the	data,	2)	transform	it	
to	the	HSCIC’s	required	XML	(eXtensible	Mark-up	Language)	format,	and	3)	submit	it	on	behalf	of	the	
NHS	Trust	to	the	HSCIC.	In	the	majority	of	cases,	the	NHS	Trust	would	not	even	hold	a	copy	of	this	final	
XML	submission.	Thus,	the	national	standard	for	the	data	generates	work	for	commercial	data	analytics	
companies,	 rather	 than	 encouraging	 every	 NHS	 organisation	 to	 standardise	 data	 capture	 and	
processing,	and	to	create	workflows	that	align	with	national	requirements.	
	
There	are,	I	believe,	multiple	reasons	for	this:	
1. Clinical	 IT	 systems	 can	 be	 highly	 specialised	 and	 proprietary.	 The	majority	 of	 healthcare	 IT	
systems	in	NHS	Trusts	today	are	relatively	old.	They	are	based	on	state-of-the-art	technology	
from	at	 least	a	decade	or	two	ago.	The	majority	have	also	not	been	upgraded	to	the	 latest	
available	system	release,	due	to	the	cost	of	modifying	the	newer	systems	to	communicate	with	
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other	legacy	IT	systems.	Thus,	these	systems	have	limited	functionality,	and	even	less	ability	
to	be	modified	for	new	data	capture	and	extraction	requirements.		
2. Limited	access	to	the	software	that	powers	the	clinical	IT	systems.	The	commercial	agreements	
that	NHS	Trusts	have	signed	with	their	IT	providers	frequently	do	not	allow	the	NHS	Trust	(the	
customer)	 to	 directly	 access	 the	 raw	 clinical	 or	 administrative	 data	 stored	 within	 these	
systems.	The	only	access	that	the	NHS	trusts	have	are	via	customised	‘portals’	that	allow	only	
a	very	narrow	range	of	queries	to	be	carried	out	on	the	underlying	databases	that	store	the	
data.	The	queries	themselves	are	not	based	on	a	standard	database	querying	language,	such	
as	 SQL	 (standard	 query	 language),	 but	 have	 customised	 and	 proprietary	 syntax,	 adding	 an	
additional	barrier	to	data	access	and	extraction.	
3. The	 IT	 expertise	 within	 an	 NHS	 Trust	 is	 limited,	 as	 the	 IT	 departments	 are	 generally	
underfunded,	with	a	high	staff	turnover	rate.	The	salaries	for	information	analysts	within	the	
NHS	are	lower	than	equivalent	salaries	in	the	commercial	sector.	In	addition,	it	is	always	more	
politically	expedient	to	spend	money	on	hiring	more	managers,	nurses,	or	doctors,	than	on	an	
IT	system	or	staff.	During	the	course	of	my	project,	I	frequently	found	that	my	IT	liaison	at	an	
NHS	Trust	had	moved	to	another	organisation.	
4. Finally,	 procedures	 to	 procure	 and	 maintain	 the	 myriad	 clinical	 information	 systems	 have	
traditionally	been	conducted	haphazardly	(in	my	opinion)	within	the	NHS.	As	a	result,	although	
the	money	 spent	 on	 these	 systems	 is	 substantial,	 the	 system	obtained	 is	 either	 not	 fit	 for	
purpose,	or	the	contracts	signed	do	not	allow	any	flexibility	without	massive	additional	costs.	
Therefore,	when	clinical	requirements	change,	the	IT	systems	are	not	appropriately	modified;	
instead,	 inappropriate	 (and	 cheap)	 modifications	 are	 employed	 to	 enable	 increased	
functionality.	 This	 creates	 an	 IT	 environment	 within	 an	 NHS	 Trust	 that	 includes	 multiple	
systems,	 all	 diverging	 from	 standard	manufacturer	 specification	 and	 industry	 best	 practice	
guidance.	Over	time,	this	complexity	increases,	and	it	becomes	even	more	difficult,	and	costly,	
to	change	and	upgrade	the	systems.	
	
To	 return	 to	my	data:	post	data	 ingestion,	 I	performed	a	number	of	 steps,	both	 to	 check	 the	data	
quality	and	to	transform	the	data	to	my	standard	format.	I	designed	a	series	of	queries	(‘scripts’)	to	
perform	these	tasks.	These	tasks	were:	
1. To	confirm	the	anonymisation	of	 the	 identifiable	 fields.	 If	anonymisation	was	 in	doubt,	another	
round	of	‘hashing’	was	carried	out	on	these	fields,	across	the	linked	data.	
2. To	confirm	the	deletion	of	non-requested	fields	(especially	identifiable	fields).	If	the	presence	of	any	
identifiers	was	 noticed,	 these	were	 immediately	 deleted	 (in	 both	 the	 original	 raw	 file	 and	 the	
database)	and	discussed	with	the	providing	NHS	Trust.	No	significant	identifiable	data	was	received	
in	this	way.	
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3. To	confirm	the	linkages	of	the	CDS.APC	data	to	the	blood	results	data.	Occasionally,	no	linkages	
across	 these	 two	were	 found.	After	 liaising	with	 the	NHS	Trusts	 concerned,	 the	most	 common	
cause	was	inappropriate	anonymisation:	i.e.	different	anonymisation	algorithms	were	employed	
to	 anonymise	 or	 ‘hash’	 the	 same	 identifiers	 in	 the	 two	 datasets	 (CDS.APC	 and	 blood	 results),	
resulting	 in	 different	 hashed	 values	 which	 did	 not	 match.	 Once	 identified,	 the	 NHS	 Trusts	
appropriately	anonymised	the	datasets	and	provided	them	to	me.	
4. A	database	‘View’	(method	of	transforming	data	and	visualising	the	new	format),	was	created	for	
each	 NHS	 Trust	 for	 the	 CDS.APC	 and	 blood	 results	 data.	 These	 ‘Views’	 transformed	 both	 the	
variable	names	from	the	original	 ‘flat	files’,	as	well	as	the	data	types	(string,	numeric,	datetime	
etc.)	into	my	standard	format.	Thus,	two	Views	(CDS.APC	and	blood	results)	were	created	for	each	
NHS	Trust.	This	step	required	multiple	iterations,	as	the	transformation	frequently	failed	due	to	
corrupted	 data,	 non-standard	 characters,	 or	 the	 assignation	 of	 data	 elements	 to	 the	 wrong	
category	(for	example,	the	date	of	admission	being	placed	in	the	‘method	of	admission’	field,	with	
the	date	being	stored	as	a	custom	data	type	(datetime),	while	method	of	admission	data	were	
numerical).	
5. Once	 these	 Views	 were	 created,	 the	 identifiers	 across	 the	 CDS.APC	 and	 blood	 results	 were	
rehashed	and	then	replaced	sequentially	by	an	 index	number,	beginning	at	 ‘1’.	Finally,	a	coded	
prefix	 unique	 to	 that	 NHS	 trust	 was	 added	 to	 each	 anonymised	 identifier.	 Thus,	 identifier	 ‘1’	
became	‘abc-1’.	This	was	to	allow	merging	of	the	data	across	NHS	Trusts	and	prevent	duplicate	
hashed	identifiers	from	occurring;	i.e.	if	two	separate	NHS	Trusts	used	different	SALTs,	it	is	possible	
that	different	NHS	numbers	could	have	been	converted	to	the	same	anonymised	‘hash’.	
6. Once	these	Views	and	new	identifiers	were	finalised	for	each	NHS	Trust,	the	data	was	transferred	
(via	the	Views)	to	a	new	database,	where	all	the	data	(across	NHS	Trusts)	were	merged	together,	
into	two	separate	tables:	1)	CDS.APC,	and	2)	ORU.Pathology	(blood	results).	
7. New	tables	were	now	created	that	extracted	key	variables	from	the	CDS.APC	table	into	additional	
linked	(relational)	tables.	These	were:	ICD10	(which	consisted	of	the	hashed	patient	identifier,	Spell	
date	of	admission	and	Spell	date	of	discharge,	and	a	single	ICD10	code.	Thus,	one	CDS.APC	row	
could	result	in	fifty	rows	in	the	ICD10	table,	as	each	ICD10	code	would	have	its	own	row.	A	similar	
table	was	created	for	OPCS-4	codes.	This	process	of	converting	data	into	singular	rows	is	referred	
to	as	conversion	from	‘wide’	to	‘tall’	format.	Additional	tables	were	created	that	held	only	patient	
demographic	data.		Rather	than	permanently	link	each	row	in	each	table	to	rows	in	other	tables	
using	unique	row	identifiers	(a	relational	structure),	I	chose	to	include	key	data	in	each	of	the	tables	
(a	flat	structure).	The	advantage	of	this	‘flat’	approach	is	that	each	table	could	be	independently	
queried	for	data;	however,	the	disadvantage	is	that	some	data	would	be	duplicated.		
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2.3.1.3	Data	Cleaning	
Once	all	the	data	was	inserted	into	the	final	database	‘RHub’,	inspection	and	cleaning	of	the	contents	
of	the	data	variables	could	begin.	The	size	of	the	dataset	at	this	time	was	immense.	The	ORU.Pathology	
(blood	results)	table	alone	consisted	of	over	1.1	billion	rows,	and	the	CDS.APC	table	had	over	16	million	
rows.	However,	this	was	the	‘uncleaned’	data,	and	was	currently	unfit	for	use	in	my	analysis.	The	steps	
I	performed	to	‘clean’	this	data	were:	
	
1. The	first	task	was	to	check	the	quality	of	the	linked	identifiers.	Frequently,	when	a	patient	arrives	
in	hospital,	although	they	have	been	admitted/registered	on	the	hospital	systems	before,	a	new	
hospital	number	(MRN)	is	assigned	to	them.	Thus,	a	patient	may	have	more	than	one	MRN.	The	
resultant	problem	is	that	all	 the	patient’s	historic	data	becomes	 inaccessible	 if	 the	new	MRN	is	
used	to	search	for	such	data	(for	example,	blood	results).	To	remedy	this	situation	in	my	dataset,	I	
searched	for	multiple	MRNs	that	were	linked	to	the	same	NHS	Number	(I	had	requested	the	hashed	
MRN	and	NHS	numbers	for	each	patient).	For	each	of	these,	I	then	checked	whether	the	date	of	
birth	(month	and	year	of	birth)	and	sex	matched;	if	so,	all	these	identifiers	were	consolidated	into	
one,	and	the	old	identifiers	deleted.	This	was	checked	across	both	the	CDS.APC	and	ORU.Pathology	
tables.	If	there	were	clashes,	such	as	if	the	linked	MRNs	and	NHS	numbers	had	different	birth	dates	
and	sexes	associated	with	them,	then	these	data	were	deleted.	Eventually,	a	final	identifier	list	was	
created	and	updated	across	all	the	tables.	
2. I	then,	for	each	of	the	variables	listed	in	Tables	2.1	and	2.2,	sequentially	checked	how	much	of	the	
data	within	each	variable	conformed	to	 the	expected	attributes.	All	data	 that	did	not	perfectly	
match	the	expected	attributes	were	either	converted	to	match	these	where	possible	(for	example,	
ethnic	category	‘British’	changed	to	‘A’),	or	deleted.	When	data	was	missing	for	a	variable,	this	was	
checked	against	the	ORU.Pathology	and	demographics	tables,	and	if	present	were	used.	
3. Admission	and	discharge	dates	prior	to	1	January	2004	and	1	October	2016	were	also	deleted,	as	
were	 rows	of	data	where	either	of	 these	values	was	missing,	or	where	 the	discharge	date	was	
before	the	admission	date.	In	addition,	all	rows	of	data	where	the	discharge	date	was	>183	days	
(more	 than	 six	months)	 from	 the	 admission	date	were	 also	 deleted.	 This	was	 because	 I	 found	
lengths	of	stays	of	five	years	or	more	for	hundreds	of	patients,	many	with	the	same	discharge	date	
(implying	that	a	default	discharge	date	had	been	inserted	when	none	was	present;	this	is	poor	but	
common	 practice	 in	 databases	 that	 have	 been	 designed	 not	 to	 accept	 empty	 values).	 I	
acknowledge	that	this	approach	does	exclude	genuine	patients	with	 lengths	of	stays	of	greater	
than	six	months,	but	these	patients	form	a	tiny	proportion	of	the	total	number	of	admissions.	
4. Date	of	birth	parameters	were	also	further	pruned.	The	remit	of	the	study	was	to	investigate	only	
adult	patients;	however,	as	the	dataset	spans	over	a	decade,	patients	who	are	now	adults	may	
have	been	admitted	when	they	were	younger	than	eighteen	years	old.	Although	these	admissions	
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would	not	be	investigated	directly,	the	past	medical	history	of	adult	patients	is	crucially	important	
in	understanding	a	patient’s	condition	and	their	likelihood	of	deterioration.	Thus,	to	comply	with	
the	 remit	of	my	project,	but	also	 to	 retain	past	medical	history	data,	 I	deleted	 the	data	 for	all	
patients	born	on	or	after	September	1995;	eighteen	years	before	the	start	of	my	project.	Thus,	
only	adult	patients,	according	to	the	approved	data	ethics	for	my	project,	were	 included	 in	the	
investigation.	 However,	 I	 also	 took	 the	 additional	 step	 of	 including	 only	 patients	 who	 were	
eighteen	years	or	over	on	the	date	of	admission	to	hospital	in	my	subsequent	analyses	(Chapters	
3	to	5).	Most	NHS	Trusts	were	not	able	to	perform	this	filtering	of	the	data	prior	to	transfer.	
5. For	 each	 blood	 result	 test,	multiple	 dates	 and	 times	were	 available:	 i.e.	 for	 sample	 collected,	
sample	received	in	laboratory,	and	result	validated.	However,	all	three	categories	were	sparsely	
populated,	with	the	most	common	variable	being	‘validated	datetime’.	Therefore,	I	used	‘validated	
datetime’	for	my	analyses.	Out-of-range	values	were	also	deleted.	
6. For	the	‘TestNames’	variable,	there	were	thousands	of	unique	blood	result	tests,	and	sorting	and	
categorising	 all	 of	 these	would	 not	 have	 been	 possible	 during	 the	 course	 of	my	 investigation.	
Therefore,	I	focussed	on	the	most	common	blood	tests	performed	in	hospital,	specifically	full	blood	
count	(FBC),	urea	and	electrolytes	(U’s	and	E’s),	and	albumin.	Each	of	these	tests	was	represented	
under	multiple	names.	Customised	searches	were	carried	out	on	common	variations	of	each	of	the	
possible	names,	and	when	it	was	confirmed	that	they	did	indeed	represent	the	test	in	question,	all	
the	differing	names	were	changed	to	the	database	standard.	All	other	tests	were	left	untouched	
for	‘cleaning’	at	a	later	date.	I	also	received	result	data	from	samples	other	than	blood;	however,	I	
analysed	only	venous	or	arterial	blood	results.	
7. One	would	expect	the	units	in	which	common	blood	tests	are	reported	to	be	the	same;	however,	
this	was	not	the	case.	For	each	blood	test,	I	confirmed	the	range	of	its	actual	results	along	with	the	
pairing	of	its	units,	and	if	they	conformed	to	reported	quality	standards,	approved	them.	However,	
when	the	ranges	and	units	did	not	match,	further	investigation	was	carried	out,	and	where	possible	
the	result	values	were	converted	to	the	appropriate	units.	
8. Finally,	I	also	carried	out	a	range	of	additional	quality	checks	for	the	distribution	of	the	data.		
	
Apart	 from	various	specific	data	cleaning	 tasks	described	above,	 I	also	deleted	all	blood	results	 for	
which	where	there	were	no	matching	patient	 identifiers	 in	 the	CDS.APC	dataset.	These	blood	tests	
were	probably	performed	by	 the	hospital	 laboratory	on	patients	who	had	never	been	admitted	 to	
hospital,	and	were	thus	not	relevant	for	my	analyses.	Duplicate	blood	results	were	also	deleted.	
	
The	size	of	the	dataset	following	these	extensive	changes	was,	for	CDS.APC,	~8	million	rows;	and	for	
ORU.Pathology,	~500	million	 rows.	 Further	details	of	 the	data	are	provided	 in	each	of	 the	analysis	
chapters	(Chapters	3	to	5).	
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2.4	Lessons	learned	
I	 believe	 the	 reason	 for	 my	 success	 for	 carrying	 out	 such	 a	 large-scale	 data	 project,	 hinge	 on	 a	
combination	of	my	clinical	and	technical	expertise,	and	following	the	principles	of	these	key	lessons.		
A. The	 ethical	 and	 legal	 requirements	 are	 not	 barriers	 to	 make	 life	 difficult	 for	 researchers,	 but	
necessary	 safeguards	 to	maintain	 trust.	 These	 ethical/legal	 requirements	 are	 complicated,	 and	
sometimes	 conflicting,	 and	 thus	 frequently	 require	 discussion	 and	 clarification	with	 individuals	
responsible	for	approving	the	data	access	
B. Technological	advancements,	especially	 in	the	field	of	encryption	and	anonymisation	are	taking	
place	faster	than	regulations	and	guidance	can	keep	up.	It	is	essential	to	follow	the	principles	of	
the	 ethical/legal	 framework	 rather	 than	 simply	 the	 guidance	 text.	 Thus,	 when	 appropriate	
additional	 steps	 would	 enhance/maintain	 these	 principles,	 then	 further	 data	 anonymisation,	
deletion,	and	limitations	in	access,	need	to	be	implemented.	
C. Individuals	working	in	a	healthcare	environment,	especially	those	involved	with	data	and	IT	are	
busy	and	have	limited	time	to	both	engage	with	researchers	and	to	extract	the	data.	They	have	
skills	specifically	suited	to	their	job	of	maintaining	the	IT	systems	for	clinical	use,	and	these	skills	
do	not	always	enable	large	scale	or	live	data	access.	However,	they	are	extremely	motivated.	Thus	
to	succeed	in	a	project	that	requires	medical	data	access,	three	key	 ingredients	are	required	1)	
patience,	2)	technical	support,	and	3)	management	support	to	prioritise	the	data	access	workload.	
D. Healthcare	 IT	 systems	 are	 generally	 proprietary	 systems,	 which	 are	 based	 both	 on	 older	
technology	frameworks	and	have	limited	access	to	the	end	user	(customer).	This	makes	accessing	
the	 data	 that	 resides	 in	 them	 difficult.	 Engagement	 with	 the	 software	 provider	 is	 frequently	
necessary	 to	 understand	 these	 proprietary	 systems,	 and	 to	 enable	 technical	 support	 to	 the	
healthcare	IT	teams.	Data	access	from	certain	IT	systems	will	be	unfeasible	either	due	to	technical	
issues,	or	because	the	software	provider	will	demand	a	large	payment	to	enable	such	data	access.		
E. Healthcare	 data	 resides	 in	 multiple	 IT	 systems,	 and	 is	 frequently	 collected	 in	 duplicate	 from	
multiple	sources.	In	cases	where	data	access	from	a	certain	healthcare	IT	system	is	unfeasible,	this	
data	may	be	accessible	from	another	data	repository	within	the	hospital.	
F. Healthcare	 data	 does	 not	 adhere	 to	 published	 international,	 national	 or	 even	 local	 standards.	
Demanding	data	 in	a	 format	 (schema	and	quality)	 suitable	 for	 the	 researcher	 is	quick	 route	 to	
alienating	 IT	 staff.	Raw	data	 is	better	 than	heavily	modified	data.	A	 significant	amount	of	 time	
needs	to	be	spent	in	examining	and	understanding	this	data.	Both	clinical	and	technical	expertise	
is	essential	in	enabling	data	transformation	to	a	canonical	standard.		
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Chapter	3	Dehydration:	simple	dual	parameter	to	ML	
One	of	the	simplest	ways	two	blood	result	variables	have	been	used	in	conjunction	has	been	the	urea	
to	creatinine	ratio	(Ur:Cr)	as	a	surrogate	for	dehydration.	In	this	chapter,	I	will	explore	the	extent	to	
which	this	ratio	is	associated	to	poor	outcome.	I	will	expand	on	the	historical	snapshot	interpretation	
of	the	ratio	and	its	association	with	outcome	by	investigating	1)	its	dynamic	change,	2)	the	effect	the	
addition	of	simple	demographic	data	modifies	outcome	prediction	and	3)	the	application	of	a	simple	
ML	technique.	
	
Made	 up	 of	 two	 of	 the	 blood	 tests	 most	 commonly	 performed	 in	 hospital	 are	 for	 urea	 (Ur)	 and	
creatinine	 (Cr).	 Individual	 results	 higher	 than	 the	 normal	 range,	 as	well	 as	 an	 elevated	Ur:Cr	 (>80	
mmol/L:mmol/L),	are	known	to	be	associated	with	poor	outcome,	 (Chapter	1,	Section	1.4.2).	More	
specifically,	Urea	and	creatinine	results	are	also	used	to	define	serious	medical	problems	prevalent	
amongst	hospitalised	patients,	as	follows:	1)	a	significant	rise	in	creatinine	is	used	to	define	AKI;	and	
2)	 a	Ur:Cr	>	80	has	historically	been	used	 to	define	dehydration.	 The	availability	of	 these	 two	 test	
results	 amongst	 data	 for	 hospitalised	 patients	 makes	 them	 obvious	 candidates	 for	 initial	 use	 in	
developing	a	risk	stratification	model	for	predicting	AEs	in	hospitalised	patients.		
	
To	explore	the	utility	of	Ur	and	Cr	test	results	in	predicting	in-hospital	decline,	I	performed	my	initial	
analyses	on	the	first	three	NHS	Trusts	from	which	I	obtained	data.	I	focused	on	emergency	admissions	
to	hospital,	as	these	have	a	high	risk	of	in-hospital	mortality.124		
3.1	Objectives	
To	 investigate	 outcome	 (mortality	 and	 length	 of	 stay)	 associated	 with	 known	 models	 of	 disease.	
Specifically,	for	dehydration,	to	explore		
I. The	significance	of	dehydration	as	measured	by	Ur:Cr	on	outcome	
II. The	 significance	 of	 dynamic	 changes	 in	 dehydration	 (Ur:Cr)	 status,	 combined	with	 AKI,	 on	
outcome	
III. The	application	of	an	ML	technique	that	incorporates	urea	and	creatinine	results	with	simple	
demographic	data	to	identify	those	at	risk	of	poor	outcome	
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3.2	Methods	
3.2.1	Data	
Data	used	included	in-hospital	blood	results	and	administrative	data	(demographics	and	ICD10	codes)	
(Chapter	2,	Section	2.1),	from	adult	(aged	18	years	or	over)	emergency	admissions	to	three	UK	NHS	
Hospital	 Trusts	 over	 156	 months	 (from	 early	 2007	 to	 mid-2013,	 dates	 varying	 slightly	 between	
hospitals).	All	three	of	these	trusts	were	rated	as	‘good’	or	‘excellent’	by	the	Care	Quality	Commission	
rating	 in	2009,125	and	had	a	Standardised	Mortality	Ratio	below	the	national	average	as	of	 January	
2014126.	Only	data	for	patients	with	complete	administrative	records	and	>2	paired	urea	and	creatinine	
blood	test	results	were	used	for	analysis.	Excluded	were	maternity	patients,	those	who	self-discharged,	
and	patients	for	whom	a	blood	test	was	not	performed	within	24	hours	of	hospital	admission	(in	whom	
a	change	 from	admission	could	not	be	assessed).	Patients	with	 ICD10	codes	associated	with	upper	
gastrointestinal	bleeding	were	also	excluded	from	the	analysis,	due	to	the	well-established	correlation	
between	changes	 in	 the	Ur:Cr	 ratio	and	 this	pathology	 (Chapter	1,	 Section	1.4.2),	 thus	making	 the	
assessment	of	AKI	or	dehydration	unreliable.		
	
The	variables	used	for	analysis	were:	1)	hospital	administrative	data	(age,	length	of	stay	(LoS),	diagnosis	
fields	 (ICD-10	 International	 Classification	 of	 Diseases,	 10th	 revision),	 method	 of	 admission	 and	
discharge);	and	2)	blood	result	data	relating	to	urea	(mmol/L)	and	creatinine	(μmol/L).	Data	available	
to	a	clinician	at	the	point	of	assessing	a	patient	informed	variable	selection.	
3.2.2	Analysis	
To	 determine	 the	 association	 of	 admission	 Ur:Cr	 (and	 its	 subsequent	 change)	 with	 AKI,	 LoS	 and	
mortality,	I	performed	two	broad	analyses:		
1. Binary	analysis:	Proportions	of	patients	with	an	admission	Ur:Cr	<80	(normal,	N)	or	>80	(high,	H),	
and	whose	admission	status	was	either	preserved	(normal	to	normal:	N->N,	high	to	high:	H->H)	or	
changed	(N->H,	H->N)	at	any	time	during	their	hospital	stay,	were	calculated.	Fluctuating	Ur:Cr	was	
not	analysed	separately.	Development	of	AKI	was	defined	using	the	 ‘Kidney	Disease:	 Improving	
Global	Outcomes’	(KDIGO)	criteria	83	(Table	1.1).	Each	patient’s	admission	creatinine	defined	their	
baseline.33	Association	between	Ur:Cr	(or	its	change)	with	outcome	was	sought	in	predefined	age	
groups	(<65,	>65	years;	traditionally	the	retirement	age).	Together,	AKI	and	Ur:Cr	yielded	16	sub-
groups	(Table	3.3	and	3.4)	where	in-hospital	mortality	(percentage)	and,	for	survivors,	median	LoS,	
were	calculated.		
2. Continuous	analysis:	Ur:Cr	was	plotted	against	 in-hospital	mortality,	 for	each	 set	of	 a	patient’s	
blood	tests	 (admission	 to	 last	blood	test	before	discharge	or	death).	The	percentage	change	 in	
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Ur:Cr	 from	 admission	 to	 last	 test	was	 calculated.	 Heatmaps	 of	 age	 vs	 Ur:Cr	 vs	mortality	were	
plotted	for	both	the	admission	and	the	last	blood	tests,	to	visualise	the	influence	of	age.	The	last	
set	of	blood	results	were	used	(Ur:Crlast)	as	these	could	be	considered	to	be	either	the	optimum,	
when	 a	 patient	 was	 discharged;	 or	 the	 worst,	 just	 prior	 to	 death.	 To	 highlight	 the	 complex	
relationship	between	all	 the	available	 variables	 (Table	3.1),	 and	 their	 change	 (upto	 the	 second	
blood	test)	and	in-hospital	mortality,	I	built	a	RF	ML	model	(ML-Dehydration).	The	ML-Dehydration	
model	 was	 built	 using	 5-fold	 cross-validation.	 The	 hyper-parameters	 of	 the	 model	 were	
determined	via	a	grid	search.	This	analytical	framework	was	applied	to	70%	of	patients	(training	
dataset).	 The	 final	 model	 was	 tested	 on	 the	 remaining	 30%	 (testing	 dataset).	 Area	 under	 the	
receiver	operator	curve	(AUROC)	was	calculated	for	the	whole	model.	From	the	trained	model,	a	
threshold	was	set	to	classify	patients	as	either	alive	or	dead	on	discharge.	I	defined	two	classifiers	
(ML20	 and	 ML33),	 based	 on	 two	 different	 thresholds	 selected	 to	 produce	 Positive	 Predictive	
Values	of	1:5	and	1:3	respectively	for	the	training	dataset.	
	
Table	3.1:	Predictor	Variables	for	the	Machine	Learning	Model	(ML-Dehydration)	
Variables	 Type	of	variable	
Age	 Numerical	
Sex	 Categorical	
Admission	Day	(Mon-Sun)	 Categorical	
Admission	Month	(Jan-Dec)	 Categorical	
Admission	method	subset127	 Categorical	
1st	Urea	 Numerical	
1st	Creatinine	 Numerical	
2nd	Urea	 Numerical	
2nd	Creatinine	 Numerical	
1st	Ur:Cr	 Numerical	
2nd	Ur:Cr	 Numerical	
Difference	of	1st	Urea	and	2nd	Urea	 Numerical	
Difference	of	1st	Creatinine	and	2nd	Creatinine	 Numerical	
2nd	Urea	/	1st	Urea	 Numerical	
2nd	Creatinine	/	1st	Creatinine	 Numerical	
Difference	of	1st	Ur:Cr	and	2nd	Ur:Cr	 Numerical	
1st	Ur:Cr	/	2nd	Ur:Cr	 Numerical	
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3.2.2.1	Rationale	for	ML	analysis	
Traditional	regression	analyses	were	not	used,	due	to	the	following	issues	of	multicollinearity	128	(which	
refers	to	direct	correlation	between	dependent	variables)	that	existed	within	the	dataset:	
1. The	Ur:Cr	ratio	is	directly	and	inversely	proportional	to	urea	and	creatinine	respectively.	
2. AKI	is	defined	by	a	rise	in	creatinine	83	and	is	thus	correlated	with	Cr.	
3. Creatinine	levels	are	linked	to	skeletal	muscle	mass,	98	which	is	non-linearly	inversely	related	to	
age.	97		
4. Both	 urea	 and	 creatinine	 values	may	 rise	 in	 a	 related	 (albeit	 non-linear	 fashion)	 with	 specific	
disease	processes,	such	as	renal	injury.	
	
	A	RF	model	allows	for	such	collinearity,	and	is	a	powerful	analytic	technique	for	classification	analyses.	
3.2.3	Statistical	Analysis	
Fisher’s	Exact	Method	and	the	Mann	Whitney	U-Test	were	used	to	establish	the	significance	of	the	
differences	between	each	age	sub-group	(<65,	>65	y)	and	their	respective	group	baselines,	as	well	as	
the	various	interactions	of	admission	Ur:Cr	and	its	subsequent	change	during	hospitalisation	for	the	
relative	 risks.	 Data	 are	 described	 as	 a	 percentage	 of	 the	 total	 (actual	 numbers)	 or	 the	 median	
(interquartile	 range).	 Jeffrey’s	 method129	 was	 used	 to	 calculate	 confidence	 intervals.	 Sensitivity,	
specificity,	PPV	and	AUROC	were	calculated	to	determine	the	performance	of	the	RF	predictive	model.		
	
The	software	used	to	perform	the	analysis	comprised	MATLAB	R2014b	(Mathworks,	MA,	USA),	R	(R	
Foundation,	Austria),	and	h2o	(h2o.ai,	Mountain	View,	CA,	USA).	
3.3	Results	
3.3.1	Basic	characteristics	
Overall,	 79,949	 admissions	 met	 the	 analysis	 inclusion	 criteria	 (Figure	 3.1;	 total	 number	 of	 tests	
analysed:	402,733).	Table	3.2	shows	the	baseline	characteristics,	and	Figure	3.2	shows	the	histogram	
of	age	at	admission.		
3.3.2	Prevalence	of	raised	Ur:Cr	ratio	and	AKI	
A	high	Ur:Cr	was	seen	on	admission	in	45.5%	(36,339)	patients,	of	whom	83.3%	(30,268)	also	had	a	
high	Ur:Cr	at	some	other	point	during	their	hospital	stay.		Of	the	54.5%	(43,610)	admitted	with	a	normal	
Ur:Cr,	this	rose	to	>80	in	28.3%	(12,337).	The	frequency	distribution	of	admission	Ur:Cr	 is	shown	in	
Figure	3.3.	Overall,	10.7%	of	patients	(8,558)	developed	AKI	in	hospital.	
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3.3.3	Length	of	stay	of	survivors	(Table	3.3)	
The	LoS	of	those	surviving	to	discharge	was	lowest	(3.5	days	(2–6))	in	the	<65y	group	with	a	sustained	
normal	Ur:Cr	from	admission	(N	->	N),	and	highest	(19	days,	(10–33.5))	in	the	>65y	group	whose	normal	
admission	 Ur:Cr	 subsequently	 became	 elevated	 and	 who	 also	 developed	 AKI	 (N->H	 +	 AKI).	 The	
differences	in	LoS	for	each	subgroup,	when	compared	to	their	respective	group	baselines	(<65,	>65	y),	
were	all	statistically	significant	(p<1x10-5).		An	exception	to	this	tendency	was	found	for	patients	who	
were	admitted	with	an	elevated	Ur:Cr	that	was	subsequently	corrected,	but	who	yet	developed	AKI	
(H->N	+	AKI:	p=0.33	and	0.06,	zval=	-0.98	and	1.85,	ranksum=	4.9x108	and	9.5x108,	for	<65	and	>65	
respectively).	The	reason	for	this	exception	is	probably	due	to	the	relatively	small	number	of	patients	
(0.6%	of	the	total)	along	with	their	wide	range	of	LoS	(2.8-14	days).	
Figure	3.1:	Consort	Diagram	
	
Figure	3.2:	Age	at	Admission	
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Histogram	of	age	(years)	of	patients	on	admissions	
	
Figure	3.3	
	
Blue:	Ur:Cr	<	80	;	Orange:	Ur:Cr	>	80	
	
	
Table	3.2:	Baseline	Characteristics	
	 Emergency	admissions	(n=79,949)	
Age	(Median	(IQR	(Inter	Quartile	Range)	years	 71	(51–83)	
Male	(%)		 38,168	(47.7%)	
Length	of	Stay	(Median	(IQR)),	days	 6.8	(3–13.2)	
In-patient	Mortality	%	(number)	 6.4	%	(5,080)	
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Table	3.3:	Length	of	Stay	of	Survivors:	Emergency	admissions	
Patient	age	group	
n=total	number	
Admission	Blood	Test	 ->	Subsequent	Blood	Tests	
Length	of	stay	
median	days	
(interquartile	range)	
Ur:Cr	status	at	admission	
median	days	(interquartile	
range)	
Ur:Cr	and	AKI	status	
(percentage	of	baseline)	
Length	of	Stay	
median	days	
(interquartile	range)	
<65	y	
n	=	31,451	
4	days	(2–8)	
High	=	H	
	
5	(3–11)	
H	->	H	(16.4%)	 6.2*	 (3–13)	
H	->	H	+	AKI	(1.1%)	 16.7*	 (7–31.1)	
H	->	N	(7.8%)	 4*	 (2–6)	
H	->	N	+	AKI	(0.2%)	 5ns1	 (2.8–10)	
Normal	=	N	
	
4	(2–7.8)	
N	->	H	(12.1%)	 8*	 (4.2–	6)	
N	->	H	+	AKI	(1.1%)	 18.8*	 (9.5–36)	
N	->	N	(56.3%)	 3.5*	 (2–6)	
N	->	N	+	AKI	(4.8%)	 6.1*	 (3.2–12)	
>65	y	
n	=	43,418	
8	days	(4–16)	
High	=	H	
	
9	(5–18)	
H	->	H	(45.2%)	 10*	 (5–18)	
H	->	H	+	AKI	(4.1%)	 18*	 (9–32.4)	
H	->	N	(7.5%)	 6*	 (3–9)	
H	->	N	+	AKI	(0.4%)	 7	ns2	 (4–14)	
Normal	=	N	
	
7	(4–14)	
N	->	H	(14.8%)	 11*	 (6–20)	
N	->	H	+	AKI	(1.8%)	 19*	 (10–33.5)	
N	->	N	(22.4%)	 5*	 (3–9)	
N	->	N	+	AKI	(3.9%)	 7.9*	 (4–14)	
*	 =	 p<1x10-5,	 zval	 range:-35.26	 to	 43.4,	 ranksum	 consistently	 >	 1x108,	 ns1	 =	 not	 significant,	 p=0.33,	 zval=-0.98,															
ranksum=	4.9x108,	ns2	=	not	significant,	p=0.06,	zval=1.85,	ranksum=	9.5x108	
3.3.4	In-hospital	mortality	
In	total,	6.4%	(5,080)	of	the	79,949	patients	died	in	hospital.	In	the	binary	analysis	(Table	3.4),	mortality	
was	strongly	associated	with	age,	Ur:Cr	ratio	and	development	of	AKI.	There	was	an	87-fold	mortality	
difference	between	patients	who	came	into	hospital	with	normal	Ur:Cr,	which	remained	normal	until	
discharge,	and	those	patients	who	arrived	in	hospital	with	a	high	Ur:Cr,	which	remained	high,	and	who	
also	developed	AKI.	AKI	patients	represented	36.7%	(1,865)	of	all	deaths,	and	80%	of	these	patients	
also	had	a	high	Ur:Cr	at	some	point	during	their	hospital	stay.	Compared	to	the	theoretical	optimal	
trajectory	of	a	hospitalised	patient,	where	the	Ur:Cr	ratio	is	reduced	below	80	(regardless	of	admission	
value)	and	they	do	not	develop	AKI,	the	relative	risk	of	dying	for	all	other	groups	of	patients	ranged	
from	6.4	to	47.9	(all	p<1x10-16,	Table	3.5).	
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Table	3.4:	Mortality:	Emergency	admissions	
Total	 no	 of	 admissions	
(baseline)	
Admission	Blood	Test	 ->	Subsequent	Blood	Tests	
Mortality	%	
total	number	(died)	
Ur:Cr	status	at	admission	
(percentage	of	baseline)	
	
Total	No.	(no.	who	died)		
=	mortality%	
Ur:Cr	and	AKI	status	
(percentage	of	baseline)	
Mortality	%	
total	no.	(no.	who	died)	
<65	y	
32,183	(732)	=	2.3	%	
High	=	H	(26%)	
	
8,394	(353)	=	4.2	%	
H	->	H	(16.7%)	 5,377	(207)	=	 3.8	%	*	
H	->	H	+	AKI	(1.4%)	 465	(116)	=	 24.9	%	*	
H	->	N	(7.7%)	 2,476	(15)	=	 0.6	%	*	
H	->	N	+	AKI	(0.2%)	 76	(15)	=	 19.7	%	*	
Normal	=	N	(74%)	
	
23,789	(379)	=	1.6	%	
N	->	H	(12.3%)	 3,946	(129)	=	 3.3	%	*	
N	->	H	+	AKI	(1.4%)	 438	(79)	=	 18	%	*	
N	->	N	(55.3%)	 17,787	(67)	=	 0.4	%	*	
N	->	N	+	AKI	(5%)	 1,618	(104)	=	 6.4	%	*	
>65	y	
47,766	(4,348)	=	9.1	%	
High	=	H	(58.5%)	
	
27,945	(3,138)	=	11.2	%	
H	->	H	(45.4%)	 21,701	(2,073)	=	
9.6	%ns	
H	->	H	+	AKI	(5.7%)	 2,725	(950)	=	 34.9	%**	
H	->	N	(6.9%)	 3,290	(51)	=	 1.6	%**	
H	->	N	+	AKI	(0.5%)	 229	(64)	=	 27.9	%**	
Normal	=	N	(41.5%)	
	
19,821	(1,210)	=	6.1	%	
N	->	H	(14.5%)	 6,926	(505)	=	 7.3	%**	
N	->	H	+	AKI	(2.2%)	 1,027	(267)	=	 26	%**	
N	->	N	(20.7%)	 9,888	(168)	=	 1.7	%**	
N	->	N	+	AKI	(4.1%)	 1,980	(270)	=	 13.6	%**	
*	=	p<0.001,	baseline:	<65	y,	2.3%;	**	=	p<1x10-6	,	baseline:	>65	y,	9.1%;	ns	=	not	significant,	p=0.0583	
	
The	continuous	nature	of	the	relationship	between	mortality	and	both	admission	Ur:Cr	and	last	Ur:Cr	
is	highlighted	by	Figure	3.4,	 though	a	more	complex	 relationship	 is	 seen	when	mortality	 is	plotted	
against	combinations	of	admission	Ur:Cr	ratio	and	its	in-hospital	change	(Figure	3.5).	
	
Decreases	 of	 25%	 or	 increases	 of	 50%	 in	 Ur:Cr	 during	 hospitalisation	 have	minimal	 effect	 on	 low	
mortality	rates	(<3%)	when	Ur:Cr	is	low	to	begin	with	(Figure	3.5:	A,	B,	C).	Elevated	Ur:Cr	on	admission,	
which	remains	uncorrected	(Figure	3.5:	D	(180	to	180))	or	worsens	(Figure	3.5:	E	(180	to	315))	during	
hospitalisation,	is	associated	with	in-patient	death	rates	ranging	from	28%	(95%	Confidence	Interval	
(CI)	22.8–33.1)	to	89%	(CI:	56.5–98)	respectively.	However,	large	(50%)	reductions	in	Ur:Cr,	in	patients	
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in	whom	Ur:Cr	is	initially	similarly	elevated,	are	associated	with	a	reduction	in	mortality	to	just	10%	
(CI:	8.2–13.9,	Figure	3.5:	F	(180	to	90))	and	12.5%	(CI	:10–15.4,	Figure	3.5:	G	(210	to	105))	respectively.	
	
Table	3.5:	Relative	Risk	of	Death	for	unresolved	or	worsening	Ur:Cr	and	AKI	
Age	Group	 Sub-group	Baseline	 Sub-group	 Relative	Risk	of	Death	
<	65y	
N->N	
N->N	+	AKI	 17.1*	
N->H	 8.7*	
N->H	+	AKI	 47.9*	
H->N	
H->N	+	AKI	 32.6*	
H->H	 6.4*	
H->H	+	AKI	 41.2*	
>	65y	
N->N	
N->N	+	AKI	 8.0*	
N->H	 4.3*	
N->H	+	AKI	 15.3*	
H->N	
H->N	+	AKI	 18*	
H->H	 6.2*	
H->H	+	AKI	 22.5*	
*	=	P<1x10-16	;	N=Ur:Cr	<80;	H=Ur:Cr	>80;	AKI=In-hospital	development	of	Acute	Kidney	Injury	
	
Figure	3.4:	Urea:Creatinine	(Admission	and	Last)	vs	Mortality	
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Figure	3.5	
	
A:	Admission	Ur:Cr	60	->	Last	Ur:Cr	60,	no	change;	B:	Admission	Ur:Cr	60	->	Last	Ur:Cr	75,	25%	increase;	C:	Admission	Ur:Cr	60	
->	Last	Ur:Cr	30,	50%	decrease;	D:	Admission	Ur:Cr	180	->	Last	Ur:Cr	180,	no	change;	E:	Admission	Ur:Cr	180	->	Last	Ur:Cr	315,	
75%	increase;	F:	Admission	Ur:Cr	180	->	Last	Ur:Cr	90,	50%	decrease;	G:	Admission	Ur:Cr	210	->	Last	Ur:Cr	105,	50%	decrease.	
	
	
Figure	3.6	
	
Blue	line	=	Ur:Cr	ratio	of	80.	A=1.7%	mortality,	B=41.9%	mortality	
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The	relative	contributions	of	urea	and	creatinine	to	their	ratio,	and	their	subsequent	association	with	
mortality,	are	also	extremely	complex,	as	demonstrated	in	a	heatmap	of	the	relationship	of	urea	and	
creatinine	(from	the	patient’s	last	blood	test	before	discharge	or	death)	to	mortality	(Figure	3.6).	With	
a	Ur:Cr	of	80,	the	mortality	varies	from	1.7%	(CI:	1.69–1.70,	Figure	3.6:	A)	to	41.9%	(CI:	41.76–42.02,	
Figure	3.6:	B).	Patient	age	also	non-linearly	interacts	with	Ur:Cr	to	influence	mortality	(Figures	3.7	and	
3.8).	
	
Figure	3.7	
	
	
	
Figure	3.8	
	
	
	
85	
3.3.5	Predicting	mortality:	ML-Dehydration	
There	 were	 no	 significant	 differences	 between	 the	 train	 and	 test	 datasets	 in	 terms	 of	 baseline	
characteristics	(Table	3.6).	The	characteristics	of	the	ML-Dehydration	model	were:	max	tree	depth:	27;	
mean	number	of	leaves:	551.7.	ML-Dehydration	achieved	an	overall	area	under	the	receiver	operator	
curve	(AUROC)	of	79.6%	(mean	squared	error:	0.055;	logloss:	0.20;	mean	per-class	error:	0.34)	(Figure	
3.9).	 This	was	 similar	 to	 the	 cross-validation	 AUROC	 of	 79.6%,	 confirming	 its	 validity.	 The	 training	
dataset’s	 AUROC	 was	 91.2%.	 At	 the	 positive	 predictive	 value	 threshold	 of	 ML20	 (1:5	 (20%)),	 the	
predictive	performance	of	ML-Dehydration	in	identifying	patients	who	died	in	hospital,	at	the	point	of	
their	second	blood	test,	had	a	sensitivity	of	49.1%	and	a	specificity	of	86.7%.	The	ML33	(1:3	(33%))	
threshold	had	a	sensitivity	of	16.6%	and	specificity	of	97.7%.	
	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
tpr:	 True	 Positive	 Rate	 (Sensitivity);	
fpr:	 False	 Positive	 Rate	 (1	 –	
Specificity);	 the	 dots	 represent	
specific	 threshold	 values	 used	 to	
discriminate	between	patients	likely	
to	live	or	die	 	
Table	3.6:	Baseline	characteristics	of	the	train	and	test	datasets	
Baseline	characteristics	
	
Train	Dataset	
n=55,964	
Test	Dataset	
n=23,985	
Median	(IQR)	age,	years	 71	(51–83)	 71	(51–83)	
No.	(%)	Male	Sex	 26,663	(47.6%)	 11,505	(48%)	
Median	(IQR)	length	of	stay,	days	 6.7	(3–13.5)	 7	(3–13)	
No.	died	in-hospital	(%)	 3,557	(6.4%)	 1,523	(6.3%)	
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3.4	Discussion	
I	have	undertaken	my	analysis	with	data	for	79,949	patients	across	three	NHS	trust	hospitals.	These	
results	 represent	the	 largest	analysis	 to	date	that	explores	the	association	of	Ur:Cr	with	 in-hospital	
outcome	 for	 a	 large	 series	 of	 unselected	 emergency	 admissions	 to	 secondary	 care.	 In	 addition,	 I	
examined	the	value	of	assessing	the	dynamic	change	in	Ur:Cr	and	the	importance	of	 its	association	
with	patient	outcome.		
	
I	found	that	an	admission	Ur:Cr	ratio	of	>80	was	present	in	nearly	half	of	all	patients	(consistent	with	
previous	smaller	studies58),	and	Ur:Cr	rose	to	>80	during	hospital	stay	in	over	a	quarter	of	those	with	
a	normal	Ur:Cr	on	admission.	A	high	Ur:Cr	 ratio	 status	was	strongly	associated	with	 increased	LoS.	
Though	 I	 cannot	 attribute	 rises	 in	 Ur:Cr	 solely	 to	 dehydration,	 such	 data	 are	 consistent	 with	 the	
doubling	of	LoS	in	acute	coronary	syndrome	patients	suffering	dehydration	(7.8	vs	3	days),	and	the	six-
fold	and	tenfold	rise	in	risk	of	AKI	and	cardiogenic	shock	respectively	in	such	patients.38			
	
AKI	affected	10.7%	of	inpatients,	matching	recently	published	data130,	and	this	figure	was	similar	to	
that	suggested	by	a	 recent	meta-analysis.78	Likewise,	my	data	confirmed	the	high	prevalence	of	an	
elevated	Ur:Cr	amongst	those	who	develop	AKI,	as	reported	by	others53,	and	its	association	with	risk	
of	dying	with	AKI.	In	contrast	to	previous	work53,130,		I	have	explored	the	impact	of	initial	ratio	status	
and	its	change	with	mortality	in	AKI	patients,	demonstrating	a	wide	range	in	risk	of	death.		
	
Higher	Ur:Cr	on	admission	was	non-linearly	associated	with	in-hospital	mortality,	and	change	in	Ur:Cr	
strongly	correlated	with	both	LoS	and	mortality	via	a	complex	relationship,	further	affected	by	age.	
The	 contributions	 of	 the	 individual	 components	 of	 the	 ratio	 also	 had	 a	 dramatic	 impact	 on	 the	
association	of	the	ratio	with	mortality.	
	
Such	complex	interactions	suggest	the	need	for	non-linear	models	for	the	prediction	of	poor	outcomes.	
The	ML-Dehydration	model,	when	used	in	a	real-world	scenario	(sequential	blood	tests,	not	knowing	
whether	it	is	to	be	the	last),	identifies	50%	(sensitivity)	of	patients	who	will	subsequently	die,	from	only	
their	second	blood	test	onwards.	The	positive	predictive	value	of	20%	means	that	if	the	model	classifies	
the	patient	as	being	likely	to	die,	there	is	a	1:5	chance	that	this	will	subsequently	occur.	
	
Reductions	 in	Ur:Cr,	when	 the	 ratio	 at	 admission	was	 >80,	 probably	 reflect	 effective	 intervention,	
though	 I	 am	unable	 to	 describe	 the	 granularity	 of	 such	 interventions.	 It	 is	 likely	 that	 treatment	of	
dehydration	 and	 sepsis	 (alone	 or	 in	 combination)	 might	 play	 a	 dominant	 role	 in	 generating	 this	
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reduction.	 Fluid	 therapy	 is	 an	 essential	 part	 of	 most	 sepsis	 bundles,	 improving	 relative	 or	 actual	
intravascular	fluid	depletion,	and	thus	outcome.131,132,133,	134,135	
	
Similarly,	new	or	persistent	rises	in	the	Ur:Cr	ratio	increase	relative	risk	of	death	(from	6.4	to	47.9),	
and	may	 represent	 opportunities	 to	 improve	 patient	management.	 Use	 of	 the	 Ur:Cr	 ratio	 and	 its	
trajectory	 in	 order	 to	 highlight	 patients	 at	 risk	 may	 provide	 guidance	 for	 interventions.	 Such	
interventions,	proposed	 in	 the	UK’s	National	 Institute	 for	Health	and	Care	Excellence	guidelines	on	
AKI78	 and	 on	 prescribing	 intravenous	 fluids6,	 include	 automated	 alerts	 to	 clinicians,	 fluid	
administration,	and	appropriate	training	in	the	assessment	of	patients’	fluid	and	electrolyte	needs.		
	
This	specific	investigation	has	particular	strengths.	It	is	the	largest	study,	in	terms	of	both	number	of	
patients	and	number	of	blood	tests	analysed,	to	have	examined	the	following	in	hospitalised	patients:	
1)	Ur:Cr,	both	its	absolute	value	and	its	change;	and	2)	AKI,	using	quantitative	biochemical	definitions.		
It	 is	also	the	 first	study	that	examines	the	relationship	between	Ur:Cr	on	admission	and	 its	change	
during	 hospitalisation,	 with	 outcome.	 The	 use	 of	 minimal	 exclusion	 criteria	 increases	 the	
generalisability	of	my	findings.	The	use	of	data	 from	three	hospital	groups,	over	approximately	the	
same	time	period,	thus	reducing	biases	associated	with	single-site	studies.	Finally,	the	study	is	topical	
and	relevant,	as	the	impact	of	dehydration	on	outcome,	and	the	search	for	measures	to	mitigate	this,	
has	become	a	concern	for	England’s	Care	Quality	Commission	(CQC)69,	the	Patient	Association70,	and	
The	British	Parliamentary	Ombudsman71,	with	such	concerns	being	echoed	in	an	independent	inquiry72	
and	in	the	media.73,74,75,76,77	
	
Nonetheless,	 this	 study	 does	 have	 limitations.	 The	 data	was	 collected	 from	 hospitals	 which	when	
compared	to	the	national	average	had	higher	quality	ratings	(CQC	and	standardised	mortality	ratio)	
than	the	England	average;	 this	could	 introduce	bias	 into	 the	results.	However,	 this	bias,	 if	 it	exists,	
would	 result	 in	 an	 underreporting	 of	 the	 problem	 of	 dehydration	 lending	 further	 support	 to	 the	
unreported	scale	of	the	problem,	and	thus	the	potential	for	improvement	of	patient	care.	It	has	not	
explored	any	excessive	deaths	amongst	those	who	had	a	high	Ur:Cr	on	admission,	and	who	failed	to	
survive	to	receive	a	second	blood	test.	Nor	has	it	examined	the	impact	of	those	discharged	prior	to	a	
second	 test.	 In	 identifying	 cases	 of	 AKI,	 baseline	 creatinine	was	 defined	 as	 the	 earliest	 blood	 test	
performed	within	24	hours	of	hospital	admission;	however,	since	these	analyses	were	carried	out,	a	
National	 NHS	 England	 algorithm	 (NHSE-algorithm)	 definition	 of	 baseline	 creatinine	 has	 been	
mandated,	which	utilises	creatinine	blood	results	obtained	up	to	one	year	prior	to	admission.	This	new	
NHSE-algorithm	definition	of	AKI	was	not	used.	Therefore,	a	proportion	of	patients	who	presented	to	
hospital	with	new	AKI	(based	on	community	creatinine	values)	were	not	classified	as	such,	nor	were	
those	who	had	a	low	out-of-hospital	creatinine	value.	However,	these	limitations	led	to	a	conservative	
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estimate	of	AKI	prevalence	in	my	analyses.	Data	on	urine	output	as	part	of	the	KDIGO	classification	
were	also	unavailable.	Further,	I	did	not	investigate	interactions	with	co-morbid	diagnoses,	as	the	data	
linkage	 across	 all	 co-morbidities	 was	 beyond	 the	 scope	 of	 this	 initial	 investigation.	Most	 of	 these	
limitations	can	be	addressed	in	a	subsequent	study.	
	
I	have	demonstrated	that	the	use	of	two	widely	available	blood	tests	(urea	and	creatinine),	combined	
with	two	demographic	variables	(age	and	sex),	when	analysed	in	a	binary	or	continuous	manner,	can	
be	operationalised	as	a	powerful	predictor	of	outcomes.	These	variables	interact	with	each	other	in	a	
complex	 fashion	 in	 determining	 such	 outcomes.	 Reductions	 in	 the	Ur:Cr	 ratio,	when	 elevated,	 are	
associated	with	improved	outcome,	and	rises	may	indicate	patient	management	that	can	be	improved	
with	targeted	interventions.	
	
Dehydration,	is	a	condition	that	is	easy	to	communicate	and	in	the	majority	of	cases	relatively	simple	
to	 treat.	 Building	 care	 pathways	 that	 continuously	 track	 hydration	 status	 in	 patients,	 and	 have	
interventions	 to	 maintain	 hydration,	 would	 be	 simple	 and	 require	 relatively	 few	 resources.	 Such	
interventions	 could	 include	 encouragement	 to	 eat	 and	 drink	more,	 along	with	 nursing	 support	 to	
enable	patients	to	do	this,	as	well	as	robust	implementation	of	existing	guidelines	on	intravenous	fluid	
administration.		
	
Finally,	from	a	practical	viewpoint,	my	research	demonstrated	that	manipulating	and	analysing	large	
datasets	 with	 multiple	 non-numerical	 categorical	 values	 was	 extremely	 memory-intensive	 and	
cumbersome	 in	MATLAB	alone,	 despite	Mathworks	 (the	maker	of	MATLAB)	having	 recently	 added	
database	feature-	‘Data	Tables’.	Therefore,	for	all	further	data	management	and	analysis,	I	made	the	
decision	to	completely	switch	from	MATLAB	to	a	dedicated	database	(Microsoft	SQLServer),	and	to	an	
alternative	analytic	suite,	consisting	of	R	and	h2o.	
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Chapter	4:	Acute	kidney	injury:	dynamic	single	parameter	to	ML	
4.1	Introduction	
The	trends	of	blood	results,	i.e.	their	rise	or	fall,	have	always	been	extremely	valuable	to	clinicians.	In	
Chapter	3,	I	demonstrated	that	in-hospital	calculations	based	on	the	dynamic	change	in	just	two	simple	
blood	test	results	can	help	to	risk-stratify	patients.	Here	I	expand	this	work	by	incorporating	additional	
variables	 and	 grouping	 patients	 into	 known	 categories	 (chronic	 kidney	 disease	 stage,	 method	 of	
admission,	ethnicity,	etc.)	to	highlight	both	the	variability,	and	complexity	of	patient	outcome	when	
these	additional	variables	are	used	to	aid	in	risk	classification.	I	then	consolidate	all	available	a	priori	
information	 (including	pre-hospital),	 as	well	 as	 the	dynamic	 change	 in	all	 the	 raw	blood	 results,	 to	
create	an	 interpretable	ML	model	 to	determine	 risk	of	poor	outcome	 (death	or	 renal	 replacement	
therapy)	 in	 hospital.	 This	 approach	 is	 applied	 to	my	 entire	 dataset,	 and	 specifically	 addresses	 the	
occurrence	of	(and	outcome	from)	AKI,	a	condition	defined	by	the	dynamic	change	of	just	one	variable:	
creatinine.	 I	 have	 also	 compared	my	ML	 approach	 with	 the	 existing	 NHS	 England	 AKI	 (NHSE-AKI)	
algorithm,	to	discriminate	between	a	patient’s	outcome	from	AKI.	
	
As	detailed	in	Chapter	1	(Section	1.4.3),	AKI	is	a	prevalent	syndrome	(upto	21%	of	hospitalised	patients	
worldwide)	 that	has	multiple	varied	aetiologies.	 It	 is	associated	with	poor	healthcare	outcome	and	
increased	healthcare	costs	(in	excess	of	£1	billion/year	in	England	and	Wales).	Thus,	initiatives	have	
been	put	in	place	to	automatically	diagnose	and	escalate	care	for	patients	with	AKI.		
	
AKI	 just	 uses	 the	 dynamic	 change	 in	 one	 variable,	 creatinine,	 for	 its	 diagnosis.	 A	 defined	 rise	 in	 a	
patient’s	serum	creatinine,	from	their	baseline	has	been	used	to	severity	stage	a	patient’s	AKI.	These	
AKI	 severity	 stages	 are	 linked	 to	 recommendations	 for	 escalation	 of	 clinical	 care	 (Figure	 1.9).83	
However,	while	more	severe	AKI	stages	are	considered	to	be	associated	with	poorer	outcomes	(death	
and	renal	replacement	therapy	(Drrt)),	and	thus	require	prioritisation	of	care,	the	risk	stratification	by	
AKI	stage	when	further	variables/parameters	are	taken	into	account	is	not	clear	at	an	individual	patient	
level.	Indeed,	it	remains	unknown	the	degree	to	which	differences	in	individual	demographic	data,	the	
context	of	a	patient’s	admission	(for	example,	day	of	the	week,	month	of	the	year	and	emergency	vs	
planned),	their	past	medical	history,	and	results	of	other	investigations,	influence	outcome	in	any	one	
AKI	stage.		
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Furthermore,	using	the	mandated	NHSE-AKI	algorithm,	the	same	AKI	stage	can	be	reached	via	multiple	
trigger	routes.	It	was	unclear	whether	the	different	routes	by	which	an	AKI	stage	is	reached	influences	
the	outcome	associated	with	that	stage.	
	
Finally,	most	trigger	routes	for	defining	the	AKI	stage	of	the	NHSE-AKI	algorithm	rely	on	the	comparison	
of	 the	 current	 serum	 creatinine	 with	 a	 calculated	 baseline	 serum	 creatinine.	 The	 baseline	 serum	
creatinine	is	defined	as	either	the	minimum	level	in	the	last	seven	days,	or	the	median	in	the	last	8–
365	days;	whichever	 is	 lower.	This	 results	 in	a	different	baseline	creatinine	being	defined	for	every	
subsequent	creatinine	result,	and	which	is	thus	used	for	calculation	of	AKI	status	and	stage.	Therefore,	
there	is	a	mathematical	possibility	that	multiple	creatinine	tests	over	a	short	period	could	result	in	a	
rise	in	the	baseline	creatinine,	such	that	an	individual	is	no	longer	defined	(via	the	NHSE-AKI	algorithm)	
as	having	AKI:	I	have	labelled	this	situation	as	‘false-negative-AKI’.	I	sought	to	investigate	whether	this	
occurred,	and	to	what	extent.	
4.2	Objectives	
The	purpose	of	this	chapter	is	to	determine	whether	analytics	that	incorporate	multiple	correlated	and	
uncorrelated	variables,	over	multiple	time-points,	could	be	used	to	provide	more	precise	 individual	
risk	prediction	for	patients	who	are	deemed	to	have	AKI.	This	could	replace	the	current	AKI	severity	
stage,	thus	creating	a	new	model	that	could	be	used	as	to	escalate	individual	patient	care.	I	specifically	
sought	to	identify:	
1. The	epidemiology	of	admissions	who	are	diagnosed	with	AKI	in	hospital.	
2. The	relationship	between	the	NHSE-AKI	algorithm-defined	AKI	stage	and	in-hospital	outcome	
(Death	or	Renal	Replacement	Therapy	(Drrt)),	and	whether	this	relationship	differs	according	
to	method	of	admission	and	existing	co-morbidities.	
3. Whether	Drrt	risk	differs	depending	on	the	route	by	which	the	AKI	stage	is	defined.	
4. Whether	the	NHSE-AKI	algorithm	fails	to	identify	patients	who	continue	to	have	AKI.	
5. Whether	 a	 ML	 approach	 can	 better	 stratify	 risk	 than	 the	 currently	 mandated	 NHSE-AKI	
algorithm.	
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4.3	Methods	
4.3.1	Patients	
The	 dataset	 described	 in	 Chapter	 2	 was	 used	 for	 these	 analyses.	 In	 brief,	 I	 collated	 continuous	
electronically	 stored	 data	 from	 all	 adults	 (18	 years	 and	 over)	 admitted	 to	 fourteen	UK	NHS	 acute	
hospital	 trusts	 from	 early	 2005	 to	 late	 2015	 (dates	 varying	 between	 trusts).	 Specifically,	 for	 this	
analysis,	I	included	patients	with	a	complete	administrative	record,	and	at	least	one	serum	creatinine	
result	during	their	admission.	Excluded	were	patients	transferred	to	another	hospital	 for	continued	
medical	care,	and	those	who	self-discharged	(discharge	destination	codes:	48,	49,	50,	51,	52,	53,	55,	
56,	 57,	 84,	 87,	 88,	 98	 and	 99).136	 Also	 excluded	 were	 those	 known	 to	 be	 dependent	 on	 renal	
replacement	therapy	prior	to	admission,	identified	by	ICD10	code	Z99.2	or	by	their	elective	admission	
for	RRT	alone	(one-day	planned	admission	and	OPCS4	codes	X40,	X40.1,	X40.2,	X40.3,	X40.8	and	X40.9).	
All	other	patients	who	 received	 renal	 replacement	 therapy	 in	hospital	were	 included	 (ICD10	codes	
Z490,	Z491,	Z492	and	OPCS4	codes	X40,	X40.1,	X40.2,	X40.3,	X40.8	and	X40.9).	These	admissions	were	
deemed	to	have	progressed	from	AKI	to	complete	renal	failure,	requiring	renal	replacement	therapy.	
	
Each	hospital	admission	was	analysed	independently.	
4.3.2	Data	
All	results	for	sodium	(mmol/L),	potassium	(mmol/L),	urea	(mmol/L),	creatinine	(µmol/L),	haemoglobin	
(g/L),	platelet	(109/L),	mean	cell	volume(fL),	red	cell	distribution	width	(%)	and	white	cell	count	(109/L)	
were	recorded	throughout	each	admission.	In	addition,	where	such	results	existed,	they	were	captured	
up	to	one	year	prior	to	admission.	Routinely	collected	administrative	data	were	also	recorded:	patient	
age,	diagnoses	(ICD10),	treatment	codes	(OPCS-4)	and	dates,	and	details	relating	to	hospital	admission	
and	discharge.	 I	 selected	 these	 variables	 because	of	 their	 ubiquity	 (available	 for	most	 hospitalised	
patients).	
	
Admissions	were	grouped	by	their	method	of	admission	(planned	vs	emergency),	and	their	chronic	
kidney	disease	(CKD)	stage137	at	admission.	The	Chronic	Kidney	Disease	Epidemiology	Collaboration	
equation138	 was	 used	 to	 calculate	 the	 estimated	 glomerular	 filtration	 rate	 (eGFR)	 using	 the	 first	
baseline	creatinine	value	on	admission.	Baseline	creatinine	was	defined	using	the	NHSE-AKI	algorithm	
(Figure	4.1)	as	the	lower	of	the	following:	minimum	creatinine	result	in	the	last	7	days,	or	the	median	
creatinine	result	in	the	last	8–365	days.	The	four	CKD	stages	used	were:	(1)	none/mild:	no	CKD/CKD1-
2,	eGFR	>	60	ml/min/1.73	m2;	(2)	moderate:	CKD3,	eGFR	30–60	ml/min/1.73	m2;	(3)	severe/endstage:	
eGFR<30	ml/min/1.73	m2;	and	(4)	‘unknown’	for	when	no	baseline	creatinine	data	were	available.137	
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The	epidemiology	of	the	resultant	dataset	was	described,	detailing	the	number	of	admissions	based	
on	their	demographics	(sex,	age	and	ethnicity)	and	admissions	details	(method	of	admission,	day	of	
the	week,	and	month	of	year	of	admission).		
	
For	each	creatinine	result,	the	NHSE-AKI	algorithm	defined	the	baseline	creatinine,	the	AKI	stage	and	
the	 trigger	 route	 for	 that	AKI	 stage.	The	maximum	AKI	 stage	attained	 for	each	patient	during	each	
admission	 (AKImax)	 was	 used	 to	 calculate	 prevalence.	 The	 ratio	 of	 measured	 creatinine:baseline	
creatinine	[Cr:BCr]	was	also	calculated,	and	its	maximal	value	[Cr:BCr]max	recorded.		
	
I	calculated	Drrt	rates	for	AKImax,	and	for	each	algorithm	route.	However,	AKImax	can	only	be	determined	
post	hoc	(unless	the	first	AKI	stage	is	3),	and	thus	has	limited	utility	as	a	‘live’	predictor	of	AKI	outcome.	
Therefore,	Drrt	rates	for	the	first	AKI	event	were	also	calculated-	AKIfirst.	Finally,	AKI-related	Drrt	rates	
were	calculated	for	admissions	grouped	by	their	co-morbidities	and	their	admission	Ur:Cr	ratio	status	
(>80,	historically	used	to	suggest	dehydration12).	
	
Cases	 of	 false-negative-AKI	were	 defined	 as	 those	 suffering	 from	 AKI	 in	whom	 a	 sustained	 rise	 in	
creatinine	(one	which	did	not	fall,	or	which	continued	to	rise)	then	led	the	NHSE-AKI	algorithm	to	define	
them	as	free	from	AKI.	
	
In	addition,	I	explored,	for	admissions	who	did	not	die	or	have	renal	replacement	therapy	in	hospital,	
their	final	AKI	stage	(AKIlast)	at	discharge	from	hospital,	as	both	a	proportion	of	total	AKI	admissions	
and	 of	 total	 admissions.	 The	 number	 of	 creatinine	 results,	 and	 AKI	 alerts	 between	 the	 different	
admission	groups,	were	also	calculated.	
4.3.3	Statistical	and	ML	Analyses	
I	used	the	Wilson	method	to	calculate	the	95%	confidence	intervals	for	Drrt	rate.	Prevalence	and	Drrt	
rates	were	compared	using	Fisher’s	Exact	Test.	Pearson’s	correlation	coefficients	were	also	calculated.	
Statistical	significance	was	defined	as	a	p-value	of	less	than	0.05.	
	
ML,	specifically	the	GB	technique139,	was	employed	to	create	a	tool	for	the	early	prediction	of	Drrt.	
Because	early	identification	of	individual	risk	might	offer	the	greatest	clinical	utility,	the	only	results	
used	to	generate	the	ML-AKI	model	were	the	summary	(mean,	standard	deviation,	frequency)	blood	
results	 from	 the	 previous	 365	 days,	 the	 first	 set	 of	 admission	 blood	 results,	 and	 those	 that	 first	
triggered	 an	 AKI	 stage,	 with	 the	 administrative	 information	 available	 at	 those	 times.	 The	 a	 priori	
predictor	 variables	 I	 used	 to	 create	 the	model	 are	 listed	 in	 Table	 4.1.	 A	 random	70%	data	 sample	
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defined	the	training-dataset.	The	model	was	built	using	5-fold	cross-validation.	The	hyper-parameters	
of	 the	 model	 were	 determined	 via	 a	 grid	 search.	 The	 final	 ML-AKI	 model	 (post	 hyper-parameter	
selection	via	grid	search)	was	then	tested	on	the	remaining	30%	of	the	data	(test-dataset).	Area	under	
the	receiver	operator	curve	(AUROC)	was	calculated	for	the	whole	model.	From	the	trained	model,	a	
threshold	needed	to	be	set	to	classify	examples	as	either	Drrt	or	non	Drrt.	I	defined	three	thresholds	
(ML50,	 ML33,	 ML25),	 selected	 to	 produce	 positive	 predictive	 values	 (PPV)	 of	 1:2,	 1:3	 and	 1:4	
respectively	on	the	train	data.	
	
The	 relative	 importance	 of	 each	 predictor	 variable	 was	 calculated	 using	 a	 function	 developed	 by	
Friedman	(2001)140	and	implemented	in	an	h2o	GB	package.	‘The	measures	are	based	on	the	number	
of	times	a	variable	is	selected	for	splitting,	weighted	by	the	squared	improvement	to	the	model	as	a	
result	of	each	split,	and	averaged	over	all	trees.	The	relative	influence	(or	contribution)	of	each	variable	
is	 scaled	 so	 that	 the	 sum	 adds	 to	 100,	 with	 higher	 numbers	 indicating	 stronger	 influence	 on	 the	
response.’	
	
The	 software	 used	 was	Microsoft	 R	 Open	 3.2.5	 (Microsoft,	 USA:	 https://mran.microsoft.com/rro),	
Microsoft	 SQLServer	 2014	 Enterprise	 (Microsoft,	 USA:	 https://www.microsoft.com/en-gb/server-
cloud/products/sql-server/overview.aspx),	RStudio	(RStudio,	USA:	https://www.rstudio.com),	R	(The	
R	Foundation,	Austria:	https://www.r-project.org),	h2o	(h2o.ai,	USA:	www.h2o.ai),	and	 .Net	and	C#	
(Microsoft,	USA)	scripts.	
	
Table	4.1:	ML-AKI	Model	Variables		
Variable	Name	 Type	of	Variable	
Age	 Numerical	
Sex	
Categorical	
Ethnic	Category	
Patient	Category	
Admission	Method	Code	
Source	of	Admission	Code	
Day	of	Admission		
Month	of	Admission	
Blood	Results	
Admission	
eGFR	group	 Categorical	
eGFR	 Numerical	
Baseline	Creatinine	
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Creatinine	
Urea	
Sodium	
Potassium	
Urea:Creatinine	Ratio	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Blood	results	at	the	First	AKI	Stage	(SI	units)	
First	AKI	Stage	
Baseline	Creatinine	
Numerical	
Creatinine	
Urea	
Sodium	
Potassium	
Urea:Creatinine	Ratio	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Ratio	of	(Ur:Cr	first	AKI	stage)	:	(Ur:Cr	admission)	
Numerical	Creatinine:Baseline	Creatinine	Ratio	at	first	AKI	stage	
Creatinine	48	hr	rise	at	first	AKI	stage	
AKI	stage	at	first	AKI	stage	 Categorical	
Summary	Pre-Admission	Blood	Results	(last	year	(365	days),	SI	units)	
Number	
Creatinine	
Numerical	
Urea	
Sodium	
Potassium	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Mean	
Creatinine	
Numerical	
Urea	
Sodium	
Potassium	
Haemoglobin	
Platelets	
White	Cell	Count	
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Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Creatinine	
Standard	deviation	
Urea	
Numerical	
Sodium	
Potassium	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Number	of	AKI	Stage	1	Alerts	
Numerical	Number	of	AKI	Stage	2	Alerts	
Number	of	AKI	Stage	3	Alerts	
Co-morbidities	
Condition	 ICD10	code	
Categorical	
Essential	(primary)	hypertension	 I10	
Type	2	diabetes	mellitus	 E11	
Atrial	fibrillation	or	flutter	 I48	
Chronic	ischaemic	heart	disease	 I25	
Chronic	kidney	disease	 N18	
Heart	Failure	 I50	
Disorders	of	lipoprotein	metabolism	and	other	lipidaemias	 E78	
Personal	history	of	diseases	of	the	circulatory	system	 Z867	
Personal	history	of	psychoactive	substance	abuse	 Z864	
Other	chronic	obstructive	pulmonary	disease	 J44	
Personal	history	of	long-term	(current)	use	of	anticoagulants	 Z921	
Personal	history	of	allergy	to	penicillin	 Z880	
Other	hypothyroidism	 E03	
Asthma	 J45	
Smoking	 F17	
Angina	Pectoris	 I20	
Depressive	episode	 F32	
Other	symptoms	and	signs	involving	the	nervous	and	
musculoskeletal	systems	
R29	
Presence	of	aortocoronary	bypass	graft	 Z951	
Presence	of	electronic	cardiac	devices	 Z950	
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Presence	of	orthopaedic	joint	implants	 Z966	
Mental	and	behavioural	disorders	due	to	use	of	alcohol	 F10	
Secondary	malignant	neoplasm	of	other	and	unspecified	sites	 C79	
Presence	of	coronary	angioplasty	implant	and	graft	 Z955	
Obesity	 E66	
Myeloid	leukaemia	 C92	
Personal	history	of	allergy	to	other	drugs,	medicaments	and	
biological	substances	
Z888	
Personal	history	of	malignant	neoplasm	of	digestive	organs	 Z850	
Epilepsy	 G40	
Multiple	myeloma	and	malignant	plasma	cell	neoplasms	 C90	
Personal	history	of	diseases	of	the	nervous	system	and	sense	
organs	
Z866	
Secondary	and	unspecified	malignant	neoplasm	of	lymph	nodes	 C77	
4.4	Results	
Overall	1,972,130	hospital	admissions	(942,061	unique	patients;	median	1	(inter-quartile	range:	1	to	
2)	admissions	per	patient)	met	the	inclusion	criteria	(Consort	Diagram:	Figure	4.1).	
4.4.1	Baseline	characteristics	
Of	the	1,972,130	admissions,	39.6%	(780,970)	were	male.	Emergency	admissions	accounted	for	57.8%	
(1,139,220)	of	all	admissions,	with	planned	admissions	accounting	for	42.2%	(832,910).	Their	baseline	
characteristics	are	described	in	Table	4.2.	A	full	breakdown	by	ethnicity,	date	of	admission	and	method	
of	admission	is	provided	in	Tables	4.3,	4.4	and	4.5	respectively.	The	largest	ethnic	group	was	British	
(49.6%)	and	the	smallest	White	and	Black	African	(0.2%).	The	distribution	of	the	top	25	co-morbidities	
of	all	the	admissions	is	also	shown	in	the	baseline	table	(Table	4.2).	The	prevalence	of	the	top	three	
conditions	were	hypertension	at	22.3%	 (439,521),	 type	2	diabetes	mellitus	at	10.1%	 (200,011)	and	
chronic	ischaemic	heart	disease	at	9.1%	(179,026).	The	distribution	and	relationship	between	by	age,	
CKD	group	and	method	of	admission	is	shown	in	Figure	4.2.	
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Figure	4.1	Consort	Diagram	
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Table	4.2:	Baseline	Characteristics	
	 Emergency	
Planned	 p	value	
Number	of	admissions	 1,139,220	 832,910	 	
Male	 425,528		(47.1%)	 355,442	(42.7%)	 	
Age	(median	(IQR)	 67	(47–80)	years	 56	(37–69)	years	 <1	x	10
-2	
Length	of	stay	(median	(IQR))	 4	(1–9)	days	 0	(0–4)	days	 <1	x	10
-2	
Drrt	(%)	 53,206	(5.9%)	 9,031	(1.1%)	 <1	x	10
-2	
CKD	Stage	 Frequency	(percentage	of	Emergency,	Planned)	
None	to	Mild	(CKD	0–2)	 470,517	(52.1%)	 556,547	(66.8%)	 <1	x	10
-2	
Moderate	(CKD	3)	 157,655	(17.5%)	 85,453	(10.3%)	 <1	x	10
-2	
Severe	(CKD	4–5)	 39,941	(4.4%)	 23,419	(2.8%)	 <1	x	10
-2	
Unknown	(CKD	?)	 234,474	(26%)	 167,491	(20.1%)	 <1	x	10
-2	
Co-Morbidities	–	ICD10	code	 Frequency	(percentage	of	Emergency,	Planned)	
Essential	(primary)	hypertension	 I10	 303,446	 26.6%	 136,075	 16.3%	 <1	x	10
-2	
Type	2	diabetes	mellitus	 E11	 144,337	 12.7%	 55,674	 6.7%	 <1	x	10
-2	
Chronic	ischaemic	heart	disease	 I25	 130,211	 11.4%	 48,815	 5.9%	 <1	x	10
-2	
Atrial	fibrillation	or	flutter	 I48	 122,345	 10.7%	 31,513	 3.8%	 <1	x	10
-2	
Disorders	of	lipoprotein	metabolism	and	other	
lipidaemias	
E78	 116,971	 10.3%	 50,492	 6.1%	 <1	x	10
-2	
Personal	history	of	psychoactive	substance	
abuse	
Z864	 86,855	 7.6%	 34,458	 4.1%	 <1	x	10
-2	
Other	chronic	obstructive	pulmonary	disease	 J44	 81,506	 7.2%	 16,871	 2.0%	 <1	x	10
-2	
Personal	history	of	diseases	of	the	circulatory	
system				
Z867	 80,334	 7.1%	 32,419	 3.9%	 <1	x	10
-2	
Heart	failure	 I50	 80,118	 7.0%	 10,684	 1.3%	 <1	x	10
-2	
Asthma	 J45	 75,699	 6.6%	 35,592	 4.3%	 <1	x	10
-2	
Smoking	 F17	 68,267	 6.0%	 23,266	 2.8%	 <1	x	10
-2	
Personal	history	of	allergy	to	penicillin	 Z880	 64,676	 5.7%	 31,708	 3.8%	 <1	x	10
-2	
Personal	history	of	long-term	(current)	use	of	
anticoagulants	
Z921	 57,213	 5.0%	 24,221	 2.9%	 <1	x	10
-2	
Chronic	kidney	disease	 N18	 56,625	 5.0%	 21,040	 2.5%	 <1	x	10
-2	
Depressive	episode	 F32	 54,119	 4.8%	 14,018	 1.7%	 <1	x	10
-2	
Other	hypothyroidism	 E03	 51,859	 4.6%	 21,345	 2.6%	 <1	x	10
-2	
Angina	Pectoris	 I20	 46,328	 4.1%	 13,616	 1.6%	 <1	x	10
-2	
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Other	symptoms	and	signs	involving	the	
nervous	and	musculoskeletal	systems	
R29	 41,548	 3.6%	 2,351	 0.3%	 <1	x	10
-2	
Mental	and	behavioural	disorders	due	to	use	
of	alcohol	
F10	 37,550	 3.3%	 3,381	 0.4%	 <1	x	10
-2	
Presence	of	orthopaedic	joint	implants	 Z966	 33,363	 2.9%	 16,687	 2.0%	 <1	x	10
-2	
Presence	of	aortocoronary	bypass	graft	 Z951	 30,427	 2.7%	 10,747	 1.3%	 <1	x	10
-2	
Presence	of	electronic	cardiac	devices				 Z950	 28,586	 2.5%	 7,503	 0.9%	 <1	x	10
-2	
Epilepsy	 G40	 28,253	 2.5%	 8,672	 1.0%	 <1	x	10
-2	
Presence	of	coronary	angioplasty	implant	and	
graft	
Z955	 25,646	 2.3%	 10,508	 1.3%	 <1	x	10
-2	
Secondary	malignant	neoplasm	of	other	and	
unspecified	sites	
C79	 17,895	 1.6%	 23,590	 2.8%	 <1	x	10
-2	
Personal	history	of	allergy	to	other	drugs,	
medicaments	and	biological	substances	
Z888	 17,533	 1.5%	 14,844	 1.8%	 <1	x	10
-2	
Personal	history	of	diseases	of	the	nervous	
system	and	sense	organs				
Z866	 17,347	 1.5%	 6,028	 0.7%	 <1	x	10
-2	
Obesity	 E66	 16,717	 1.5%	 17,294	 2.1%	 <1	x	10
-2	
Personal	history	of	malignant	neoplasm	of	
digestive	organs				
Z850	 13,839	 1.2%	 9,192	 1.1%	 <1	x	10
-2	
Secondary	and	unspecified	malignant	
neoplasm	of	lymph	nodes	
C77	 6,470	 0.6%	 20,853	 2.5%	 <1	x	10
-2	
Multiple	myeloma	and	malignant	plasma	cell	
neoplasms	
C90	 5,381	 0.5%	 34,780	 4.2%	 <1	x	10
-2	
Myeloid	leukaemia	 C92	 4,116	 0.4%	 24,218	 2.9%	 <1	x	10
-2	
		
A	 total	 of	 6,343,530	 serum	 creatinine	 tests	 were	 performed	 during	 hospital	 admissions,	 with	 the	
median	creatinine	per	admission	being	1	(IQR:	1	to	3).	For	emergency	admissions,	there	was	a	total	of	
4,315,120	during-admission	 creatinine	 results,	with	 a	median	per	 admission	of	 2	 (IQR:	1	 to	4).	 For	
planned	admissions,	the	total	for	during-admission	creatinine	results	was	2,028,410,	with	a	median	
per	admission	of	1	(IQR:	1	to	2).	However,	a	total	of	22,601,915	serum	creatinine	results	were	analysed,	
comprising	during-admission	blood	results	(6,343,530)	as	well	as	those	obtained	up	to	one	year	before	
admission	(16,258,385).	Because	each	admission	was	treated	independently,	patients	admitted	more	
than	once	during	the	span	of	a	year	would	have	the	results	from	those	separate	admissions	analysed	
separately.	Some	continuous	variables	were	correlated	(r:	-0.26	to	0.83,	p	<	1	x	10-5;	Table	4.3).	
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Table	4.3:	Correlation	Coefficients	
First	AKI	 Cr	48h		 Cr:BCr	 BCr	 Cr	 Ur	 Na	 K	 Hb	 Plts	 WCC	 MCV	
RDW	
Age	 -0.04	 -0.02	 0.01	 0.01	 0.27	 0.02	 0.08	 0.03	 0.07	 0.07	 0.09	
0.04	
Creatinine	
(Cr)48h	Rise	
	 0.44	 0.37	 0.61	 0.34	 -0.03	 0.21	 0.00	 -0.03	 0.01	 0.00	 -0.02	
Cr:BCr	 	 	 -0.11	 0.33	 0.28	 -0.05	 0.15	 0.03	 0.03	 0.04	 -0.01	
0.01	
Baseline	Cr	
(BCr)	
	 	 	 0.83	 0.48	 0.00	 0.20	 -0.12	 -0.09	 -0.04	 0.00	 -0.01	
Creatinine	
(Cr)	
	 	 	 	 0.63	 -0.02	 0.29	 -0.10	 -0.07	 -0.02	 0.01	 0.00	
Urea	(Ur)	 	 	 	 	 	 0.02	 0.34	 -0.05	 -0.04	 0.06	 0.02	
0.08	
Sodium	(Na)	 	 	 	 	 	 	 -0.17	 0.04	 -0.07	 -0.01	 0.16	
0.06	
Potassium	
(K)	
	 	 	 	 	 	 	 -0.05	 0.13	 0.04	 0.01	 0.03	
Hemoglobin	
(Hb)	
	 	 	 	 	 	 	 	 0.09	 0.04	 0.07	 -0.26	
Platelets	
(Plts)	
	 	 	 	 	 	 	 	 	 0.14	 -0.12	 -0.01	
White	cell	
count	
(WCC)	
	 	 	 	 	 	 	 	 	 	 0.00	 0.06	
Mean	Cell	
Volume	
(MCV)	
	 	 	 	 	 	 	 	 	 	 	 -0.15	
4.4.2	Epidemiology	/	Variation	in	Prevalence	and	Progression	of	AKI	Admissions	
AKI	 occurred	 in	 170,596	 (8.6%)	 admissions,	 representing	 122,696	 (13%)	 unique	 patients.	Of	 these,	
170,596	admissions	with	AKI,	65,772	(38.6%)	were	diagnosed	with	AKI	on	their	first	creatinine	test	in	
hospital,	indicating	community-acquired	AKI.		Tables	4.4,	4.5	and	4.6	show	the	AKI	prevalence	by	ethnic	
group,	 and	 by	 month,	 day	 and	 method	 of	 admission	 respectively.	 The	 highest	 proportion	 of	 AKI	
admissions	 occurred	 in	 Bangladeshi	 (10.2%),	 Caribbean	 (9.8%),	 Indian	 (9.7%)	 and	 Irish	 (9.7%)	
ethnicities,	with	the	lowest	in	those	with	a	mixed	background	(6.5%	to	7.2%).		The	highest	proportion	
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of	 AKI	 admissions	 occurred	 over	 winter	 (January	 (9.2%)	 and	 December	 (9.2%))	 and	 the	 weekend	
(Saturday	(10.3%)	and	Sunday	(10.5%)).	Analysing	the	data	by	method	of	admission,	AKI	was	almost	
twice	as	common	in	emergency	as	in	planned	admissions	(10.7%	(122,346)	vs	5.8%	(48,240),	p<1	x	10-
10).	 However,	 even	 within	 these	 groups	 (Planned	 and	 Emergency)	 there	 was	 significant	 variation.	
Within	Planned	admissions,	maternity	related	admissions	had	the	lowest	AKI	prevalence	(maternity	
(3%)	vs	rest	of	Planned	(6.4%))	and	those	transferred	from	another	hospital	the	highest	(17%).	
	
Table	4.4:	Ethnicity	
Ethnicity	
All	Admissions	
N	(%	of	total)	
Total	=	1,972,130	
AKI	only	Admissions	
N	(%	Total	AKI	admissions)	
(Total	AKI	s	=	170,596)	
Sub-category	prevalence	
(Percentage	of	AKI	admissions	
by	Total	admissions)	
British	(A)	
977,717	
(49.6%)	
85,463	
(50.1%)	
8.7%	
Not	stated	(Z)	
481,395	
(24.4%)	
42,173	
(24.7%)	
8.8%	
Any	other	white	
background	(C)	
144,337	
(7.3%)	
10,744	
(6.3%)	
7.4%	
Any	other	ethnic	
group	(S)	
63,986	
(3.2%)	
4,930	
(2.9%)	
7.7%	
African	(N)	
53,095	
(2.7%)	
4,245	
(2.5%)	
8.0%	
Indian	(H)	
44,810	
(2.3%)	
4,357	
(2.6%)	
9.7%	
Caribbean	(M)	
41,297	
(2.1%)	
4,042	
(2.4%)	
9.8%	
Any	other	Asian	
background	(L)	
40,313	
(2.0%)	
3,628	
(2.1%)	
9.0%	
Irish	(B)	
33,739	
(1.7%)	
3,283	
(1.9%)	
9.7%	
Bangladeshi	(K)	
25,430	
(1.3%)	
2,600	
(1.5%)	
10.2%	
Any	other	black	
background	(P)	
20,318	
(1.0%)	
1,563	
(0.9%)	
7.7%	
Pakistani	(J)	
18,414	
(0.9%)	
1,528	
(0.9%)	
8.3%	
Chinese	(R)	
8,585	
(0.4%)	
757	
(0.4%)	
8.8%	
Any	other	mixed	
background	(G)	
8,165	
(0.4%)	
531	
(0.3%)	
6.5%	
White	and	black	
Caribbean	(D)	
4,404	
(0.2%)	
315	
(0.2%)	
7.2%	
White	and	Asian	
(F)	
3,082	
(0.2%)	
214	
(0.1%)	
6.9%	
White	and	black	
African	(E)	
3,043	
(0.2%)	
213	
(0.1%)	
7.0%	
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Table	4.5:	Date	of	Admission	
	
All	Admissions	
N	(%	of	total)	
Total	=	1,972,130	
AKI	only	Admissions	
N	(%	of	Total	AKI	admissions)	
(Total	AKI	admissions	=	
170,596)	
Sub-category	
prevalence	
(Percentage	of	AKI	
admissions	by	Total	
admissions)	
Admission	Month	
January	
172,004	
(8.7%)	
15,868	
(9.3%)	
9.2%	
February	
157,964	
(8.0%)	
14,285	
(8.4%)	
9.0%	
March	
166,252	
(8.4%)	
14,609	
(8.6%)	
8.8%	
April	
162,938	
(8.3%)	
13,889	
(8.1%)	
8.5%	
May	
169,118	
(8.6%)	
14,136	
(8.3%)	
8.4%	
June	
157,386	
(8.0%)	
13,221	
(7.8%)	
8.4%	
July	
166,086	
(8.4%)	
13,861	
(8.1%)	
8.3%	
August	
158,295	
(8.0%)	
13,336	
(7.8%)	
8.4%	
September	
161,344	
(8.2%)	
13,500	
(7.9%)	
8.4%	
October	
171,459	
(8.7%)	
14,618	
(8.6%)	
8.5%	
November	
166,452	
(8.4%)	
14,325	
(8.4%)	
8.6%	
December	
162,832	
(8.3%)	
14,938	
(8.8%)	
9.2%	
Admission	Day	of	Week	
Monday	
327,787	
(16.6%)	
27,769	
(16.3%)	
8.5%	
Tuesday	
349,597	
(17.7%)	
28,863	
(16.9%)	
8.3%	
Wednesday	
332,633	
(16.9%)	
26,951	
(15.8%)	
8.1%	
Thursday	
330710	
(16.8%)	
27,357	
(16%)	
8.3%	
Friday	
301005	
(15.3%)	
25,384	
(14.9%)	
8.4%	
Saturday	
162,819	
(8.3%)	
16,697	
(9.8%)	
10.3%	
Sunday	
167,579	
(8.5%)	
17,565	
(10.3%)	
10.5%	
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Table	4.6:	Method	of	Admission	
Method	of	admission	
All	
Admissions	
N	(%	of	total)	
Total	=	
1,972,130	
AKI	only	
Admissions	
N	(%	of	Total	AKI	
admissions)	
Total	AKI	
admissions=	
170,596	
Sub-category	
prevalence	
(Percentage	of	AKI	
admissions	by	
Total	admissions)	
Emergency	 –	 Accident	 and	 emergency	 of	 the	
health	care	provider	(21)	
855,020	
(43.4%)	
90,929	
(53.3%)	
10.6%	
Planned	–	Elective	planned	(13)	
305,875	
(15.5%)	
13,233	
(7.8%)	
4.3%	
Planned	–	Elective	waiting	list	(11)	
257,598	
(13.1%)	
18,012	
(10.6%)	
7.0%	
Emergency	–	General	practitioner	(22)	
156,829	
(8.0%)	
13,362	
(7.8%)	
8.5%	
Planned	–	Elective	booked	(12)	
118,528	
(6.0%)	
6,888	
(4.0%)	
5.8%	
Planned	–	Maternity	admitted	ante-partum	(31)	
106,904	
(5.4%)	
3,228	
(1.9%)	
3.0%	
Emergency	 –	 Transfer	 of	 any	 admitted	 patient	
from	another	hospital	provider	in	an	emergency	
(28)	
80,034	
(4.1%)	
11,611	
(6.8%)	
14.5%	
Planned	–	Transfer	of	any	admitted	patient	from	
another	 hospital	 provider	 other	 than	 in	 an	
emergency	(81)	
39,033	
(2.0%)	
6,655	
(3.9%)	
17.0%	
Emergency	–	Consultant	clinic,	of	this	or	another	
health	care	provider	(24)	
36,202	
(1.8%)	
5023	
(2.9%)	
13.9%	
Emergency	–	Bed	bureau	(23)	
8,608	
(0.4%)	
998	
(0.6%)	
11.6%	
Planned	–	Admitted	post-partum	(32)	
4,510	
(0.2%)	
188	
(0.1%)	
4.2%	
Emergency	–	Other	emergency	admission	(2D)	
1,749	
(0.1%)	
260	
(0.2%)	
14.9%	
Emergency	–	Admission	via	mental	health	crisis	
resolution	team	(25)	
414	
(0.0%)	
29	
(0.0%)	
7.0%	
Planned	–	Not	known	/	validation	error	(99)	
308	
(0.0%)	
25	
(0.0%)	
8.1%	
Emergency	–	Other	means	(2B)	
259	
(0.0%)	
103	
(0.1%)	
39.8%	
Planned	–	The	birth	of	a	baby	in	this	health	care	
provider	(82)	
125	
(0.0%)	
8	
(0.0%)	
6.4%	
Emergency	–	Accident	and	emergency	
department	of	another	provider	where	the	
patient	had	not	been	admitted	(2A)	
105	
(0.0%)	
31	
(0.0%)	
29.5%	
Planned	–	Transfer	of	any	admitted	patient	
from	another	hospital	provider	other	than	in	an	
emergency	(83)	
29	
(0.0%)	
3	
(0.0%)	
10.3%	
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The	total	number	of	in-hospital	creatinine	tests	performed	on	those	with	(or	who	developed)	AKI	was	
1,927,488,	representing	30.4%	of	all	in-hospital	creatinine	tests.	Of	these	1,927,488	results,	461,546	
(23.9%)	 triggered	 an	 AKI	 alert	 as	 per	 the	 NHSE-AKI	 algorithm.	 Breaking	 this	 down	 by	 method	 of	
admission,	24%	(100	*	(337,101	/	1,407,425))	of	creatinine	tests	done	in	Emergency	admissions	with	
AKI	resulted	in	an	AKI	alert,	which	was	similar	to	that	of	Planned	admissions	with	AKI	at	23.9%	(100	*	
(124,445	/	520,063)).	The	median	number	of	AKI	alerts	per	admission	with	AKI	was	1	(IQR:	1	to	3).	This	
remained	the	same	even	when	admissions	were	further	divided	into	Emergency	and	Planned.	
	
AKI	prevalence	 in	admissions	with	hypertension,	type	2	diabetes	mellitus,	heart	 failure	and	chronic	
obstructive	pulmonary	disease	(COPD)	were	13.3%,	16.8%,	24.5%	and	15.4%	respectively.	Overall,	an	
AKImax	of	stage	1,	2	and	3	occurred	in	5.6%,	1.5%	and	1.5%	respectively.	There	was	also	variation	in	the	
characteristics	of	admissions	with	AKI,	with	respect	to	their	CKD	status/AKI	triggering	route	(range:	
0.01%–17.3%,	Figure	4.3),	and	co-morbidities	(range:	1.4%–41%,	Table	4.7).	For	example,	41%	of	AKI	
admissions	were	dehydrated	on	admission,	13%	had	heart	failure	and	8.9%	had	COPD.	
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Table	4.7:	Co-morbidities:	Prevalence/Drrt	rates	in	AKI	admissions	
Co-morbidity	
ICD10	
code	
Prevalence	%	
(n)	
Drrt	rate	(%)	
p	<	
0.05	
Condition	Present	 Condition	Not	Recorded	
	
Essential	(primary)	
hypertension	
I10	 34.2%	(58,278)	
21.9%	
(21.5–22.2)	
20.6%	
(20.3–20.8)	
Y	
Type	2	diabetes	mellitus	 E11	
19.7%	
(33,572)	
23.7%	
(23.3–24.2)	
20.3%	
(20.1–20.6)	
Y	
Atrial	fibrillation	or	flutter	 I48	
17.2%	
(29,421)	
32.7%	
(32.1–33.2)	
18.6%	
(18.4–18.8)	
Y	
Chronic	ischaemic	heart	
disease	
I25	 17.0%	(28,961)	
26.2%	
(25.7–26.7)	
19.9%	
(19.7–20.2)	
Y	
Chronic	kidney	disease	 N18	
13.5%	
(23,110)	
31.8%	
(31.2–32.4)	
19.3%	
(19.1–19.5)	
Y	
Heart	Failure	 I50	
13.0%	
(22,217)	
36.9%	
(36.2–37.5)	
18.6%	
(18.4–18.8)	
Y	
Disorders	of	lipoprotein	
metabolism	and	other	
lipidaemias	
E78	 12.1%	(20,665)	
19.2%	
(18.7–19.7)	
21.3%	
(21.0–21.5)	
Y	
Personal	history	of	diseases	
of	the	circulatory	system	
Z867	 9.1%	(15,524)	
23.7%	
(23.0–24.4)	
20.7%	
(20.5–20.9)	
Y	
Personal	history	of	
psychoactive	substance	
abuse	
Z864	 9.0%	(15,340)	
24.7%	
(24.1–25.4)	
20.6%	
(20.4–20.8)	
Y	
Other	chronic	obstructive	
pulmonary	disease	
J44	 8.9%	(15,135)	
30.8%	
(30.1–31.5)	
20.1%	
(19.9–20.3)	
Y	
Personal	history	of	long-
term	(current)	use	of	
anticoagulants	
Z921	 7.0%	(11,905)	
22.8%	
(22.1-23.6)	
20.9%	
(20.7-21.1)	
Y	
Personal	history	of	allergy	to	
penicillin	
Z880	 5.6%	(9,608)	
18.1%	
(17.4–18.9)	
21.2%	
(21.0–21.4)	
Y	
Other	hypothyroidism	 E03	
5.6%	
(9,530)	
23.1%	
(22.2–23.9)	
20.9%	
(20.7–21.1)	
Y	
Asthma	 J45	
5.6%	
(9,494)	
18.3%	
(17.5–19.0)	
21.2%	
(21.0–21.4	
Y	
Smoking	 F17	
4.8%	
(8,257)	
20.4%	
(19.6–21.3)	
21.0%	
(20.8–21.2)	
N	
Angina	Pectoris	 I20	
4.3%	
(7,321)	
24.0%	
(23.0–25.0)	
20.9%	
(20.7–21.1)	
Y	
Depressive	episode	 F32	
4.2%	
(7,142)	
19.6%	
(18.7–20.6)	
21.1%	
(20.9–21.3)	
Y	
Other	symptoms	and	signs	
involving	the	nervous	and	
musculoskeletal	systems	
R29	 4.0%	(6,806)	
26.8%	
(25.7–27.9)	
20.8%	
(20.6–21.0)	
Y	
Presence	of	aortocoronary	
bypass	graft	
Z951	 3.7%	(6,336)	
24.0%	
(23.0–25.1)	
20.9%	
(20.7–21.1)	
Y	
	
106	
	
The	relationship	of	first	to	subsequent	maximum	AKI	stage	is	shown	in	Table	4.8:	AKI	stage	advanced	
from	that	first	detected	in	13.6%	(23,226)	of	cases.	
	 	
Presence	of	electronic	
cardiac	devices	
Z950	 3.6%	(6,131)	
28.8%	
(27.7–29.9)	
20.7%	
(20.5–20.9)	
Y	
Presence	of	orthopaedic	
joint	implants	
Z966	 3.5%	(6,019)	
21.7%	
(20.7–22.8)	
21.0%	
(20.8–21.2)	
N	
Mental	and	behavioural	
disorders	due	to	use	of	
alcohol	
F10	 3.0%	(5,137)	
23.0%	
(21.8–24.1)	
20.9%	
(20.7–21.1)	
Y	
Secondary	malignant	
neoplasm	of	other	and	
unspecified	sites	
C79	 2.8%	(4,734)	
36.0%	
(34.6–37.4)	
20.6%	
(20.4–20.8)	
Y	
Presence	of	coronary	
angioplasty	implant	and	
graft	
Z955	 2.6%	(4,391)	
20.7%	
(19.5–21.9)	
21.0%	
(20.8–21.2)	
N	
Obesity	 E66	
2.4%	
(4,129)	
21.6%	
(20.4–22.9)	
21.0%	
(20.8–21.2)	
N	
Myeloid	leukaemia	 C92	
2.3%	
(3,853)	
11.5%	
(10.5–12.5)	
21.2%	
(21.0–21.4)	
Y	
Personal	history	of	allergy	to	
other	drugs,	medicaments	
and	biological	substances	
Z888	 2.2%	(3,819)	
11.4%	
(10.4–12.5)	
21.2%	
(21.0–21.4)	
Y	
Epilepsy	 G40	
2.1%	
(3,639)	
20.8%	
(19.5–22.2)	
21.0%	
(20.8–21.2)	
N	
Personal	history	of	
malignant	neoplasm	of	
digestive	organs	
Z850	 2.0%	(3,389)	
19.6%	
(18.3–20.9)	
21.0%	
(20.8–21.2)	
Y	
Multiple	myeloma	and	
malignant	plasma	cell	
neoplasms	
C90	 1.9%	(3,159)	
16.5%	
(15.2–17.8)	
21.1%	
(20.9–21.3)	
Y	
Personal	history	of	diseases	
of	the	nervous	system	and	
sense	organs	
Z866	 1.7%	(2,948)	
23.3%	
(21.8–24.9)	
21.0%	
(20.8–21.2)	
Y	
Secondary	and	unspecified	
malignant	neoplasm	of	
lymph	nodes	
C77	 1.4%	(2,354)	
25.2%	
(23.5–27.0)	
20.9%	
(20.8–21.1)	
Y	
	
Urea	:	Creatinine	Ratio	 	
>	80	 <	80	
Admission	(First)	
Urea	:	Creatinine	Ratio	
41%	
(69,941)	
26.5%	
(26.2–26.8)	
17.4%	
(17.2–17.6)	
Y	
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Table	4.8:	First	AKI	to	Max	AKI	stage	
First	AKI	 Subsequent	Max	AKI	
AKI	Stage	 Frequency	 AKI	Stage	 Frequency	(percentage	of	First	AKI	Stage)	
1	 131,324	
1	 111,163	(84.6%)	
2	 11,211	(8.5%)	
3	 8,950	(6.8%)	
2	 21,537	
2	 18,472	(85.8%)	
3	 3,065	(14.2%)	
3	 17,725	 3	 17,725	(100%)	
	
4.4.3	AKIlast	and	false-negative-AKI	
Of	134,754	AKI	admissions	who	were	successfully	discharged	 from	hospital	and	did	not	have	 renal	
replacement	therapy	(no	Drrt),	43,369	(32.2%)	still	had	an	AKI	stage	on	their	last	creatinine	test	before	
discharge.	The	AKI	stage	of	these	non-Drrt	AKI	discharges	were:	AKIlast	stage	1:	35,378;	AKIlast	stage	2:	
6,101;	and	AKIlast	stage	3:	1,890.		
	
Separately,	51.9%	(88,609)	of	those	suffering	from	AKI	had	a	subsequent	in-hospital	creatinine	result	
that	indicated	they	were	no	longer	classified	as	having	AKI.	Of	these,	over	a	fifth	(21.3%,	18,902)	had	a	
false-negative-AKI.	 The	 Drrt	 rate	 in	 these	was	 higher	 than	 in	 those	 cases	 in	which	 a	 fall	 in	 serum	
creatinine	 had	 appropriately	 led	 to	 an	 AKI	 diagnosis	 ceasing	 to	 be	made	 (29.4%	 (5,564)	 vs	 15.8%	
(10,986),	p<0.01).	
4.4.4	Variation	of	Drrt	in	AKI	admissions	
A	total	of	64,296	(3.3%	of	admissions)	either	died	(56,076;	2.8%)	or	had	renal	replacement	therapy	
(10,053;	 0.5%)	 in	 hospital.	 Of	 the	 64,296,	 55.7%	 (35,832:	 died=30,047;	 renal	 replacement	
therapy=7,476)	had	suffered	AKI.	Overall,	Drrt	occurred	in	21%	(35,832)	of	those	who	developed	AKI,	
compared	with	 1.6%	 (28,464:	 died=26,029;	 RRT=2,577)	 (p<0.001)	 in	 those	who	did	 not.	 Such	poor	
outcome	in	AKI	admissions	was	more	prevalent	in	emergency	than	planned	admissions	(25.1%	(30,726)	
vs	10.6%	(5,106)	respectively,	p<1	x	10-5).	Drrt	risk	was	related	to	higher	AKImax	and	AKIfirst	stages,	with	
Drrt	rates	ranging	from	13.6%	to	42.4%	for	AKImax	and	18.7%	to	32.8%	for	AKIfirst	(Table	4.9).		
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The	incidence	of	Drrt	also	varied	with	the	algorithm	route	by	which	any	given	AKI	stage	was	reached.	
Thus,	Drrt	occurred	in	12.7%	(95%	CI:	12.5–12.9)	of	those	whose	stage	1	AKImax	was	triggered	by	a	1.5-
fold	 increase	 in	creatinine	over	baseline,	but	16.6%	 (CI:	16.2–17.1)	when	 triggered	by	a	 rise	of	>26	
mmol/L	over	48	hours.	For	AKI	3,	Drrt	rates	varied	from	38.6%	to	45.9%	depending	on	the	triggering	
route	(Figure	4.4).	
	
Grouping	by	AKImax	 stage	 (and	 trigger	 route),	 admission	 route	and	CKD	status	 results	 in	56	groups,	
further	increasing	the	heterogeneity	in	Drrt	rates	(Figure	4.5).	The	absolute	creatinine	result	as	well	as	
the	Cr:BCr	ratio	also	influences	the	Drrt	rate.	The	complex	pattern	of	this	interaction	is	shown	in	the	
heatmap	(Figure	4.7)	which	plots	Drrt	rates	against	[Cr:BCr]max:	here,	Drrt	rates	for	AKImax	3	range	from	
~0.5%	to	~70%	(p<0.01).	Thus,	some	stage	1	AKImax	cases	may	have	a	100-fold	higher	risk	of	Drrt	(50%:	
Figure	4.7,	X)	than	some	stage	3	AKImax	cases	(0.5%:	Figure	4.6,	Y).	
	
Prevalence	of	Drrt	associated	with	AKImax	also	varied	with	the	presence	of	co-morbidities,	being	11.5%	
in	those	with	myeloid	leukaemia	and	36.9%	in	those	with	heart	failure	(Table	4.7).	
	
Table	4.9:	Drrt	rates/positive	predictive	values	
	 Drrt	 Total	 Drrt	rate	(95%	Confidence	Interval)	
Sensitivity	 Specificity	 Positive	
Predictive	
Value	
MAX	AKI	Stage	
	
1	 15,114	 111,163	 13.6	%	
(13.4–13.8)	
42.2	 65.1	 1	in	7.4	
2	 8,101	 29,683	 27.3	%	
(26.8–27.8)	
22.6	 80.3	 1	in	3.7	
3	 12,617	 29,740	 42.4	%	
(41.9–43)	
35.2	 83.5	 1	in	2.4	
Combining	2&3	 20,718	 59,423	 34.9	%	
(34.4–35.4)	
57.8	 86.4	 1	in	2.9	
First	AKI	Stage	
	
1	 24,528	 131,324	 18.7	%	
(18.5–18.9)	
68.5	 71.2	 1	in	5.4	
2	 5,493	 21,537	 25.5	%	
(25–26.1)	
15.3	 79.6	 1	in	3.9	
3	 5,811	 17,725	 32.8	%	
(32.1–33.5)	
16.2	 80.4	 1	in	3.1	
Combining	2&3	 11,304	 39,262	 28.8	%	
(28.2–29.5)	
31.5	 81.3	 1	in	3.5	
ML-AKI	Model	
	 	 	 	 	 	 	
ML25	 na	 na	 25	%	 na	 99.6	 21.3	 1	in	4	
ML33	 na	 na	 33.3	%	 na	 95.3	 49.4	 1	in	3	
ML50	 na	 na	 50	%	 na	 74.3	 80.3	 1	in	2	
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4.4.5	ML	Model:	ML-AKI	
Increased	AKI	severity	stage	is	a	poor	indicator	of	individual	risk	of	death	or	renal	replacement	therapy	
in	hospital	(Drrt),	due	to	the	substantial	heterogeneity	within	patient	populations,	and	the	complex	
interaction	of	these	heterogeneous	variables.	Modelling	all	of	these,	the	ML-AKI	model	achieved	an	
AUROC	for	Drrt	of	85.9%	(with	Drrt	was	coded	as	0/1:		log	loss:	0.36,	mean	squared	error:	0.11,	and	
mean	per	class	error:	0.24)	on	the	test	dataset.	The	training	dataset	and	the	cross-validation	AUROCs	
were	96%	and	85.2%	respectively.	The	sensitivities,	specificities	and	PPVs	of	the	ML-model	and	NHSE-
AKI	algorithm	are	shown	in	Figure	4.7	and	Table	4.9.	The	final	hyper-parameters	of	the	model	were;	
number	of	trees:	3000,	max	depth:	7,	maximum	leaves:	90,	and	learn	rate:	0.02.		
	
Overall,	predictive	performance	of	the	ML-AKI	model	exceeded	that	of	the	NHSE-AKI	algorithm.	The	
rate	of	Drrt	for	ML33	(33.3%)	and	ML50	(50%)	was	higher	than	for	any	AKIfirst	stage	(18.7	to	32.8%).	
Even	when	merging	AKI	stages	2	and	3	together,	their	performance	fell	short	of	both	ML33	and	ML50	
for	Drrt	(AKIfirst	2&3	=	28.8%)	and	sensitivity	(AKIfirst	2&3	=	31.5%,	ML33	=	95.3%,	ML50	=	74.3%).	
	
The	application	of	the	ML-AKI	model	would	better	target	escalation	of	care	when	compared	with	the	
existing	 stages	of	 the	AKI	algorithm.	 If,	 at	 first	AKI	presentation,	 the	ML50	 threshold	were	used	 to	
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escalate	care	to	specialist	staff,	the	referral	rate	would	be	312	per	1,000	admissions	with	AKI,	of	which	
156	of	those	seen	would	suffer	Drrt	in	the	future.	Were	all	AKIfirst	stage	2	and	3	admissions	referred,	
230	of	every	1,000	AKI	admissions	would	be	seen,	of	which	66	would	develop	Drrt.	Thus,	26.3%	(82)	
fewer	admissions	would	be	seen	than	if	escalated	by	ML50,	but	at	the	expense	of	missing	90	future	
Drrt	cases	(66	vs	156:	57.7%	fewer	than	those	seen	with	the	ML50	trigger).	ML50’s	performance	is	also	
superior	when	compared	to	AKImax	2&3	stage	(were	it	possible	to	recognise	this	a	priori),	with	13.1%	
(312	vs	359	per	1,000)	lower	referral	rates	and	24.8%	(156	vs	125)	more	Drrt	admissions	seen.	
	
Figure	4.7:	ML-AKI	Model:	Area	Under	the	Receiver	Operator	Curve	85.9%		
	
The	green	dots	(ML20,	ML33,	ML50)	represent	specific	threshold	values	used	to	discriminate	between	patients	likely	to	have	
Drrt	or	not;	The	red	and	blue	dots	are	representations	of	the	sensitivity	and	specificity	of	the	AKI	Stages	of	the	existing	NHSE-
AKI	algorithm.	
	
For	ML33,	the	referral	rate	would	be	600	per	1,000	AKI	admissions,	of	which	200	(95.6%	of	all	Drrt)	
would	suffer	from	Drrt.	This	would	result	in	366	(159%)	more	admissions	being	seen	than	for	AKIfirst	
stages	2	and	3,	but	40%	less	than	all	AKI	admissions	(AKI	stages	1,	2	and	3).	However,	the	Drrt	cases	
identified	would	be	134	(203%)	more	or	10	(4.7%)	less	than	AKIfirst	stages	2	and	3	or	all	AKI	(stages	1,	2	
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and	3)	respectively.		For	ML25,	the	referral	rate	would	be	836	per	1,000	AKI	admissions,	of	which	209	
(99.3%	of	all	Drrt)	would	suffer	from	Drrt.	
	
Finally,	 Table	 4.10	 lists	 the	 relative	 importance	 of	 the	 top	 thirty	 variables	 of	 the	ML-AKI	model	 in	
descending	order,	highlighting	the	influence	of	demographic	and	administrative	data	in	an	admission’s	
AKI	outcome.	
	
Table	4.10:	ML-AKI	Variable	Importance	
Variable	 Scaled	Importance	 Percentage	importance	
Urea	at	first	AKI	stage	 1.000	 21.65%	
Admission	method	code	 0.409	 8.85%	
Ethnic	category	 0.284	 6.15%	
White	cell	count	at	first	AKI	stage	 0.211	 4.57%	
Age	 0.197	 4.26%	
Sodium	at	first	AKI	stage	 0.188	 4.07%	
Creatinine	48	hr	rise	at	first	AKI	stage	 0.155	 3.35%	
Source	of	admission	code	 0.154	 3.34%	
Platelets	at	first	AKI	stage	 0.135	 2.92%	
AKI	stage	at	first	AKI	stage	 0.124	 2.68%	
Red	cell	distribution	width	at	first	AKI	stage	 0.123	 2.67%	
Month	of	admission	 0.119	 2.57%	
Urea:creatinine	ratio	at	first	AKI	stage	 0.102	 2.20%	
I50	(ICD10	code)	 0.088	 1.90%	
Admission	estimated	glomerular	filtration	rate	 0.084	 1.81%	
Creatinine	at	first	AKI	stage	 0.083	 1.80%	
Mean	sodium	 0.072	 1.56%	
Potassium	at	first	AKI	stage	 0.065	 1.41%	
Haemoglobin	first	AKI	stage	 0.061	 1.32%	
Mean	creatinine	 0.060	 1.30%	
I48	(ICD10	code)	 0.059	 1.27%	
Admission	baseline	creatinine	 0.057	 1.23%	
Admission	urea:creatinine	ratio	 0.047	 1.02%	
C79	(ICD10	code)	 0.045	 0.97%	
Day	of	admission	 0.033	 0.72%	
Admission	sodium	 0.033	 0.71%	
Admission	red	cell	distribution	width	 0.030	 0.66%	
Admission	haemoglobin	 0.029	 0.63%	
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Admission	potassium	 0.027	 0.58%	
Admission	white	cell	count	 0.027	 0.57%	
4.5	Discussion	
I	have	performed	the	one	of	largest	analysis	yet	undertaken	relating	to	AKI	incidence,	outcomes	and	
prediction	of	mortality	and	renal	replacement	therapy,	having	studied	1.9	million	hospital	admissions	
in	14	NHS	acute	trusts,	using	data	for	over	22.6	million	creatinine	results.	I	found	AKI	to	be	common,	
occurring	in	over	1	in	11	(8.6%)	of	hospital	admissions,	in	line	with	data	from	China	(7%)	141,	but	lower	
than	both	the	pooled	northern	European	(14.7%)	84	and	worldwide	rates	(21%).	84	Incidence	amongst	
emergency	 admissions	 (10.7%)	 was	 also	 lower	 than	 in	 recently	 reported	 studies	 (25.4%142	 and	
12.3%143).	The	proportion	of	community-acquired	AKI	(AKI	diagnosed	on	the	first	in-hospital	creatinine	
result,	i.e.	on	admission)	in	my	study	was	38.6%,	with	no	firm	comparison	available.	AKI	patients	in	my	
study	did,	however,	have	a	similar	prevalence	of	co-morbidities	to	that	reported	in	past	studies	(e.g.	
hypertension	 and	 diabetes	mellitus,	 34.2%	 vs	 33.8%144	 and	 19.7%	 vs	 23%144	 respectively),	 and	 the	
proportion	developing	AKI	who	presented	with	a	Ur:Cr	ratio	>80	was	also	similar	(41%	vs	39%145).	The	
prevalence	of	heart	failure	in	my	study	was,	however,	a	little	lower	than	in	previous	research	(13%	vs	
18.3%144).		
	
I	confirmed	that	AKI	is	associated	with	poor	outcome.	Drrt	occurred	in	a	little	over	1	in	5	of	those	with	
AKI	(21%;	death,	17.6%),	but	less	than	1	in	62	(1.6%;	death,	1.6%)	of	those	without.	Such	findings	are	
not	dissimilar	 from	 those	 reported	worldwide	 (AKI	mortality	 =	23.3%).84	 Finally,	 I	 confirmed	 that	 a	
higher	 AKI	 stage	was	 associated	with	 poorer	 outcome:	 both	Drrt	 (Table	 4.8)	 and	mortality	 (AKI	 1:	
12.3%;	2:	26.6%;	3:	28.4%)	rose	with	rising	stages.		
	
Over	a	decade	of	research	culminating	in	the	KDIGO	guidelines,	and	the	potential	for	improving	care	
of	patients	developing	AKI	led	to	NHS	England	to	developing	and	subsequently	mandating	the	NHSE-
AKI	 algorithm.	 This	 is	without	 a	 doubt	 a	 positive	 incremental	 improvement	 in	 the	management	of	
patients	with	renal	injury.	However,	I	have	demonstrated	there	is	room	for	a	further	significant	step	
change	improvement,	as	there	are	weaknesses	in	the	KDIGO-based	NHSE-AKI	algorithm.	Outcome	is	
dependent	 not	 just	 on	 the	 AKI	 stage,	 but	 also	 on	 the	 route	 within	 the	 algorithm	 by	 which	 it	 is	
determined,	 resulting	 in	 significant	 variability	 of	 Drrt	 risk.	 More	 importantly,	 Drrt	 is	 affected	 by	
multiple	factors,	including	patient	demographics,	disease	states,	and	method	and	dates	of	admission.	
None	of	these	are	incorporated	into	either	the	NHSE-AKI	algorithm	or	the	original	KDIGO	guidelines	
from	which	the	former	is	derived.	Overall,	the	current	AKI	staging	results	in	poorly	stratified	individual	
risk.	
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Consistent	 with	 these	 observations,	 I	 found	 that	 the	 performance	 of	 my	 ML-AKI	 model	 greatly	
exceeded	that	of	the	NHSE-AKI	algorithm	in	predicting	Drrt.	 Indeed,	my	ML-AKI	model	achieved	an	
AUROC	of	85.9%.	Using	the	ML50	threshold	(1	in	2	cases	predicted	to	die,	or	need	RRT,	did	so),	I	was	
able	to	identify	74.3%	of	all	AKI	admissions	who	suffered	such	outcomes	(sensitivity).	If	this	threshold	
were	used	to	direct	escalation	of	care,	as	opposed	to	the	existing	KDIGO	AKI	staging,	only	31.2%	of	
admissions	 on	 first	 presentation	with	AKI	would	 trigger	 the	 efferent	 limb	 (rapid	 response	 team	or	
dedicated	AKI	nephrologist),	while	capturing	almost	three	out	of	every	four	patients	 likely	to	suffer	
from	Drrt.	The	positive	predictive	value	of	1	 in	2,	means	that	for	every	two	patients	escalated,	one	
would	suffer	from	Drrt	subsequently	in-hospital.	The	ML50	Drrt	rate	(50%)	is	higher	than	that	of	any	
of	the	existing	KDIGO	AKI	Stages	at	AKIfirst	1:	18.7%,	AKIfirst	2:	25.5%,	and	AKIfirst	3:	32.8%	(i.e.	higher	PPV	
and	specificity),	while	at	the	same	time	identifying	1.1,	4.9,	and	4.6	as	many	patients	likely	to	suffer	
from	Drrt	(higher	sensitivity),	compared	to	the	KDIGO	AKI	Stages,	respectively.	
	
My	 study	 does	 have	 some	 limitations.	 A	 small	 number	 of	 admissions	 received	 renal	 replacement	
therapy	without	AKI	having	been	diagnosed	by	 the	algorithm	 (2,577).	Of	 these,	 2,019	actually	had	
existing	 CKD-4/5,	 and	may	 thus	 already	 have	 been	 dependent	 on	 renal	 replacement	 therapy.	 This	
suggests	a	possible	failure	of	appropriate	in-hospital	diagnostic	coding.	Alternatively,	acute	on	chronic	
kidney	 injury	associated	with	a	<1.5-fold	 increase	 in	 creatinine	 from	 the	baseline	 (and	 thus	no	AKI	
diagnosis)	 may	 yet	 have	 led	 to	 renal	 replacement	 therapy.	 However,	 as	 these	 patients	 were	 not	
classified	as	having	AKI,	 they	were	excluded	 from	the	AKI	analysis,	 regardless	of	whether	 the	 renal	
replacement	therapy	was	planned	or	due	to	undiagnosed	AKI	(which	cannot	be	discriminated	between	
from	my	dataset).	It	is	also	worthy	of	note	that	patients	transferred	to	another	hospital	were	excluded,	
which	 would	 not	 have	 been	 known	 a	 priori.	 Nor	 were	 all	 ‘detrimental	 outcomes’	 (length	 of	 stay,	
hospital	 readmission	 or	 development	 of	 CKD)	 modelled.	 Future	 studies	 might	 also	 expand	 my	
definition	of	‘false-negative-AKI’	to	include	cases	where	creatinine	did	fall	(leading	to	the	lack	of	an	AKI	
alert),	 but	 incompletely	 and	 without	 clinically	 significant	 resolution;	 such	 studies	 might	 also	
incorporate	complete	resolution	of	AKI	(return	to	baseline	values).	Finally,	this	is	a	retrospective	study.	
	
A	major	strength	of	my	study	is	the	use	of	the	AKIfirst	stage.	My	ML-AKI	model	also	only	utilised	data	up	
to	this	point.	I	chose	this	for	being	both	a	practical	measurement	(as	AKImax	is	only	known	post	hoc)	
and	probably	the	most	effective,	reflecting	when	early	intervention	might	stand	the	greatest	chance	
of	improving	the	subsequent	clinical	course.	Another	strength	is	that	the	data	were	collected	before	
the	NHSE-AKI	algorithm	was	implemented,	and	thus	the	Drrt	rates	were	not	confounded	by	NHSE-AKI	
algorithm-related	detection/interventions.	
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The	‘importance’	of	non-creatinine-related	variables	in	the	ML-AKI	model	(a	48	hr	change	in	creatinine	
is	seventh	in	relative	importance)	does	highlight	that	it	 is	misleading	to	focus	on	just	the	creatinine	
result	to	determine	AKI	stage,	as	a	proxy	risk	of	poor	outcome.	Other	blood	results	–	urea,	white	cell	
count	and	sodium	–	all	make	higher	relative	contributions	to	the	ML-AKI	model,	as	do	the	variables	of	
ethnicity,	month	and	method	of	admission	(Table	4.10).	Further	work	is	needed	to	understand	these	
associative	links	and	to	determine	causality.	Nonetheless,	these	a	priori	data	are	used	by	clinicians	in	
their	diagnosis/treatment	of	a	patient,	and	should	therefore	be	incorporated	into	any	risk	prediction	
model	for	AKI-diagnosed	patients.	
	
Finally,	it	is	of	great	concern	that	32.2%	of	all	AKI	admissions	who	do	not	die	or	have	renal	replacement	
therapy	in	hospital	are	discharged	from	hospital	when	still	demonstrating	an	AKI	stage.	Future	studies	
should	further	investigate	and	follow	up	these	patients	to	deem	the	appropriateness	of	this	course	of	
action	(discharge	from	hospital	with	an	AKI	stage).	
	
In	summary,	I	have	shown	that:	
1. AKI	stage	is	poor	indicator	of	individual	risk	of	Drrt.		
2. Method	 of	 admission,	 demographics,	 other	 blood	 results	 and	 co-morbidities	 significantly	
modify	Drrt	risk.		
3. ML	applied	to	common	blood	tests	and	administrative	data	can	offer	individual	risk	prediction	
with	a	precision	well	beyond	that	delivered	by	existing/conventional	risk	stratification.	
4. Variables	other	than	creatinine	have	more	influence	on	the	risk	of	Drrt	in	AKI	admissions	than	
creatinine	itself.		
	
My	ML-AKI	model	(implemented	in	Java	code)	can	be	integrated	with	existing	hospital	systems,	and	
would	 immediately	 target	 clinical	 resources	 to	 patients	 at	 the	 highest	 risk	 of	 Drrt,	 on	 their	 first	
presentation	with	AKI.	This	would	enable	early	diagnosis	and	intervention,	which	has	been	shown	to	
increase	clinical	effectiveness,	and	which	may	also	reduce	costs	associated	with	health	care.	
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Chapter	5:	ML	EWSCs	
5.1	Introduction		
Patients	may	die	in	hospital	from	a	variety	of	conditions.	They	may	not	be	dehydrated,	nor	may	they	
develop	AKI.	They	also	arrive	in	hospital	via	multiple	methods	(emergency,	elective,	maternity,	etc.);	
thus,	an	 ideal	EWSC	would	be	applicable	 to	all	hospitalised	patients,	 regardless	of	 their	method	of	
admission	or	disease	state.	Preferably,	such	an	EWSC	would	be	able	to	risk-stratify	patients	as	early	in	
their	hospitalisation	as	possible,	 i.e.	on	admission.	In	addition,	the	capability	to	provide	an	updated	
prediction	 of	 in-hospital	 mortality	 once	 initial	 treatment	 has	 taken	 place	 would	 also	 help	 target	
resources	to	those	patients	who	are	either	at	continued	risk	or	have	deteriorated	since	admission.	As	
discussed	 in	Chapter	1	 (Section	1.4.4),	 there	have	been	attempts	at	building	such	 laboratory-based	
EWSCs	 in	 the	 past.	 However,	 none	 of	 these	 previous	 attempts	 can	 be	 applied	 to	 all	 hospitalised	
patients,	due	to	limitations	which	include:		
a) Poor	generalisability:	their	effectiveness	has	not	been	proven	in	diverse	hospital	patients,	as	
they	are	either	specific	to	a	type	of	patient	(medical,	surgical,	emergency,	elective,	etc.),	or	
they	have	been	created	and	tested	using	patients	from	only	one	or	two	hospitals.	
b) Simplistic	analysis:	they	take	account	of	neither	the	dynamic	change	(trends),	nor	the	inter-
correlations	between	blood	results.	
c) Lack	of	patient	specific	information:	they	do	not	account	for	a	patient’s	co-morbidities.	
d) Lack	 of	 context	 sensitive	 information:	 they	 account	 for	 neither	 the	 date	 of	 a	 patient’s	
admission	 (e.g.	 weekday	 vs	 weekend,	 summer	 vs	 winter)	 nor	 the	 time	 a	 blood	 test	 was	
performed	(e.g.	3pm	vs	3am).	
e) Poor	performance:	their	ability	to	discriminate	between	patients	likely	to	live	or	die	is	low.		
	
To	overcome	the	limitations	of	these	previous	approaches	in	this	thesis,	it	was	necessary	to	1)	collect	
a	large	dataset	from	multiple	diverse	hospitals,	and	2)	to	apply	advanced	analytical	techniques	that	
both	accounted	for	multicollinearity	and	were	able	to	produce	highly	accurate	models.	
5.2	Objectives		
To	 build	 advanced	 EWSCs	 (hereafter	 referred	 to	 as	 a	 ‘model’	 that	 1)	 use	 a	wide	 range	 of	 existing	
available	information,	2)	incorporate	the	dynamic	change	in	the	input	variables,	and	3)	can	be	utilised	
on	all	patients	admitted	to	hospital.	
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In	this	chapter,	I	have	focussed	on	creating	two	such	ML	models.	Both	can	be	applied	to	all	hospitalised	
patients.	The	first	model,	‘ML_Admission’,	to	be	applied	at	the	point	of	a	patient’s	admission,	predicts	
the	risk	of	in-hospital	mortality	using	the	very	first	set	of	blood	test	results.	The	second	model,	‘ML-
Two-Tests’,	provides	a	prediction	of	a	patient’s	in-hospital	mortality	at	the	moment	when	a	second	set	
of	blood	test	results	 is	available;	 i.e.	at	a	 later	time	point	during	a	patient’s	stay	 in	hospital,	during	
which	it	is	expected	that	some	treatment	has	been	initiated.	
	
The	input	variables	of	the	models	consist	of:		
§ A	 subset	 of	 the	 most	 common	 blood	 tests	 performed	 on	 hospitalised	 patients:	 Urea	 and	
Electrolytes	(sodium,	potassium,	urea,	and	creatinine),	Full	Blood	Count	(haemoglobin,	white	cell	
count,	platelets,	red	cell	distribution	width,	and	mean	cell	volume),	and	Albumin;	
§ Known	a	priori	information	about	the	patient:		
o method	and	source	of	admission	
o co-morbidities	
o demographics	(age,	sex,	and	ethnicity)	
5.3	Methods	
5.3.1	Patients	
The	dataset	described	in	Chapter	2	was	used	as	the	basis	for	this	analysis.	In	brief,	I	collated	continuous	
electronically	stored	data	for	all	adults	(18	years	and	over)	admitted	to	fourteen	UK	NHS	acute	hospital	
trusts	from	early	2005	to	late	2015.	Specifically,	for	this	analysis,	I	included	patients	with	a	complete	
administrative	record,	and	at	least	one	sodium	and	haemoglobin	blood	test	result,	taken	during	their	
admission.	 Excluded	were	patients	 transferred	 to	 another	hospital	 for	 continued	medical	 care	 and	
those	who	self-discharged	from	hospital,	for	whom	the	outcome	of	their	hospitalisation	was	unknown.	
Each	hospital	admission	was	analysed	independently.	
5.3.2	Data	
The	 following	 results	 were	 collated	 from	 each	 admission:	 the	 first	 and	 second	 sodium	 (mmol/L),	
potassium	(mmol/L),	urea	(mmol/L),	creatinine	(µmol/L),	haemoglobin	(g/L),	platelet	(109/L),	mean	cell	
volume	 (fL),	 red	 cell	 distribution	 width	 (%),	 white	 cell	 count	 (109/L)	 results,	 and	 albumin	 (g/L).	 In	
addition,	where	such	data	existed,	they	were	captured	up	to	one	year	prior	to	admission.	Routinely	
collected	administrative	data	were	also	recorded:	patient	age,	diagnoses	(ICD-10),	 treatment	codes	
(OPCS4)	and	dates,	and	details	relating	to	hospital	admission	and	discharge.	I	selected	these	variables	
because	of	their	ubiquity	(available	for	most	hospitalised	patients).	
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I	performed	feature	engineering	on	this	raw	data,	to	extract:		
§ For	blood	results	tested	during	an	admission:	
- The	hour	of	the	day	each	blood	test	result	became	available	(24-hour	clock).	
- The	 absolute	 difference	 between	 the	 second	 and	 first	 blood	 results,	 for	 each	 test	 per	
admission.	
- The	relative	difference	(second	blood	test	/	first	blood	test),	for	each	test	per	admission.	
§ For	blood	results	in	the	year	prior	to	a	patient’s	admission:	
- The	total	number	of	each	test	performed,	for	each	test	per	admission.	
- The	mean	of	each	blood	test,	for	each	test	per	admission.	
- The	standard	deviation	of	each	blood	test,	for	each	test	per	admission.	
§ For	administrative	data:	
- The	day	of	the	week	of	admission	(Monday	to	Sunday).	
- The	month	of	admission	(January	to	December).	
	
For	ML-Admission,	 this	 entire	 dataset	 was	 used.	 For	ML-Two-Tests,	 only	 admissions	with	 both	 an	
additional	in-hospital	sodium	and	haemoglobin	result	were	included.	
	
Prevalence	and	in-hospital	mortality	were	calculated	for:	each	ethnic	category,	admission	method,	day	
of	week	of	 admission,	month	of	 admission,	 and	each	 ICD-10	 code.	 I	 also	 calculated	 the	mean	and	
interquartile	range,	and	the	number	of	missing	values	for	each	blood	test.	
5.3.3	ML	
I	used	Wilson’s	method	to	calculate	the	95%	confidence	intervals	for	mortality	rate.	Prevalence	and	
mortality	rates	were	compared	using	Fisher’s	Exact	Test.	
	
I	used	the	GB	ML	technique	to	build	the	models	to	predict	in-hospital	mortality.	The	two	models	built	
were:		
1. ML_Admission:	to	be	used	on	all	patients	who	have	at	least	one	sodium	and	one	haemoglobin	
blood	result	in-hospital,	at	the	point	their	first	set	of	blood	results	is	available.	
2. ML_Two_Tests:	to	be	used	on	all	patients	who	have	at	least	two	sodium	and	two	haemoglobin	
in-hospital	blood	results,	at	the	point	their	second	set	of	blood	results	is	available.	
	
The	full	list	of	variables	used	to	create	these	two	models	is	shown	in	Tables	5.1	and	5.2	respectively.	
	 	
	
119	
Table	5.1:	ML-Admission:	Variables		
Variable	Name	 Type	of	Variable	
Age	 Numerical	
Sex	
Categorical	
Ethnic	category	
Admission	method	code	
Source	of	admission	code	
Day	of	admission		
Month	of	admission	
Blood	Results	
Admission	Sodium	
Numerical	
Admission	Potassium	
Admission	Urea	
Admission	Creatinine	
Admission	Urea:Creatinine	Ratio	
Admission	Haemoglobin	
Admission	Platelets	
Admission	White	Cell	Count	
Admission	Mean	Cell	Volume		
Admission	Red	Cell	Distribution	Width	
Admission	Albumin	
Hour	of	Validation	of	the	Admission	Blood	Result	
Hour	of	validation	of	admission	
Sodium	
Potassium	
Urea	
Creatinine	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Albumin	
Numerical	(0	–	24)	
Summary	Pre-Admission	Blood	Results	(last	year	(365	days),	SI	units)	
Number	of		
Sodium	
Potassium	
Urea	
Creatinine	
Haemoglobin	
Numerical	
Mean	 Numerical	
	
120	
Standard	deviation	of	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Albumin	
Numerical	
Co-morbidities	
Condition	 ICD10	code	 	
Essential	(primary)	hypertension	 I10	
Categorical	
Angina	Pectoris	 I20	
Chronic	ischaemic	heart	disease	 I25	
Atrial	fibrillation	or	flutter	 I48	
Heart	Failure	 I50	
Secondary	and	unspecified	malignant	neoplasm	of	lymph	nodes	 C77	
Secondary	malignant	neoplasm	of	other	and	unspecified	sites	 C79	
Multiple	myeloma	and	malignant	plasma	cell	neoplasms	 C90	
Myeloid	leukaemia	 C92	
Other	hypothyroidism	 E03	
Type	2	diabetes	mellitus	 E11	
Obesity	 E66	
Disorders	of	lipoprotein	metabolism	and	other	lipidaemias	 E78	
Mental	and	behavioural	disorders	due	to	use	of	alcohol	 F10	
Smoking	 F17	
Depressive	episode	 F32	
Epilepsy	 G40	
Other	chronic	obstructive	pulmonary	disease	 J44	
Asthma	 J45	
Chronic	kidney	disease	 N18	
Other	symptoms	and	signs	involving	the	nervous	and	
musculoskeletal	systems	
R29	
Personal	history	of	malignant	neoplasm	of	digestive	organs	 Z850	
Personal	history	of	psychoactive	substance	abuse	 Z864	
Personal	history	of	diseases	of	the	nervous	system	and	sense	
organs	
Z866	
Personal	history	of	diseases	of	the	circulatory	system	 Z867	
Personal	history	of	allergy	to	penicillin	 Z880	
Personal	history	of	allergy	to	other	drugs,	medicaments	and	 Z888	
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biological	substances	
Presence	of	electronic	cardiac	devices	 Z950	
Presence	of	aortocoronary	bypass	graft	 Z951	
Presence	of	coronary	angioplasty	implant	and	graft	 Z955	
	
For	each	model	I	split	the	appropriate	dataset	into	a	seventy	per	cent	‘Train	Dataset’	and	a	thirty	per	
cent	 ‘Test	Dataset’.	Five-fold	cross-validation	was	employed	to	prevent	overfitting	and	to	help	with	
final	model	selection.	I	built	multiple	models	for	each	use	case	(ML-Admission	and	ML-Two-Tests)	by	
modifying	the	hyper-parameters	of	the	GB	model.	The	hyper-parameters	in	this	case	were	1)	learning	
rate,	2)	depth	of	trees,	3)	number	of	trees	and	4)	nodesize.	A	grid	search	of	these	hyper-parameters	
was	used	to	determine	the	best	model,	based	on	its	mean	cross-validation	performance	(i.e.	the	model	
with	 the	 smallest	mean	 cross-validation	 log	 loss).	 The	 range	 of	 the	 hyper-parameters	 for	 the	 grid	
search	were:	 learning	 rate:	0.1	 to	0.01;	depth	of	 trees:	5	 to	9;	number	of	 trees:	800	 to	5,000;	and	
nodesize:	500	to	12,000.	The	selected	model	was	then	used	to	predict	outcome	on	the	independent	
Test	Dataset	to	determine	the	AUROC.	Two	threshold	values	were	selected	that	resulted	in	positive	
predictive	values	(PPV)	of	1:5	and	1:3,	for	identifying	whether	a	patient	had	died	in	hospital	or	not.	A	
PPV	of	1:5	means	that	if	the	model	predicts	a	patient	is	likely	to	die,	then	one	out	of	every	five	predicted	
patients	will	do	so	(20%).	Similarly,	a	PPV	of	1:3	means	that	if	the	model	predicts	a	patient	is	likely	to	
die,	then	one	out	of	every	three	predicted	patients	will	do	so	(33.33%).		For	each	PPV	threshold,	the	
sensitivity	and	specificity	were	also	calculated.		
	
The	relative	importance	of	each	predictor	variable	was	calculated	as	in	Chapter	4	(Section	4.3.3).	The	
same	software	as	in	Chapter	4	(Section	4.3.3)	was	also	used.	
	
Table	5.2:	ML-Two-Tests:	Variables		
Variable	Name	
Type	of	
Variable	
All	Variables	from	Table	5.1	 Mixed	
Blood	Results	
Second	Sodium	
Numerical	
Second	Potassium	
Second	Urea	
Second	Creatinine	
Second	Urea:Creatinine	Ratio	
Second	Haemoglobin	
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Second	Platelets	
Second	White	Cell	Count	
Second	Mean	Cell	Volume		
Second	Red	Cell	Distribution	Width	
Second	Albumin	
Hour	of	Validation	of	Blood	Result	
Hour	of	validation	of	second	blood	result:	
Sodium	
Potassium	
Urea	
Creatinine	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Albumin	
Numerical	
(0–24)	
Difference	between	Second	and	Admission	Blood	Result	
Absolute	difference	between	Second	and	Admission:		
(second	blood	result	/	admission	blood	result)	
Sodium	
Potassium	
Urea	
Creatinine	
Ur:Cr	
Haemoglobin	
Platelets	
White	Cell	Count	
Mean	Cell	Volume	
Red	Cell	Distribution	Width	
Albumin	
Numerical	
Relative	difference	between	Second	and	Admission:	
(second	blood	result	/	admission	blood	result)	
Numerical	
Number	of	hours’	difference	between	Second	and	
Admission	blood	result:	
Numerical	
5.4	Results	
5.4.1	Admission_Cohort	
5.4.1.1	Baseline	Characteristics	
There	were	1,874,325	admissions	who	met	 the	 inclusion	criteria.	Of	 these,	3.14	%	 (58,843)	died	 in	
hospital.	The	median	length	of	stay	(LoS)	was	2	days	(IQR):	0–6	days).	Female	admissions	were	54.86%	
of	the	total.	The	median	age	was	60	years	(IQR	41–75).	The	histogram	of	the	ages	of	admissions,	along	
with	the	number	of	patients	who	died,	is	shown	in	Figure	5.1.		
	
Grouped	emergency,	elective	and	maternity	admissions	accounted	for	57.6%,	34.6%	and	5.7%	of	the	
total	respectively	(Table	2.3).	The	full	distribution	of	the	admissions	by	ethnic	category,	method,		
month,	and	day	of	week	are	shown	in	Tables	5.3,	5.4,	5.5	and	5.6	respectively.	The	ethnic	category	
‘British’	had	the	highest	proportion	of	admissions	at	42.8%,	followed	by	the	‘Not	Stated’	category	at	
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30.4%.	The	prevalence	of	the	various	ICD-10	codes	is	shown	in	Table	5.7.	The	median	(IQR)	values	of	
all	the	blood	tests,	including	the	number	of	admissions	with	missing	values,	are	shown	in	Table	5.8.	Of	
particular	note	are	the	proportions	of	admissions	with	no	results	 for	platelets,	RDW	or	albumin,	at	
28.6%,	29.4%	and	21.08%	respectively.	The	presence	of	both	a	sodium	and	a	haemoglobin	result	were	
part	of	the	inclusion	criteria,	hence	the	presence	of	these	in	all	admissions.	
	
	
	
The	in-hospital	mortality	rates	for	each	group	of	admissions	are	also	shown	in	Tables	5.3	to	5.6.	The	
highest	in-hospital	mortality	occurred	in	the	‘Not	Stated’	and	‘British’	ethnic	categories,	at	4.1%	and	
3.4%	respectively.	Both	of	these	were	significantly	higher	than	for	all	other	ethnicities.	Mortality	by	
method	of	admission	(Emergency:	4.9%;	Elective:	0.4%;	and	Maternity:	0.07%;	p<0.01)	substantiates	
the	 view	 that	 patients	 admitted	 as	 an	 emergency	 are	 significantly	 more	 likely	 to	 die	 than	 those	
admitted	via	either	the	elective	or	maternity	methods.	The	‘Other’	method	of	admission	(the	bulk	of	
which	was	made	up	of	non-emergency	inter-hospital	transfers)	has	a	small	prevalence	(2.1%),	but	the	
highest	mortality	rate	of	all,	at	9%.	The	months	of	admission	with	the	highest	mortality	were	January	
(3.5%)	 and	 December	 (3.9%).	 Weekend	 admissions	 had	 higher	 mortality	 when	 compared	 with	
weekdays	 (4.3%	vs	2.9%,	p<0.01).	However,	 this	weekend	vs	weekday	difference	 in	mortality	 rates	
decreased	from	1.4%	to	0.31%	when	only	emergency	admissions	were	examined	(5.13%	vs	4.82%).	
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Table	5.3:	Admission_Cohort:	Ethnic	category	prevalence,	and	in-hospital	mortality	rates	
Ethnic	Category	
Number	of	
Admissions	
Prevalence	
%	of	total	
Total	=	1,874,325	
In-Hospital	Mortality	
(95%	CI)	
British	(A)	 802,570	 42.8	%	
3.37	%	
(3.33–3.41)	
Irish	(B)	 31,973	 1.71	%	
2.90	%	
(2.72–3.09)	
Any	other	white	background	(C)	 139,363	 7.44	%	
1.84	%	
(1.77–1.91)	
White	and	black	Caribbean	(D)	 4,329	 0.23	%	
0.97	%	
(0.72–1.31)	
White	and	black	African	(E)	 2,753	 0.15	%	
1.09	%	
(0.76–1.55)	
White	and	Asian	(F)	 2,588	 0.14	%	
1.31	%	
(0.94–1.83)	
Any	other	mixed	background	(G)	 7,944	 0.42	%	
1.27	%	
(1.05–1.54)	
Indian	(H)	 41,824	 2.23	%	
1.96	%	
(1.83–2.1)	
Pakistani	(J)	 17,658	 0.94	%	
1.39	%	
(1.23–1.58)	
Bangladeshi	(K)	 27,899	 1.49	%	
1.47	%	
(1.34-–1.62)	
Any	other	Asian	background	(L)	 39,093	 2.09	%	
1.57	%	
(1.45–1.7)	
Caribbean	(M)	 43,785	 2.34	%	
1.77	%	
(1.65–1.9)	
African	(N)	 55,177	 2.94%	
0.85	%	
(0.78–0.93)	
Any	other	black	background	(P)	 21,603	 1.15%	
1.11	%	
(0.98–1.26)	
Chinese	(R)	 8,864	 0.47%	
1.83	%	
(1.57–2.13)	
Any	other	ethnic	group	(S)	 58,089	 3.10%	
1.97	%	
(1.86–2.09)	
Not	Stated	(Z)	 568,813	 30.35%	
4.08	%	
(4.03–4.13)	
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Table	5.4:	Admission_Cohort:	Method	of	admission	prevalence,	and	in-hospital	mortality	rates	
Method	of	Admission	
Number	of	
Admissions	
Prevalence:	
%	of	total	
Total	=	1,874,325	
In-Hospital	
Mortality	
(95%	CI)	
Elective	
Elective	Waiting	list	(11)	 219,310	 11.70	%	
0.54	%	
(0.51–0.57)	
Elective	Booked	(12)	 97,146	 5.18	%	
0.79	%	
(0.74–0.85)	
Elective	Planned	(13)	 333,124	 17.77	%	
0.20	%	
(0.19–0.22)	
Emergency	
Accident	and	emergency	or	
dental	casualty	department	of	
the	health	care	provider	(21)	
762,307	 40.67	%	
5.03	%	
(4.98–5.08)	
General	practitioner	(22)	 163,152	 8.70	%	
5.15	%	
(5.05–5.26)	
Bed	bureau	(23)	 8,814	 0.47	%	
3.8	%	
(3.42–4.22)	
Consultant	clinic,	of	this	or	
another	health	care	provider	
(24)	
33,385	 1.78	%	
2.83	%	
(2.66–3.02)	
Admission	via	mental	health	
crisis	resolution	team	(25)	 474	 0.03	%	
5.27	%	
(3.6–7.67)	
Transfer	of	an	admitted	
patient	from	another	hospital	
provider	in	an	emergency	(28)	
107,525	 5.74	%	
4.19	%	
(4.07–4.31)	
Accident	and	emergency	
department	of	another	
provider	where	the	patient	
had	not	been	admitted	(2A)	
149	 0.01	%	
10.07	%	
(6.2–15.95)	
Other	means	(2B)	 385	 0.02	%	
12.47	%	
(9.53–16.14)	
Other	emergency	admission	
(2D)	 2,498	 0.13	%	
0.76	%	
(0.49–1.18)	
Maternity	
Admitted	ante-partum	(31)	 101,982	 5.44	%	
0.01	%	
(0.01–0.02)	
Admitted	post-partum	(32)	 4,317	 0.23	%	
0.05	%	
(0.01–0.17)	
Other	
Transfer	of	any	admitted	
patient	from	another	hospital	
provider	other	than	in	an	
emergency	(81)	
39,262	 2.09	%	
9.07	%	
(8.79–9.36)	
The	birth	of	a	baby	in	this	
health	care	provider	(82)	 140	 0.01	%	
1.43	%	
(0.39–5.06)	
Baby	born	outside	the	health	
care	provider	except	when	
born	at	home	as	intended	(83)	
30	 0.00	%	
6.67	%	
(1.85–21.32)	
Not	known	/	validation	error	
(99)	 325	 0.02	%	
4.92	%	
(3.05–7.85)	
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Table	5.5:	Admission_Cohort:	Month	of	admission	prevalence,	and	in-hospital	mortality	rates	
Month	 Number	of	Admissions	
Prevalence:	%	of	total	
Total	=	1,874,325	
In-Hospital	Mortality	
(95%	CI)	
January	 163,785	 8.74	%	
3.54	%	
(3.46–3.63)	
February	 150,886	 8.05	%	
3.35	%	
(3.26–3.44)	
March	 157,378	 8.4	%	
3.29	%	
(3.2–3.38)	
April	 154,892	 8.26	%	
3.14	%	
(3.05–3.23)	
May	 160,491	 8.56	%	
2.85	%	
(2.77–2.93)	
June	 149,226	 7.96	%	
2.78	%	
(2.69–2.86)	
July	 155,801	 8.31	%	
2.84	%	
(2.75–2.92)	
August	 150,825	 8.05	%	
2.91	%	
(2.83–3)	
September	 153,985	 8.22	%	
2.81	%	
(2.73–2.89)	
October	 162,718	 8.68	%	
3.1	%	
(3.02–3.18)	
November	 158,649	 8.46	%	
3.18	%	
(3.1–3.27)	
December	 155,689	 8.31	%	
3.86	%	
(3.76–3.95)	
	
Table	5.6:	Admission_Cohort:	Day	of	admission	prevalence,	and	in-hospital	mortality	rates	
Day	of	Admission	 Number	of	Admissions	
Prevalence:	%	of	total	
Total	=	1,874,325	
In-Hospital	Mortality	
(95%	CI)	
Weekday	
Monday	 307,401	 16.4	%	
2.97	%	
(2.91–3.03)	
Tuesday	 326,864	 17.44	%	
2.83	%	
(2.77–2.88)	
Wednesday	 323,169	 17.24	%	
2.74	%	
(2.69–2.8)	
Thursday	 320,625	 17.11	%	
2.78	%	
(2.72–2.84)	
Friday	 281,399	 15.01	%	
3.24	%	
(3.17–3.3)	
Weekend	
Saturday	 155,174	 8.28	%	
4.43	%	
(4.33–4.53)	
Sunday	 159,693	 8.52	%	
4.2	%	
(4.11–4.3)	
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Table	5.7:		Admission_Cohort:	Prevalence	of	ICD10	codes	
Co-morbidity	
ICD10	
code	
No.	of	
admissions	
Prevalence:	%	
of	total	
(1,874,325)	
Essential	(primary)	hypertension	 I10	 431,609	 23.03	%	
Angina	Pectoris	 I20	 60,181	 3.21	%	
Chronic	ischaemic	heart	disease	 I25	 174,610	 9.32	%	
Atrial	fibrillation	or	flutter	 I48	 151,808	 8.1	%	
Heart	Failure	 I50	 79,226	 4.23	%	
Personal	history	of	diseases	of	the	circulatory	system	 Z867	 111,968	 5.97	%	
Secondary	malignant	neoplasm	of	lymph	nodes	 C77	 25,351	 1.35	%	
Secondary	malignant	neoplasm	of	other	and	unspecified	sites	 C79	 37,953	 2.02	%	
Multiple	myeloma	and	malignant	plasma	cell	neoplasms	 C90	 37,608	 2.01	%	
Myeloid	leukaemia	 C92	 25,511	 1.36	%	
Other	hypothyroidism	 E03	 70,281	 3.75	%	
Type	2	diabetes	mellitus	 E11	 199,260	 10.63	%	
Obesity	 E66	 32,739	 1.75	%	
Disorders	of	lipoprotein	metabolism	and	other	lipidaemias	 E78	 155,255	 8.28	%	
Mental	and	behavioural	disorders	due	to	use	of	alcohol	 F10	 43,076	 2.30	%	
Smoking	 F17	 94,122	 5.02	%	
Depressive	episode	 F32	 66,164	 3.53	%	
Epilepsy	 G40	 35,559	 1.90	%	
Other	chronic	obstructive	pulmonary	disease	 J44	 99,895	 5.33	%	
Asthma	 J45	 113,837	 6.07	%	
Chronic	kidney	disease	 N18	 117,982	 6.29	%	
Other	symptoms	and	signs	involving	the	nervous	and	
musculoskeletal	systems	
R29	 38,476	 2.05	%	
Personal	history	of	malignant	neoplasm	of	digestive	organs	 Z850	 21,552	 1.15	%	
Personal	history	of	psychoactive	substance	abuse	 Z864	 119,672	 6.38	%	
Personal	history	of	diseases	of	the	nervous	system	and	sense	
organs	
Z866	 24,251	 1.29	%	
Personal	history	of	allergy	to	penicillin	 Z880	 90,515	 4.83	%	
Personal	history	of	allergy	to	other	drugs,	and	biological	
substances	
Z888	 32,564	 1.74	%	
Presence	of	electronic	cardiac	devices	 Z950	 34,612	 1.85	%	
Presence	of	aortocoronary	bypass	graft	 Z951	 38,428	 2.05	%	
Presence	of	coronary	angioplasty	implant	and	graft	 Z955	 31,323	 1.67	%	
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Table	5.8:	Admission_Cohort:	Median	(Interquartile	Range)	of	Blood	Tests	
Blood	Test	 Median	(Interquartile	Range)	
Percentage	missing	of	total	
(total	=	1,872,345)	
Sodium	 139	(136–141)	 0	%	
Potassium	 4.2	(3.9–4.5)	 3.26	%	
Urea	 5.3	(3.9–7.6)	 3.64	%	
Creatinine	 77	(62–100)	 8.88	%	
Ur:Cr	 66.2	(51.2–84.7)	 9.88	%	
Haemoglobin	 12.4	(10.9–13.8)	 0	%	
Platelets	 236	(185–295)	 28.62	%	
White	Cell	Count	 8.2	(6.1–11)	 0.2	%	
Mean	Cell	Volume	 89.2	(85.1–93.3)	 0.13	%	
Red	Cell	Distribution	Width	 13.9	(13.1–15.4)	 29.44	%	
Albumin	 40	(35–44)	 21.08	%	
	
5.4.1.2	ML-Admission	Model	
The	Train	Dataset	and	Test	Dataset	were	randomised	effectively,	with	both	having	the	same	proportion	
of	patients	who	died,	at	3.14%.	The	hyper-parameters	 that	produced	 the	 lowest	mean	 logloss	and	
highest	mean	AUROC	via	cross-validation	were:	number	of	trees:	1,600;	tree	depth:	7;	and	learning	
rate:	0.04.	
	
The	ML-Admission	model	achieved	an	AUROC	of	93%	(logloss:	0.088,	Figure	5.2)	on	the	Test	Dataset,	
which	was	similar	to	the	mean	cross-validation	AUROC	of	92.9%	(logloss:	0.088).	At	the	PPV	1:5	(20%)	
threshold,	 the	model	 achieved	 a	 sensitivity	 of	 76.1%,	 and	 a	 specificity	 of	 90.2%	 (the	 highest	 ever	
achieved).	This	means	that,	if	a	rapid	response	team	were	directed	to	all	admissions	who	triggered	the	
model	at	this	threshold,	only	11.9%	of	admissions	would	be	referred,	but	these	referrals	would	include	
76.1%	of	all	patients	likely	to	die.	In	other	words,	for	every	1,000	admissions	to	hospital,	there	would	
be	approximately	31	(31.4)	admissions	who	would	die	in	hospital.	The	referral	rate	of	the	model	in	this	
scenario	would	be	119	per	1,000	admissions,	within	which	would	be	24	of	the	31	patients	likely	to	die.	
	
Similarly,	for	the	PPV	1:3	(33%)	threshold,	the	model’s	sensitivity	was	49.3%,	with	a	specificity	of	96.8%.	
For	every	1,000	admissions	to	hospital,	the	referral	rate	would	be	approximately	46	per	1,000	(4.6%)	
admissions,	within	which	would	be	15	of	the	31	patients	likely	to	die.	
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The	scaled	variable	importance	of	the	twenty-five	most	‘important’	predictor	variables	is	displayed	in	
Figure	5.3.	The	four	most	important	variables	were	Age,	Method	of	Admission,	Albumin	and	Urea.	
Figure	5.2:	ML-	Admission:	Receiver	Operator	Curve	(AUROC	93%)	
	
tpr	(true	positive	rate):	sensitivity;	fpr	(false	positive	rate):	1	–	specificity;	PPV	1:5	:	positive	predictive	value	of	1	in	5	threshold;	
PPV	1:3	:	positive	predictive	value	of	1	in	3	threshold	
	
Figure	5.3:	ML-Admission:	Scaled	variable	importance	for	the	top	25	variables	
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5.4.2	Two_Tests_Cohort	
5.4.2.1	Baseline	characteristics	
Of	all	admissions	to	hospital	(1,874,325),	43.28%	remained	there	and	had	a	second	set	of	blood	tests.	
Thus	 811,268	 admissions	met	 the	 inclusion	 criteria	 for	 the	ML_Two_Tests_Cohort.	 Of	 these,	 6.1%	
(49,818)	died	in	hospital.	The	median	LoS	was	6	days	(IQR:	3–13	days).	Female	admissions	were	52.64%	
of	the	total.	The	median	age	was	66	years	(IQR	47–80).	 	The	histogram	of	the	ages	of	admissions	is	
shown	in	Figure	5.3.	
	
	
Emergency,	 elective,	 and	 maternity	 admissions	 accounted	 for	 71.9%,	 20.6%	 and	 4%	 of	 the	 total	
respectively,	 the	 remainder	 being	 composed	 of	 the	 ‘Other’	 category.	 The	 full	 distribution	 of	 the	
admissions	by	ethnic	category,	method,	month,	and	day	of	the	week	are	shown	in	Tables	5.9	to	5.12	
respectively.	The	ethnic	category	‘British’	had	the	highest	proportion	of	admissions	at	43.7%,	followed	
by	the	‘Not	Stated’	category	at	31.7%.	The	prevalence	of	the	various	ICD-10	codes	is	shown	in	Table	
5.13.	Hypertension	(I10)	and	type	2	diabetes	mellitus	had	the	highest	prevalence,	at	29.8%	and	14.7%	
respectively.	 The	median	 values	 of	 all	 the	 second	 blood	 tests,	 including	 the	 number	 with	missing	
values,	are	shown	in	Table	5.14;	of	note	are	the	proportion	of	admissions	with	no	results	for	platelets,	
RDW	and	albumin,	 at	31.1%,	31.1%	and	34.8%	 respectively.	 The	presence	of	both	a	 sodium	and	a	
haemoglobin	result	were	part	of	the	inclusion	criteria,	hence	the	presence	of	these	in	all	admissions.	
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The	 in-hospital	mortality	 rates	 for	each	group	of	admissions	 is	 shown	 in	Tables	5.9	 to	5.12.	Within	
ethnic	categories,	the	highest	mortality	rates	(significantly	higher	than	in	all	other	ethnicities)	occurred	
in	 the	 ‘Not	 Stated’	 and	 ‘British’	 categories,	 at	 7.6%	and	6.5%	 respectively.	Mortality	by	method	of	
admission	(Emergency:	7.6%;	Elective:	1.5%;	and	Maternity:	0.04%;	p<0.01)	substantiates	the	view	that	
patients	admitted	as	an	emergency	are	more	likely	to	die	than	those	admitted	via	either	the	elective	
or	 the	maternity	 method.	 The	 ‘Other’	 method	 of	 admission	 (the	 bulk	 of	 which	 consisted	 of	 non-
emergency	inter-hospital	transfers)	had	a	small	prevalence	(1.6%),	but	the	highest	mortality	rate	of	all,	
at	 10.3%.	 The	 month	 of	 admission	 with	 the	 highest	 mortality	 was	 December,	 at	 7.5%.	 Weekend	
admissions	had	marginally	higher	mortality	rates	when	compared	with	weekdays,	at	6.81%	vs	5.97%	
(p<0.05),	but	the	difference	was	only	0.84%.	
	
Table	5.9:	Two_Tests_Cohort:	Ethnic	category	prevalence,	and	in-hospital	mortality	rates	
Ethnic	Category	
Number	of	
Admissions	
Prevalence	
%	of	total	
Total	=		811,268	
In-Hospital	Mortality	
(95%	CI)	
British	(A)	 354,127	 43.65	%	
6.45	%	
(6.37–6.53)	
Irish	(B)	 14,776	 1.82	%	
5.48	%	
(5.13–5.86)	
Any	other	white	background	(C)	 55,958	 6.9	%	
3.85	%	
(3.7–4.02)	
White	and	black	Caribbean	(D)	 1,618	 0.2	%	
2.29	%	
(1.66–3.14)	
White	and	black	African	(E)	 951	 0.12	%	
2.94	%	
(2.04–4.22)	
White	and	Asian	(F)	 1,001	 0.12	%	
2.9	%	
(2.02–4.13)	
Any	other	mixed	background	(G)	 3,114	 0.38	%	
2.79	%	
(2.27–3.43)	
Indian	(H)	 16,297	 2.01	%	
4.4	%	
(4.1-4.73)	
Pakistani	(J)	 6,910	 0.85	%	
3.13	%	
(2.74–3.56)	
Bangladeshi	(K)	 11,429	 1.41	%	
3.08	%	
(2.78–3.41)	
Any	other	Asian	background	(L)	 15,182	 1.87	%	
3.58	%	
(3.29–3.88)	
Caribbean	(M)	 16,680	 2.06	%	
4	%	
(3.72–4.31)	
African	(N)	 21,084	 2.6	%	
1.98	%	
(1.80–2.18)	
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Any	other	black	background	(P)	 8,404	 1.04	%	
2.52	%	
(2.21–2.88)	
Chinese	(R)	 3,333	 0.41	%	
3.96	%	
(3.35–4.68)	
Any	other	ethnic	group	(S)	 23,396	 2.88	%	
4.17	%	
(3.92–4.43)	
Not	Stated	(Z)	 257,008	 31.68	%	
7.63	%	
(7.52–7.73)	
	
	
Table	5.10:	Two_Tests_Cohort:	Method	of	admission	prevalence,	and	in-hospital	mortality	rates	
Method	of	Admission	
Number	of	
Admissions	
Prevalence:	
%	of	total	
Total	=		811,268	
In-Hospital	
Mortality	
(95%	CI)	
Elective	
Elective	Waiting	list	(11)	 96,854	 11.94%	
1.16	%	
(1.09–1.23)	
Elective	Booked	(12)	 34,476	 4.25%	
2.03	%	
(1.89–2.19)	
Elective	Planned	(13)	 35,586	 4.39%	
1.68	%	
(1.55–1.82)	
Emergency	
Accident	and	emergency	or	
dental	casualty	department	of	
the	health	care	Provider	(21)	
423,340	 52.18%	
7.60	%	
(7.52–7.68)	
General	practitioner	(22)	 77,195	 9.52%	
9.22	%	
(9.01–9.42)	
Bed	bureau	(23)	 5,016	 0.62%	
6.02	%	
(5.4–6.71)	
Consultant	clinic,	of	this	or	
another	health	care	provider	
(24)	
20,562	 2.53%	
4.27	%	
(4.01–4.56)	
Admission	via	mental	health	
crisis	resolution	team	(25)	 239	 0.03%	
10.04	%	
(6.84–14.51)	
Transfer	of	an	admitted	
patient	from	another	hospital	
provider	in	an	emergency	(28)	
55,374	 6.83%	
6.9	%	
(6.69–7.11)	
Accident	and	emergency	
department	of	another	
provider	where	the	patient	
had	not	been	admitted	(2A)	
124	 0.02%	
11.29	%	
(6.85–18.06)	
Other	means	(2B)	 352	 0.04%	
13.07	%	
(9.94–16.99)	
Other	emergency	admission	
(2D)	 896	 0.11%	
2.01	%	
(1.27–3.15)	
Maternity	 Admitted	ante-partum	(31)	 30,753	 3.79%	
0.04	%	
(0.02–0.06)	
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Admitted	post-partum	(32)	 1,470	 0.18%	
0.14	%	
(0.04-0.49)	
Other	
Transfer	of	any	admitted	
patient	from	other	hospital	
provider	other	than	in	an	
emergency	(81)	
28,756	 3.54%	
10.36	%	
(10.01–10.71)	
The	birth	of	a	baby	in	this	
health	care	provider	(82)	 55	 0.01%	
3.64	%	
(1–12)	
Baby	born	outside	the	health	
care	provider	except	when	
born	at	home	as	intended	(83)	
18	 0.00%	
11.11	%	
(3.1–32.8)	
Not	known	/	validation	error	
(99)	 202	 0.02%	
6.93	%	
(4.17–11.3)	
	
	
Table	5.11:	Two_Tests_Cohort:	Month	of	admission	prevalence,	and	in-hospital	mortality	rates	
Month	
Number	of	
Admissions	
Prevalence:	%	of	total	
Total	=	811,268	
In-Hospital	Mortality	
(95%	CI)	
January	 72,058	 8.88%	
6.78	%	
(6.6–6.97)	
February	 65,963	 8.13%	
6.54	%	
(6.35–6.73)	
March	 68,533	 8.45%	
6.44	%	
(6.26–6.62)	
April	 66,598	 8.21%	
6.17	%	
(5.99-6.35)	
May	 68,435	 8.44%	
5.64	%	
(5.47–5.82)	
June	 64,384	 7.94%	
5.4	%	
(5.23–5.58)	
July	 66,981	 8.26%	
5.6	%	
(5.43–5.77)	
August	 64,552	 7.96%	
5.8	%	
(5.62–5.98)	
September	 67,004	 8.26%	
5.5	%	
(5.33–5.67)	
October	 70,569	 8.70%	
6.1	%	
(5.92–6.28)	
November	 68,395	 8.43%	
6.29	%	
(6.11–6.47)	
December	 67,796	 8.36%	
7.35	%	
(7.16–7.55)	
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Table	5.12:	Two_Tests_Cohort:	Day	of	admission	prevalence,	and	in-hospital	mortality	rates	
Day	of	Admission	
Number	of	
Admissions	
Prevalence:	%	of	
total	
Total	=		811,268	
In-Hospital	
Mortality	
(95%	CI)	
Weekday	
Monday	 131,627	 16.22%	
5.91	%	
(5.79–6.04)	
Tuesday	 137,863	 16.99%	
5.72	%	
(5.6–5.84)	
Wednesday	 130,647	 16.10%	
5.75	%	
(5.62–5.87)	
Thursday	 127,933	 15.77%	
5.96	%	
(5.83–6.09)	
Friday	 117,523	 14.49%	
6.58	%	
(6.44–6.73)	
Weekend	
Saturday	 79,278	 9.77%	
7.18	%	
(7–7.36)	
Sunday	 86,397	 10.65%	
6.47	%	
(6.31–6.64)	
	
	
Table	5.13:		Two_Tests_Cohort:	Prevalence	of	ICD10	codes	
Co-morbidity	
ICD10	
code	 No.	of	admissions	
Prevalence:	%	of	
total	(811,268)	
Essential	(primary)	hypertension	 I10	 241,620	 29.78%	
Angina	Pectoris	 I20	 34,132	 4.21%	
Chronic	ischaemic	heart	disease	 I25	 109,753	 13.53%	
Atrial	fibrillation	or	flutter	 I48	 102,601	 12.65%	
Heart	Failure	 I50	 61,157	 7.54%	
Personal	history	of	diseases	of	the	circulatory	system	 Z867	 64,779	 7.98%	
Secondary	malignant	neoplasm	of	lymph	nodes	 C77	 8,263	 1.02%	
Secondary	malignant	neoplasm	of	other	sites	 C79	 16,522	 2.04%	
Multiple	myeloma	and	malignant	plasma	cell	neoplasms	 C90	 7,309	 0.90%	
Myeloid	leukaemia	 C92	 6,847	 0.84%	
Other	hypothyroidism	 E03	 39,889	 4.92%	
Type	2	diabetes	mellitus	 E11	 118,876	 14.65%	
Obesity	 E66	 18,622	 2.30%	
Disorders	of	lipoprotein	metabolism	and	other	
lipidaemias	
E78	 87,028	 10.73%	
Mental	and	behavioural	disorders	due	to	use	of	alcohol	 F10	 24,108	 2.97%	
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Table	5.14:	Two_Tests_Cohort:	Median	(Interquartile	Range)	of	Blood	Tests	
Blood	Test	 Median	(Interquartile	Range)	
Percentage	missing	of	total	
(total	=	811,268)	
Sodium	 138	(136–141)	 0	%	
Potassium	 4.1	(3.8–4.5)	 3.9	%	
Urea	 5.4	(3.8–8.4)	 4.9	%	
Creatinine	 78	(62–107)	 9.9	%	
Ur:Cr	 65.8	(50–86.3)	 10.9	%	
Haemoglobin	 11.6	(10.2–13.1)	 0	%	
Platelets	 227	(173–292)	 31.1	%	
White	Cell	Count	 8.5	(6.3–11.4)	 1.1	%	
Mean	Cell	Volume	 89.2	(85–93.4)	 1	%	
Red	Cell	Distribution	Width	 14.2	(13.2–15.6)	 31.1	%	
Albumin	 35	(30–40)	 34.8	%	
	
Smoking	 F17	 47,218	 5.82%	
Depressive	episode	 F32	 34,828	 4.29%	
Epilepsy	 G40	 18,547	 2.29%	
Other	chronic	obstructive	pulmonary	disease	 J44	 65,617	 8.09%	
Asthma	 J45	 54,683	 6.74%	
Chronic	kidney	disease	 N18	 58,916	 7.26%	
Other	symptoms	and	signs	involving	the	nervous	and	
musculoskeletal	systems	
R29	 26,540	 3.27%	
Personal	history	of	malignant	neoplasm	of	digestive	
organs	
Z850	 12,958	 1.60%	
Personal	history	of	psychoactive	substance	abuse	 Z864	 70,416	 8.68%	
Personal	history	of	diseases	of	the	nervous	system	and	
sense	organs	
Z866	 13,896	 1.71%	
Personal	history	of	allergy	to	penicillin	 Z880	 46,756	 5.76%	
Personal	history	of	allergy	to	other	drugs,	and	biological	
substances	
Z888	 17,042	 2.10%	
Presence	of	electronic	cardiac	devices	 Z950	 21,788	 2.69%	
Presence	of	aortocoronary	bypass	graft	 Z951	 23,444	 2.89%	
Presence	of	coronary	angioplasty	implant	and	graft	 Z955	 17,357	 2.14%	
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5.4.2.2	ML-Two-Tests	Model	
The	Train	Dataset,	and	Test	Dataset	were	randomised	effectively,	and	both	had	the	same	mortality	
rate	of	6.1%.	The	hyper-parameters	 (determined	by	a	grid	 search)	 that	produced	 the	 lowest	mean	
logloss	and	highest	mean	AUROC	via	cross-validation	were:	number	of	trees:	5,000;	tree	depth:	8;	and	
learning	rate:	0.01.		
	
The	ML-Two-Tests	model	achieved	an	AUROC	of	90.6%	(log	loss:	0.152,	Figure	5.5)	on	the	Test	Dataset,	
which	was	similar	to	the	mean	cross-validation	AUROC	of	90.3%	(logloss:	0.154).	At	the	PPV	1:5	(20%)	
threshold,	 the	 model	 achieved	 a	 sensitivity	 of	 88.2%,	 and	 a	 specificity	 of	 77%	 (the	 highest	 ever	
achieved).	This	means	that,	if	a	rapid	response	team	were	directed	to	all	admissions	who	triggered	the	
model	at	this	threshold	(at	an	 in-hospital	mortality	rate	of	6.1%),	only	27%	of	admissions	would	be	
referred;	however,	88.2%	of	all	patients	likely	to	die	would	be	seen.	In	other	words,	for	every	1,000	
admissions	to	hospital	for	whom	there	are	two	sets	of	blood	tests,	approximately	61	admissions	would	
be	 likely	to	die.	The	referral	rate	of	the	model	 in	this	scenario	would	be	270	per	1,000	admissions,	
within	which	would	be	54	of	the	61	patients	likely	to	die.	
	
Figure	5.5:	ML-Two-Tests:	Receiver	Operator	Curve	(AUROC	90.6%)	
	
	
tpr	(true	positive	rate):	sensitivity;	fpr	(false	positive	rate):	1	–	specificity;	PPV	1:5	:	positive	predictive	value	of	1	in	5	threshold;	
PPV	1:3	:	positive	predictive	value	of	1	in	3	threshold	
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Similarly,	for	the	PPV	1:3	(33%)	threshold,	the	model’s	sensitivity	was	65%,	with	a	specificity	of	91.5%.	
For	every	1,000	admissions	to	hospital,	the	referral	rate	would	be	approximately	120	per	1,000	(12%)	
admissions,	within	which	would	be	40	of	the	61	patients	likely	to	die.	
	
The	 scaled	 variable	 importance	 of	 the	 twenty-five	most	 important	 predictor	 variables	 is	 shown	 in	
Figure	5.6.	The	four	most	important	variables	were	Second	Urea,	Age,	Second	Albumin	and	Method	of	
Admission.	
	
Figure	5.6:	ML-Two-Tests:	Scaled	variable	importance	of	the	top	25	variables	
	
	
5.5	Discussion	
This	analysis	uses	the	largest	cohort	of	admissions	(1,874,325)	yet	investigated	for	mortality	in	relation	
to	blood	test	results.	Examining	the	distribution	of	patient	admissions	highlights	a	few	key	patterns,	
which	vary	depending	on	whether	or	not	the	patient	stayed	in	hospital	to	have	a	second	set	of	blood	
tests	(i.e.	between	the	two	cohorts).	For	the	Admission	cohort,	the	mode	of	age	for	male	admissions	
was	67	years.	However,	 for	 female	admissions	 this	was	32	years;	on	 further	 investigation,	 this	was	
found	 to	 be	 due	 to	 the	 prevalence	 of	maternity	 admissions	 in	 this	 lower	 age	 group.	 The	 effect	 of	
maternity	admissions	on	the	burden	of	in-hospital	care	decreased	in	the	Two_Tests_Cohort,	where,	
although	a	slight	‘bump’	was	seen	at	age	32	years,	the	mode	for	female	admissions	was	now	85	years.	
The	mode	age	for	male	admissions	in	the	Two_Tests_Cohort	increased	by	ten	years	to	77	years.	Thus,	
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older	 patients	 underwent	more	 investigations	 in	 hospital.	 The	 burden	 of	 admissions	 also	 changed	
between	 the	 cohorts	 when	 the	 patients’	 method	 of	 admission	 was	 examined.	 The	 prevalence	 of	
emergency	 admissions	 rose	 from	 57.6%	 to	 71.9%	 (p<0.01)	 from	 the	 Admission	 to	 the	
Two_Tests_Cohort,	 with	 concurrent	 falls	 in	 elective	 admissions	 and	 maternity	 admissions.	 This	
indicates	that	elective	admissions,	when	compared	with	emergency	admissions,	are	more	likely	to	be	
discharged	after	their	first	set	of	blood	results.	Patients	who	have	a	second	set	of	blood	tests	are	sicker	
than	 those	who	 just	 have	 one	 set.	 This	 is	 demonstrated	 by	 the	 increase	 in	 the	 prevalence	 of	 co-
morbidities	 in	 the	 Two_Tests_Cohort,	 in	 comparison	with	 the	Admission	 cohort:	 the	proportion	of	
patients	with	hypertension,	chronic	ischaemic	heart	disease,	heart	failure,	type	2	diabetes	and	COPD	
all	increased,	by	6.7%,	4.1%,	3.3%,	4%	and	2.7%	respectively	(p	values	<0.01).	In	addition,	the	median	
LoS	increased	by	four	days,	and	the	mortality	by	3%,	from	the	Admission	to	the	Two_Tests_Cohort.	
	
In	 the	Admission_Cohort,	 regarding	 admissions	 over	 the	weekend	 vs	weekdays,	 the	mortality	 rate	
difference	in	these	groups	fell	to	non-clinically	significant	levels	(1.4%	to	0.3%)	when	only	emergency	
admissions	were	examined,	as	opposed	 to	all	 admissions.	 This	 indicates	 that	 the	much	 referred-to	
‘weekend	effect’	may	be	purely	due	to	a	cohort	difference:	i.e.	there	are	far	fewer	elective	admissions	
over	the	weekend,	and	elective	admissions	have	an	extremely	low	mortality	rate.	
	
The	in-hospital	mortality	results	for	both	cohorts	do,	however,	reinforce	the	notion	that	without	any	
statistical	corrections	(for	age,	disease	groups	or	method	of	admission),	mortality	is	higher	for	patients	
admitted	 over	 the	 winter	 (December	 and	 January)	 vs	 the	 summer	 (May–September).	 Patients	
admitted	 as	 emergencies	 had	 higher	 rates	 of	 dying	 in	 hospital	 than	 either	 elective	 or	 maternity	
admissions	 (Admission:	 4.9%	 vs	 0.4%	 &	 0.07%;	 Two_Tests:	 7.6%	 vs	 1.5%	 &	 0.04%).	 Surprisingly,	
however,	non-emergency	transfers	from	another	hospital	had	the	highest	in-hospital	mortality	of	all	
methods	of	admission,	which	was	even	greater	than	for	emergency	transfers	(Admission:	9.1%	vs	4.2%;	
Two_Tests:	10.4%	vs	6.9%	(p	values	<0.01)).	A	possible	explanation	is	that	these	patients	may	have	
been	 pre-arranged	 transfers	 between	 critical	 care	 units,	 or	 the	 movement	 of	 especially	 complex	
patients	to	or	from	specialist	care	centres,	 i.e.	the	sickest	patients	 in	hospital.	Further	 investigation	
would	need	to	be	carried	out	to	explore	this	further.	
	
The	 ML-Admission	 and	 ML-Two-Tests	 models	 are	 by	 far	 the	 most	 accurate	 models	 to	 date	 for	
predicting	a	patient’s	risk	of	dying	in	hospital.	Not	only	do	the	models	when	used	together	enable	an	
initial	prediction	to	be	made	at	the	point	of	admission,	but	they	also	allow	for	a	modification	of	this	
prediction,	as	 the	patient	undergoes	 further	 investigations	 in	hospital	 in	 the	context	of	a	 changing	
hospital	patient	population.	The	AUROCs	of	93%	and	90.1%	surpass	all	previous	EWSCs,	thus	providing	
better	discrimination	between	patients	likely	to	live	or	die.	Two	previous	EWSCs	by	Assadalohi31	and	
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Jarvis96	achieved	AUROCS	of	only	76.1%	and	78.9%	respectively,	for	my	Admission	cohort.	What	makes	
my	two	EWSCs	especially	remarkable	is	the	fact	that	the	models	achieved	this	performance	despite	
significant	proportions	of	missing	blood	test	results:	creatinine,	platelets,	RDW,	and	albumin	results	
were	missing	in	8.9%,	28.6%,	29.4%	and	21.1%	of	admissions	respectively	for	the	Admission_Cohort,	
and	in	9.9%,	31.3%,	31.1%	and	34.8%	of	admissions	respectively	in	the	Two_Tests_Cohort.	
	
The	change	in	importance	of	different	variables	(Figures	5.3	and	5.6)	in	both	these	models	is	complex,	
but	 they	 do	 both	 reinforce	 known	 risk	 predictors	 as	 well	 as	 indicate	 new	 avenues	 for	 further	
investigation.	The	latest	blood	results	(second)	become	more	important	for	predicting	risk	than	the	
admission	blood	results	as	patients	have	multiple	tests	done.	This	makes	sense,	as	the	 latest	blood	
result	is	a	more	accurate	reflection	of	an	individual	patient’s	current	physiology.	The	fall	in	importance	
Method	of	Admission	from	ML-Admission	to	ML-Two-Tests	could	however	be	because	of	the	change	
in	 the	underlying	data,	 there	are	a	 lot	 less	patients	 in	 the	Two_Tests_Cohort	admitted	as	elective/	
maternity	vs	emergency.	As	emergency	patients	have	a	higher	mortality,	the	probability	of	mortality	
gleaned	 from	 Method	 of	 Admission	 decreases	 slightly	 (as	 the	 probability	 of	 patient	 being	 an	
emergency	 increases),	 this	 is	also	probably	the	reason	that	Urea	at	First	Aki	stage	 in	ML-AKI	 (Table	
4.10)	has	a	higher	importance	than	Method	of	Admission.	Albumin	however,	despite	being	absent	in	
>21.1%	 (Admission_Cohort)	and	34.5%	 (Two_Tests_Cohort)	 cases	still	have	a	high	 influence	on	 the	
model	result,	reinforcing	the	complexity	of	the	contribution	of	a	variable	to	the	model.	It	is	important	
to	note	that	the	scaled	variable	 importance	 is	purely	based	on	mathematical	analysis	of	 the	model	
structure	 itself,	 and	 does	 not	mean	 a	 higher	 or	 lower	 value	 results	 in	 increased	 risk,	 just	 that	 the	
defined	variable	influences	the	final	result	of	the	model	more	than	(or	less	than	others).		
	
Deciding	on	 the	optimum	threshold	at	which	a	patient	 should	be	escalated	 to	either	1)	 immediate	
review	by	a	consultant	(as	opposed	to	the	current	guidelines’	recommendation	of	review	within	12	
hours),	or	2)	a	rapid	response	team,	is	still	a	matter	of	discussion.	From	a	patient’s	perspective,	it	would	
be	understandable	to	expect	be	told	if	he/she	has	an	in-hospital	risk	of	death	of	at	least	20%,	and	also	
for	 enhanced	 clinical	 care	 to	 be	 initiated,	 to	 reduce	 such	 risk.	 Thus,	 this	would	 support	 the	 lower	
threshold	of	PPV	1:5	(20%).	On	admission,	this	threshold	would	reliably	 identify	75%	of	all	patients	
likely	to	die	within	their	current	hospital	stay,	but	would	also	result	 in	12%	of	all	admissions	having	
their	care	escalated.	A	single	dedicated	RRT	may	struggle	to	cope	with	assessing	and	managing	the	
care	of	such	a	high	total	number	of	hospital	admissions.	Therefore,	at	the	point	of	admission,	it	may	
be	 prudent	 to	 redirect	 all	 referrals	 at	 this	 level	 for	 an	 immediate	 consultant	 review,	 rather	 than	
requiring	a	review	within	12	hours,	as	per	current	guidelines.	However,	by	the	time	a	patient	has	a	
second	set	of	blood	tests,	the	situation	has	changed,	as	follows:	1)	there	are	56%	fewer	patients,	and	
2)	as	some	time	has	elapsed	between	sets	of	blood	tests,	it	could	be	expected	that	some	treatment	or	
	
140	
intervention	to	improve	the	patient’s	outcome	has	been	initiated.	At	this	point,	a	continued	proven	
20%	 risk	of	 dying	 in	hospital	 should	be	unacceptable;	 unfortunately,	 this	 encompasses	 27%	of	 the	
remaining	patients	in	hospital.	Therefore,	although	at	the	outset	a	lower	threshold	(PPV	1:5)	seems	to	
be	the	appropriate	trigger	level	for	escalation	of	patient	care,	the	existing	resources	in	hospitals	may	
not	be	able	to	deliver	this	effectively.	Hence,	the	PPV	1:3	(33.3%)	could	be	an	alternative,	where	the	
referral/escalation	rates	would	be	4.6	%	at	admission	and	12%	at	the	Two_Tests	stage.	The	PPV	1:3	
(33.3%)	threshold	could	thus	provide	a	balance	between:	1)	severity	of	a	patient’s	condition,	2)	RRT	
workload,	and	3)	the	proportion	of	patients	likely	to	die	being	identified	(sensitivity).	The	disadvantage	
of	using	a	higher	threshold	 is	that	 it	 identifies	a	smaller	proportion	of	the	total	number	of	patients	
likely	to	die	(sensitivity):	Two_Tests	PPV	1:3:	65%	vs	PPV	1:5:	88.2%;	Admission	PPV	1:3:	49.3%	vs	PPV	
1:5:	76.1%.	
	
It	is	important	to	note,	though,	that	these	models	were	from	data	obtained	in	an	environment	where	
patients	are	already	receiving	treatment	in	hospital.	This	means	that	if	a	patient	is	predicted	to	live,	
this	does	not	necessarily	equate	to	that	patient	being	well;	it	could	also	mean	that	this	patient	is	unwell	
but	being	effectively	treated	by	their	existing	clinical	 teams.	Similarly,	a	prediction	that	a	patient	 is	
likely	to	die	does	not	always	mean	that	this	patient’s	death	is	completely	preventable.	Other	limitations	
of	 my	 models	 include	 the	 fact	 that	 patients	 on	 a	 palliative	 pathway	 are	 not	 reliably	 identified;	
therefore,	some	of	the	in-hospital	deaths	may	be	expected.	Another	issue	with	this	approach	is	that	
the	cause	of	a	patient’s	imminent	mortality	is	not	described;	thus	the	rapid	response	team	may	have	
to	perform	additional	investigations	on	the	patient	to	determine	the	optimum	intervention	to	prevent	
the	patient’s	death.	These	limitations	are	common	to	all	EWSCs,	whether	they	are	laboratory-based,	
vital	sign	or	co-morbidity	based,	and	are	not	unique	to	my	models.	Despite	these	issues,	EWSCs	are	
mandated	across	the	globe.	
	
In	summary,	I	have	created	two	EWSCs,	that	when	deployed	together	can	be	used	for	all	hospitalised	
patients,	 to	both	provide	risk	of	death	at	 the	point	of	admission,	and	also	modify	 this	 risk	while	 in	
hospital.	The	positive	predictive	values	of	identifying	patients	likely	to	die	exceed	those	of	any	other	
EWSC	yet	developed,	while	at	the	same	time	capturing	the	majority	of	patients	likely	to	die	(i.e.	a	high	
sensitivity).	The	efficacy	of	affecting	patient	care	is	still	open	for	debate;	however,	the	deployment	of	
EWSCs	are	a	requirement	of	multiple	national	guidelines,	and	are	thus	standard	practice.	The	increased	
accuracy	of	my	two	models	(ML-Admission	and	ML-Two-Tests)	would	better	direct	resources	to	those	
groups	of	patients	most	likely	to	die	than	any	current	system.	The	technological	mechanism	needed	to	
implement	such	a	blood	test	EWSC	for	real-time	patient	data	 is,	however,	not	straightforward:	 the	
solving	of	this	technological	problem	will	be	the	focus	of	my	next	chapter.	
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Finally,	it	is	important	to	note,	that	there	are	a	multitude	of	additional	data	sources	that	could	be	easily	
be	incorporated	into	a	future	EWSC.	The	most	simple	being	activity	data	from	wearables	(Fitbit,	apple	
watch,	etc.)	or	patient’s	smartphones.	Mobility	after	an	operation	is	a	key	metric	to	judge	the	success	
(and	 recovery)	 of	 a	 patient	 after	 certain	 operations,	 and	 now	 tracking	 this	 has	 become	 simple.	
Monitoring	 could	 also	 continue	 once	 a	 patient	 is	 discharged	 home,	 with	 no	 additional	 complex	
hardware,	 allowing	 for	 a	 home	 based	 EWSC	 on	 the	 most	 vulnerable	 patients.	 In	 fact,	 there	 are	
companies	providing	such	services	in	the	community	already	such	as	Sentrian.	Sentrian	allows	for	the	
early	 identification	 of	 patients	 at	 risk	 of	 deterioration	 at	 home,	 and	 enables	 the	 direction	 of	 the	
appropriate	resources	to	that	patient.	The	opportunities	to	track	and	enhance	patient	care	are	thus	
just	beginning.	
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Chapter	6:	Patient	Rescue:	technology	platform	
6.1	Introduction	
So	far	in	this	thesis,	I	have	focussed	on	creating	models	that	can	identify	hospitalised	patients	who	are	
deteriorating	 or	 likely	 to	 deteriorate,	 using	 existing	 electronic	 data	 sets.	 However,	 none	 of	 these	
models	were	implemented	in	a	real	world	hospital	environment.	A	certified	technology	platform	that	
would	enable	the	implementation	of	such	models	as	I	have	created	in	real	time,	i.e.	milliseconds	after	
data	is	generated,	in	a	clinical	environment,	does	not,	as	far	as	I	know	exist.	Therefore,	it	is	necessary	
to	create	such	a	platform	if	real	time	tracking	of	a	patient’s	AE	risk	is	to	be	implemented.	
	
Such	a	system	could	be	created	by	either	1)	significant	modifications	to	an	existing	electronic	health	
records	 system,	 or	 2)	 by	 building	 a	 new	 system	 focussed	 on	 real-time	 analytics.	 As	 access	 to	 and	
modification	of	a	proprietary	commercial	electronic	system	was	not	feasible	(the	commercial	products	
do	not	allow	for	such	modification),	this	chapter	describes	the	creation	of	an	independent	real-time	
analytics	platform	for	use	in	health	care.	This	technology	proof	of	concept	I	have	created,	titled	‘Patient	
Rescue’,	 is	based	on	principles	and	technologies	that	are	now	common	practice	in	existing	financial	
and	event-based	analytic	systems.	
	
In	order	to	fund	the	significant	development	of	‘Patient	Rescue’,	I	successfully	applied	for	an	extremely	
competitive	 NHS	 England	 ‘Regional	 Innovation	 Fund	 Award’,	 and	 in	 January	 2014	 was	 awarded	
£183,000	to	create	the	prototype	technology	platform.	The	focus	of	this	award	was	to	create	a	real-
time	analytics	system	and	demonstrate	its	capability	by	implementing	the	NHS	England	Acute	Kidney	
Injury	Algorithm,	which	at	the	time	could	not	be	implemented	by	the	incumbent	LIMS	providers.	
	
I	 conceived,	 led,	managed,	and	wrote	part	of	 the	software	code	 for	 the	Patient	Rescue	technology	
platform.	I	was	supported	by	a	core	team	consisting	of	a	part-time	software	developer	(Simon	Brown),	
a	 part-time	 NHS	 information	 analyst	 (Aniruddha	 Dwarakanath),	 and	 a	 part-time	 project	 manager	
(Prashant	Lele).	The	programming	and	implementation	was	a	team	effort,	and	the	system	described	
in	this	chapter	had	contributions	from	the	core	team.	
	
In	addition	to	the	core	team	above,	representatives	from	partner	hospitals	advised	on	issues	relating	
to	 information	 governance,	 and	 specifically	 their	 hospital’s	 AKI	 service.	 Members	 of	 the	 various	
hospitals’	IT	teams	also	created	(by	replicating	existing	information	channels)	and	maintained	the	‘data	
pipes’	that	inputted	data	into	my	technology	platform.	
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The	key	challenges	to	creating	a	real-time	analytics	platform	for	healthcare,	and	a	summary	of	the	key	
components	of	my	platform,	are	described	below.		
6.2	The	Challenges	
The	implementation	of	such	models	as	I	have	developed,	especially	in	real-time,	would	be	a	challenge	
in	any	hospital.	There	are	three	primary	reasons	for	this:		
1. Access	
2. Analytics	
3. Clinical	Communication	
6.2.1	Access	
In	order	to	 implement	a	model,	all	the	various	data	variables	of	the	model	must	be	accessible.	The	
variables	for	my	models	are	inputted	into	and	reside	in	different	systems	within	an	NHS	hospital.	Blood	
result	 data	 is	 part	 of	 the	 laboratory	 information	management	 system	 (LIMS).	 Co-morbidity	 data	 is	
stored	within	an	electronic	health	record	(if	such	exists)	or	in	a	business	intelligence	database	(used	to	
create	the	NHS	Trust’s	CDS.APC	submission	to	HSCIC	(NHS	England)).	Admission	and	discharge	from	
hospital	 would	 traditionally	 be	 part	 of	 a	 patient	 administration	 system	 (PAS).	 Thus,	 although	 the	
various	data	elements	exist	in	electronic	form,	accessing	them	requires	extracting	them	from	multiple	
systems.	The	two	approaches	to	access	such	data	are	1)	‘Push’:	to	‘push’	the	data	out	of	the	system	as	
and	when	it	is	created;	and	2)	‘Pull’:	to	allow	an	external	system	to	‘query’	the	system	the	data	resides	
in,	and	if	relevant	data	is	present,	for	the	host	system	to	then	send	this	data,	i.e.	‘pull’	the	data	out.	
The	problem	with	the	‘pull’	approach	is	that	most	hospital	IT	systems	are	not	designed	for	intensive	
querying,	so	that	if	many	queries	are	made	on	the	system,	the	entire	systems	slows	down	or	crashes.	
These	 host	 information	 systems	 are	 based	 on	 old	 database	 architectures	 and	 optimised	 for	 the	
performance	 of	 very	 specific	 queries,	 which	 were	 defined	 when	 the	 information	 system	was	 first	
integrated	with	the	rest	of	the	hospital’s	systems.	The	‘Push’	approach,	on	the	other	hand,	 is	more	
viable,	as	the	workload	on	the	existing	hospital	system	is	quantifiable;	and	more	 importantly,	most	
hospital	systems	already	communicate	their	core	 information	to	other	systems	within	the	hospital.	
Acquiring	the	data	required	to	implement	the	model	could,	therefore,	theoretically	be	extracted	from	
one	of	these	existing	‘Push’	data	channels.	Although	possible,	this	is	a	substantial	task:	the	previously	
described	(Chapter	2,	Section	2.3)	challenges	of	pre-processing	the	data	are	all	present	when	the	data	
are	accessed	in	real-time	using	this	method,	and	need	to	be	overcome.	My	solution	to	this	challenge	
comprised	the	following	steps:	1)	to	consume	the	data	from	these	‘Push’	data	channels;	2)	to	store	all	
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the	data	in	an	unstructured	raw	format	in	a	‘data	lake’;	and	3)	to	pre-process	only	those	data	elements	
required	for	the	implementation	of	the	current	models.		
	
The	standard	communication	protocol	for	health	care	systems	are	HL7	messages.	‘HL7’	refers	to	Health	
Level	 Seven	 International146,	 an	 American	 National	 Standards	 Institute	 accredited	 standards-
developing	organisation	dedicated	to	providing	a	comprehensive	framework	and	related	standards	for	
the	exchange,	integration,	sharing	and	retrieval	of	electronic	health	information	that	supports	clinical	
practice	 and	 the	 management,	 delivery	 and	 evaluation	 of	 health	 services.	 An	 HL7	 message	 is	 a	
hierarchically	structured	message	with	multiple	segments	in	a	defined	sequence.	
	
The	term	‘data	lake’	was	supposedly	coined	by	James	Dixon,	the	Chief	Technology	Officer	of	Pentaho.	
In	a	blog	entry	he	said:	‘If	you	think	of	a	datamart	as	a	store	of	bottled	water	–	cleansed	and	packaged	
and	structured	for	easy	consumption	–	the	data	lake	is	a	large	body	of	water	in	a	more	natural	state.	
The	contents	of	the	data	lake	stream	in	from	a	source	to	fill	the	lake,	and	various	users	of	the	lake	can	
come	to	examine,	dive	in,	or	take	samples.’147	148	
6.2.2	Analytics	
I	have	referred	to	analytics	as	an	all-encompassing	term	that	includes	pre-processing	of	the	acquired	
data,	as	well	as	the	implementation	of	the	pre-defined	models.	However,	this	is	an	oversimplification.	
Some	of	the	tasks	that	form	part	of	pre-processing	are	described	in	Chapter	2,	Section	2.3;	all	those	
steps	now	need	to	be	implemented	for	data	that	is	constantly	being	ingested	into	the	system.	Thus,	
the	system	needs	to	carry	out	these	tasks	automatically,	and	must	also	have	robust	quality	control	and	
monitoring	mechanisms	built	in,	to	confirm	that	the	automatic	tasks	are	indeed	performing	their	tasks	
accurately.	Another	 issue	with	 the	application	of	 the	model	concerns	 the	 time	when	such	a	model	
should	be	applied	to	the	data.	The	results	of	the	various	data	variables	may	arrive	at	different	times	
(for	example,	a	sodium	test	result	may	arrive	30	minutes	after	the	sample	is	received	in	the	laboratory,	
while	the	haemoglobin	test	result	may	take	60	minutes),	or	they	may	arrive	for	patients	no	longer	in	
hospital	(outpatient/GPs’	tests).	Therefore,	rules	to	cater	for	all	of	these	scenarios	must	be	created.	A	
specific	user	case	for	Acute	Kidney	Injury	would	be	a	patient	newly	admitted	to	hospital	via	accident	
and	emergency,	where	he/she	had	already	undergone	blood	tests.	In	this	scenario,	an	AKI	algorithm	
should	be	run	on	the	data	of	this	new	admission,	despite	the	possibility	of	no	new	blood	tests	being	
requested	 on	 admission	 (as	 blood	 tests	 had	 been	 carried	 out	 recently).	 In	 addition	 to	 the	 rules	
described	above,	the	analytics	platform	must	also	be	designed	to	such	a	standard	that	it	will	eventually	
be	approved	by	the	appropriate	Medical	Health	Regulatory	Agency	(MHRA)	standards	for	a	medical	
device.	Such	a	system	would	be	a	‘Class	2’	(2A	or	2B	depending	on	implementation)	medical	device,	
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which	would	require	robust	quality	control	and	logs	of	all	calculations	performed,	among	many	other	
requirements.	
6.2.3	Clinical	Communication	
Finally,	once	a	model	has	successfully	been	applied	to	a	patient’s	data	in	a	timely	manner	(real-time),	
relevant	 information	 relating	 to	 the	 outcome	of	 the	model’s	 result	must	 be	 communicated	 to	 the	
relevant	 clinical	 team	 in	 the	 hospital.	 However,	 merely	 informing	 the	 clinical	 team	 member	 of	 a	
positive	or	negative	outcome	of	the	model	may	not	necessarily	aid	patient	care.	Therefore,	early	in	the	
process	I	made	the	decision	that	the	system	would	need	to	provide	‘actionable	insight’:	clinical	decision	
support,	by	incorporating	not	only	the	result	of	the	model,	but	also	other	information	on	the	patient.	
As	 the	demonstration	of	 ‘Patient	Rescue’	was	 focused	on	AKI,	 I	 created	a	 report	 that	 incorporated	
information	 that	a	nephrologist	would	 request	 if	 referred	a	patient	diagnosed	with	AKI.	The	actual	
delivery	 of	 the	 report	 to	 the	 clinician	 was	 beyond	 the	 scope	 of	 the	 project;	 but	 to	 demonstrate	
communication,	a	simple	secure	email	system	was	built.	This	system	utilised	the	secure	and	encrypted	
NHS.net	email	facility,	and	allowed	reports	for	each	AKI	patient	to	be	sent	to	dedicated	NHS.net	email	
addresses	within	1	second	of	the	system	identifying	a	patient	as	having	new	AKI.		
	
Communicating	the	condition	of	a	deteriorating	patient	is,	however,	a	much	bigger	problem,	which	
needs	further	investigation	and	was	beyond	the	scope	of	my	study.	The	challenges	involved	include	
identifying	the	appropriate	team	and	the	appropriate	method	of	communication,	and	verification	of	
communication.	All	these	parameters	may	change	on	a	daily	basis	for	the	multiple	hospital	teams.	The	
teams	may	 themselves	 change,	when	 a	 patient	 is	 transferred	 to	 another	 physical	 location	 or	 to	 a	
different	medical/surgical	specialty.	The	time	of	day	will	also	influence	the	choice	of	which	teams	are	
to	be	contacted.	
6.3	The	Solution:	Patient	Rescue	
6.3.1	System	Overview	
The	Patient	Rescue	platform	ingests	HL7	messages	from	multiple	channels,	then	performs	real-time	
analysis	of	the	information	in	these	messages	with	respect	to	previous	information	received	about	a	
patient.	Based	on	the	outcome	of	this	analysis,	the	platform	can	generate	alerts	and/or	reports.	
	
Data	received	via	HL7	channels	is	persisted	in	a	database	and	combined	with	any	bulk	imported	data	
(for	example,	historic	patient	information).	Along	with	real-time	analysis	of	messages,	algorithms	can	
be	run	on	the	persisted	data	in	order	to	perform	one-off	analyses.		
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The	platform	has	the	following	features:	
1. Data	 from	 different	 sources	 are	 mapped	 to	 a	 canonical	 form	 before	 being	 analysed	 and	
persisted.	 This	 overcomes	 the	 issue	 of	 variations	 in	 the	 terminology	 and	 meaning	 of	
information	sent	(which	are	allowed	within	the	HL7	framework).	
2. The	 components	 of	 the	 platform	 are	 loosely	 coupled.	 This	 means	 that	 different	
implementation	technologies,	algorithms	and	actions	as	a	result	of	analysis	can	be	plugged	in	
to	the	system.	This	design	leads	to	increased	flexibility	and	allows	rapid	deployment	of	new	
algorithms	and	actions	triggered	by	these	algorithms.	
3. The	platform	is	highly	scalable,	in	that:	
a. New	sources	of	data	can	be	added	quickly.	
b. The	 database	 schema	 is	 optimised	 for	 large	 quantities	 of	 data,	 and	 the	 database	
software	makes	use	of	 in-memory	 tables,	 allowing	exceptionally	 fast	 queries	 to	be	
performed	on	large	datasets.	
c. Components	can	be	distributed	across	multiple	servers.	
d. Components	that	are	‘plugged	into’	the	system	(e.g.	algorithms	and	alerting	modules)	
can	subscribe	to	‘topics’	of	interest.	Given	the	large	volumes	of	data	flowing	through	
the	system,	this	means	they	only	receive	the	information	they	define	as	necessary	to	
perform	their	function,	which	reduces	their	processing	demands.	
6.3.2	System	Schematic	
A	schematic	of	the	live	element	of	the	Patient	Rescue	platform	is	shown	in	Figure	6.1	
	Figure	6.1	Patient	Rescue	System	Schematic	
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6.3.3	Component	Description	
6.3.3.1	HL7	Gateway	
The	 platform	 uses	 the	 gateway	 component	 of	 the	 open	 source	Mirth	 Connect149	 to	 consume	HL7	
messages.	 This	 ensures	 resilient	 delivery	 of	messages	 to	 the	 platform	 from	multiple	 sources,	 and	
manages	the	protocol	‘conversation’	between	the	platform	and	the	message	source.	Its	admin	console	
allows	new	sources	(channels)	to	be	added	quickly,	and	configures	the	delivery	and	persistence	(to	file)	
of	these	messages.	Each	individual	HL7	message	from	a	given	channel	is	saved	as	an	individual	file,	and	
also	concatenated	into	a	single	file	for	that	channel	and	message	type.	Both	individual	messages	and	
concatenated	files	are	saved	as	plain	text	files,	allowing	visual	inspection	and	replay	of	messages	(thus	
facilitating	resilience	and	testing).	
6.3.3.2	NHUB	
This	is	a	bespoke	.NET	component,	which	performs	the	following	tasks:	
§ Consuming	HL7	messages	saved	to	disk	by	the	Mirth	Connect.	
§ Mapping	the	information	in	the	messages	into	the	canonical	form.	
§ Persistence	of	the	information	in	the	messages	to	the	database.	
§ Placing	the	information	in	the	messages	on	the	Service	Bus,	to	enable	notification	of	interested	
consumers	(e.g.	algorithms).	
	
Multiple	instances	of	NHub	are	run	on	the	server,	typically	one	per	data	source	(hospital	HL7	feed).	
Each	data	source	has	different	ways	of	representing	medical	data,	so	each	instance	of	NHub	uses	a	
different	configuration	file	and	mapping	data	in	order	to	translate	the	data	into	a	canonical	form.	While	
each	instance	is	single-threaded,	as	many	instances	can	be	run	as	are	needed	to	deliver	the	throughput	
required.	
	
For	resilience,	messages	are	placed	on	the	Service	Bus	only	once	they	have	been	persisted	into	the	
database.	Following	acknowledgement	of	successful	posting	on	the	Service	Bus,	the	individual	HL7	text	
file	is	deleted,	thus	preventing	the	duplicate	processing	of	messages.	
6.3.3.3	Service	Bus	
An	 open-source	 messaging	 framework,	 Rabbit	 MQ150,	 with	 .NET	 extensions	 was	 selected	 for	 the	
Service	 Bus,	 and	 configured/coded	 for	 the	 platform.	 The	 Service	 Bus	 allows	 processes	 to	 post	
information	(for	example,	a	set	of	blood	test	results),	with	metadata	describing	that	information	(for	
example,	the	types	of	blood	tests),	which	is	termed	the	‘topic’.	Other	processes	can	subscribe	to	listen	
to	 topics.	When	 a	 topic	 relevant	 to	 the	 subscriber	 is	 published	 on	 the	 Service	 Bus,	 the	 subscriber	
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receives	an	update	and	can	act	upon	the	information.	Information	is	held	on	the	Service	Bus	until	all	
the	subscribers	have	acknowledged	receipt	of	the	posted	information,	thus	facilitating	resilience.		
	
In	the	case	of	the	Patient	Rescue	platform,	the	NHub	process	publishes	information	in	canonical	form	
to	the	Service	Bus,	and	relevant	algorithms	are	subscribed	to	data	updates	containing	information	they	
require	to	perform	their	function.	
6.3.3.4	CDS.APC	Gateway	
This	component	allows	for	the	monthly	ingestion	of	the	CDS.APC	data	that	the	NHS	hospitals	submit	
to	NHS	England.	This	component	was	built	using	Microsoft	SQL	Server	Integration	Services.	As	with	the	
HL7	gateway,	this	component	enables	the	conversion	of	the	raw	hospital-submitted	CDS.APC	data	to	
be	quality	checked,	converted	to	canonical	form,	and	persisted	into	the	database.	The	data	from	the	
CDS.PCS	reports	 is	regarded	as	the	highest-quality	data;	thus,	during	persistence	into	the	database,	
the	entire	database	is	updated	and	quality	checked.	
6.3.3.5	Algorithms			
Algorithms	 for	 the	 platform	were	written	 in	 C#	 and	Matlab.	 These	 algorithms	 subscribe	 to	 topics	
posted	on	the	Service	Bus.	When	relevant	data	(for	example,	creatinine	blood	result)	is	posted	on	the	
Bus,	they	are	notified	and	executed.	Typically,	the	algorithms	require	contextual	information	(patient	
history	and	demographics)	to	determine	their	output.	They	extract	this	data	from	the	database,	using	
Structured	Query	Language	(SQL).	For	the	purposes	of	this	proof	of	concept,	the	only	algorithm	written	
and	tested	was	the	NHS	England	AKI	algorithm.	After	execution,	the	algorithms:	
§ Persist	information	to	the	database	for	audit	purposes	(at	what	time	they	were	executed,	for	which	
patient,	etc.).		
§ Publish	messages	to	the	Service	Bus	containing	information	that	Alert	processes	can	act	upon	(in	
this	case,	AKI	level	and	patient	identifiers).	
6.3.3.6	Alert	Service	
Alert	Services	subscribe	to	the	Service	Bus,	listening	for	topics	of	interest	(AKI	alerts).	On	receipt	of	an	
alert,	they	enrich	it	with	the	additional	information	they	require	by	querying	the	database.	Following	
this,	they	schedule	an	AKI	report	to	be	generated	and	sent	to	relevant	parties.	It	is	important	to	note	
that	Alert	Services	can	easily	be	developed	to	perform	other	functions,	for	example	sending	an	SMS	
message	to	relevant	parties.	
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6.3.3.7	SQL	Server	Reporting	Services	(SSRS)	
SQL	Server	Reporting	Services	(SSRS)	is	a	Microsoft	product	which	generates	reports	in	various	formats	
from	data	stored	 in	SQLServer.	 It	also	allows	 these	 reports	 to	be	sent	via	email.	The	Alert	Services	
trigger	SSRS	to	create	and	send	AKI	alerts	to	practitioners	via	email.	These	emails	contain	complex	PDF	
(portable	 document	 format)	 reports,	 including	 patient	 history	 (in	 tabular	 and	 chart	 form),	
demographics	and	identifiers.	
The	Patient	Rescue	reporting	system	provides	two	levels	of	insight:		
1) Patient	 level:	 real-time	 detection,	 alerting,	 decision	 support,	 management	 tracking	 and	
automated	referral.	The	system:	
a) Tracks	all	blood	and	radiology	result	data	relating	to	every	hospitalised	patient.	
b) Applies	the	NHS	England	AKI	Patient	Safety	Alert	Algorithm	to	all	newly	admitted	patients	and	
all	creatinine	results.	
c) For	patients	identified	to	have	AKI	(stages	1	to	3),	a	custom	report	is	created.	An	example	of	
one	of	my	AKI	reports	on	a	fictional	patient	is	shown	in	Figure	6.2.	This	report,	the	decision	
support	tool,	contains	patient-specific	information:	
i) Administrative	 Information:	 patient	 demographics,	 location	 in	 hospital,	 and	 days	 since	
admission.	
ii) Background	Risk	Factors:	Past	medical	history	of	the	patient	that	is	relevant	in	the	context	
of	AKI,	e.g.	previous	AKI,	chronic	kidney	disease,	neoplasms,	heart	disease.	
iii) Acute	complications	of	AKI:	markers	of	sepsis,	hyperkalaemia,	hyperphosphatamia.	
iv) Result	Visualisation:	Blood	results	of	creatinine	(Cr),	urea	(Ur),	Ur:Cr,	c	reactive	protein	and	
white	cell	count	are	graphically	visualised	to	enable	the	clinician	to	understand	the	trends	
and	context	of	the	current	alert;	i.e.	whether	it	is	a	repeat,	whether	the	patient	has	been	
progressively	worsening	or	improving,	etc.	
v) Radiology	Reports:	Reports	on	any	renal-relevant	radiological	investigations	performed	on	
the	patient	in	the	last	month	are	displayed,	potentially	enabling	the	cause	of	the	current	
AKI	to	be	determined.	
vi) Further	 Advice:	 Additional	 analyses	 are	 performed	 on	 the	 entire	 patient	 dataset	 to	
determine	if	there	are	any	other	abnormalities,	or	whether	further	investigations	should	
be	requested	to	exclude	specific	pathologies.	
vii) Automating	 the	 referral	 pathway:	 The	 report	 is	 sent	 (using	 dedicated	 NHS.net	 email	
addresses)	 to	the	Critical	Care	Outreach	Team	and	for	predefined	severity	 levels	of	AKI	
also	to	the	Renal	Consultant	in	charge	of	AKI.	Tracking	of	report	delivery,	reading	of	reports	
and	interventions	are	all	built	into	the	system.		
1) Trust-Wide	AKI	Dashboards:	Patient	Rescue	also	populates	a	continuously	updating	dashboard	of	
all	 patients	with	AKI	 in	 the	hospital.	 This	 allows	 the	AKI	 caseload	 to	be	 tracked	and	prioritised	
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across	a	large,	multi-site	organisation	such	as	the	Royal	Free	NHS	Trust.	Patients	can	be	selected	
from	 the	 dashboard,	 and	 the	 full	 AKI	 report	 (as	 described	 above)	may	 be	 viewed.	 It	 will	 also	
continuously	populate	a	 live	AKI	performance	 report.	This	presents	data	on	 the	number	of	AKI	
episodes	per	 timeframe,	 incidences	of	hospital-	vs.	 community-acquired	AKI,	AKI	mortality,	AKI	
recovery,	AKI	length	of	stay,	and	the	proportion	of	AKI	patients	who	have	timely	follow-up	blood	
tests	and	renal	imaging.		
	
The	Patient	Rescue	platform	was	deployed	in	three	NHS	Hospitals.	It	was	hosted	in	compliance	with	
all	NHS	information	governance	principles	and	requirements	(IGSOC),	and	was	independently	tested	
to	ensure	security	and	resilience.	No	research	was	carried	out	on	the	data	processed	by	the	platform,	
and	the	only	algorithm	deployed	was	the	NHSE-AKI	algorithm.	No	ML	models	were	implemented	on	
the	live	data	flows,	as	these	had	not	been	peer	reviewed,	published	nor	validated	as	a	standard	for	
patient	care.	Patient	Rescue	was	officially	only	a	Data	Processor	for	legal,	regulatory	and	governance	
purposes.	Although	we	reached	required	standards	of	quality,	as	the	platform	was	not	MHRA-certified,	
it	was	never	used	to	treat	any	patients.	The	Patient	Rescue	platform	was	disconnected	from	the	NHS	
hospitals	once	it	had	demonstrated	that	such	a	real-time	analytics	system	could	be	built	and	deployed	
on	real-time	data	flows	in	the	NHS,	and	that	such	a	system	could	monitor	patients	in	real-time	for	their	
risk	of	deterioration.	The	core	team	and	myself	continue	to	work	together,	and	are	pursuing	avenues	
to	enable	deployment	of	such	a	platform	at	scale.	
	
Since	 the	 start	 of	 my	 PhD,	 there	 have	 been	 a	 number	 of	 initiatives/solutions,	 in	 the	 UK	 and	
internationally,	 that	 are	 tackling	 the	 problem	 of	 real	 time	 integration	 of	 disparate	 healthcare	
repositories	and	enabling	live	analytics.	The	most	prominent	in	the	UK	being	Datawell,	a	Connected	
Health	Cities	project	of	the	Northern	Health	Science	Alliance.	Datawell	builds	on	a	platform	developed	
by	 LumiraDx,	 and	 focusses	on	 connecting	multiple	providers	of	 healthcare	 (GP’s,	 hospitals,	 private	
providers,	etc.)	and	enabling	patient	centred	care	and	analytics.	In	the	USA,	multiple	hospital	groups	
have	built	their	own	data	and	analytic	solutions,	and	are	carrying	out	machine	learning	analysis,	two	
particular	examples	being	the	Mayo	Clinic	and	the	Children’s	Hospital	of	Orange	County.	The	Watson	
Health	division	within	 IBM	is	also	building	on	 its	cognitive	computing	solutions	to	gain	 insight	 from	
existing	 data,	 both	 within	 the	 hospital	 but	 also	 from	 public	 research	 repositories	 (e.g.	 pubmed).	
Overall,	this	is	a	rapidly	advancing	field,	and	I	believe	in	just	a	few	years,	it	will	be	commonplace	for	IT	
solutions	 to	 be	 augmenting	 the	 intelligence	 of	 doctors	 (and	 other	 healthcare	 professionals)	 and	
enabling	better	quality	of	patient	care.			 	
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Figure	6.2	Example	Patient	Rescue:	AKI	report	
	 	
NHSNumber ϭϮϯϰϱϲϳϴϵ
Name Dƌ͘EĞƉŚƌŽŶ<ŝĚŶĞǇƐŽŶ Sex M Age ϲϱ
DOB 0ϭͬϬϭͬϭϵϱϬ
Location
Hospital Number ϵϵϵϵϵϵ  Hospital ^ƚ͘ůƐĞǁŚĞƌĞΖƐ
ĐƵƚĞ<ŝĚŶĞǇhŶŝƚ
AKI alert time: 19 January 2015 ϭϲ:00:00Stage of AKI: 3
Background risk factors 
Neoplasms
Further advice͗
WůĂƚĞůĞƚƐůŽǁ͗ Consider microangŝŽƉĂƚŚǇͲƉĞƌĨŽƌŵ blood film, reticulocytes and haptoglobins
Lactate dehydrogenase: no results available in the last 48 hours
IŵŵƵŶŽŐůŽďƵůŝŶƐĂƌĞĂďŶŽƌŵĂů: consider myeloma
     Radiology report date: 1ϳ January 2015 ϭϬ͗ϬϬ
US RENAL TRACT͗Both kidneys are enlarged͕ with increasedreflectivity in keeping with a nephritic process. There is a  complexcyst at the left upper pole . 
No other renalůĞƐŝŽŶŝĚĞŶƚŝĨŝĞĚ͘
AKI Complications
Urea is high: 29.5 mmol/LͲ ĂƐƐĞƐƐĨŽƌ uraemia
C reactive protein is high: 33 mg/LͲ ĐŽŶƐŝĚĞƌ sepsis
WŚŽƐƉŚĂƚĞŝƐŚŝŐŚ͗Ϯ͘ϴϵŵŵŽůͬ>
Renal Rescue - Acute Kidney Injury Report
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Chapter	7:	Summary	and	Discussion	
Hospitalised	 patients	 are	 at	 risk	 of	 deteriorating	 and	 suffering	 an	 AE	while	 in	 hospital.	 These	 AEs	
include	 unexpected	 admissions	 to	 the	 intensive	 care	 unit,	 surgery,	 cardiac	 arrest,	 and	 death;	 and	
almost	half	of	these	AEs	are	thought	to	be	preventable.4,5,8,9,11		Identifying	these	deteriorating	patients,	
or	those	at	risk	of	deteriorating,	is	a	current	priority	for	our	health	care	system.	
	
It	 is	well	 known	 (Chapter	 1,	 Section	 1.2)	 that	 prior	 to	 an	AE,	 distinct	 patterns	 of	 vital	 signs	 occur.	
Therefore,	current	initiatives	have	focussed	on	identifying	patients	with	these	vital	sign	patterns,	and	
escalating	their	care	in	accordance	with	the	severity	of	their	vital	sign	abnormalities	(as	indicated	by	
their	EWSC)	to	a	RRT.	This	combination	of	a	pattern	detection	mechanism	(the	afferent	pathway)	and	
the	RRT	(the	efferent	pathway)	is	known	as	a	‘rapid	response	system’.	However,	the	effectiveness	of	
these	 vital-sign-based	 models	 is	 problematic.	 Patient	 vital	 sign	 measurements	 are	 carried	 out	
infrequently,	and	even	when	they	are	measured,	they	are	often	inaccurate.		In	addition,	the	vital-sign-
based	EWSCs	themselves	have	poor	sensitivity	and	specificity,	resulting	in	a	poor	positive	predictive	
value	in	discriminating	between	patients	likely	to	suffer	an	AE	and	those	who	are	not.	Thus,	the	current	
systems	do	not	adequately	capture	those	at	risk	of	an	AE	in	hospital.	
	
In	this	thesis,	I	have	sought	to	address	these	issues	by	assessing	if	variables	other	than	vital	signs	can	
better	 identify	patients	most	at	risk	of	an	AE	during	a	hospital	admission.	 I	have	explored	variables	
which	are	routinely	and	universally	collected	on	hospitalised	patients,	and	stored	electronically,	thus	
enabling	the	easy	 implementation	of	any	system	that	 is	developed.	Specifically,	 I	have	focussed	on	
blood	test	results	as	well	as	administrative	data	such	as	demographics,	method	of	admission,	dates	of	
admission,	ICD10	codes	of	diagnoses	and	co-morbidities,	and	OPCS	(procedure/intervention)	codes.	A	
few	existing	studies	have	explored	the	use	of	other	variables	such	as	these.	The	limitations	of	these	
existing	non-vital-sign-based	EWSCs	include:			
a) Poor	generalisability:	their	effectiveness	has	not	been	proven	in	diverse	hospital	patients,	as	
they	are	either	specific	to	a	type	of	patient	(medical,	surgical,	emergency,	elective,	etc.),	or	
they	have	been	created	and	tested	using	patients	from	only	one	or	two	hospitals.	
b) Simplistic	analysis:	they	take	account	of	neither	the	dynamic	change	(trends),	nor	the	inter-
correlations	between	blood	results.	
c) Lack	of	patient	specific	information:	they	do	not	account	for	a	patient’s	co-morbidities.	
d) Lack	 of	 context	 sensitive	 information:	 they	 account	 for	 neither	 the	 date	 of	 a	 patient’s	
admission	(weekday	vs	weekend,	summer	vs	winter)	nor	the	time	a	blood	test	was	performed	
(3pm	vs	3am).	
e) Poor	performance:	their	ability	to	discriminate	between	patients	likely	to	live	or	die	is	low.		
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To	overcome	the	limitations	of	these	previous	approaches	in	this	thesis,	it	was	necessary	to	1)	collect	
a	large	dataset	from	multiple	diverse	hospitals,	and	2)	to	apply	advanced	analytical	techniques	that	
both	accounted	for	multicollinearity	and	were	able	to	produce	highly	accurate	models.	
	
I	first	addressed	and	interpreted	the	conflicting	legal	and	ethical	landscape	pertinent	to	the	collection	
of	patient	data	across	multiple	hospitals.	A	thorough	understanding	of	the	legal	framework	was	a	key	
component	of	my	success	in	collecting	this	multisite	linked	hospitalised	patient	dataset.	As	detailed	in	
Chapter	 2,	 the	 data	 were	 legally	 categorised	 as	 ‘data	 for	 limited	 disclosure’.	 Robust	 linkage	 and	
anonymisation	procedures	were	followed,	and	assurances	were	made	to	each	NHS	Trust,	that	the	data	
would	only	be	analysed	1)	for	the	purposes	of	this	study,	and	2)	by	myself,	the	chief	investigator.		
	
I	identified	common	sources	for	the	data	which	were	accessible	from	multiple	NHS	trusts,	and	from	
these	 I	 selected	universally	 collected	 variables.	 The	data	 sources	were	1)	CDS.APC	 (Commissioning	
Dataset	 for	 Admitted	 Patient	 Care)	 for	 all	 administrative	 data,	 and	 2)	 ‘Blood	 Test	 Results’	 using	 a	
combination	of	hospital	LIMS	(Laboratory	Information	Management	System)	and	pathology	databases.	
A	lot	of	work	went	into	acquiring	this	data,	I	overcame	significant	governance	and	technical	challenges	
(Chapter	2,	Section	2.3.1).	The	challenges	continued	with	the	pre-processing	of	the	data,	specifically	
their	ingestion	into	a	common	database,	their	transformation	to	a	canonical	(standard)	form,	and	their	
cleaning	(identification	and	removal	of	incomplete,	 inaccurate	and	irrelevant	data)	(Chapter	2).	This	
entire	process	took	over	2	years.	
		
My	dataset	captures	>8	million	admissions	across	14	NHS	Trusts	between	2005	and	2015.	Of	these,	
blood	tests	were	performed	in	hospital	for	~2	million	admissions.	Over	500	million	blood	test	results	
(both	in	and	out	of	hospital)	were	collected	for	analyses.	
	
My	initial	analysis	focussed	on	the	utility	of	using	simple	blood	tests,	such	as	urea	(Ur)	and	creatinine	
(Cr),	to	identify	patients	at	risk	of	 in-hospital	death.	I	found	that	whilst	Ur	and	Cr	have	a	non-linear	
relationship,	 the	 Ur:Cr	 ratio	 is	 a	 useful	marker.	 A	 low	 or	 falling	 Ur:Cr	 ratio	was	 associated	with	 a	
reduced	risk	of	in-hospital	mortality.	Similarly,	a	high	or	rising	ratio	increased	the	relative	risk	of	death	
when	compared	with	a	normal	Ur:Cr,	ranging	from	6.4	to	47.9.	It	was	also	apparent	that,	for	the	same	
ratio	values,	the	raw	values	of	urea	and	creatinine	non-linearly	influenced	mortality	risk.	In	addition	to	
correlating	with	outcome,	the	Ur:Cr	ratio	is	also	a	surrogate	marker	for	dehydration;	thus,	a	high	or	
rising	ratio	also	provides	a	clinical	team	with	insight	into	a	patient’s	condition,	potentially	informing	
their	decisions	for	the	ongoing	management	of	the	patient.	Given	my	finding	that	dehydration	was	
present	on	admission	to	hospital	in	45.5%	of	patients,	and	additionally	occurred	in	28.3%	of	remaining	
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patients	in-hospital,	any	means	of	improving	their	care	could	potentially	save	a	large	number	of	lives	
(Chapter	3).	
	
AKI	is	a	serious	syndrome	that	costs	the	NHS	£1	billion	annually	in	England	and	Wales	alone.	I	found	
AKI,	as	defined	using	 the	NHS	England	Algorithm,	 to	be	prevalent	 in	hospitalised	patients	affecting	
8.6%	(170,596	/	1,972,130)	of	all	admissions	with	an	in-hospital	creatinine	result;	this	figure	is	lower	
than	those	reported	previously	(14.7%	in	northern	Europe,	20%	worldwide).	Also,	amongst	patients	
with	 AKI,	 over	 one-third	 (38.6%)	 of	 these	 patients	 had	 AKI	 on	 admission	 to	 hospital	 (community-
acquired	AKI).	AKI	was	twice	as	common	in	emergency	(10.7%)	than	in	planned	(5.8%)	admissions,	and	
occurs	more	frequently	in	patients	admitted	during	the	winter	(December	and	January:	9.2%)	than	in	
the	summer	(May	to	August:	8.4%).		
	
AKI	was	associated	with	poor	outcome:	of	the	170,596	of	admissions	who	developed	AKI,	21%	died	or	
underwent	unplanned	renal	replacement	therapy	(Drrt)	in	hospital.	I	found	an	increased	rate	of	Drrt	
in	AKI	patients	with	cardiac	disease	(heart	failure:	36.9%,	atrial	fibrillation:	32.7%,	chronic	ischaemic	
heart	 disease:	 26.2%,	 angina:	 24%;	 or	 presence	 of	 electronic	 cardiac	 devices:	 28.8%),	 chronic	
obstructive	 pulmonary	 disease	 (30.8%)	 and	 malignancy	 (36%).	 Increasing	 AKI	 stages	 (1	 to	 3)	 are	
designed	to	risk-stratify	AKI	patients	by	worsening	outcomes.	Although	the	Drrt	rates	increased	with	
each	AKI	stage	(AKImax	Stage	1:	13.6%;	Stage	2:	27.3%;	Stage	3:	42.4%),	 I	 found	significant	variation	
within	 each	 AKI	 stage	 when	 these	 were	 interrogated	 in	 the	 context	 of	 additional	 variables.	 For	
example,	the	variation	in	the	Drrt	rate	of	a	patient	diagnosed	with	AKImax	Stage	3	ranged	from	~0.5%	
to	~70%	(p	<	0.01)	when	the	actual	creatinine	value	is	considered	in	addition	to	the	AKI	stage	(Figure	
4.7).	Similar	variations	in	stage-specific	Drrt	rates	were	seen	when	patients	were	grouped	by	method	
of	admission	or	by	chronic	kidney	disease	status,	thus	highlighting	the	inadequacy	of	the	current	stage	
classification	in	identifying	patients	at	risk	of	Drrt	(Chapter	4).	
	
Analysing	the	data	for	all	1.87	million	hospitalised	patients	who	had	both	a	full	blood	count	and	‘urea	
and	electrolyte’	blood	tests	 (i.e.,	not	 just	 those	who	were	dehydrated	or	who	suffered	 from	AKI),	 I	
observed	an	in-hospital	mortality	rate	of	3.14%	and	a	median	length	of	stay	of	2	days	(interquartile	
range:	0–6	days).	Emergency,	elective	and	maternity	admissions	accounted	for	57.6%,	34.6%	and	5.7%	
of	the	total	respectively.	The	ethnic	category	‘British’	described	the	highest	proportion	of	admissions	
at	42.8%,	followed	by	the	‘Not	Stated’	category	at	30.4%.	The	top	three	co-morbidities	were	primary	
hypertension,	type	2	diabetes	mellitus,	and	chronic	ischaemic	heart	disease,	at	23%,	10.6%	and	9.3%	
respectively.		
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In	this	cohort	(Admission_Cohort),	mortality	by	method	of	admission	(Emergency:	4.9%;	Elective:	0.4%;	
and	Maternity:	0.07%;	p	<	0.01)	substantiates	the	view	that	patients	admitted	as	an	emergency	are	
significantly	more	likely	to	die	than	those	admitted	via	either	the	elective	or	maternity	methods.	The	
‘Other’	 method	 of	 admission	 (the	 bulk	 of	 which	 were	 made	 up	 of	 non-emergency	 inter-hospital	
transfers)	while	accounting	for	only	2.1%	of	admissions	had	the	highest	mortality	rate	of	all,	at	9%.	The	
months	 of	 admission	 with	 the	 highest	 mortality	 were	 January	 (3.5%)	 and	 December	 (3.9%).	 As	
expected,	admissions	at	the	weekend	had	a	higher	mortality	than	weekday	admissions	(4.3%	vs	2.9%,	
p	<	0.01)	given	the	lack	of	elective	admissions	taking	place	at	a	weekend.	Thus,	mortality	for	weekend	
vs	weekday	admissions	was	less	marked	(5.13%	vs	4.82%,	p	<	0.01),	though	still	significantly	higher,	
when	only	emergency	admissions	were	examined.	There	is	currently	a	major	workforce	restructuring	
underway	 led	 by	 the	Department	 of	Health	 and	NHS	 England	 to	 increase	 the	 provision	 of	 doctors	
available	over	the	weekends,	citing	that	this	may	mitigate	the	so	called	weekend	effect.	My	analyses,	
highlight	that	in-hospital	mortality	varies	to	a	greater	degree	by	the	season	(rather	than	the	day	of	the	
week)	of	admission.	There	could	be	multiple	 causes	 for	 such	an	 increase.	Although	not	 specifically	
analysed,	 I	 believe	 that	 a	 rise	 in	 acute	 infective	 respiratory	 diseases	 (e.g.	 viral	 and	 bacterial	
flu/pneumonia)	 during	 the	 winter	 months	 have	 a	 detrimental	 effect.	 Social	 isolation	 of	
elderly/chronically	ill	patients	may	exacerbate	their	illnesses	prior	to	being	admitted	to	hospital,	and	
once	they	are	admitted,	pressure	on	already	stretched	hospital	resources,	may	also	all	have	an	effect.	
All	of	these	need	to	explored	in	more	detail	to	precisely	understand	the	causes.	
	
I	 next	 explored	 the	 benefits	 of	 assessing	 patients	 at	 different	 time	 points	 in	 their	 hospital	 stay	
trajectory	 to	 better	 identify	 those	 at	 risk	 of	 deterioration	 in	 hospital.	 Patients	 change	during	 their	
hospital	stay;	some	get	better	and	are	discharged	home,	while	others	remain,	due	to	either	inadequate	
improvement	or	worsening	in	their	condition.	Understanding	the	characteristics	of	these	patients	is	
important	to	better	characterise	their	risk	of	deterioration	leading	to	mortality.	Of	the	original	1.87	
million	 admissions,	 43.28%	 (811,268)	 remained	 in	 hospital	 to	 undergo	 a	 second	 set	 of	 blood	 tests	
(Two_Tests_Cohort).	The	mortality	in	this	group	rose	from	3.14%	to	6.1%	(Emergency	7.6%;	Elective:	
1.5%;	 and	 Maternity:	 0.04%),	 and	 the	 median	 length	 of	 stay	 rose	 from	 2	 to	 6	 days.	 The	
Two_Test_Cohort	patients,	when	compared	to	the	Admission_Cohort,	were	also	older	(median	age	
increased	from	60	to	66);	comprised	of	more	emergency	admissions	(prevalence	increased	from	57.6%	
to	 71.9%,	 p	 <	 0.01);	 and	 more	 patients	 had	 co-morbidities	 (the	 proportion	 of	 patients	 with	
hypertension,	chronic	ischaemic	heart	disease,	heart	failure,	type	2	diabetes	and	COPD	all	increased,	
by	an	absolute	6.7%,	4.1%,	3.3%,	4%	and	2.7%	respectively	(p	<	0.01)).	
	
Having	highlighted	the	importance	of	variables	such	as	Ur:Cr,	dehydration	or	AKI,	co-morbidities,	age,	
method	and	timing	of	admission,	on	a	patient’s	risk	of	mortality,	I	then	went	on	to	develop	a	detailed	
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system	(the	ML	–	Early	Warning	System	(ML-EWS))	that	enables	accurate	recognition	of	hospitalised	
patients	likely	to	suffer	an	AE.	I	used	existing	and	routinely	electronically	collected	patient	data:	blood	
test	 results	 and	 administrative	 (demographics,	 comorbidity,	 method	 of	 admission,	 etc.)	 data.	 The	
development	 comprised	 two	 key	 parts.	 First,	 I	 created	 various	 ML	 models	 (using	 the	 RF	 and	 GB	
techniques),	and	assessed	how	effectively	 they	discriminated	between	patients	 likely	or	unlikely	 to	
have	an	poor	outcome.	Excitingly,	I	then	developed	a	technology	platform	called	‘Patient	Rescue’	that	
can	continuously	apply	these	models	to	patient	data	as	soon	as	they	are	generated,	and	communicate	
patient	specific-reports	to	clinicians	in	real	time.	
	
The	aims	of	my	models	were	to	enable	accurate	discrimination	between	patients	likely	or	unlikely	to	
suffer	an	AE,	thus	enabling	their	use	as	the	afferent	limb	of	a	rapid	response	system.	The	threshold	for	
referral	of	to	a	RRT	should	ideally	be	based	only	on	the	patient’s	individual	risk.	However,	in	a	resource-
limited	environment	such	as	the	NHS,	efficiency	of	resource	utilisation	must	also	be	taken	into	account.	
I	therefore	made	an	a	priori	selection	of	three	positive	predictive	value	(PPV)	thresholds	to	test	the	
performance	of	my	models.	These	PPVs	were	1:2	(ML50),	1:3	(ML33)	and	1:5	(ML20).	A	PPV	of	1	in	2	
means	that	 if	 the	model	 identifies	the	patient	as	 likely	to	die,	 then	one	out	every	two	patients	will	
subsequently	do	so.	Similarly,	a	PPV	of	1:5	means	that	one	out	of	every	five	patients	identified	will	die	
in	hospital.	Thus,	the	mortality	rates	of	the	patients	identified	by	these	thresholds	are	50%	(ML50),	
33.33%	(ML33)	and	20%	(ML20).	
	
The	four	models	I	built	were	1)	ML-Dehydration,	2)	ML-AKI,	3)	ML-Admission,	and	4)	ML-Two-Tests.	
The	performance	of	the	models	 increased	as	additional	variables	were	added.	 I	calculated	the	area	
under	the	receiver	operator	curve	(AUROC),	as	well	as	the	individual	PPV	thresholds	for	each	model.	
Each	model	is	briefly	summarised	below.		
	
1. ML-Dehydration	(AUROC:	79.6%):	this	model	was	applicable	only	to	emergency	admissions,	
and	utilised	two	types	of	blood	test	results	(urea	and	creatinine),	along	with	the	most	basic	
demographic	data	 (age	and	sex).	At	a	PPV	of	1:5	 (ML20:	mortality	 rate	of	20%),	 the	model	
identified	49.1%	(sensitivity)	of	admissions	likely	to	die	(specificity:	86.7%).	Thus,	if	the	model	
(at	this	threshold)	identifies	a	patient	as	likely	to	die,	he/she	has	a	3.1x	increased	risk	of	dying	
relative	to	the	overall	mean	(the	mean	mortality	in	this	group	of	79,949	admissions	was	6.4%).	
	
2. ML-AKI	(AUROC:	85.9%):	this	model	was	built	both	to	replace	the	existing	KDIGO	AKI	Stages,	
and	also	to	be	used	upon	a	patient’s	first	diagnosis	of	AKI	(AKIfirst).	The	mean	Drrt	rate	among	
AKI	admissions	was	already	very	high	at	21%;	hence	a	PPV	of	1:2	(ML50:	mortality	rate	50%)	
was	used.	At	this	threshold,	the	model	identified	almost	three	out	of	every	four	admissions	
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likely	to	subsequently	suffer	from	Drrt	(sensitivity:	74.3%;	specificity:	80.3%).	Thus,	compared	
with	the	AKI	mean,	a	patient	identified	by	my	model	(at	this	threshold)	had	a	2.4	relative	risk	
of	Drrt.	 If	 this	 threshold	were	used	 to	direct	escalation	of	 care,	 as	opposed	 to	 the	existing	
KDIGO	AKI	staging,	only	31.2%	of	admissions	on	first	presentation	with	AKI	would	trigger	the	
efferent	limb	(rapid	response	team	or	dedicated	AKI	nephrologist).	The	ML50	Drrt	rate	(50%)	
is	also	higher	than	that	of	any	of	the	existing	KDIGO	AKI	Stages,	at	AKIfirst	1:	18.7%;	AKIfirst	2:	
25.5%;	and	AKIfirst	3:	32.8%	(i.e.	higher	PPV	and	specificity),	while	at	the	same	time	identifying	
1.1,	4.9,	and	4.6	times	as	many	patients	likely	to	suffer	from	Drrt	(higher	sensitivity),	compared	
with	the	respective	KDIGO	AKI	Stages.	
	
3. ML-Admission	(AUROC:	93%):	this	model	was	built	to	be	applicable	to	all	hospitalised	patients	
on	receipt	of	their	first	set	of	blood	results,	regardless	of	method	of	admission	or	syndrome	
(e.g.,	 AKI,	 etc.).	 The	mean	mortality	 rate	 of	 this	 combined	 cohort	 (Admission_Cohort)	was	
3.14%;	thus,	the	performance	of	the	lowest	PPV	of	1:5	(ML20:	mortality	rate	20%)	is	described.	
At	this	threshold,	three-quarters	of	patients	likely	to	die	can	be	identified	(sensitivity:	76.1%;	
specificity:	90.2%).	Compared	with	the	cohort	mean,	a	patient	identified	by	the	model	(at	this	
threshold)	has	a	6.4	relative	risk	of	dying.	Escalating	the	care	of	these	patients	would	result	in	
12%	of	all	admissions	being	referred	to	the	RRT.	This	may	result	in	an	unacceptably	high	and	
possibly	 inefficient	workload,	especially	since	the	patient’s	own	clinical	 team	may	not	have	
had	an	opportunity	to	initiate	treatment	as	the	patient	had	just	been	admitted.	Thus,	rather	
than	escalation	to	a	RRT,	I	have	suggested	that	for	these	identified	admissions,	an	immediate	
consultant	 clinical	 (or	 senior	 clinician)	 review	 be	 undertaken,	 as	 opposed	 to	 the	 existing	
guidelines	that	arbitrarily	recommends	that	a	senior	clinical	review	every	hospital	admission	
within	12	hours.	
	
4. ML-Two-Tests	(AUROC	90.6%):	this	model	was	built	to	track	patients	who	have	remained	in	
hospital	and	have	undergone	at	least	two	sets	of	blood	tests	(Two_Tests_Cohort).	At	this	point,	
there	 are	 56%	 fewer	 patients	 than	 the	 total	 who	 were	 admitted	 to	 hospital	
(Admission_Cohort),	 and	 these	 remaining	 patients	 are	 distinctly	 different,	 being	 older	 and	
sicker	 (mortality	 rate	 6.1%).	 Additionally,	 as	 some	 time	 has	 elapsed	 between	 the	 first	 and	
second	sets	of	blood	tests,	it	is	reasonable	to	expect	that	some	treatment	or	intervention	to	
improve	 the	 patient’s	 outcome	 has	 been	 initiated.	 At	 this	 stage,	 a	mortality	 risk	 of	 33.3%	
should	 be	 unacceptable,	 and	 thus	 the	 performance	 of	 the	 PPV	 1:3	 (ML33:	 mortality	 rate	
33.33%)	is	highlighted,	as	it	provides	the	optimal	balance	between	relative	risk	of	death	and	
RRT	workload.	At	this	threshold,	the	model	identifies	65%	of	patients	likely	to	die,	each	with	a	
relative	risk	of	dying	5.5	times	higher	than	that	of	the	cohort	mean	(sensitivity:	65%;	specificity:	
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91.5%).	Escalating	the	care	of	these	admissions	would	result	in	only	12%	of	all	these	patients	
being	referred	to	the	RRT.	
	
The	predictive	performance	of	my	models	surpass	those	of	any	current	alternative	in	the	published	
medical	 literature,	 and	 provides	 an	 opportunity	 to	 substantially	 improve	 the	 recognition	 of	 the	
deteriorating	(or	at	risk	of	death)	patient.	
	
An	 exciting	 challenge	 encountered	during	 the	 course	 of	 this	 PhD	 research	was	 exploring	 the	most	
effective	 way	 to	 apply	 these	 advanced	 patient	 AE	 detection	models	 within	 clinical	 care,	 and	 thus	
positively	affecting	patient	care.	As	no	such	technology	platform	exists	that	allows	such	models	to	be	
implemented	across	diverse	hospitals	with	different	clinical	care	systems,	I	created	my	own:	‘Patient	
Rescue’.	 Using	 a	 cloud-based	 platform,	 and	 complying	 with	 all	 legal	 and	 information	 governance	
requirements,	Patient	Rescue	was	developed	by	myself,	 leading	a	core	team	comprising	a	software	
developer	 (Simon	 Brown),	 an	 NHS	 information	 analyst	 (Ani	 Dwarakanath),	 and	 a	 project	manager	
(Prashant	 Lele).	 To	 fund	 this	 innovative	 development,	 I	 successfully	 competed	 for	 the	 Regional	
Innovation	Fund,	and	was	awarded	£183,000	from	NHS	England,	for	the	team	and	the	software.	The	
challenges	we	faced	and	our	solutions	are	described	in	Chapter	6,	but	in	summary,	we	overcame	the	
live	 access,	 analytic	 and	 communication	 problems,	 and	 successfully	 created	 a	modular	 technology	
framework	based	on	a	mixture	of	open-source	and	Microsoft	components.	Patient	Rescue	was	based	
on	 a	 ‘Publisher-Subscriber’	 architecture,	 and	was	 successfully	 integrated	within	 three	hospitals.	 By	
analysing	millions	of	data	points,	milliseconds	after	they	were	generated,	Patient	Rescue	generated	
rich	 patient-level	 reports	 that	 provided	 ‘actionable	 insight’	 to	 clinicians,	 as	 well	 as	 hospital-wide	
dashboards	that	could	be	used	to	track	AKI	incidence	and	quality	of	care.	As	Patient	Rescue	was	a	proof	
of	concept,	and	we	did	not	have	MHRA	certification,	it	was	not	used	to	treat	any	patients,	and	only	
implemented	the	NHSE-AKI	algorithm.		
	
Since	 the	 start	 of	 my	 PhD,	 there	 have	 been	 a	 number	 of	 initiatives/solutions,	 in	 the	 UK	 and	
internationally,	 that	 are	 tackling	 the	 problem	 of	 real	 time	 integration	 of	 disparate	 healthcare	
repositories	and	enabling	live	analytics.	My	core	team	and	myself	continue	to	pursue	relevant	avenues	
and	to	forge	partnerships	for	deploying	such	a	system	on	a	large	scale.	In	parallel,	one	of	the	NHS	trusts	
in	which	we	tested	Patient	Rescue	has	partnered	with	Google	DeepMind,	 taken	the	concept	of	my	
platform,	copied	its	documentation,	and	is	developing	their	version.	A	leader	in	this	space,	Enlitic,	in	
2015	started	providing	real	time	clinical	decision	support	to	radiologists	in	Australia,	using	advanced	
ML	on	x-ray	images.	The	most	prominent	in	the	UK	being	Datawell,	a	Connected	Health	Cities	project	
of	the	Northern	Health	Science	Alliance.	Datawell	builds	on	a	platform	developed	by	LumiraDx,	and	
focusses	on	connecting	multiple	providers	of	healthcare	(GP’s,	hospitals,	private	providers,	etc.)	and	
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enabling	patient	centred	care	and	analytics.	In	the	USA,	multiple	hospital	groups	have	built	their	own	
data	and	analytic	solutions,	and	are	carrying	out	machine	learning	analysis,	two	particular	examples	
being	the	Mayo	Clinic	and	the	Children’s	Hospital	of	Orange	County.	The	Watson	Health	division	within	
IBM	is	also	building	on	its	cognitive	computing	solutions	to	gain	insight	from	existing	data,	both	within	
the	 hospital	 but	 also	 from	 public	 research	 repositories	 (e.g.	 pubmed).	 Overall,	 this	 is	 a	 rapidly	
advancing	 field,	 and	 I	 believe	 in	 just	 a	 few	 years,	 it	 will	 be	 commonplace	 for	 IT	 solutions	 to	 be	
augmenting	 the	 intelligence	 of	 doctors	 (and	 other	 healthcare	 professionals)	 and	 enabling	 better	
quality	of	patient	care.			
	
For	 future	work,	 there	are	still	numerous	challenges	 to	be	 faced.	Medicine	needs	 to	be	more	data	
driven,	rather	than	paying	lip	service	to	an	evidence	based	medicine	approach,	healthcare	data	needs	
to	 be	 accessible	 (respecting	 privacy),	 to	 the	 patient	 and	 to	 healthcare	 professionals	 both	 on	 an	
individual	basis	but	also	as	cohorts.	Simple	presentation	of	real	time	data	would	help	identify	issues	
that	need	further	exploration,	such	as	the	unequivocal	seasonal	variation	on	mortality.	Further	down	
the	line,	issues	relating	to	the	effect	of	the	new	models	themselves	on	the	healthcare	system	need	to	
be	understood.	From	an	analytic	point	of	view,	the	actual	deployment	of	any	model	directly	affects	its	
subsequent	performance	in	predicting	death	in	those	patients	previously	identified.	This	is	because	in	
an	ideal	environment,	a	prediction	of	death	and	subsequent	RRT	referral	should	result	in	those	patients	
not	dying,	i.e.	a	100%	successful	intervention.	However,	as	highlighted	earlier,	the	‘Chain	of	Prevention’	
consists	of	multiple	components;	and	understanding	the	influence	of	each	of	these	components	in	an	
environment	where	complex	predictive	models	are	already	deployed	will	require	further	advances	in	
ML	as	applied	to	healthcare.	In	addition,	understanding	which	information	should	be	communicated	
to	 clinicians	 and	what	 clinical	 decisions/interventions	 could	 be	 automated	 is	 key	 to	 the	 successful	
deployment	 of	 such	 a	 system.	 My	 models	 themselves	 can	 be	 improved	 as	 more	 patient	 data	 is	
incorporated.	A	recommendation	for	future	work	would	be	the	addition	of	vital	sign	variables,	OPCS-
4	codes	and	routinely	collected	perioperative	medicine	variables.	
	
In	my	opinion,	one	key	feature	that	must	be	present	in	any	future	system	is	the	ability	to	communicate	
health	status	(and	risk)	directly	to	the	patient.	The	patient	should	be	a	partner	in	his/her	medical	care,	
rather	 than	 being	merely	 the	 recipient	 of	 investigations	 and	 interventions.	Patient	 Rescue	 has	 the	
capability	to	communicate	directly	with	patients;	however,	this	function	was	not	used,	due	to	both	
regulatory	and	clinical	concerns.	Direct	and	real-time	communication	with	patients	 is,	 I	believe,	the	
key	factor	that	will	enable	full-scale	implementation	of	automated	ML	in	health	care.	
	
Overall,	my	study	has	significantly	advanced	the	field	of	detection	of	patients	likely	to	suffer	an	SAE	in	
hospital.	I	have	curated	a	large	dataset	of	UK	hospitalised	patients,	and	utilised	the	most	current	ML	
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techniques	to	create	ML	models	that	can	be	used	1)	with	limited	data,	2)	for	specific	syndromes,	and	
3)	 on	 all	 hospitalised	 patients	 at	 different	 time	 points	 in	 their	 hospital	 trajectory.	 I	 have	 also	
demonstrated	a	modular	cloud-based	technology	platform	that	enables	the	implementation	of	such	
models	and	provides	actionable	insight	to	clinicians	in	real	time.		
	
During	2015-2016,	283,000	patients	died	in	hospital	(or	within	30	days	of	hospitalisation)	in	England	
alone.	Based	on	the	reports	previously	described,	almost	half	of	these	patients	received	poor	quality	
care	at	some	point	 in	 their	hospital	 stay	 (141,500).	This	poor	quality	care	 is	cited	as	a	contributing	
factor	 to	 their	 ultimate	 poor	 outcome	 (in	 this	 case	 death),	 in	 at	 least	 half	 of	 all	 these	 patients.	
Implementation	of	such	a	system	of	advanced	algorithms	and	real	time	identification	with	appropriate	
intervention,	could	theoretically	save	anywhere	between	70,750	to	141,500	lives	in	England	alone	(the	
figure	 probably	 being	 closer	 to	 70,750	 as	 some	 patients	 would	 probably	 be	 palliative,	 or	 no	
interventions	 could	 change	outcome).	 The	potential	 impact,	both	nationally	 and	 internationally,	of	
such	 an	 approach	 is	 clear	 and	 I	 hope	my	work	motivates	 others	 to	 develop	 this	 field	 and	make	 a	
significant	positive	impact	on	patient	quality	of	care.		
	
In	June	2016,	I	was	selected	into	the	first	cohort	of	NHS	England’s	Clinician	Entrepreneurs.	This	unique	
programme	 is	 giving	me	 the	 opportunity	 to	 translate	 this	 research	 into	 clinical	 practice,	 and	 I	 am	
working	with	a	range	of	partners	to	fulfil	this	vision.	
	 	
	
161	
8	References	
1	 National	Patient	Safety	Agency	(NPSA).		(National	Confidential	Enquiry	into	Patient	Outcome	
and	Death	(NCEPOD),						2005).	
2	 Wachter,	R.	Understanding	Patient	Safety.		(McGraw-Hill	Education	/	Medical,	2012).	
3	 Levinson,	D.	Adverse	events	 in	hospitals:	national	 incidence	among	medicare	beneficiaries.	
Report	No.	OEI-06-09-00090,	(2010).	
4	 Knowing	the	Risk	A	review	of	the	peri-operative	care	of	surgical	patients.	(National	Confidential	
Enquiry	into	Patient	Outcome	and	Death,		2011).	
5	 Adding	Insult	to	Injury:	a	Review	of	the	Care	of	Patients	who	Died	in	Hospital	with	a	Primary	
Diagnosis	 of	 Acute	 Kidney	 Injury	 (acute	 renal	 failure).	 (National	 Confidential	 Enquiry	 into	
Patient	Outcome	and	Death,	2009).	
6	 Centre,	N.	 C.	G.	 Intravenous	 Fluid	 Therapy-	 Intravenous	 fluid	 therapy	 in	 adults	 in	 hospital.	
Report	No.	CG174,	(National	Institute	for	Health	and	Care	Excellence,	2013).	
7	 NIfHaC,	E.	NICE	clinical	guideline	50	Acutely	ill	patients	in	hospital:	recognition	of	and	response	
to	 acute	 illness	 in	 adults	 in	 hospital.	 London:	 National	 Institute	 for	 Health	 and	 Clinical	
Excellence	(2007).	
8	 An	Acute	Problem	?	,		(National	Confidential	Enquiry	into	Patient	Outcome	and	Death,						2005).	
9	 Martin,	I.	C.	et	al.	Emergency	Admissions:	A	Journey	in	the	Right	Direction?	,		(NCEPOD,						2007).	
10	 Caring	to	the	End?	A	review	of	the	care	of	patients	who	died	in	hospital	within	four	days	of	
admissions.		(2009).	
11	 Time	to	Intervene?	A	review	of	patients	who	underwent	cardiopulmonary	resuscitation	as	a	
result	 of	 in-hospital	 cardiorespiratory	 arrest.	 	 (National	 Confidential	 Enquiry	 into	 Patient	
Outcome	and	Death,		2012).	
12	 Just	Say	Sepsis!	A	review	of	the	process	of	care	received	by	patients	with	sepsis.	 	 (National	
Confidential	Enquiry	into	Patient	Outcome	and	Death,		2015).	
13	 Federal	 Register	 Volume	 68.	 68	 FR	 3454	 (U.S.	 Government	 Publishing	 Office,	 2003).	
<https://www.gpo.gov/fdsys/pkg/FR-2003-01-24/content-detail.html>	
14	 Commissioning	 for	 Quality	 and	 Innovation	 (CQUIN),	 <https://www.england.nhs.uk/nhs-
standard-contract/cquin/>	(	
15	 Smith,	 G.	 B.	 In-hospital	 cardiac	 arrest:	 is	 it	 time	 for	 an	 in-hospital	 'chain	 of	 prevention'?	
Resuscitation	81,	1209-1211,	doi:10.1016/j.resuscitation.2010.04.017	(						2010).	
16	 Jones,	D.	A.,	DeVita,	M.	A.	&	Bellomo,	R.	Rapid-response	teams.	N	Engl	J	Med	365,	139-146,	
doi:10.1056/NEJMra0910926	(2011).	
17	 National	Early	Warning	Score	(NEWS)	Standardising	the	assessment	acute	 illness	severity	 in	
the	NHS.		(Royal	College	of	Physicians,						2012).	
18	 			(ed	Department	of	Health)	(2013).	
19	 Gardner-Thorpe,	J.,	Love,	N.,	Wrightson,	J.,	Walsh,	S.	&	Keeling,	N.	The	value	of	Modified	Early	
Warning	Score	(MEWS)	in	surgical	in-patients:	a	prospective	observational	study.	Ann	R	Coll	
Surg	Engl	88,	571-575,	doi:10.1308/003588406X130615	(2006).	
20	 Smith,	G.	B.,	Prytherch,	D.	R.,	Schmidt,	P.	E.,	Featherstone,	P.	 I.	&	Higgins,	B.	A	review,	and	
performance	evaluation,	of	single-parameter	"track	and	trigger"	systems.	Resuscitation	79,	11-
21,	doi:10.1016/j.resuscitation.2008.05.004	(						2008).	
21	 Smith,	G.	B.,	Prytherch,	D.	R.,	Schmidt,	P.	E.	&	Featherstone,	P.	 I.	Review	and	performance	
evaluation	 of	 aggregate	 weighted	 'track	 and	 trigger'	 systems.	 Resuscitation	 77,	 170-179,	
doi:10.1016/j.resuscitation.2007.12.004	(						2008).	
22	 Salamonson,	Y.,	Kariyawasam,	A.,	van	Heere,	B.	&	O'Connor,	C.	The	evolutionary	process	of	
Medical	 Emergency	Team	 (MET)	 implementation:	 reduction	 in	unanticipated	 ICU	 transfers.	
Resuscitation	49,	135-141	(2001).	
23	 Harrison,	G.	A.,	Jacques,	T.	C.,	Kilborn,	G.	&	McLaws,	M.	L.	The	prevalence	of	recordings	of	the	
signs	 of	 critical	 conditions	 and	 emergency	 responses	 in	 hospital	wards--the	 SOCCER	 study.	
Resuscitation	65,	149-157,	doi:10.1016/j.resuscitation.2004.11.017	(2005).	
	
162	
24	 Smith,	G.	B.,	Prytherch,	D.	R.,	Meredith,	P.,	Schmidt,	P.	E.	&	Featherstone,	P.	I.	The	ability	of	
the	National	Early	Warning	Score	(NEWS)	to	discriminate	patients	at	risk	of	early	cardiac	arrest,	
unanticipated	 intensive	 care	 unit	 admission,	 and	 death.	 Resuscitation	 84,	 465-470,	
doi:10.1016/j.resuscitation.2012.12.016	(2013).	
25	 Bleyer,	A.	 J.	et	al.	 Longitudinal	analysis	of	one	million	vital	 signs	 in	patients	 in	an	academic	
medical	center.	Resuscitation,	doi:10.1016/j.resuscitation.2011.06.033	(2011).	
26	 Romero-Brufau,	S.	et	al.	Widely	used	track	and	trigger	scores:	are	they	ready	for	automation	
in	practice?	Resuscitation	85,	549-552,	doi:10.1016/j.resuscitation.2013.12.017	(2014).	
27	 Ranson,	 J.	 H.	 et	 al.	 Prognostic	 signs	 and	 the	 role	 of	 operative	 management	 in	 acute	
pancreatitis.	Surg	Gynecol	Obstet	139,	69-81	(1974).	
28	 Ozarda,	Y.	Reference	intervals:	current	status,	recent	developments	and	future	considerations.	
Biochem	Med	(Zagreb)	26,	5-16,	doi:10.11613/BM.2016.001	(2016).	
29	 Grasbeck,	R.	&	Fellman,	 J.	Normal	values	and	statistics.	Scand	J	Clin	Lab	 Invest	21,	193-195	
(1968).	
30	 Defining,	Establishing,	and	Verifying	Reference	Intervals	in	the	Clinical	Laboratory;	Approved	
Guideline—Third	 Edition	 C28-A3c	 EP28-A3c*	 3/16/2012.	 Clinical	 and	 Laboratory	 Standards	
Institute,	Wayne,	PA,	USA	
31	 Asadollahi,	K.,	Hastings,	I.	M.,	Gill,	G.	V.	&	Beeching,	N.	J.	Prediction	of	hospital	mortality	from	
admission	laboratory	data	and	patient	age:	a	simple	model.	Emerg	Med	Australas	23,	354-363,	
doi:10.1111/j.1742-6723.2011.01410.x	(2011).	
32	 Loekito,	E.	et	al.	Common	laboratory	tests	predict	 imminent	medical	emergency	team	calls,	
intensive	 care	 unit	 admission	 or	 death	 in	 emergency	 department	 patients.	 Emerg	 Med	
Australas	25,	132-139,	doi:10.1111/1742-6723.12040	(2013).	
33	 Weinberg,	A.	D.	&	Minaker,	K.	L.	Dehydration.	Evaluation	and	management	 in	older	adults.	
Council	on	Scientific	Affairs,	American	Medical	Association.	JAMA	274,	1552-1556	(						1995).	
34	 Hooper,	L.,	Bunn,	D.,	Jimoh,	F.	O.	&	Fairweather-Tait,	S.	J.	Water-loss	dehydration	and	aging.	
Mech	Ageing	Dev,	doi:10.1016/j.mad.2013.11.009	(2013).	
35	 González-Alonso,	 J.,	 Mora-Rodríguez,	 R.,	 Below,	 P.	 R.	 &	 Coyle,	 E.	 F.	 Dehydration	 reduces	
cardiac	output	and	 increases	 systemic	and	cutaneous	vascular	 resistance	during	exercise.	 J	
Appl	Physiol	(1985)	79,	1487-1496	(1995).	
36	 Popkin,	B.	M.,	D'Anci,	K.	E.	&	Rosenberg,	I.	H.	Water,	hydration,	and	health.	Nutr	Rev	68,	439-
458,	doi:10.1111/j.1753-4887.2010.00304.x	(2010).	
37	 Kelly,	J.	et	al.	Dehydration	and	venous	thromboembolism	after	acute	stroke.	QJM	97,	293-296	
(2004).	
38	 Briongos	 Figuero,	 S.	 et	 al.	 Dehydration	 and	 serum	 hyperosmolarity	 as	 new	 predictors	 of	
mortality	 after	 acute	 coronary	 syndrome.	 Int	 J	 Cardiol,	 doi:10.1016/j.ijcard.2014.01.033	
(2014).	
39	 Lin,	H.-L.	et	al.	High	preoperative	ratio	of	blood	urea	nitrogen	to	creatinine	increased	mortality	
in	gastrointestinal	cancer	patients	who	developed	postoperative	enteric	fistulas.	Kaohsiung	J	
Med	Sci	28,	418-422,	doi:10.1016/j.kjms.2012.02.011	(2012).	
40	 Beier,	K.	et	al.	Elevation	of	blood	urea	nitrogen	is	predictive	of	long-term	mortality	in	critically	
ill	 patients	 independent	 of	 "normal"	 creatinine.	 Crit	 Care	 Med	 39,	 305-313,	
doi:10.1097/CCM.0b013e3181ffe22a	(2011).	
41	 Mortensen,	P.	B.,	Nohr,	M.,	Moller-Petersen,	J.	F.	&	Balslev,	I.	The	diagnostic	value	of	serum	
urea/creatinine	ratio	in	distinguishing	between	upper	and	lower	gastrointestinal	bleeding.	A	
prospective	study.	Danish	Medical	Bulletin	41,	237-240	(1994).	
42	 Witting,	M.	D.	et	al.	ED	predictors	of	upper	gastrointestinal	tract	bleeding	in	patients	without	
hematemesis.	Am	J	Emerg	Med	24,	280-285,	doi:10.1016/j.ajem.2005.11.005	(2006).	
43	 Beaufrere,	B.	et	al.	Glucocorticosteroids	increase	leucine	oxidation	and	impair	leucine	balance	
in	humans.	The	American	journal	of	physiology	257,	E712-721	(1989).	
44	 Combe,	C.	et	al.	Influence	of	nutritional	factors	and	hemodialysis	adequacy	on	the	survival	of	
1,610	French	patients.	Am	J	Kidney	Dis	37,	S81-88	(2001).	
	
163	
45	 Cartin-Ceba,	R.,	Afessa,	B.	&	Gajic,	O.	Low	baseline	serum	creatinine	concentration	predicts	
mortality	in	critically	ill	patients	independent	of	body	mass	index.	Crit	Care	Med	35,	2420-2423	
(2007).	
46	 Lieberman,	H.	R.	Hydration	and	cognition:	a	critical	review	and	recommendations	for	future	
research.	J	Am	Coll	Nutr	26,	555S-561S	(2007).	
47	 Maughan,	R.	J.	Impact	of	mild	dehydration	on	wellness	and	on	exercise	performance.	Eur	J	Clin	
Nutr	57	Suppl	2,	S19-23,	doi:10.1038/sj.ejcn.1601897	(2003).	
48	 Armstrong,	L.	E.	et	al.	Mild	dehydration	affects	mood	in	healthy	young	women.	 J	Nutr	142,	
382-388,	doi:10.3945/jn.111.142000	(2012).	
49	 Maughan,	 R.	 J.	 Hydration,	morbidity,	 and	mortality	 in	 vulnerable	 populations.	Nutr	 Rev	70	
Suppl	2,	S152-155,	doi:10.1111/j.1753-4887.2012.00531.x	(2012).	
50	 Murray,	B.	Hydration	and	physical	performance.	J	Am	Coll	Nutr	26,	542S-548S	(2007).	
51	 Namdar,	T.	et	al.	Impact	of	hypernatremia	on	burn	wound	healing:	results	of	an	exploratory,	
retrospective	study.	Ostomy	Wound	Manage	57,	30-34	(2011).	
52	 Kateros,	K.	et	al.	Analysis	of	kidney	dysfunction	in	orthopaedic	patients.	BMC	Nephrol	13,	101,	
doi:10.1186/1471-2369-13-101	(2012).	
53	 Uchino,	S.,	Bellomo,	R.	&	Goldsmith,	D.	The	meaning	of	 the	blood	urea	nitrogen/creatinine	
ratio	in	acute	kidney	injury.	Clinical	Kidney	Journal	5,	187-191,	doi:10.1093/ckj/sfs013	(2012).	
54	 Oksa,	H.,	Pasternack,	A.	&	Pasanen,	M.	Serum	urea-creatinine	ratio	as	a	prognostic	index	in	
hemodialysis	patients.	Clinical	Nephrology	27,	125-130	(1987).	
55	 De	Lima,	J.	J.,	da	Fonseca,	J.	A.	&	Godoy,	A.	D.	Baseline	variables	associated	with	early	death	
and	extended	survival	on	dialysis.	Renal	Failure	20,	581-587	(1998).	
56	 Lin,	L.	C.	et	al.	Predictors	of	early	clinical	deterioration	after	acute	ischemic	stroke.	Am	J	Emerg	
Med	29,	577-581,	doi:10.1016/j.ajem.2009.12.019	(2011).	
57	 Schrock,	 J.	W.,	Glasenapp,	M.	&	Drogell,	K.	Elevated	blood	urea	nitrogen/creatinine	ratio	 is	
associated	with	poor	outcome	 in	patients	with	 ischemic	stroke.	Clin	Neurol	Neurosurg	114,	
881-884,	doi:10.1016/j.clineuro.2012.01.031	(2012).	
58	 Rowat,	 A.,	 Graham,	 C.	 &	 Dennis,	 M.	 Dehydration	 in	 hospital-admitted	 stroke	 patients:	
detection,	 frequency,	 and	 association.	 Stroke	 43,	 857-859,	
doi:10.1161/STROKEAHA.111.640821	(2012).	
59	 Feinfeld,	 D.	 A.,	 Bargouthi,	 H.,	 Niaz,	 Q.	 &	 Carvounis,	 C.	 P.	 Massive	 and	 disproportionate	
elevation	of	blood	urea	nitrogen	in	acute	azotemia.	International	urology	and	nephrology	34,	
143-145	(2002).	
60	 Gotsman,	 I.	 et	 al.	 The	 significance	of	 serum	urea	and	 renal	 function	 in	patients	with	heart	
failure.	Medicine	89,	197-203	(2010).	
61	 Aronson,	D.	et	al.	Serum	blood	urea	nitrogen	and	long-term	mortality	 in	acute	ST-elevation	
myocardial	infarction.	International	Journal	of	Cardiology	127,	380-385	(2008).	
62	 Stookey,	J.	D.,	Pieper,	C.	F.	&	Cohen,	H.	J.	Is	the	prevalence	of	dehydration	among	community-
dwelling	older	adults	really	low?	Informing	current	debate	over	the	fluid	recommendation	for	
adults	aged	70+years.	Public	Health	Nutrition	8,	1275-1285	(2005).	
63	 Mukand,	 J.	 A.,	 Cai,	 C.,	 Zielinski,	 A.,	 Danish,	M.	&	Berman,	 J.	 The	 effects	 of	 dehydration	 on	
rehabilitation	 outcomes	 of	 elderly	 orthopedic	 patients.	 Arch	 Phys	Med	 Rehabil	 84,	 58-61,	
doi:10.1053/apmr.2003.50064	(2003).	
64	 Fine,	 M.	 J.	 et	 al.	 A	 prediction	 rule	 to	 identify	 low-risk	 patients	 with	 community-acquired	
pneumonia.	N	Engl	J	Med	336,	243-250,	doi:10.1056/NEJM199701233360402	(1997).	
65	 Lim,	W.	S.	et	al.	Defining	community	acquired	pneumonia	severity	on	presentation	to	hospital:	
an	international	derivation	and	validation	study.	Thorax	58,	377-382	(2003).	
66	 Wu,	 B.	 U.	 et	 al.	 Blood	 urea	 nitrogen	 in	 the	 early	 assessment	 of	 acute	 pancreatitis:	 an	
international	 validation	 study.	 Arch	 Intern	 Med	 171,	 669-676,	
doi:10.1001/archinternmed.2011.126	(2011).	
67	 Hartz,	A.	J.,	Kuhn,	E.	M.,	Kayser,	K.	L.	&	Johnson,	W.	D.	BUN	as	a	risk	factor	for	mortality	after	
coronary	artery	bypass	grafting.	The	Annals	of	thoracic	surgery	60,	398-404	(1995).	
	
164	
68	 Fonarow,	 G.	 C.	 et	 al.	 Risk	 stratification	 for	 in-hospital	mortality	 in	 acutely	 decompensated	
heart	 failure:	 classification	 and	 regression	 tree	 analysis.	 JAMA	 293,	 572-580,	
doi:10.1001/jama.293.5.572	(2005).	
69	 Commission,	C.	Q.	Dignity	and	nutrition	inspection	programme:	national	overview.	Newcastle	
upon	Tyne:	Care	Quality	Commission	(2011).	
70	 Association,	P.	Listen	to	patients,	Speak	up	for	change.	Harrow:	Patients	Association	(2010).	
71	 Parliamentary	 &	 Ombudsman,	 H.	 S.	 Care	 and	 Compassion?:	 Report	 of	 the	 Health	 Service	
Ombudsman	on	Ten	 Investigations	 Into	Nhs	Care	of	Older	People.	 Vol.	 778	 (The	 Stationery	
Office,	2011).	
72	 Francis,	 R.	 Report	 of	 the	Mid	 Staffordshire	 NHS	 Foundation	 Trust	 Public	 Inquiry:	 Executive	
Summary.	Vol.	947	(TSO	Shop,	2013).	
73	 Feinmann,	J.	How	hundreds	of	patients	are	dying	of	thirst	in	hospital:	The	story	of	a	22-year-
old	 who	 died	 in	 hospital	 from	 dehydration	 shocked	 Britain.	 But	 his	 tragedy	 is	 horrifyingly	
common,	 <http://www.dailymail.co.uk/health/article-2177969/How-hundreds-patients-
dying-thirst-hospital-The-story-22-year-old-died-hospital-dehydration-shocked-Britain-But-
tragedy-horrifyingly-common.html>	(2012).	
74	 Borland,	S.	Thousands	dying	of	thirst	on	NHS:	Watchdog	forced	to	issue	guidelines	on	giving	
patients	 water,	 <http://www.dailymail.co.uk/news/article-2403501/Thousands-dying-thirst-
NHS-Watchdog-forced-issue-guidelines-giving-patients-water.html>	(2013).	
75	 Hodgekiss,	A.	1,000	patients	a	month	are	dying	in	hospital	from	'avoidable'	kidney	problems	
caused	by	dehydration,	<http://www.dailymail.co.uk/health/article-2609542/1-000-patients-
month-dying-hospital-avoidable-kidney-problems-caused-dehydration.html>	(2014).	
76	 Ellicott,	 C.	 Patient	 dying	 of	 thirst	 rang	 999:	 Inquest	 hears	 of	 mother's	 fury	 at	 nurses	 who	
neglected	son,	<http://www.dailymail.co.uk/news/article-2167643/Patient-dying-thirst-rang-
999-Inquest-hears-mothers-fury-nurses-neglected-son.html>	(2014).	
77	 Borland,	 S.	Four	elderly	patients	a	week	are	dying	of	hunger	and	 thirst	 'utterly	 scandalous'	
figures	 reveal,	 <http://www.dailymail.co.uk/news/article-2516692/Four-elderly-patients-
week-dying-hunger-thirst-utterly-scandalous-figures-reveal.html>	(2013).	
78	 (GDG),	G.	d.	g.				(ed	National	Institute	for	Health	and	Care	Excellence	(NICE))	(National	Clinical	
Guideline	Centre,	http://guidance.nice.org.uk/CG169,	2013).	
79	 Kerr,	M.,	Bedford,	M.,	Matthews,	B.	&	O'Donoghue,	D.	The	economic	impact	of	acute	kidney	
injury	 in	England.	Nephrology,	dialysis,	transplantation	:	official	publication	of	the	European	
Dialysis	 and	 Transplant	 Association	 -	 European	 Renal	 Association,	 doi:10.1093/ndt/gfu016	
(2014).	
80	 England,	 N.	 Hospital	 Episode	 Statistics,	 Admitted	 Patient	 Care,	 England	 -	 2012-13	 [NS],	
<http://www.hscic.gov.uk/searchcatalogue?productid=13264&q=title%3a%22Hospital+Episo
de+Statistics%2c+Admitted+patient+care+-
+England%22&sort=Relevance&size=10&page=1#top>	(2013).	
81	 Crary,	M.	A.	et	al.	Dysphagia,	nutrition,	and	hydration	in	ischemic	stroke	patients	at	admission	
and	discharge	from	acute	care.	Dysphagia	28,	69-76,	doi:10.1007/s00455-012-9414-0	(2013).	
82	 Ftouh,	S.,	Thomas,	M.	&	Acute	Kidney	Injury	Guideline	Development,	G.	Acute	kidney	injury:	
summary	of	NICE	guidance.	BMJ	347,	f4930,	doi:10.1136/bmj.f4930	(2013).	
83	 KDIGO,	A.	K.	I.	Work	Group:	KDIGO	clinical	practice	guideline	for	acute	kidney	injury.	Kidney	
Int	Suppl	2,	1-138	(2012).	
84	 Susantitaphong,	 P.	 et	 al.	 World	 incidence	 of	 AKI:	 a	 meta-analysis.	 Clinical	 journal	 of	 the	
American	Society	of	Nephrology	:	CJASN	8,	1482-1493,	doi:10.2215/CJN.00710113	(2013).	
85	 Wang,	H.	E.,	Muntner,	P.,	Chertow,	G.	M.	&	Warnock,	D.	G.	Acute	kidney	injury	and	mortality	
in	hospitalized	patients.	Am	J	Nephrol	35,	349-355,	doi:10.1159/000337487	(2012).	
86	 Aitken,	 E.	 et	 al.	 Acute	 kidney	 injury:	 outcomes	 and	 quality	 of	 care.	 QJM	 106,	 323-332,	
doi:10.1093/qjmed/hcs237	(2013).	
87	 Metcalfe,	W.	 et	 al.	 Acute	 renal	 failure	 requiring	 renal	 replacement	 therapy:	 incidence	 and	
outcome.	QJM	95,	579-583	(2002).	
	
165	
88	 Chawla,	L.	S.,	Amdur,	R.	L.,	Amodeo,	S.,	Kimmel,	P.	L.	&	Palant,	C.	E.	The	severity	of	acute	kidney	
injury	 predicts	 progression	 to	 chronic	 kidney	 disease.	 Kidney	 Int	 79,	 1361-1369,	
doi:10.1038/ki.2011.42	(2011).	
89	 Selby,	N.	M.,	 Hill,	 R.,	 Fluck,	 R.	 J.	&	 Programme,	N.	H.	 S.	 E.	 T.	 K.	 A.	 Standardizing	 the	 Early	
Identification	of	Acute	Kidney	Injury:	The	NHS	England	National	Patient	Safety	Alert.	Nephron	
131,	113-117,	doi:10.1159/000439146	(2015).	
90	 Moonesinghe,	S.	R.,	Mythen,	M.	G.,	Das,	P.,	Rowan,	K.	M.	&	Grocott,	M.	P.	Risk	stratification	
tools	 for	 predicting	 morbidity	 and	 mortality	 in	 adult	 patients	 undergoing	 major	 surgery:	
qualitative	 systematic	 review.	 Anesthesiology	 119,	 959-981,	
doi:10.1097/ALN.0b013e3182a4e94d	(2013).	
91	 Prytherch,	D.	R.	et	al.	The	use	of	routine	laboratory	data	to	predict	in-hospital	death	in	medical	
admissions.	Resuscitation	66,	203-207,	doi:10.1016/j.resuscitation.2005.02.011	(						2005).	
92	 Hucker,	T.	R.	et	al.	Identifying	the	sick:	can	biochemical	measurements	be	used	to	aid	decision	
making	on	presentation	to	the	accident	and	emergency	department.	Br	J	Anaesth	94,	735-741,	
doi:10.1093/bja/aei122	(2005).	
93	 Silke,	B.,	Kellett,	J.,	Rooney,	T.,	Bennett,	K.	&	O'Riordan,	D.	An	improved	medical	admissions	
risk	system	using	multivariable	fractional	polynomial	logistic	regression	modelling.	QJM	103,	
23-32,	doi:10.1093/qjmed/hcp149	(2010).	
94	 Loekito,	 E.	 et	 al.	 Common	 laboratory	 tests	 predict	 imminent	 death	 in	 ward	 patients.	
Resuscitation,	doi:10.1016/j.resuscitation.2012.07.025	(2012).	
95	 Mohammed,	M.	A.	et	al.	Which	is	more	useful	in	predicting	hospital	mortality--dichotomised	
blood	test	results	or	actual	test	values?	A	retrospective	study	 in	two	hospitals.	PLoS	One	7,	
e46860,	doi:10.1371/journal.pone.0046860	(2012).	
96	 Jarvis,	S.	W.	et	al.	Development	and	validation	of	a	decision	tree	early	warning	score	based	on	
routine	 laboratory	 test	 results	 for	 the	 discrimination	 of	 hospital	 mortality	 in	 emergency	
medical	 admissions.	 Resuscitation	 84,	 1494-1499,	 doi:10.1016/j.resuscitation.2013.05.018	
(2013).	
97	 Baxmann,	A.	 C.	 et	 al.	 Influence	of	muscle	mass	 and	physical	 activity	on	 serum	and	urinary	
creatinine	and	serum	cystatin	C.	Clinical	journal	of	the	American	Society	of	Nephrology	:	CJASN	
3,	348-354,	doi:10.2215/CJN.02870707	(2008).	
98	 Kalyani,	R.	R.,	Corriere,	M.	&	Ferrucci,	L.	Age-related	and	disease-related	muscle	loss:	the	effect	
of	 diabetes,	 obesity,	 and	 other	 diseases.	 Lancet	 Diabetes	 Endocrinol	 2,	 819-829,	
doi:10.1016/S2213-8587(14)70034-8	(2014).	
99	 Samuel,	A.	L.	Some	studies	 in	machine	 learning	using	the	game	of	checkers.	 IBM	Journal	of	
research	and	development	3,	210-229	(1959).	
100	 Mitchell,	T.	M.	Machine	learning.	1997.	Burr	Ridge,	IL:	McGraw	Hill	45,	37	(1997).	
101	 Enlitic,	<www.enlitic.com>	(2017).	
102	 Ho,	T.	K.	in	Document	Analysis	and	Recognition,	1995.,	Proceedings	of	the	Third	International	
Conference	on.		278-282	(IEEE).	
103	 Breiman,	L.	Random	forests.	Machine	learning	45,	5-32	(2001).	
104	 C	Click,	M.	M.,	V	Parmar,	H	Roark,	A	Candel.					(2016).	
105	 h2o,	<www.h2o.ai>	
106	 HSCIC.	 Commissioning	 Data	 Sets,	
<http://www.datadictionary.nhs.uk/web_site_content/cds_supporting_information/commis
sioning_data_sets_overview.asp?shownav=1>	(2016).	
107	 Nouraei,	 S.	 et	 al.	 A	 study	of	 clinical	 coding	 accuracy	 in	 surgery:	 implications	 for	 the	use	of	
administrative	big	data	for	outcomes	management.	Annals	of	surgery	261,	1096-1107	(2015).	
108	 England,	N.				(ed	National	Pathology	Programme)	(NHS	England,	2014).	
109	 Regenstrief	 Institute,	 I.	 Logical	 Observation	 Identifiers	 Names	 and	 Codes,	
<http://loinc.org/background>	(2016).	
110	 HSCIC.	 National	 Laboratory	 Medicine	 Catalogue	 (NLMC)	
<http://systems.hscic.gov.uk/pathology/projects/nlmc>	(2016).	
111	 McDonald,	C.	J.	et	al.	LOINC,	a	universal	standard	for	identifying	laboratory	observations:	a	5-
year	update.	Clinical	chemistry	49,	624-633	(2003).	
	
166	
112	 Association,	W.	M.	World	Medical	Association	Declaration	of	Helsinki:	ethical	principles	 for	
medical	research	involving	human	subjects.	Jama	310,	2191	(2013).	
113	 Health,	D.	o.				(ed	Department	of	Health)	54	(2005).	
114	 Authority,	 H.	 R.	 Research	 requiring	 NHS	 review	 but	 not	 ethical	 review,	
<http://www.hra.nhs.uk/resources/before-you-apply/research-requiring-nhs-rd-review-but-
not-ethical-review/>	(	
115	 Health,	D.	o.				(ed	Department	of	Health)	(www.dh.gov.uk,	2011).	
116	 ICO.				(ed	Information	Commissioner's	Office)	(https://ico.org.uk/for-organisations/guide-to-
data-protection/anonymisation/,	2012).	
117	 The	 Caldicott	 Committee	 -	 Chair:	 Dame	 Caldicott,	 F.	 	 	 	 (ed	 Department	 of	 Health)	 137	
(http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Pu
blicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4068403,	1997).	
118	 Caldicott,	 F.	 (ed	 National	 Data	 Guardian)	 139	
(https://www.gov.uk/government/publications/the-information-governance-review,	2013).	
119	 Guardian,	 N.	 D.	 	 	 	 (ed	 Department	 of	 Health)	
(https://www.gov.uk/government/consultations/the-role-of-the-national-data-guardian-for-
health-and-social-care,	2015).	
120	 Carter,	P.,	Laurie,	G.	T.	&	Dixon-Woods,	M.	The	social	licence	for	research:	why	care.	data	ran	
into	trouble.	Journal	of	medical	ethics,	medethics-2014-102374	(2015).	
121	 NHS	 Care.data	 PR	 Fiasco	 Continues	 as	 Google	 Pulls	 Out	 of	 Secret	 Deal,	
<http://www.infosecurity-magazine.com/news/nhs-caredata-pr-fiasco-continues/>	(	
122	 Martin,	 A.	 J.	 Care.data	 is	 a	 complete	 omnishambles,	 says	 study	 into	 hated	 scheme,	
<http://www.theregister.co.uk/2015/08/12/caredata_case_study/>	(	
123	 medconfidential.org.	The	Care.data	shambles,	<https://medconfidential.org/>	(	
124	 Ingraham,	A.	M.,	Cohen,	M.	E.,	Raval,	M.	V.,	Ko,	C.	Y.	&	Nathens,	A.	B.	Comparison	of	hospital	
performance	in	emergency	versus	elective	general	surgery	operations	at	198	hospitals.	J	Am	
Coll	Surg	212,	20-28.e21,	doi:10.1016/j.jamcollsurg.2010.09.026	(2011).	
125	 Commission,	C.	Q.	Annual	Health	Check	Report	2008-09.xlsx,	2009).	
126	 dr	foster	intelligence,	<http://myhospitalguide.drfosterintelligence.co.uk/#/mortality>	(2014).	
127	 Admission	 Method:	 NHS	 Data	 Dictionary,	
<(http://www.datadictionary.nhs.uk/data_dictionary/attributes/a/add/admission_method_
de.asp)>	
128	 Yoo,	W.	et	al.	A	study	of	effects	of	multicollinearity	in	the	multivariable	analysis.	International	
journal	of	applied	science	and	technology	4,	9	(2014).	
129	 Jeffreys	Interval,	<https://en.wikipedia.org/wiki/Binomial_proportion_confidence_interval>	(	
130	 Porter,	C.	J.	et	al.	A	real-time	electronic	alert	to	improve	detection	of	acute	kidney	injury	in	a	
large	 teaching	 hospital.	 Nephrology,	 dialysis,	 transplantation	 :	 official	 publication	 of	 the	
European	 Dialysis	 and	 Transplant	 Association	 -	 European	 Renal	 Association,	
doi:10.1093/ndt/gfu082	(2014).	
131	 Barochia,	A.	V.	et	al.	Bundled	care	for	septic	shock:	an	analysis	of	clinical	trials.	Crit	Care	Med	
38,	668-678,	doi:10.1097/CCM.0b013e3181cb0ddf	(2010).	
132	 Westphal,	G.	A.	et	al.	Reduced	mortality	after	the	implementation	of	a	protocol	for	the	early	
detection	of	severe	sepsis.	J	Crit	Care	26,	76-81,	doi:10.1016/j.jcrc.2010.08.001	(2011).	
133	 Pestana,	D.	et	al.	Compliance	with	a	sepsis	bundle	and	its	effect	on	intensive	care	unit	mortality	
in	surgical	septic	shock	patients.	J	Trauma	69,	1282-1287,	doi:10.1097/TA.0b013e3181c4539f	
(2010).	
134	 Chen,	Q.	H.	et	al.	[The	impact	of	sepsis	bundles	on	mortality	in	patients	with	sepsis	shock:	a	
prospective	clinical	study].	Zhongguo	Wei	Zhong	Bing	Ji	Jiu	Yi	Xue	20,	534-537	(2008).	
135	 Castellanos-Ortega,	A.	 et	al.	 Impact	of	 the	Surviving	Sepsis	Campaign	protocols	on	hospital	
length	of	stay	and	mortality	in	septic	shock	patients:	results	of	a	three-year	follow-up	quasi-
experimental	 study.	 Crit	 Care	 Med	 38,	 1036-1043,	 doi:10.1097/CCM.0b013e3181d455b6	
(2010).	
	
167	
136	 Discharge	 destination.	 NHS	 Data	 Dictionary,	
<http://www.datadictionary.nhs.uk/data_dictionary/attributes/d/disc/discharge_destination
_de.asp?shownav=1?query=%22discharge+destination%22&rank=100&shownav=1>	(2017).	
137	 Association,	 T.	 R.	 CKD	 Stages,	 <http://www.renal.org/information-resources/the-uk-eckd-
guide/ckd-stages>	(2016).	
138	 Levey,	A.	S.	et	al.	A	new	equation	to	estimate	glomerular	filtration	rate.	Ann	Intern	Med	150,	
604-612	(2009).	
139	 Harasymiv,	V.	Lessons	from	2	Million	Machine	Learning	Models	on	Kaggle.	
140	 Friedman,	J.	H.	Greedy	function	approximation:	A	gradient	boosting		 	 	 	
machine.	1189-1232,	doi:10.1214/aos/1013203451	(2001).	
141	 Yang,	L.	et	al.	Acute	kidney	injury	in	China:	a	cross-sectional	survey.	Lancet	386,	1465-1471,	
doi:10.1016/S0140-6736(15)00344-X	(2015).	
142	 Challiner,	 R.,	 Ritchie,	 J.	 P.,	 Fullwood,	 C.,	 Loughnan,	 P.	 &	 Hutchison,	 A.	 J.	 Incidence	 and	
consequence	of	acute	kidney	injury	in	unselected	emergency	admissions	to	a	large	acute	UK	
hospital	trust.	BMC	Nephrol	15,	84,	doi:10.1186/1471-2369-15-84	(2014).	
143	 Roberts,	G.	et	al.	Acute	kidney	injury	risk	assessment	at	the	hospital	front	door:	what	is	the	
best	measure	of	risk?	Clin	Kidney	J	8,	673-680,	doi:10.1093/ckj/sfv080	(2015).	
144	 Pankhurst,	T.	et	al.	Acute	kidney	injury	following	unselected	emergency	admission:	role	of	the	
inflammatory	 response,	 medication	 and	 co-morbidity.	 Nephron	 Clin	 Pract	 126,	 81-89,	
doi:10.1159/000357845	(2014).	
145	 Mehta,	R.	L.	et	al.	Recognition	and	management	of	acute	kidney	 injury	 in	the	 International	
Society	of	Nephrology	0by25	Global	Snapshot:	a	multinational	cross-sectional	study.	Lancet	
387,	2017-2025,	doi:10.1016/S0140-6736(16)30240-9	(2016).	
146	 HL7,	<www.hl7.org>	
147	 Dixon,	 J.	 Pentaho,	 Hadoop,	 and	 Data	 Lakes,	
<https://jamesdixon.wordpress.com/2010/10/14/pentaho-hadoop-and-data-lakes/>	(2010).	
148	 Woods,	 D.	 Big	 data	 requires	 a	 big	 architecture,	
<http://www.forbes.com/sites/ciocentral/2011/07/21/big-data-requires-a-big-new-
architecture/>	(2011).	
149	 Mirth,	<https://www.mirth.com/>	
150	 Rabbit	MQ,	<https://www.rabbitmq.com/>	
	
	
	
-	
	
	 	
	
168	
Appendices	
Appendix	1:	Table:	Commissioning	Data	Sets	
Table:	Commissioning	Data	Sets	106	
Commissioning	Data	Set	 Overview	
Accident	and	Emergency	Commissioning	Data	Set	Type	
CDS	V6-2	Type	010	-	Accident	and	
Emergency	CDS	
An	Accident	and	Emergency	Attendance	is	an	individual	visit	by	one	PATIENT	to	an	
Accident	 and	 Emergency	 Department	 to	 receive	 treatment	 from	 the	 accident	 and	
emergency	service.	
Out	Patient	Commissioning	Data	Set	Types	
CDS	 V6-2	 Type	 020	 -	 Outpatient	
CDS	
Carries	the	data	for	an	Outpatient	Attendance	or	a	cancelled/missed	APPOINTMENT.	
It	 covers	 all	 NHS	 and	 private	 Outpatient	 ACTIVITY	 taking	 place	 in	 any:	 acute,	
community,	mental	health	NHS	Trust	or	NHS	Foundation	Trust,	other	NHS	hospital,	
non-NHS	hospitals	or	institutions	where	the	care	delivered	is	NHS-funded;	under	the	
care	of	a	CONSULTANT,	MIDWIFE	or	NURSE,	where	an	appropriate	MAIN	SPECIALTY	
CODE	and	TREATMENT	FUNCTION	CODE	exists.			
Admitted	Patient	Care	Commissioning	Data	Set	Types	
CDS	 V6-2	 Type	 120	 -	 Admitted	
Patient	 Care	 -	 Finished	 Birth	
Episode	CDS	
Carries	 the	data	 for	 a	 Finished	Birth	 Episode.	 This	 is	 required	when	a	delivery	has	
resulted	in	a	REGISTRABLE	BIRTH	which	has	taken	place	in	either	an	NHS	Hospital	or	
in	a	non-NHS	ORGANISATION	funded	by	the	NHS.	The	information	is	taken	from	the	
birth	notification	for	each	baby	born.	
CDS	 V6-2	 Type	 130	 -	 Admitted	
Patient	 Care	 -	 Finished	 General	
Episode	CDS	
Carries	the	data	for	a	Finished	General	Episode.	It	covers	all	NHS	and	private	Admitted	
Patient	Care	(day	case	and	inpatient)	ACTIVITY	taking	place	in	any:	acute,	community,	
mental	 health	 NHS	 Trust	 or	 NHS	 Foundation	 Trust,	 other	 NHS	 hospital,	 non-NHS	
hospitals	or	institutions	where	the	care	delivered	is	NHS-funded;	under	the	care	of	a	
CONSULTANT,	MIDWIFE	or	NURSE,	where	an	appropriate	MAIN	SPECIALTY	CODE	and	
TREATMENT	FUNCTION	CODE	exists.	
CDS	 V6-2	 Type	 140	 -	 Admitted	
Patient	 Care	 -	 Finished	 Delivery	
Episode	CDS	
Carries	the	data	for	a	Finished	Delivery	Episode	which	is	required	when	a	delivery	has	
resulted	in	a	REGISTRABLE	BIRTH.	This	may	take	place	in	either	NHS	Hospitals	or	in	
non-NHS	ORGANISATIONS	funded	by	the	NHS.	The	information	is	taken	from	the	birth	
notification	for	each	baby	born.	
CDS	 V6-2	 Type	 150	 -	 Admitted	
Patient	 Care	 -	 Other	 Birth	 Event	
CDS	
Applies	 to:	NHS	 funded	home	births	and	all	other	birth	events	which	are	not	NHS-
funded,	 either	 directly	 or	 under	 an	 NHS	 SERVICE	 AGREEMENT.	 The	 data	 in	 these	
records	originates	from	birth	notification	records	and	requires	only	a	limited	data	set	
to	be	completed	
CDS	 V6-2	 Type	 160	 -	 Admitted	
Patient	 Care	 -	 Other	 Delivery	
Event	CDS	
Applies	to:	NHS	funded	home	deliveries	and	all	other	delivery	events	which	are	not	
NHS-funded,	either	directly	or	under	an	NHS	SERVICE	AGREEMENT.	The	data	in	these	
records	originates	from	birth	notification	records	and	requires	only	a	limited	data	set	
to	be	completed.	
CDS	 V6-2	 Type	 170	 -	 Admitted	
Patient	 Care	 -	 Detained	 and/or	
Long	Term	Psychiatric	Census	CDS	
a	record	for	every	PATIENT	admitted	as	at	31	March	each	year	for	which	the	PATIENT	
is	detained	or	the	Episode	is	part	of	a	Hospital	Provider	Spell	which	has	lasted	longer	
than	one	year	and	for	which	the	majority	of	time	has	been	spent	under	the	care	of	a	
CONSULTANT	in	one	of	the	psychiatric	specialties.	
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CDS	 V6-2	 Type	 180	 -	 Admitted	
Patient	 Care	 -	 Unfinished	 Birth	
Episode	CDS	
Carries	the	data	for	an	Unfinished	Birth	Episode.	This	is	required	when	a	delivery	has	
resulted	in	a	REGISTRABLE	BIRTH	which	has	taken	place	in	either	an	NHS	Hospital	or	
in	a	non-NHS	ORGANISATION	funded	by	the	NHS.	The	information	is	taken	from	the	
birth	notification	for	each	baby	born.	Unfinished	Birth	Episode	Commissioning	Data	
Set	records	are	required	for	all	Unfinished	Birth	Episodes	as	at	midnight	on	31st	March	
each	year	
CDS	 V6-2	 Type	 190	 -	 Admitted	
Patient	Care	-	Unfinished	General	
Episode	CDS	
Carries	 the	 data	 for	 an	Unfinished	General	 Episode.	 It	 covers	 all	 NHS	 and	 private	
Admitted	Patient	Care	(day	case	and	inpatient)	ACTIVITY	taking	place	in	any:	acute,	
community,	mental	health	NHS	Trust	or	NHS	Foundation	Trust,	other	NHS	hospital,		
non-NHS	hospitals	or	institutions	where	the	care	delivered	is	NHS-funded;	under	the	
care	of	a	CONSULTANT,	MIDWIFE	or	NURSE,	where	an	appropriate	MAIN	SPECIALTY	
CODE	and	TREATMENT	FUNCTION	CODE	exists.			
CDS	 V6-2	 Type	 200	 -	 Admitted	
Patient	Care	-	Unfinished	Delivery	
Episode	CDS	
Carries	the	data	for	an	Unfinished	Delivery	Episode.	This	may	take	place	in	either	NHS	
Hospitals	or	in	non-NHS	ORGANISATIONS	funded	by	the	NHS.	The	information	is	taken	
from	the	birth	notification	for	each	baby	born.	Unfinished	Birth	and	Delivery	Episode	
Commissioning	Data	 Set	 records	are	 required	 for	 all	Unfinished	Birth	and	Delivery	
Episodes	as	at	midnight	on	31	March	each	year.	
Elective	Admission	List	Commissioning	Data	Set	Types	-	End	Of	Period	Census	Types	
CDS	 V6-2	 Type	 030	 -	 Elective	
Admission	 List	 -	 End	 of	 Period	
Census	(Standard)	CDS	
Carries	the	data	for	all	booked,	planned	and	waiting	list	admissions.	This	consists	of	
records	for	PATIENTS	waiting	for	Elective	Admission	at	a	specified	date	and	should	be	
sent	to	the	Secondary	Uses	Service	within	one	month	of	the	end	of	the	period	to	which	
they	relate	unless	a	shorter	time-scale	has	been	agreed	with	the	recipient.	It	covers	
ELECTIVE	ADMISSION	LIST	ENTRIES	under	the	care	of	a	CONSULTANT,	MIDWIFE	or	
NURSE,	where	an	appropriate	MAIN	SPECIALTY	CODE	and	TREATMENT	FUNCTION	
CODE	exists.	
CDS	 V6-2	 Type	 040	 -	 Elective	
Admission	 List	 -	 End	 Of	 Period	
Census	(Old)	CDS	
Is	used	to	report	to	the	previous	(old)	Commissioner	that	the	ELECTIVE	ADMISSION	
LIST	ENTRY	is	now	the	responsibility	of	another	Commissioner.	This	CDS	Type	should	
be	sent	within	one	month	of	the	end	of	the	period	to	which	it	relates	unless	a	shorter	
time-scale	has	been	agreed	with	 the	 recipient.	 It	 covers	ELECTIVE	ADMISSION	LIST	
ENTRIES	under	the	care	of	a	CONSULTANT,	MIDWIFE	or	NURSE,	where	an	appropriate	
MAIN	SPECIALTY	CODE	and	TREATMENT	FUNCTION	CODE	exists.	
CDS	 V6-2	 Type	 050	 -	 Elective	
Admission	 List	 -	 End	 Of	 Period	
Census	(New)	CDS	
Is	used	to	report	to	a	new	Commissioner	an	ELECTIVE	ADMISSION	LIST	ENTRY	that	
had	previously	been	the	responsibility	of	another	Commissioner.	This	CDS	Type	should	
be	sent	within	one	month	of	the	end	of	the	period	to	which	it	relates	unless	a	shorter	
time-scale	has	been	agreed	with	 the	 recipient.	 It	 covers	ELECTIVE	ADMISSION	LIST	
ENTRIES	under	the	care	of	a	CONSULTANT,	MIDWIFE	or	NURSE,	where	an	appropriate	
MAIN	SPECIALTY	CODE	and	TREATMENT	FUNCTION	CODE	exists.	
Elective	Admission	List	Commissioning	Data	Set	Types	-	Event	During	Period	Types	
CDS	 V6-2	 Type	 060	 -	 Elective	
Admission	 List	 -	 Event	 During	
Period	(Add)	CDS	
Is	used	to	make	an	initial	report	that	an	ELECTIVE	ADMISSION	LIST	ENTRY	has	been	
added	 to	 the	Health	Care	Provider's	ELECTIVE	ADMISSION	LIST.	 It	 covers	ELECTIVE	
ADMISSION	 LIST	 ENTRIES	 under	 the	 care	 of	 a	 CONSULTANT,	MIDWIFE	 or	 NURSE,	
where	 an	 appropriate	 MAIN	 SPECIALTY	 CODE	 and	 TREATMENT	 FUNCTION	 CODE	
exists.	Elective	Admission	List	Event	During	Period	CDS	Types	are	intended	for	those	
ORGANISATIONS	 who	 have	 the	 capability	 to	 implement	 transaction-based	
processing,	 and	 are	 transmitted	 using	 Net	 Change	 Commissioning	 Data	 Set	
Submission	Protocol.		They	should	be	supplemented	where	required	by	an	annual	(or	
other	agreed	time-cycle)	submission	of	the	CDS	V6-2	Type	030	-	Elective	Admission	
List	-	End	of	Period	Census	(Standard)	Commissioning	Data	Set.	
CDS	 V6-2	 Type	 070	 -	 Elective	
Admission	 List	 -	 Event	 During	
Period	(Remove)	CDS	
Is	used	to	report	that	the	ELECTIVE	ADMISSION	LIST	ENTRY	has	been	removed	from	
the	Health	Care	Provider's	ELECTIVE	ADMISSION	LIST.	It	covers	ELECTIVE	ADMISSION	
LIST	 ENTRIES	 under	 the	 care	 of	 a	 CONSULTANT,	 MIDWIFE	 or	 NURSE,	 where	 an	
appropriate	MAIN	SPECIALTY	CODE	and	TREATMENT	FUNCTION	CODE	exists.	Elective	
Admission	List	Event	During	Period	CDS	Types	are	intended	for	those	ORGANISATIONS	
who	 have	 the	 capability	 to	 implement	 transaction-based	 processing,	 and	 are	
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transmitted	using	Net	Change	Commissioning	Data	Set	Submission	Protocol.	 	They	
should	be	supplemented	where	required	by	an	annual	(or	other	agreed	time-cycle)	
submission	of	the	CDS	V6-2	Type	030	-	Elective	Admission	List	-	End	of	Period	Census	
(Standard)	Commissioning	Data	Set.	
CDS	 V6-2	 Type	 080	 -	 Elective	
Admission	 List	 -	 Event	 During	
Period	(Offer)	CDS	
Is	used	 to	 report	 that	an	OFFER	OF	ADMISSION	has	been	made	to	 the	PATIENT.	 It	
covers	 ELECTIVE	 ADMISSION	 LIST	 ENTRIES	 under	 the	 care	 of	 a	 CONSULTANT,	
MIDWIFE	or	NURSE,	where	an	appropriate	MAIN	SPECIALTY	CODE	and	TREATMENT	
FUNCTION	CODE	exists.	Elective	Admission	List	Event	During	Period	CDS	Types	are	
intended	 for	 those	 ORGANISATIONS	 who	 have	 the	 capability	 to	 implement	
transaction-based	processing,	and	are	transmitted	using	Net	Change	Commissioning	
Data	Set	Submission	Protocol.		They	should	be	supplemented	where	required	by	an	
annual	(or	other	agreed	time-cycle)	submission	of	the	CDS	V6-2	Type	030	-	Elective	
Admission	List	-	End	of	Period	Census	(Standard)	Commissioning	Data	Set.	
CDS	 V6-2	 Type	 090	 -	 Elective	
Admission	 List	 -	 Event	 During	
Period	 (Available	 or	 Unavailable)	
CDS	
Is	 used	 to	 report	 changes	 in	 the	 PATIENT's	 availability	 for	 treatment.	 It	 covers	
ELECTIVE	ADMISSION	LIST	ENTRIES	under	the	care	of	a	CONSULTANT,	MIDWIFE	or	
NURSE,	where	an	appropriate	MAIN	SPECIALTY	CODE	and	TREATMENT	FUNCTION	
CODE	exists.	Elective	Admission	List	Event	During	Period	CDS	Types	are	intended	for	
those	 ORGANISATIONS	 who	 have	 the	 capability	 to	 implement	 transaction-based	
processing,	 and	 are	 transmitted	 using	 Net	 Change	 Commissioning	 Data	 Set	
Submission	Protocol.		They	should	be	supplemented	where	required	by	an	annual	(or	
other	agreed	time-cycle)	submission	of	the	CDS	V6-2	Type	030	-	Elective	Admission	
List	-	End	of	Period	Census	(Standard)	Commissioning	Data	Set.	
CDS	 V6-2	 Type	 100	 -	 Elective	
Admission	 List	 -	 Event	 During	
Period	 (Old	 Service	 Agreement)	
CDS	
Is	used	to	report	 to	 the	previous	Commissioner	 that	 the	ELECTIVE	ADMISSION	LIST	
ENTRY	 is	 now	 the	 responsibility	 of	 a	 new	 Commissioner.	 It	 covers	 ELECTIVE	
ADMISSION	 LIST	 ENTRIES	 under	 the	 care	 of	 a	 CONSULTANT,	MIDWIFE	 or	 NURSE,	
where	 an	 appropriate	 MAIN	 SPECIALTY	 CODE	 and	 TREATMENT	 FUNCTION	 CODE	
exists.	Elective	Admission	List	Event	During	Period	CDS	Types	are	intended	for	those	
ORGANISATIONS	 who	 have	 the	 capability	 to	 implement	 transaction-based	
processing,	 and	 are	 transmitted	 using	 Net	 Change	 Commissioning	 Data	 Set	
Submission	Protocol.		They	should	be	supplemented	where	required	by	an	annual	(or	
other	agreed	time-cycle)	submission	of	the	CDS	V6-2	Type	030	-	Elective	Admission	
List	-	End	of	Period	Census	(Standard)	Commissioning	Data	Set.	
CDS	 V6-2	 Type	 110	 -	 Elective	
Admission	 List	 -	 Event	 During	
Period	 (New	 Service	 Agreement)	
CDS	
Is	used	to	make	an	initial	report	to	a	new	Commissioner	of	an	ELECTIVE	ADMISSION	
LIST	ENTRY	that	had	previously	been	the	responsibility	of	another	Commissioner.	 It	
covers	 ELECTIVE	 ADMISSION	 LIST	 ENTRIES	 under	 the	 care	 of	 a	 CONSULTANT,	
MIDWIFE	or	NURSE,	where	an	appropriate	MAIN	SPECIALTY	CODE	and	TREATMENT	
FUNCTION	CODE	exists.	Elective	Admission	List	Event	During	Period	CDS	Types	are	
intended	 for	 those	 ORGANISATIONS	 who	 have	 the	 capability	 to	 implement	
transaction-based	processing,	and	are	transmitted	using	Net	Change	Commissioning	
Data	Set	Submission	Protocol.		They	should	be	supplemented	where	required	by	an	
annual	(or	other	agreed	time-cycle)	submission	of	the	CDS	V6-2	Type	030	-	Elective	
Admission	List	-	End	of	Period	Census	(Standard)	Commissioning	Data	Set.	
	
	 	
	
171	
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Summary	
The	aim	of	this	study	is	to	employ	Machine	Learning	methods	of	analysis	to	predict	in-hospital	
deterioration	of	patients.		
	
Patients	who	deteriorate,	may	face	the	need	for	emergency	resuscitation,	surgery,	intensive	
care	unit	admission	or	if	all	else	fails	they	may	die.	Stopping	this	happening	requires	identifying	
those	at	risk	as	early	as	possible.	I	aim	therefore	to	develop	a	computer	based	system,	that	is	
constantly	 analysing	 individual	 patient	 data	 to	 identify	 these	 patients	 prior	 to	 them	
deteriorating.	Implementation	of	a	working	system	(not	part	of	this	study),	will	help	clinicians	
make	 the	 right	 decisions	 on	 further	 investigations,	 referral	 to	 specialist	 teams	 and	 specific	
treatment	earlier	than	what	currently	occurs.	
	
The	 study	 will	 analyse	 anonymised	 data	 from	 all	 patients	 who	 have	 been	 admitted	 and	
subsequently	discharged	from	a	range	of	hospitals.	The	data	(without	patient	name,	date	of	
birth,	address,	hospital	number,	etc)	will	be	extracted	from	existing	hospital	databases,	and	
will	 comprise	 electronic	 patient	 administration	 information	 (age,	 sex,	 illnesses,	 etc)	 and	
electronically	stored	blood	test	results.	The	information	teams	at	each	individual	NHS	trust	will	
be	responsible	for	providing	the	anonymised	data	from	their	respective	existing	databases.	
Background	Information	
Serious	adverse	events	(SAEs,	such	as	cardiac	arrest,	unexpected	intensive	care	unit	admission,	
the	 need	 for	 emergency	 surgery,	 or	 death)	 are	 commonplace	 in	 hospitalised	patients,	 and	
reducing	 these	 is	 a	national	priority[1-5].	 Physiological	deterioration	generally	precedes	 in-
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hospital	SAEs[1-5].	Recognition	of	such	decline,	with	appropriate	intervention,	can	reduce	SAE	
frequency6	 and	 is	 broadly	 advocated	 by	 National	 Institute	 of	 Clinical	 Excellence	 (NICE)[2],	
National	Confidential	Enquiry	 into	Patient	Outcome	and	Death	 (NCEPOD)3-5	and	The	Royal	
College	of	Physicians	(RCP)[1].	In	response,	the	RCP	developed	an	aggregated	scoring	system	
of	vital	signs:	the	NHS	Early	Warning	Score	(NEWS)1	(based	on	the	ViEWS[7]	system).	I	have	
previously	 shown	 that	 applying	 novel	multivariate	 approaches	 to	 this	 dataset	 can	 improve	
sensitivity	 for	 detecting	 SAEs	 by	 5%	 (while	 conserving	 specificity)	 for	 each	 trigger	 value	 of	
NEWS.	This	approach,	though,	is	inherently	limited	by	the	use	of	‘snapshot’	vital	signs,	without	
reference	 to	 separate	prospective	 risk	 classification.	As	 such,	a	patient	 is	only	 identified	as	
being	‘at	risk’	when	physiological	derangement	is	already	causing	significant	compromise-	a	
point	at	which	the	window	of	opportunity	for	effective	clinical	 intervention	may	already	be	
closing.	 Here,	 I	 propose	 a	 research	 programme	 focused	 on	 a	 new	 and	 complementary	
approach.	
	
Haematological	 tests	 are	 routinely	 conducted	 in	 hospital	 patients	 both	 on	 and	 during	
admission.	Their	use	might,	in	theory,	offer	a	universal	and	simple	means	of	stratifying	risk	or	
predicting	decline,	that	would	require	little	or	no	significant	additional	resource.	Efforts	have	
thus	been	made	to	develop	automatic	interpretation	and	prediction	systems	based	on	blood	
results	[8-12].	However,	their	scope	has	been	limited	by	the	use	of	conventional	analyses	of	
small	single-centre	datasets	of	single-timepoint	blood	tests.	Furthermore,	none	use	dynamic	
change	over	time	in	blood	results,	marry	such	data	with	co-morbidities	(ICD	codes)	or	modify	
their	predictions	when	new	procedures	are	performed	on	the	patient:	yet,	as	clinicians,	we	
take	all	these	factors	into	account	every	time	we	interpret,	request	and	repeat	a	blood	test.	
	
I	therefore	hypothesise	that	serious	adverse	events	(and	other	indicators	of	morbidity)	will	be	
predictable	by	applying	novel	multivariate	analyses	to	large	scale	time-series	data	of	hospital	
inpatient	 blood	 tests,	 married	 with	 data	 relating	 to	 co-morbidities.	 My	 preliminary	 data	
demonstrate	 that	 using	 reference	 ranges	 to	 dichotomise	 routine	 blood	 test	 results	 into	
‘normal’	and	‘abnormal’	groups	is	less	accurate	in	predicting	in-hospital	mortality	than	using	
actual	(continuous)	test	values	[12].		
	
I	 propose	 to	 further	 develop	 and	 refine	 these	 algorithms,	 whilst	 concurrently	 developing	
entirely	new	machine	learning	models	to	significantly	enhance	predictive	power,	incorporating	
both	multivariate	and	time	series	analyses.	
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Study	Aims	and	Objectives	
Aim	
To	develop	a	computer	programme	that	analyses	routinely	collected	electronic	patient	data	
to	identify	those	patients	at	risk	of	deterioration.		
Objectives	
1. To	investigate	the	mortality	associated	with	blood	results	within	the	normal	reference	
range	 and	 determine	 those	 interrelationships	 that	 represent	minimal	mortality	 i.e.	
optimal	health.	
2. To	 identify	 clusters	 of	 patients	 with	 above-average	mortality	 and	 characterize	 the	
specific	 relationships	 between	 their	 blood	 results	 and	 their	 associated	 clinical	
conditions.	
3. To	map	 the	 temporal	 pattern	 of	 biochemical	 and	 haematological	 derangement,	 in	
specific	clusters	of	patients,	that	precede	serious	adverse	events.	
4. To	build	and	validate	a	computer-based	inference	system	that	predicts	serious	adverse	
events,	in	all	hospitalized	patients.	
Study	Design	
Investigator	
Dr	Vishal	Nangalia	will	be	the	chief	investigator	and	will	be	supervised	by	Dr	Reecha	Sofat	and	Dr	David	
Barber.	
Local	Collaborators	
- A	 local	 collaborator	will	 be	 identified	 at	 each	 individual	NHS	 trust.	 The	 local	 collaborators	will	
normally	be	from	the	Biochemistry	and/or	Intensive	Care	Departments.	
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The	Data	
- The	anonymised	data	(without	patient	name,	date	of	birth,	address,	hospital	number,	etc)	will	be	
extracted	 from	existing	hospital	 databases,	 and	will	 comprise	electronic	patient	 administration	
information	(age,	sex,	illnesses,	etc)	and	biological	data	(e.g.	blood	results).	
- Data	anonymisation	will	be	confirmed	prior	to	the	investigators	receiving	the	data.	All	data	will	be	
anonymised	by	the	respective	organisations	providing	the	data.	The	researchers	will	therefore	not	
have	access	to	any	patient	identifiable	data.	
- The	anonymised	data	that	will	be	analysed	is	all	in	electronic	format	on	existing	hospital	databases	
and	is	collected	as	part	of	the	routine	care	of	patients.			
Data	Collection	
- A	 local	 collaborator	will	 be	 identified	 at	 each	 individual	NHS	 trust.	 The	 local	 collaborators	will	
normally	be	from	the	Biochemistry	and	Intensive	Care	Departments.	
- The	 data	 extraction	 and	 anonymisation	 will	 be	 carried	 out	 by	 the	 information	 teams	 at	 the	
respective	NHS	trusts	using	existing	hospital	systems.	The	process	is	simple	and	straightforward	
within	existing	hospital	IT	infrastructure.	
- Each	NHS	 Trust's	 Research	 and	Development,	 Information	Governance	 and	 Caldicott	 Guardian	
teams	will	approve	the	anonymised	data	extraction.	
- No	patient	identifiable	data	will	leave	the	NHS	trust	or	be	shared	with	the	researchers.	
- The	 data	 will	 be	 collected	 by	 the	 Chief	 Investigator	 from	 each	 individual	 trust,	 using	 a	 NHS	
approved	encrypted	USB	stick	"IRONKEY".	
Data	Cleaning	
- Once	the	anonymised	dataset	is	obtained,	missing	and	abnormal	values	will	be	removed	under	the	
guidance	of	the	project	team,	who	have	relevant	expertise.	
Data	linkage	 	
- We	will	 not	 attempt	 to	 link	 the	 data	 obtained	 from	 the	 various	 organisations	 with	 any	 other	
research	database. 	
Data	Sharing	 	
- The	data	will	not	be	shared	with	any	other	investigators.	
- The	data	will	be	used	solely	for	this	project.		
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Data	Storage	 and	Analysis	
- Appropriate	computational	technologies	will	be	used	to	store	and	handle	the	data,	and	all	will	be	
compliant	(in	terms	of	security	and	so	forth)	with	data	protection	needs.		
Study	Population	
- All	adult	patients	admitted	to	hospital,	who	have	had	a	blood	test,	will	be	included	in	the	database	
analysis.		
Inclusion	Criteria	
- The	total	sample	size	will	consist	of	all	patients	who	have	at	some	point	been	admitted	to	hospital	
and	subsequently	discharged	from	hospital	and	who	have	had	a	blood	test.		
- Age>=18	years	old.	
Exclusion	Criteria	
- Patients	not	admitted	to	hospital.		
- Patients	who	have	not	had	a	blood	test.	
- Age<18	years	old.	
Sample	Size	
- 500,000	to	1	million	anonymised	patient	admission	episodes	only.	
- The	investigational	plan	has	been	co-written	with	world	leading	statistical	experts	in	the	field,	and	
has	been	reviewed	by	MRC	experts	and	found	valid.	This	Machine	Learning	approach	relies	on	very	
large	datasets,	of	the	magnitude	described.	
Analysis	
The	 data	 to	 be	 interrogated	 consist	 of	millions	 of	 data	 points,	 distributed	 over	 a	 high	 number	 of	
dimensions.	 The	 dimensions	 themselves	 represent	 a	mixture	 of	 discrete	 and	 continuous	 variables,	
some	of	which	have	 temporal	 components.	This	volume	and	complexity	 requires	a	combination	of	
three	methodologies	to	achieve	the	inferential	goals:	
1. Building	on	my	preliminary	service	evaluation/audit	highlighting	 the	problems	with	 the	current	
“normal	range”,	I	shall	use	probabilistic	pattern-recognition	(supervised	learning)	to	identify	the	
inter-relationships	 between	 routine	 haematological/biochemical	 data	 that	 result	 in	 minimum	
mortality	 and	 morbidity.	 Patients	 will	 be	 subdivided	 into	 demographic-,	 co-morbidity-	 and	
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intervention-based	 groups.	 Support	 Vector	 Machines	 will	 then	 be	 used	 for	 classification	 and	
regression.	
2. Utilising	 neural	 networks	 (unsupervised	 learning)	 and	 the	 subsequent	 identified	 clusters,	 I	 will	
determine	 the	 relationship	 of	 the	 co-morbidities/diagnoses	 (ICD	 codes)	 and	 interventions	
(procedure	codes)	to	these	clusters	and	their	association	with	mortality.	
3. My	next	two	objectives	are	to	determine	if	there	are	patterns	in	the	repeated	blood	results	and	
associated	data	that	are	highly	predictive	of	serious	adverse	events.	This	requires	a	different	class	
of	 techniques	 than	 standard	 abnormality	 detection:	 latent	models	with	 time	 series	 analysis.	A	
simple	approach	is	to	take	along	with	each	measurement,	vt,	the	end-class	label,	cT,	and	attempt	
to	form	a	classifier	of	the	end-time	class	based	on	the	measurements	at	time	t.	This	is	conceptually	
straightforward	but	suffers	from	being	potentially	inconsistent	–	that	is,	the	method	may	predict	
that	the	patient	is	likely	to	die;	yet	based	on	subsequent	results,	may	predict	the	patient	is	likely	
to	be	discharged.	I	therefore	need	a	way	to	make	temporally	consistent	predictions.	I	will	achieve	
this	 by	 initially	 dividing	 the	 datasets	 into	 the	 previously	 identified	 clusters	 and	 then	 use	 a	
generative	model,	(Hidden	Markov	Model),	of	blood	results	v1:t	with	the	outcome	label	cT	.	Non-
standard	approaches	will	be	utilised	to	train	these	models.	 In	addition,	separate	models	will	be	
based	 on	 a	 continuous	 latent	 h(t)	 to	 track	 the	 ‘health’	 of	 the	 patient.	 At	 all	 stages,	 medical	
knowledge	will	be	used	to	supplement	and	direct	the	mathematical	approach.	
Performance	endpoints	
A	range	of	cross	validation	techniques	and	independent	testing	between	the	various	samples	of	the	
database	will	be	used	to	assess	the	accuracy,	sensitivity,	specificity	and	performance	of	the	models	
generated.	
Research	Environment	and	Developmental	Opportunities	
Dr	David	Barber	(Reader,	Computer	Science)	has	over	70	published	works	in	the	field	of	the	application	
and	theories	of	Bayesian	methods	to	 large-scale	time	series	data.	He	has	recently	explored	switch-
reset	models	(models	where	the	underlying	processes	can	be	both	discrete	and	continuous),	concave	
Gaussian	 variational	 approximations	 for	 inference	 in	 large-scale	 Bayesian	 linear	models	 as	well	 as	
investigating	variational	methods	 for	 reinforcement	 learning.	His	 involvement	provides	a	medically	
unbiased	and	mathematically	rigorous	approach	to	inference	of	complex	datasets.		
	
Additionally,	there	exists	a	framework	that	supports	such	interdisciplinary	research,	as	evidenced	by	
the	existence	of	the	Computational	Life	and	Medical	Sciences	Network	and	the	Systems	Medicine	
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Consortia	for	Research	Computing,	of	which	I	hold	membership.	This	 infrastructure	comprises	high	
performance	 computing	 systems	 (e.g.	 LEGION	 and	 GPU	 clusters),	 secure	 data	 transmission	 and	
storage,	 some	 of	 the	 best	machine	 learning	 courses	 in	 the	world	 and	 a	 culture	 among	 experts	 of	
interdisciplinary	research.	All	these	make	UCL,	a	centre	of	international	excellence	in	biomedical	fields	
and	computer	science,	the	perfect	location	to	base	this	research.	
Adverse	Event	Reporting	
Not	applicable	as	only	anonymised	and	retrospective	data	is	to	be	acquired	and	analysed.	
Peer	Review	
The	 project	 and	 protocol	 have	 already	 undergone	 external	 peer	 review	 in	 an	 internationally	
competitive	forum	(the	Medical	Research	Council).	
Ethics	
NHS	Ethics	has	been	granted:	REC	Ref:	13/WS/0243	
Monitoring	and	Audit	
The	principal	investigator	will	be	responsible	for	the	day-to-day	monitoring	and	management	of	the	
study.	The	Joint	UCLH/UCL/RFH	Biomedical	Research	(R&D)	Unit,	on	behalf	of	the	Sponsor,	UCL,	will	
monitor	and	conduct	random	audits	on	a	selection	studies	in	its	clinical	research	portfolio.	Monitoring	
and	auditing	will	be	conducted	in	accordance	with	the	Department	of	Health	Research	Governance	
Framework	 for	 Health	 &	 Social	 Care,	 and	 in	 accordance	 with	 the	 Sponsor’s	 monitoring	 and	 audit	
policies	and	procedures.	
Financing	
The	study	is	funded	as	part	of	a	Medical	Research	Council	Clinical	research	Training	Fellowship,	that	
has	been	awarded	to	Dr	Vishal	Nangalia.	Medical	Research	Council	Reference:	MR/K024051/1.	
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Sponsorship	
University	College	London	will	be	the	sponsor	
Publication	Policy	
Multiple	manuscripts	to	leading	peer	reviewed	General	Medical	and	Computer	Science	journals	will	be	
submitted.	
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